

511582002500




CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL 744471223 US

Date of Deposit: June 28, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Box Missing Parts, Washington, D.C. 20231.

Fami M. Procopio
Fami M. Procopio



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Pia M. CHALLITA-EID et al.

Serial No.: 10/024,652

Filing Date: December 17, 2001

For: NUCLEIC ACID AND ENCODED ZINC
TRANSPORTER ENTITLED 108P5H8
USEFUL IN TREATMENT AND
DETECTION OF CANCER

Examiner: To be Assigned

Group Art Unit: 1645

RESPONSE TO NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION**BOX MISSING PARTS**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to File Missing Parts of Nonprovisional Application mailed April 3, 2002, for which a response was due on June 3, 2002. Accordingly, a request and a petition for extension of time from June 3, 2002 to July 3, 2002, is included herewith.

Please enter the following sequence listing, amendments and remarks.

Substitute Specification

Please enter the following substitute specification, submitted in compliance with 37 CFR 1.125(b) and CFR 1.52(e). A marked-up version of the specification accompanies this response.

AMENDMENT**In the Specification**

Please replace the paragraph of the substitute specification beginning on page 1, line 7, with the following rewritten paragraph:

--SUBMISSION ON COMPACT DISC

The contents of the following submission on compact discs are incorporated herein by reference in its entirety: A compact disc copy of the Sequence Listing (COPY 1) (file name: 511582002500, date recorded: 02 June 2002, size: 434 KB); a duplicate compact disc copy of Sequence Listing (COPY 2) (file name: 511582002500, date recorded: 02 June 2002, size: 434 KB); a computer readable form copy of the Sequence Listing (CRF COPY) (file name: 511582002500, date recorded: 02 June 2002, size: 434 KB).--

In the Sequence Listing

Please insert the attached compact disc copy of the Sequence Listing on CD-R (COPY 1) in the above-captioned application. A duplicate compact disc copy of the Sequence Listing on CD-R (COPY 2) and a computer readable form copy of the Sequence Listing on CD-R (CRF COPY) accompany this response.

REMARKS

Applicant has submitted a substitute specification in response to the Notice to File Missing Parts of Nonprovisional Application, due to the number of the amendments made to the specification in accordance with 37 C.F.R. 1.125(b) and 1.52(e). As to the substitute specification, applicants submit that no new matter was added. Applicants have inserted all the appropriate sequence identification numbers and deleted any mislabeled or unnecessary sequence identification numbers placed in the application as-filed. Applicants have also provided a reference to Figure 4C in Example 46 and in the Brief Description of the Figures. Additionally, the Tables and certain Figures have been reformatted to comply with the margin requirements. A typographical page break error, which resulted in "Page 144" of the specification as filed being blank has been corrected. No subject matter was omitted in this filing. Finally, an amendment has been made to the substitute specification for entry of applicant's submission on compact disk.

Attached hereto is a marked-up version of the changes made to the substitute specification by the current amendment. The attached page is captioned **"Version with markings to show changes made."**

The undersigned hereby states that the compact disc copy of the Sequence Listing and the computer readable form copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the patent office determines that extensions and/or other relief is required, applicant petition for any required relief including extensions of time and authorize the assistant commissioner to charge the cost of such petitions and/or fees due to our deposit account no. 03-1952 under order no. 511582002500. The assistant commissioner is not authorized to charge the cost of the issue fee to the deposit account.

511582002500

Respectfully submitted,

Dated: June 28, 2002

By: Kate H. Murashige
Kate H. Murashige
Registration No. (29,959)

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125



10/024,652 .062802

511582002500

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The following paragraph has been added to the specification beginning on page 1, line 7:

SUBMISSION ON COMPACT DISC

The contents of the following submission on compact discs are incorporated herein by reference in its entirety: A compact disc copy of the Sequence Listing (COPY 1) (file name: 511582002500, date recorded: 02 June 2002, size: 434 KB); a duplicate compact disc copy of Sequence Listing (COPY 2) (file name: 511582002500, date recorded: 02 June 2002, size: 434 KB); a computer readable form copy of the Sequence Listing (CRF COPY) (file name: 511582002500, date recorded: 28 March 2002, size: 434 KB).



10024652 .062202 #9

PATENT
Docket No. 511582002500

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL 744471223 US

Date of Deposit: June 28 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Box Missing Parts, Washington, D.C. 20231.

Tami M. Procopio

Tami M. Procopio

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Pia M. CHALLITA-EID, *et al.*

Serial No.: 10/024,652

Filing Date: December 17, 2001

For: NUCLEIC ACID AND ENCODED ZINC
TRANSPORTER ENTITLED 108P5H8
USEFUL IN TREATMENT AND
DETECTION OF CANCER

Examiner: To be assigned

Group Art Unit: 1645

REQUEST FOR CORRECTION OF DRAWINGS

BOX MISSING PARTS
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed are twenty (15) substitute sheets of drawings for Figures 1, 2A-C, 3A-B, 4A-B and 25A-C, in connection with the above-identified application. In addition, please find enclosed drawings showing the proposed changes in red.

The Figures are amended to include sequence identification numbers which were inadvertently omitted at the time of filing. Applicants respectfully request the entry of these amendments.


sd-98214

In the unlikely event that the transmittal letter is separated from this request and the U.S. Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing to our **Deposit Account No. 03-1952**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: June 28, 2002

By:



Kate H. Murashige
Registration No. (29,959)

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

**NUCLEIC ACID AND ENCODED ZINC TRANSPORTER PROTEIN
ENTITLED 108P5H8
USEFUL IN TREATMENT AND DETECTION OF CANCER**

RELATED APPLICATIONS

5 This application claims priority from provisional application US Serial No 60/256,210 filed 15 December 2000, the contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

10 The invention described herein relates to a gene and its encoded protein, termed 108P5H8, expressed in certain cancers such as those listed in Table I, and to diagnostic, prognostic, prophylactic and/or therapeutic methods and compositions useful in the management of cancers that express 108P5H8.

BACKGROUND OF THE INVENTION

15 Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from cancer every year. In the United States alone, as reported by the American Cancer Society, cancer causes the death of well over a half-million people annually, with over 1.2 million new cases diagnosed per year. While deaths from heart disease have been declining significantly, those resulting from cancer generally are on the rise. In the early part of the next century, cancer is predicted to become the leading cause of death.

20 Worldwide, several cancers stand out as the leading killers. In particular, carcinomas of the lung, prostate, breast, colon, pancreas, and ovary represent the primary causes of cancer death. These and virtually all other carcinomas share a common lethal feature. With very few exceptions, metastatic disease from a carcinoma is fatal. Moreover, even for those cancer patients who initially survive their primary cancers, common experience has shown that their lives are dramatically altered. Many cancer patients experience strong anxieties driven by the awareness of the potential for recurrence or treatment failure. Many cancer patients experience physical debilitations following treatment. Furthermore, many cancer patients experience a recurrence.

25 Worldwide, prostate cancer is the fourth most prevalent cancer in men. In North America and Northern Europe, it is by far the most common cancer in males and is the second leading cause of cancer death in men. In the United States alone, well over 30,000 men die annually of this disease - second only to lung cancer. Despite the magnitude of these figures, there is still no effective treatment for metastatic prostate cancer. Surgical prostatectomy, radiation therapy, hormone ablation therapy, surgical castration and chemotherapy continue to be the main treatment modalities. Unfortunately, these treatments are ineffective for many and are often associated with undesirable consequences.

30 On the diagnostic front, the lack of a prostate tumor marker that can accurately detect early-stage, localized tumors remains a significant limitation in the diagnosis and management of this disease.

Although the serum prostate specific antigen (PSA) assay has been a very useful tool, however its specificity and general utility is widely regarded as lacking in several important respects.

Progress in identifying additional specific markers for prostate cancer has been improved by the generation of prostate cancer xenografts that can recapitulate different stages of the disease in mice. The LAPC (Los Angeles Prostate Cancer) xenografts are prostate cancer xenografts that have survived passage in severe combined immune deficient (SCID) mice and have exhibited the capacity to mimic the transition from androgen dependence to androgen independence (Klein *et al.*, 1997, Nat. Med. 3:402). More recently identified prostate cancer markers include PCTA-1 (Su *et al.*, 1996, Proc. Natl. Acad. Sci. USA 93: 7252), prostate-specific membrane (PSM) antigen (Pinto *et al.*, Clin Cancer Res 1996 Sep 2 (9): 1445-51), STEAP (Hubert, *et al.*, Proc Natl Acad Sci U S A. 1999 Dec 7; 96(25): 14523-8) and prostate stem cell antigen (PSCA) (Reiter *et al.*, 1998, Proc. Natl. Acad. Sci. USA 95: 1735).

While previously identified markers such as PSA, PSM, PCTA and PSCA have facilitated efforts to diagnose and treat prostate cancer, there is need for the identification of additional markers and therapeutic targets for prostate and related cancers in order to further improve diagnosis and therapy.

Renal cell carcinoma (RCC) accounts for approximately 3 percent of adult malignancies. Once adenomas reach a diameter of 2 to 3 cm, malignant potential exists. In the adult, the two principal malignant renal tumors are renal cell adenocarcinoma and transitional cell carcinoma of the renal pelvis or ureter. The incidence of renal cell adenocarcinoma is estimated at more than 29,000 cases in the United States, and more than 11,600 patients died of this disease in 1998. Transitional cell carcinoma is less frequent, with an incidence of approximately 500 cases per year in the United States.

Surgery has been the primary therapy for renal cell adenocarcinoma for many decades. Until recently, metastatic disease has been refractory to any systemic therapy. With recent developments in systemic therapies, particularly immunotherapies, metastatic renal cell carcinoma may be approached aggressively in appropriate patients with a possibility of durable responses. Nevertheless, there is a remaining need for effective therapies for these patients.

Of all new cases of cancer in the United States, bladder cancer represents approximately 5 percent in men (fifth most common neoplasm) and 3 percent in women (eighth most common neoplasm). The incidence is increasing slowly, concurrent with an increasing older population. In 1998, there was an estimated 54,500 cases, including 39,500 in men and 15,000 in women. The age-adjusted incidence in the United States is 32 per 100,000 for men and 8 per 100,000 in women. The historic male/female ratio of 3:1 may be decreasing related to smoking patterns in women. There were an estimated 11,000 deaths from bladder cancer in 1998 (7,800 in men and 3,900 in women). Bladder cancer incidence and mortality strongly increase with age and will be an increasing problem as the population becomes more elderly.

Most bladder cancers recur in the bladder. Bladder cancer is managed with a combination of transurethral resection of the bladder (TUR) and intravesical chemotherapy or immunotherapy. The multifocal and recurrent nature of bladder cancer points out the limitations of TUR. Most muscle-invasive cancers are not cured by TUR alone. Radical cystectomy and urinary diversion is the most effective means

to eliminate the cancer but carry an undeniable impact on urinary and sexual function. There continues to be a significant need for treatment modalities that are beneficial for bladder cancer patients.

5 An estimated 130,200 cases of colorectal cancer occurred in 2000 in the United States, including 93,800 cases of colon cancer and 36,400 of rectal cancer. Colorectal cancers are the third most common cancers in men and women. Incidence rates declined significantly during 1992-1996 (-2.1% per year). Research suggests that these declines have been due to increased screening and polyp removal, preventing progression of polyps to invasive cancers. There were an estimated 56,300 deaths (47,700 from colon cancer, 8,600 from rectal cancer) in 2000, accounting for about 11% of all U.S. cancer deaths.

10 At present, surgery is the most common form of therapy for colorectal cancer, and for cancers that have not spread, it is frequently curative. Chemotherapy, or chemotherapy plus radiation, is given before or after surgery to most patients whose cancer has deeply perforated the bowel wall or has spread to the lymph nodes. A permanent colostomy (creation of an abdominal opening for elimination of body wastes) is occasionally needed for colon cancer and is infrequently required for rectal cancer. There continues to be a need for effective diagnostic and treatment modalities for colorectal cancer.

15 There were an estimated 164,100 new cases of lung and bronchial cancer in 2000, accounting for 14% of all U.S. cancer diagnoses. The incidence rate of lung and bronchial cancer is declining significantly in men, from a high of 86.5 per 100,000 in 1984 to 70.0 in 1996. In the 1990s, the rate of increase among women began to slow. In 1996, the incidence rate in women was 42.3 per 100,000.

20 Lung and bronchial cancer caused an estimated 156,900 deaths in 2000, accounting for 28% of all cancer deaths. During 1992-1996, mortality from lung cancer declined significantly among men (-1.7% per year) while rates for women were still significantly increasing (0.9% per year). Since 1987, more women have died each year of lung cancer than breast cancer, which, for over 40 years, was the major cause of cancer death in women. Decreasing lung cancer incidence and mortality rates most likely resulted from decreased smoking rates over the previous 30 years; however, decreasing smoking patterns among women lag behind those of men. Of concern, although the declines in adult tobacco use have slowed, tobacco use in youth is increasing again.

25 Treatment options for lung and bronchial cancer are determined by the type and stage of the cancer and include surgery, radiation therapy, and chemotherapy. For many localized cancers, surgery is usually the treatment of choice. Because the disease has usually spread by the time it is discovered, radiation therapy and chemotherapy are often needed in combination with surgery. Chemotherapy alone or combined with radiation is the treatment of choice for small cell lung cancer; on this regimen, a large percentage of patients experience remission, which in some cases is long lasting. There is however, an ongoing need for effective treatment and diagnostic approaches for lung and bronchial cancers.

30 An estimated 182,800 new invasive cases of breast cancer were expected to occur among women in the United States during 2000. Additionally, about 1,400 new cases of breast cancer were expected to be diagnosed in men in 2000. After increasing about 4% per year in the 1980s, breast cancer incidence rates in women have leveled off in the 1990s to about 110.6 cases per 100,000.

In the U.S. alone, there were an estimated 41,200 deaths (40,800 women, 400 men) in 2000 due to breast cancer. Breast cancer ranks second among cancer deaths in women. According to the most recent data, mortality rates declined significantly during 1992–1996 with the largest decreases in younger women, both white and black. These decreases were probably the result of earlier detection and improved treatment.

Taking into account the medical circumstances and the patient's preferences, treatment of breast cancer may involve lumpectomy (local removal of the tumor) and removal of the lymph nodes under the arm; mastectomy (surgical removal of the breast) and removal of the lymph nodes under the arm; radiation therapy; chemotherapy; or hormone therapy. Often, two or more methods are used in combination. Numerous studies have shown that, for early stage disease, long-term survival rates after lumpectomy plus radiotherapy are similar to survival rates after modified radical mastectomy. Significant advances in reconstruction techniques provide several options for breast reconstruction after mastectomy. Recently, such reconstruction has been done at the same time as the mastectomy.

Local excision of ductal carcinoma *in situ* (DCIS) with adequate amounts of surrounding normal breast tissue may prevent the local recurrence of the DCIS. Radiation to the breast and/or tamoxifen may reduce the chance of DCIS occurring in the remaining breast tissue. This is important because DCIS, if left untreated, may develop into invasive breast cancer. Nevertheless, there are serious side effects or sequelae to these treatments. There is, therefore, a need for efficacious breast cancer treatments.

There were an estimated 23,100 new cases of ovarian cancer in the United States in 2000. It accounts for 4% of all cancers among women and ranks second among gynecologic cancers. During 1992–1996, ovarian cancer incidence rates were significantly declining. Consequent to ovarian cancer, there were an estimated 14,000 deaths in 2000. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.

Surgery, radiation therapy, and chemotherapy are treatment options for ovarian cancer. Surgery usually includes the removal of one or both ovaries, the fallopian tubes (salpingo-oophorectomy), and the uterus (hysterectomy). In some very early tumors, only the involved ovary will be removed, especially in young women who wish to have children. In advanced disease, an attempt is made to remove all intra-abdominal disease to enhance the effect of chemotherapy. There continues to be an important need for effective treatment options for ovarian cancer.

There were an estimated 28,300 new cases of pancreatic cancer in the United States in 2000. Over the past 20 years, rates of pancreatic cancer have declined in men. Rates among women have remained approximately constant but may be beginning to decline. Pancreatic cancer caused an estimated 28,200 deaths in 2000 in the United States. Over the past 20 years, there has been a slight but significant decrease in mortality rates among men (about –0.9% per year) while rates have increased slightly among women.

Surgery, radiation therapy, and chemotherapy are treatment options for pancreatic cancer. These treatment options can extend survival and/or relieve symptoms in many patients but are not likely to

produce a cure for most. There is a significant need for additional therapeutic and diagnostic options for pancreatic cancer.

SUMMARY OF THE INVENTION

The present invention relates to a gene, designated 108P5H8, that has now been found to be over-expressed in the cancer(s) listed in Table I. Northern blot expression analysis of 108P5H8 gene expression in normal tissues shows a restricted expression pattern in adult tissues. The nucleotide (Figure 2) and amino acid (Figure 2, and Figure 3) sequences of 108P5H8 are provided. The tissue-related profile of 108P5H8 in normal adult tissues, combined with the over-expression observed in the tumors listed in Table I, shows that 108P5H8 is aberrantly over-expressed in at least some cancers, and thus serves as a useful diagnostic, prophylactic, prognostic, and/or therapeutic target for cancers of the tissue(s) such as those listed in Table I.

The invention provides polynucleotides corresponding or complementary to all or part of the 108P5H8 genes, mRNAs, and/or coding sequences, preferably in isolated form, including polynucleotides encoding 108P5H8-related proteins and fragments of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more than 25 contiguous amino acids; at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100 or more than 100 contiguous amino acids of a 108P5H8-related protein, as well as the peptides/proteins themselves; DNA, RNA, DNA/RNA hybrids, and related molecules, polynucleotides or oligonucleotides complementary or having at least a 90% homology to the 108P5H8 genes or mRNA sequences or parts thereof, and polynucleotides or oligonucleotides that hybridize to the 108P5H8 genes, mRNAs, or to 108P5H8-encoding polynucleotides. Also provided are means for isolating cDNAs and the genes encoding 108P5H8. Recombinant DNA molecules containing 108P5H8 polynucleotides, cells transformed or transduced with such molecules, and host-vector systems for the expression of 108P5H8 gene products are also provided. The invention further provides antibodies that bind to 108P5H8 proteins and polypeptide fragments thereof, including polyclonal and monoclonal antibodies, murine and other mammalian antibodies, chimeric antibodies, humanized and fully human antibodies, and antibodies labeled with a detectable marker or therapeutic agent. In certain embodiments there is a proviso that the entire nucleic acid sequence of Figure 2 is not encoded and/or the entire amino acid sequence of Figure 2 is not prepared. In certain embodiments, the entire nucleic acid sequence of Figure 2 is encoded and/or the entire amino acid sequence of Figure 2 is prepared, either of which are in respective human unit dose forms.

The invention further provides methods for detecting the presence and status of 108P5H8 polynucleotides and proteins in various biological samples, as well as methods for identifying cells that express 108P5H8. A typical embodiment of this invention provides methods for monitoring 108P5H8 gene products in a tissue or hematology sample having or suspected of having some form of growth dysregulation such as cancer.

The invention further provides various immunogenic or therapeutic compositions and strategies for treating cancers that express 108P5H8 such as cancers of tissues listed in Table I, including therapies

aimed at inhibiting the transcription, translation, processing or function of 108P5H8 as well as cancer vaccines. In one aspect, the invention provides compositions, and methods comprising them, for treating a cancer that expresses 108P5H8 in a human subject wherein the composition comprises a carrier suitable for human use and a human unit dose of one or more than one agent that inhibits the production or function of 108P5H8. Preferably, the carrier is a uniquely human carrier. In another aspect of the invention, the agent is a moiety that is immunoreactive with 108P5H8 protein. Non-limiting examples of such moieties include, but are not limited to, antibodies (such as single chain, monoclonal, polyclonal, humanized, chimeric, or human antibodies), functional equivalents thereof (whether naturally occurring or synthetic), and combinations thereof. The antibodies can be conjugated to a diagnostic or therapeutic moiety. In another aspect, the agent is a small molecule as defined herein.

In another aspect, the agent comprises one or more than one peptide which comprises a cytotoxic T lymphocyte (CTL) epitope that binds an HLA class I molecule in a human to elicit a CTL response to 108P5H8 and/or one or more than one peptide which comprises a helper T lymphocyte (HTL) epitope which binds an HLA class II molecule in a human to elicit an HTL response. The peptides of the invention may be on the same or on one or more separate polypeptide molecules. In a further aspect of the invention, the agent comprises one or more than one nucleic acid molecule that expresses one or more than one of the CTL or HTL response stimulating peptides as described above. In yet another aspect of the invention, the one or more than one nucleic acid molecule may express a moiety that is immunologically reactive with 108P5H8 as described above. The one or more than one nucleic acid molecule may also be, or encode, a molecule that inhibits production of 108P5H8. Non-limiting examples of such molecules include, but are not limited to, those complementary to a nucleotide sequence essential for production of 108P5H8 (e.g. antisense sequences or molecules that form a triple helix with a nucleotide double helix essential for 108P5H8 production) or a ribozyme effective to lyse 108P5H8 mRNA.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1. The 108P5H8 SSH sequence of 448 nucleotides.

Figure 2. The cDNA (SEQ ID NO:) and amino acid sequence (SEQ ID NO:) of 108P5H8 v.1 is shown in Figure 2A. The start methionine is underlined. The open reading frame extends from nucleic acid 253-1542 including the stop codon. The nucleic acid and amino acid sequence of 108P5H8 variant 2 (SEQ ID NO:) is shown in Figure 2B, the codon for the start methionine is underlined. The open reading frame for variant 2 extends from nucleic acid 1 to 1290 including the stop codon. The nucleic acid and amino acid sequence of 108P5H8 variant 3 (SEQ ID NO:) is shown in Figure 2C, the codon for the start methionine is underlined. The open reading frame for variant 3 extends from nucleic acid 1-1290 including the stop codon.

Figure 3. Amino acid sequence of 108P5H8 variant 1 (SEQ ID NO:) and of 108P5H8 variant 2 (SEQ ID NO:) is shown in Figure 3A. The proteins encoded by the variant 1 and variant 2 nucleic acid sequences are identical and each have 429 amino acids. The amino acid sequence of

108P5H8 variant 3 (SEQ ID NO. 3) is shown in Figure 3B, the 108P5H8 v.3 protein has 429 amino acids.

Figure 4. Amino acid alignments of 108P5H8 variants 1-3.

Figure 5. Hydrophilicity amino acid profile of 108P5H8 determined by computer algorithm sequence analysis using the method of Hopp and Woods (Hopp T.P., Woods K.R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828) accessed on the ProtScale website (www.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.

Figure 6. Hydrophobicity amino acid profile of 108P5H8 determined by computer algorithm sequence analysis using the method of Kyte and Doolittle (Kyte J., Doolittle R.F., 1982. J. Mol. Biol. 157:105-132) accessed on the ProtScale website (www.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.

Figure 7. Percent accessible residues amino acid profile of 108P5H8 determined by computer algorithm sequence analysis using the method of Janin (Janin J., 1979 Nature 277:491-492) accessed on the ProtScale website (www.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.

Figure 8. Average flexibility amino acid profile of 108P5H8 determined by computer algorithm sequence analysis using the method of Bhaskaran and Ponnuswamy (Bhaskaran R., and Ponnuswamy P.K., 1988. Int. J. Pept. Protein Res. 32:242-255) accessed on the ProtScale website (www.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.

Figure 9. Beta-turn amino acid profile of 108P5H8 determined by computer algorithm sequence analysis using the method of Deleage and Roux (Deleage, G., Roux B. 1987 Protein Engineering 1:289-294) accessed on the ProtScale website (www.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.

Figure 10. Expression of 108P5H8 by RT-PCR. First strand cDNA was prepared from vital pool 1 (VP1: liver, lung and kidney), vital pool 2 (VP2, pancreas, colon and stomach), prostate xenograft pool (LAPC-4AD, LAPC-4AI, LAPC-9AD, LAPC-9AI), normal thymus, prostate cancer pool, bladder cancer pool, kidney cancer pool, colon cancer pool, lung cancer pool, ovary cancer pool, breast cancer pool, metastasis cancer pool, pancreas cancer pool, and from prostate cancer metastasis to lymph node from 2 different patients. Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR using primers to 108P5H8 was performed at 26 and 30 cycles of amplification. Strong expression of 108P5H8 was observed in prostate cancer xenograft pool, prostate cancer pool and in the 2 different prostate cancer metastasis samples. Lower expression was detected in bladder cancer pool, kidney cancer pool, colon cancer pool, lung cancer pool, ovary cancer pool, breast cancer pool, metastasis pool, pancreas cancer pool, VP1 and VP2.

Figure 11. Expression of 108P5H8 in normal human tissues and in prostate cancer xenografts. (A and B) Two multiple tissue Northern blots, with 2 mg of mRNA/lane, were probed with 108P5H8 sequence. Size standards in kilobases (kb) are indicated on the side. The results show strong expression of an approximately 7kb 108P5H8 transcript in prostate and lower expression in other tissues. (C) RNA was

extracted from normal prostate, and from prostate cancer xenografts, LAPC-4AD, LAPC-4AI, LAPC-9AD, and LAPC-9AI. Northern blot with 10 mg of total RNA/lane was probed with 108P5H8 sequence. Size standards in kilobases (kb) are indicated on the side. The results show expression of 108P5H8 in all 4 xenografts and in normal prostate.

Figure 12. Expression of 108P5H8 in prostate cancer xenografts. RNA was extracted from prostate cancer xenografts, LAPC-4AD, and LAPC-9AD, injected either subcutaneously (sc) or intra-tibially (it) within the mouse bone. LAPC-4 was also grown within a human bone implant in SCID mice (LAPC-4 AD2). Northern blots with 10 µg of total RNA/lane were probed with the 108P5H8 SSH fragment. Size standards in kilobases (kb) are indicated on the side. Results show expression of 108P5H8 in all prostate cancer xenograft tissues tested.

Figure 13. Expression of 108P5H8 in human cancer cell lines. RNA was extracted from a panel of human cancer cell lines. Northern blots with 10 mg of total RNA/lane were probed with the 108P5H8 SSH fragment. Size standards in kilobases (kb) are indicated on the side. Results show that 108P5H8 is expressed in all cell lines tested such as prostate, bladder, brain, lung, kidney, breast, testis and ovary cancer cell lines.

Figure 14. Expression of 108P5H8 in patient cancer specimens and cancer cell lines. Expression of 108P5H8 was assayed in a panel of human cancers (T) and their respective matched normal tissues (N) on RNA dot blots. 108P5H8 expression was seen in prostate, kidney, uterus and stomach cancers. The expression detected in some normal adjacent tissues (isolated from diseased tissues), but not in normal tissues (isolated from healthy donors), may indicate that these tissues are not fully normal and that 108P5H8 may be expressed in early stage tumors. 108P5H8 was also expressed in all 9 human cancer cell lines tested.

Figure 15. Expression of 108P5H8 in prostate cancer patient specimens. RNA was extracted from prostate tumors (T) and matched normal adjacent tissue (NAT) isolated from prostate cancer patients. Northern blots with 10 mg of total RNA/lane were probed with 108P5H8 sequence. Size standards in kilobases (kb) are indicated on the side. The results show expression of 108P5H8 in the two prostate tumors and in the normal matched tissues.

Figure 16. 108P5H8 is not Androgen-Regulated. LNCaP cells were grown in charcoal-stripped medium and stimulated with the synthetic androgen mibolerone, for either 14 or 24 hours. Northern blots with 10 mg of total RNA/lane were probed with either the 108P5H8 sequence (A), or with the androgen-regulated gene PSA (B). A picture of the ethidium-bromide staining of the RNA gel is also presented (C). Results show expression of 108P5H8 is not regulated by androgen. The experimental samples were confirmed by testing for the expression of the androgen-regulated prostate cancer gene PSA (B). This experiment shows that, as expected, PSA levels go down in presence of charcoal-stripped serum, and expression is induced at 14 and 24 hours in presence of the synthetic androgen.

Figure 17. Expression of 108P5H8 in cancer metastasis patient specimens. RNA was extracted from prostate cancer metastasis to lymph node obtained from two different patient, as well as from normal

bladder (NB), normal kidney (NK), normal lung (NL), normal breast (NBr), normal ovary (NO), and normal pancreas (NP). Northern blots with 10 mg of total RNA/lane were probed with 108P5H8 sequence. Size standards in kilobases (kb) are indicated on the side. The results show expression of 108P5H8 in both cancer metastasis samples but not in normal tissues.

Figure 18. Secondary structure and transmembrane prediction for 108P5H8. The secondary structure of 108P5H8 protein was predicted using the HNN - Hierarchical Neural Network method (Guermeur, 1997, http://pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_nn.html), accessed from the ExPasy molecular biology server (<http://www.expasy.ch/tools/>). This method predicts the presence and location of alpha helices, extended strands, and random coils from the primary protein sequence. The percent of the protein in a given secondary structure is also given.

Figure 19. Transmembrane prediction for 108P5H8. A. Schematic representation of the probability of existence of transmembrane regions and orientation of 108P5H8 based on the TMPred algorithm of Hofmann and Stoffel which utilizes TMBASE (K. Hofmann, W. Stoffel. TMBASE - A database of membrane spanning protein segments Biol. Chem. Hoppe-Seyler 374:166, 1993). B. Schematic representation of the probability of the existence of transmembrane regions and the extracellular and intracellular orientation of 108P5H8 based on the TMHMM algorithm of Sonnhammer, von Heijne, and Krogh (Erik L.L. Sonnhammer, Gunnar von Heijne, and Anders Krogh: A hidden Markov model for predicting transmembrane helices in protein sequences. In Proc. of Sixth Int. Conf. on Intelligent Systems for Molecular Biology, p 175-182 Ed J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, CA: AAAI Press, 1998). The TMPred and TMHMM algorithms are accessed from the ExPasy molecular biology server (<http://www.expasy.ch/tools/>). The results of the transmembrane prediction programs presented in A and B depict 108P5H8 as containing 6 transmembrane domains.

Figure 20. Androgen-independent expression of 108P5H8 in prostate cancer cells. Western analysis of the indicated cell lysates were carried out with a 1:2000 dilution of an anti-108P5H8 polyclonal antibody derived from immunization of a rabbit with a GST-fusion protein encoding amino acids 1-112 of 108P5H8. 108P5H8 specific bands were developed by incubation with an anti-rabbit HRP-conjugated secondary antibody and visualized by enhanced chemiluminescence and exposure to autoradiography film. Indicated with an arrow is the full length 108P5H8 protein. 293T cells overexpressing Myc His-tagged 108P5H8 serves as a positive control

Figure 21. Surface expression of 108P5H8 in prostate cancer cells. LNCaP and LAPC4 cells were subjected to flow cytometric and fluorescence microscopic analysis of 108P5H8 expression using an anti-108P5H8 polyclonal antibody or control rabbit IgG. Fluorescence was monitored following incubation with an FITC-conjugated anti-rabbit IgG secondary antibody

Figure 22. Surface expression of 108P5H8 in 293T cells. 293T cells were transfected with either empty control vector or with pCDNA 3.1 encoding the 108P5H8 cDNA and subjected to flow cytometry and fluorescence microscopy using an anti-108P5H8 polyclonal antibody (1:100 dilution). Fluorescence

was monitored following incubation with an FITC-conjugated anti-rabbit IgG secondary antibody. 293T-108P5H8 cells exhibited strong surface fluorescence.

Figure 23. Expression of 108P5H8 in prostate and ovarian cancer patient specimens. Lysates from tumor (PCa) and normal adjacent tissue (NAT) from 2 prostate cancer patients and from a prostate cancer metastasis and tumor and normal adjacent tissue from an ovarian cancer patient were subjected to Western analysis using anti-108P5H8 polyclonal antibody as described in figure 20. Indicated with an arrow is a 48 kD band representing full length 1-08P5H8. 108P5H8 protein was present in the tumor tissue from the 2 prostate cancer patients and the metastasis sample and in the normal adjacent tissue of 1 of the patients. 108P5H8 was also expressed in the ovarian cancer sample but not in normal ovary. Low expression is seen in RNA positive 293T cells and strong expression in the overexpressed 293T-108P5H8 cells.

Figure 24. Expression of 108P5H8 in engineered cell lines. PC3 human prostate cancer cells and NIH3T3 murine fibroblasts were engineered to stably express 108P5H8 through infection with retrovirus harboring the 108P5H8 cDNA. Stable lines were generated by G418 selection for neomycin resistance. 108P5H8 expression was verified by Western blot analysis with anti-108P5H8 polyclonal antibody as described in figure 20, using the respective cell lines expressing only the neomycin resistance gene as negative controls.

Figure 25. 108P5H8 protein variants show homology to human zinc transporter 4.

Figure 26. Detection of 108P5H8 protein by immunocytochemistry in LNCaP cells. Immunocytochemical staining of LNCaP cells (an androgen dependant prostate cancer cell line) showing expression of 108P5H8, which is not androgen regulated. LNCaP cell preparations were made from either cells grown in medium containing 10% fetal bovine serum (Panel A) or from cells grown for 72 hours in androgen free, serum depleted medium (by growing in charcoal dextran stripped medium) (Panel B) or from previously androgen starved cells which were subsequently stimulated with 10mmol mibolerone, a synthetic androgen, for 48 hours (Panel C). LNCaP cells incubated with Rabbit IgG instead of rabbit antibody to- 108P5H8 was included to show no non-specific binding of rabbit immunoglobulin to the cells (Panel D).

Figure 27. Detection of 108P5H8 protein by immunohistochemistry in prostate cancer patient specimens. Immunohistochemical staining of frozen sections of a prostate carcinoma specimen (Gleason grade 6) showing expression of 108P5H8 in the neoplastic glands (Panel A) and no non-specific binding of rabbit immunoglobulin in the Rabbit IgG control (Panel B).

Figure 28. Figures 28A & 28B show a vertical alignment comparison between nucleotide and amino acid sequences of the variants.

DETAILED DESCRIPTION OF THE INVENTION

Outline of Sections

I.) Definitions

- II.) 108P5H8 Polynucleotides
- II.A.) Uses of 108P5H8 Polynucleotides
- II.A.1.) Monitoring of Genetic Abnormalities
- II.A.2.) Antisense Embodiments
- II.A.3.) Primers and Primer Pairs
- II.A.4.) Isolation of 108P5H8-Encoding Nucleic Acid Molecules
- II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems
- III.) 108P5H8-related Proteins
- III.A.) Motif-bearing Protein Embodiments
- III.B.) Expression of 108P5H8-related Proteins
- III.C.) Modifications of 108P5H8-related Proteins
- III.D.) Uses of 108P5H8-related Proteins
- IV.) 108P5H8 Antibodies
- V.) 108P5H8 Cellular Immune Responses
- VI.) 108P5H8 Transgenic Animals
- VII.) Methods for the Detection of 108P5H8
- VIII.) Methods for Monitoring the Status of 108P5H8-related Genes and Their Products
- IX.) Identification of Molecules That Interact With 108P5H8
- X.) Therapeutic Methods and Compositions
- X.A.) Anti-Cancer Vaccines
- X.B.) 108P5H8 as a Target for Antibody-Based Therapy
- X.C.) 108P5H8 as a Target for Cellular Immune Responses
- X.C.1. Minigene Vaccines
- X.C.2. Combinations of CTL Peptides with Helper Peptides
- X.C.3. Combinations of CTL Peptides with T Cell Priming Agents
- X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL Peptides
- X.D.) Adoptive Immunotherapy
- X.E.) Administration of Vaccines for Therapeutic or Prophylactic Purposes
- XI.) Diagnostic and Prognostic Embodiments of 108P5H8.
- XII.) Inhibition of 108P5H8 Protein Function
- XII.A.) Inhibition of 108P5H8 With Intracellular Antibodies
- XII.B.) Inhibition of 108P5H8 with Recombinant Proteins
- XII.C.) Inhibition of 108P5H8 Transcription or Translation
- XII.D.) General Considerations for Therapeutic Strategies
- XIII.) KITS

I.) Definitions:

Unless otherwise defined, all terms of art, notations and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. Many of the techniques and procedures described or referenced herein are well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual 2nd. edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer defined protocols and/or parameters unless otherwise noted.

The terms "advanced prostate cancer", "locally advanced prostate cancer", "advanced disease" and "locally advanced disease" mean prostate cancers that have extended through the prostate capsule, and are meant to include stage C disease under the American Urological Association (AUA) system, stage C1 - C2 disease under the Whitmore-Jewett system, and stage T3 - T4 and N+ disease under the TNM (tumor, node, metastasis) system. In general, surgery is not recommended for patients with locally advanced disease, and these patients have substantially less favorable outcomes compared to patients having clinically localized (organ-confined) prostate cancer. Locally advanced disease is clinically identified by palpable evidence of induration beyond the lateral border of the prostate, or asymmetry or induration above the prostate base. Locally advanced prostate cancer is presently diagnosed pathologically following radical prostatectomy if the tumor invades or penetrates the prostatic capsule, extends into the surgical margin, or invades the seminal vesicles.

"Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence 108P5H8 (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence 108P5H8. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.

The term "analog" refers to a molecule which is structurally similar or shares similar or corresponding attributes with another molecule (e.g. a 108P5H8-related protein). For example an analog of a 108P5H8 protein can be specifically bound by an antibody or T cell that specifically binds to 108P5H8.

The term "antibody" is used in the broadest sense. Therefore an "antibody" can be naturally occurring or man-made such as monoclonal antibodies produced by conventional hybridoma technology. Anti-108P5H8 antibodies comprise monoclonal and polyclonal antibodies as well as fragments containing the antigen-binding domain and/or one or more complementarity determining regions of these antibodies.

An "antibody fragment" is defined as at least a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen-binding region. In one embodiment it specifically covers single anti-108P5H8 antibodies and clones thereof (including agonist, antagonist and neutralizing antibodies) and anti-108P5H8 antibody compositions with polypeptopic specificity.

The term "codon optimized sequences" refers to nucleotide sequences that have been optimized for a particular host species by replacing any codons having a usage frequency of less than about 20%. Nucleotide sequences that have been optimized for expression in a given host species by elimination of spurious polyadenylation sequences, elimination of exon/intron splicing signals, elimination of transposon-like repeats and/or optimization of GC content in addition to codon optimization are referred to herein as an "expression enhanced sequences."

The term "cytotoxic agent" refers to a substance that inhibits or prevents the expression activity of cells, function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof. Examples of cytotoxic agents include, but are not limited to maytansinoids, yttrium, bismuth, ricin, ricin A-chain, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, croton, calicheamicin, saponaria officinalis inhibitor, and glucocorticoid and other chemotherapeutic agents, as well as radioisotopes such as At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³² and radioactive isotopes of Lu. Antibodies may also be conjugated to an anti-cancer pro-drug activating enzyme capable of converting the pro-drug to its active form.

The term "homolog" refers to a molecule which exhibits homology to another molecule, by for example, having sequences of chemical residues that are the same or similar at corresponding positions.

"Human Leukocyte Antigen" or "HLA" is a human class I or class II Major Histocompatibility Complex (MHC) protein (*see, e.g., Stites, et al., IMMUNOLOGY*, 8TH ED., Lange Publishing, Los Altos, CA (1994)).

The terms "hybridize", "hybridizing", "hybridizes" and the like, used in the context of polynucleotides, are meant to refer to conventional hybridization conditions, preferably such as hybridization in 50% formamide/6XSSC/0.1% SDS/100 µg/ml ssDNA, in which temperatures for hybridization are above 37 degrees C and temperatures for washing in 0.1XSSC/0.1% SDS are above 55 degrees C.

The phrases "isolated" or "biologically pure" refer to material which is substantially or essentially free from components which normally accompany the material as it is found in its native state. Thus, isolated peptides in accordance with the invention preferably do not contain materials normally associated with the peptides in their *in situ* environment. For example, a polynucleotide is said to be "isolated" when it is substantially separated from contaminant polynucleotides that correspond or are complementary to genes

other than the 108P5H8 genes or that encode polypeptides other than 108P5H8 gene product or fragments thereof. A skilled artisan can readily employ nucleic acid isolation procedures to obtain an isolated 108P5H8 polynucleotide. A protein is said to be "isolated," for example, when physical, mechanical or chemical methods are employed to remove the 108P5H8 proteins from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated 108P5H8 protein. Alternatively, an isolated protein can be prepared by chemical means.

The term "mammal" refers to any organism classified as a mammal, including mice, rats, rabbits, dogs, cats, cows, horses and humans. In one embodiment of the invention, the mammal is a mouse. In another embodiment of the invention, the mammal is a human.

The terms "metastatic prostate cancer" and "metastatic disease" mean prostate cancers that have spread to regional lymph nodes or to distant sites, and are meant to include stage D disease under the AUA system and stage TxNxM+ under the TNM system. As is the case with locally advanced prostate cancer, surgery is generally not indicated for patients with metastatic disease, and hormonal (androgen ablation) therapy is a preferred treatment modality. Patients with metastatic prostate cancer eventually develop an androgen-refractory state within 12 to 18 months of treatment initiation. Approximately half of these androgen-refractory patients die within 6 months after developing that status. The most common site for prostate cancer metastasis is bone. Prostate cancer bone metastases are often osteoblastic rather than osteolytic (i.e., resulting in net bone formation). Bone metastases are found most frequently in the spine, followed by the femur, pelvis, rib cage, skull and humerus. Other common sites for metastasis include lymph nodes, lung, liver and brain. Metastatic prostate cancer is typically diagnosed by open or laparoscopic pelvic lymphadenectomy, whole body radionuclide scans, skeletal radiography, and/or bone lesion biopsy.

The term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the antibodies comprising the population are identical except for possible naturally occurring mutations that are present in minor amounts.

A "motif", as in biological motif of an 108P5H8-related protein, refers to any pattern of amino acids forming part of the primary sequence of a protein, that is associated with a particular function (e.g. protein-protein interaction, protein-DNA interaction, etc) or modification (e.g. that is phosphorylated, glycosylated or amidated), or localization (e.g. secretory sequence, nuclear localization sequence, etc.) or a sequence that is correlated with being immunogenic, either humorally or cellularly. A motif can be either contiguous or capable of being aligned to certain positions that are generally correlated with a certain function or property. In the context of HLA motifs, "motif" refers to the pattern of residues in a peptide of defined length, usually a peptide of from about 8 to about 13 amino acids for a class I HLA motif and from about 6 to about 25 amino acids for a class II HLA motif, which is recognized by a particular HLA molecule. Peptide motifs for HLA binding are typically different for each protein encoded by each human HLA allele and differ in the pattern of the primary and secondary anchor residues.

A "pharmaceutical excipient" comprises a material such as an adjuvant, a carrier, pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservative, and the like.

"Pharmaceutically acceptable" refers to a non-toxic, inert, and/or composition that is physiologically compatible with humans or other mammals.

The term "polynucleotide" means a polymeric form of nucleotides of at least 10 bases or base pairs in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, and is meant to include single and double stranded forms of DNA and/or RNA. In the art, this term is often used interchangeably with "oligonucleotide". A polynucleotide can comprise a nucleotide sequence disclosed herein wherein thymidine (T), as shown for example in Figure 2, can also be uracil (U); this definition pertains to the differences between the chemical structures of DNA and RNA, in particular the observation that one of the four major bases in RNA is uracil (U) instead of thymidine (T).

The term "polypeptide" means a polymer of at least about 4, 5, 6, 7, or 8 amino acids. Throughout the specification, standard three letter or single letter designations for amino acids are used. In the art, this term is often used interchangeably with "peptide" or "protein".

An HLA "primary anchor residue" is an amino acid at a specific position along a peptide sequence which is understood to provide a contact point between the immunogenic peptide and the HLA molecule. One to three, usually two, primary anchor residues within a peptide of defined length generally defines a "motif" for an immunogenic peptide. These residues are understood to fit in close contact with peptide binding groove of an HLA molecule, with their side chains buried in specific pockets of the binding groove. In one embodiment, for example, the primary anchor residues for an HLA class I molecule are located at position 2 (from the amino terminal position) and at the carboxyl terminal position of a 8, 9, 10, 11, or 12 residue peptide epitope in accordance with the invention. In another embodiment, for example, the primary anchor residues of a peptide that will bind an HLA class II molecule are spaced relative to each other, rather than to the termini of a peptide, where the peptide is generally of at least 9 amino acids in length. The primary anchor positions for each motif and supermotif are set forth in Table IV. For example, analog peptides can be created by altering the presence or absence of particular residues in the primary and/or secondary anchor positions shown in Table IV. Such analogs are used to modulate the binding affinity and/or population coverage of a peptide comprising a particular HLA motif or supermotif.

A "recombinant" DNA or RNA molecule is a DNA or RNA molecule that has been subjected to molecular manipulation *in vitro*.

Non-limiting examples of small molecules include compounds that bind or interact with 108P5H8, ligands including hormones, neuropeptides, chemokines, odorants, phospholipids, and functional equivalents thereof that bind and preferably inhibit 108P5H8 protein function. Such non-limiting small molecules preferably have a molecular weight of less than about 10 kDa, more preferably below about 9, about 8, about 7, about 6, about 5 or about 4 kDa. In certain embodiments, small molecules physically associate with, or bind, 108P5H8 protein; are not found in naturally occurring metabolic pathways; and/or are more soluble in aqueous than non-aqueous solutions

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured nucleic acid sequences to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature that can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel *et al.*, Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, are identified by, but not limited to, those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42 °C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42 °C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55 °C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55 °C. "Moderately stringent conditions" are described by, but not limited to, those in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

An HLA "supermotif" is a peptide binding specificity shared by HLA molecules encoded by two or more HLA alleles.

As used herein "to treat" or "therapeutic" and grammatically related terms, refer to any improvement of any consequence of disease, such as prolonged survival, less morbidity, and/or a lessening of side effects which are the byproducts of an alternative therapeutic modality; full eradication of disease is not required.

A "transgenic animal" (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an

embryonic stage. A "transgene" is a DNA that is integrated into the genome of a cell from which a transgenic animal develops.

As used herein, an HLA or cellular immune response "vaccine" is a composition that contains or encodes one or more peptides of the invention. There are numerous embodiments of such vaccines, such as a cocktail of one or more individual peptides; one or more peptides of the invention comprised by a polypeptopic peptide; or nucleic acids that encode such individual peptides or polypeptides, *e.g.*, a minigene that encodes a polypeptopic peptide. The "one or more peptides" can include any whole unit integer from 1-150 or more, *e.g.*, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 or more peptides of the invention. The peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences. HLA class I peptides of the invention can be admixed with, or linked to, HLA class II peptides, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes. HLA vaccines can also comprise peptide-pulsed antigen presenting cells, *e.g.*, dendritic cells.

The term "variant" refers to a molecule that exhibits a variation from a described type or norm, such as a protein that has one or more different amino acid residues in the corresponding position(s) of a specifically described protein (*e.g.* the 108P5H8 protein shown in Figure 2 or Figure 3. An analog is an example of a variant protein. Splice isoforms and single nucleotides polymorphisms (SNPs) are further examples of variants.

The "108P5H8-related proteins" of the invention include those specifically identified herein, as well as allelic variants, conservative substitution variants, analogs and homologs that can be isolated/generated and characterized without undue experimentation following the methods outlined herein or readily available in the art. Fusion proteins that combine parts of different 108P5H8 proteins or fragments thereof, as well as fusion proteins of a 108P5H8 protein and a heterologous polypeptide are also included. Such 108P5H8 proteins are collectively referred to as the 108P5H8-related proteins, the proteins of the invention, or 108P5H8. The term "108P5H8-related protein" refers to a polypeptide fragment or an 108P5H8 protein sequence of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more than 25 amino acids; or, at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100 or more than 100 amino acids.

II.) 108P5H8 Polynucleotides

One aspect of the invention provides polynucleotides corresponding or complementary to all or part of an 108P5H8 gene, mRNA, and/or coding sequence, preferably in isolated form, including polynucleotides encoding an 108P5H8-related protein and fragments thereof, DNA, RNA, DNA/RNA hybrid, and related molecules, polynucleotides or oligonucleotides complementary to an 108P5H8 gene or mRNA sequence or a part thereof, and polynucleotides or oligonucleotides that hybridize to an 108P5H8 gene, mRNA, or to an 108P5H8 encoding polynucleotide (collectively, "108P5H8 polynucleotides"). In all instances when referred to in this section, T can also be U in Figure 2.

Embodiments of a 108P5H8 polynucleotide include: a 108P5H8 polynucleotide having the sequence shown in Figure 2, the nucleotide sequence of 108P5H8 as shown in Figure 2 wherein T is U; at

least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in Figure 2; or, at least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in Figure 2 where T is U. For example, embodiments of 108P5H8 nucleotides comprise, without limitation:

(I) ~~(I)~~ a polynucleotide comprising, consisting essentially of, or consisting of a sequence as shown in Figure 2 (SEQ ID Nos.: 2569, 2571, & 2573), wherein T can also be U;

(II) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in Figure 2A (SEQ ID NO.: 2569), from nucleotide residue number 253 through nucleotide residue number 1542, wherein T can also be U;

(III) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in Figure 2B (SEQ ID NO.: 2571), from nucleotide residue number 1 through nucleotide residue number 1290, wherein T can also be U;

(IV) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in Figure 2C (SEQ ID NO.: 2573), from nucleotide residue number 1 through nucleotide residue number 1290, wherein T can also be U;

(V) a polynucleotide that encodes an 108P5H8-related protein that is at least 90% homologous to an entire amino acid sequence shown in Figure 2A-C (SEQ ID Nos.: 2570, 2572, & 2574);

(VI) a polynucleotide that encodes an 108P5H8-related protein that is at least 90% identical to an entire amino acid sequence shown in Figure 2A-C (SEQ ID Nos.: 2570, 2572, & 2574);

(VII) a polynucleotide that encodes at least one peptide set forth in Tables V-XVIII, XXII, and XXIII;

(VIII) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of Figure 3A or 3B in any whole number increment up to 429 that includes an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of Figure 5;

(IX) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of Figure 3A or 3B in any whole number increment up to 429 that includes an amino acid position having a value less than 0.5 in the Hydrophobicity profile of Figure 6;

- (X) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of Figure 3A or 3B in any whole number increment up to 429 that includes an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of Figure 7;
- (XI) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of Figure 3A or 3B in any whole number increment up to 429 that includes an amino acid position having a value greater than 0.5 in the Average Flexibility profile on Figure 8;
- (XII) a polynucleotide that encodes a peptide region of at least 5 amino acids of a peptide of Figure 3A or 3B in any whole number increment up to 429 that includes an amino acid position having a value greater than 0.5 in the Beta-turn profile of Figure 9;
- (XIII) a polynucleotide that encodes a 108P5H8-related protein whose sequence is encoded by the cDNAs contained in the plasmid designated p108P5H8-C deposited with American Type Culture Collection as Accession No. PTA-2198;
- (XIV) a polynucleotide that is fully complementary to a polynucleotide of any one of (I)-(XIII);
- (XV) a polynucleotide that selectively hybridizes under stringent conditions to a polynucleotide of (I)-(XIV);
- (XVI) a peptide that is encoded by any of (I)-(XIII); and,
- (XLII) a polynucleotide of any of (I)-(XV) or peptide of (XVI) together with a pharmaceutical excipient and/or in a human unit dose form.

As used herein, a range is understood to specifically disclose all whole unit positions thereof.

Typical embodiments of the invention disclosed herein include 108P5H8 polynucleotides that encode specific portions of 108P5H8 mRNA sequences (and those which are complementary to such sequences) such as those that encode the proteins and/or fragments thereof, for example:

4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 250, 275, 300, 325, 350, 375, 400, 425, or 429 contiguous amino acids of variants 1, 2 or 3.

For example, representative embodiments of the invention disclosed herein include: polynucleotides and their encoded peptides themselves encoding about amino acid 1 to about amino acid 10 of the 108P5H8 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 10 to about amino acid 20 of the 108P5H8 protein shown in Figure 2, or Figure 3, polynucleotides encoding about amino acid 20 to about amino acid 30 of the 108P5H8 protein shown in Figure 2 or Figure 3,

polynucleotides encoding about amino acid 30 to about amino acid 40 of the 108P5H8 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 40 to about amino acid 50 of the 108P5H8 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 50 to about amino acid 60 of the 108P5H8 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 60 to about amino acid 70 of the 108P5H8 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 70 to about amino acid 80 of the 108P5H8 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 80 to about amino acid 90 of the 108P5H8 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 90 to about amino acid 100 of the 108P5H8 protein shown in Figure 2 or Figure 3, in increments of about 10 amino acids, ending at the carboxyl terminal amino acid set forth in Figure 2 or Figure 3. Accordingly polynucleotides encoding portions of the amino acid sequence (of about 10 amino acids), of amino acids 100 through the carboxyl terminal amino acid of the 108P5H8 protein are embodiments of the invention. Wherein it is understood that each particular amino acid position discloses that position plus or minus five amino acid residues.

Polynucleotides encoding relatively long portions of a 108P5H8 protein are also within the scope of the invention. For example, polynucleotides encoding from about amino acid 1 (or 20 or 30 or 40 etc.) to about amino acid 20, (or 30, or 40 or 50 etc.) of the 108P5H8 protein shown in Figure 2 or Figure 3 can be generated by a variety of techniques well known in the art. These polynucleotide fragments can include any portion of the 108P5H8 sequence as shown in Figure 2.

Additional illustrative embodiments of the invention disclosed herein include 108P5H8 polynucleotide fragments encoding one or more of the biological motifs contained within a 108P5H8 protein sequence, including one or more of the motif-bearing subsequences of a 108P5H8 protein set forth in Tables V-XVIII, XXII, and XXIII. In another embodiment, typical polynucleotide fragments of the invention encode one or more of the regions of 108P5H8 that exhibit homology to a known molecule. In another embodiment of the invention, typical polynucleotide fragments can encode one or more of the 108P5H8 N-glycosylation sites, cAMP and cGMP-dependent protein kinase phosphorylation sites, casein kinase II phosphorylation sites or N-myristoylation site and amidation sites.

II.A.) Uses of 108P5H8 Polynucleotides

II.A.1.) Monitoring of Genetic Abnormalities

The polynucleotides of the preceding paragraphs have a number of different specific uses. The human 108P5H8 gene maps to the chromosomal location set forth in Example 3. For example, because the 108P5H8 gene maps to this chromosome, polynucleotides that encode different regions of the 108P5H8 proteins are used to characterize cytogenetic abnormalities of this chromosomal locale, such as abnormalities that are identified as being associated with various cancers. In certain genes, a variety of chromosomal abnormalities including rearrangements have been identified as frequent cytogenetic abnormalities in a number of different cancers (see e.g. Krajnovic *et al.*, *Mutat. Res.* 382(3-4): 81-83 (1998); Johansson *et al.*, *Blood* 86(10): 3905-3914 (1995) and Finger *et al.*, *P.N.A.S.* 85(23): 9158-9162

(1988)). Thus, polynucleotides encoding specific regions of the 108P5H8 proteins provide new tools that can be used to delineate, with greater precision than previously possible, cytogenetic abnormalities in the chromosomal region that encodes 108P5H8 that may contribute to the malignant phenotype. In this context, these polynucleotides satisfy a need in the art for expanding the sensitivity of chromosomal screening in order to identify more subtle and less common chromosomal abnormalities (see e.g. Evans *et al.*, Am. J. Obstet. Gynecol 171(4): 1055-1057 (1994)).

Furthermore, as 108P5H8 was shown to be highly expressed in bladder and other cancers, 108P5H8 polynucleotides are used in methods assessing the status of 108P5H8 gene products in normal versus cancerous tissues. Typically, polynucleotides that encode specific regions of the 108P5H8 proteins are used to assess the presence of perturbations (such as deletions, insertions, point mutations, or alterations resulting in a loss of an antigen etc.) in specific regions of the 108P5H8 gene, such as regions containing one or more motifs. Exemplary assays include both RT-PCR assays as well as single-strand conformation polymorphism (SSCP) analysis (see, e.g., Marrogi *et al.*, J. Cutan. Pathol. 26(8): 369-378 (1999), both of which utilize polynucleotides encoding specific regions of a protein to examine these regions within the protein.

II.A.2.) Antisense Embodiments

Other specifically contemplated nucleic acid related embodiments of the invention disclosed herein are genomic DNA, cDNAs, ribozymes, and antisense molecules, as well as nucleic acid molecules based on an alternative backbone, or including alternative bases, whether derived from natural sources or synthesized, and include molecules capable of inhibiting the RNA or protein expression of 108P5H8. For example, antisense molecules can be RNAs or other molecules, including peptide nucleic acids (PNAs) or non-nucleic acid molecules such as phosphorothioate derivatives, that specifically bind DNA or RNA in a base pair-dependent manner. A skilled artisan can readily obtain these classes of nucleic acid molecules using the 108P5H8 polynucleotides and polynucleotide sequences disclosed herein.

Antisense technology entails the administration of exogenous oligonucleotides that bind to a target polynucleotide located within the cells. The term "antisense" refers to the fact that such oligonucleotides are complementary to their intracellular targets, e.g., 108P5H8. See for example, Jack Cohen, Oligodeoxynucleotides, Antisense Inhibitors of Gene Expression, CRC Press, 1989; and Synthesis 1:1-5 (1988). The 108P5H8 antisense oligonucleotides of the present invention include derivatives such as S-oligonucleotides (phosphorothioate derivatives or S-oligos, see, Jack Cohen, *supra*), which exhibit enhanced cancer cell growth inhibitory action. S-oligos (nucleoside phosphorothioates) are isoelectronic analogs of an oligonucleotide (O-oligo) in which a nonbridging oxygen atom of the phosphate group is replaced by a sulfur atom. The S-oligos of the present invention can be prepared by treatment of the corresponding O-oligos with 3H-1,2-benzodithiol-3-one-1,1-dioxide, which is a sulfur transfer reagent. See, e.g., Iyer, R. P. *et al.*, J. Org. Chem. 55:4693-4698 (1990); and Iyer, R. P. *et al.*, J. Am. Chem. Soc. 112:1253-1254 (1990). Additional 108P5H8 antisense oligonucleotides of the present invention include

morpholino antisense oligonucleotides known in the art (see, e.g., Partridge *et al.*, 1996, *Antisense & Nucleic Acid Drug Development* 6: 169-175).

The 108P5H8 antisense oligonucleotides of the present invention typically can be RNA or DNA that is complementary to and stably hybridizes with the first 100 5' codons or last 100 3' codons of a 108P5H8 genomic sequence or the corresponding mRNA. Absolute complementarity is not required, although high degrees of complementarity are preferred. Use of an oligonucleotide complementary to this region allows for the selective hybridization to 108P5H8 mRNA and not to mRNA specifying other regulatory subunits of protein kinase. In one embodiment, 108P5H8 antisense oligonucleotides of the present invention are 15 to 30-mer fragments of the antisense DNA molecule that have a sequence that hybridizes to 108P5H8 mRNA. Optionally, 108P5H8 antisense oligonucleotide is a 30-mer oligonucleotide that is complementary to a region in the first 10 5' codons or last 10 3' codons of 108P5H8. Alternatively, the antisense molecules are modified to employ ribozymes in the inhibition of 108P5H8 expression, see, e.g., L. A. Couture & D. T. Stinchcomb; *Trends Genet* 12: 510-515 (1996).

II.A.3.) Primers and Primer Pairs

Further specific embodiments of this nucleotides of the invention include primers and primer pairs, which allow the specific amplification of polynucleotides of the invention or of any specific parts thereof, and probes that selectively or specifically hybridize to nucleic acid molecules of the invention or to any part thereof. Probes can be labeled with a detectable marker, such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator or enzyme. Such probes and primers are used to detect the presence of a 108P5H8 polynucleotide in a sample and as a means for detecting a cell expressing a 108P5H8 protein.

Examples of such probes include polypeptides comprising all or part of the human 108P5H8 cDNA sequence shown in Figure 2. Examples of primer pairs capable of specifically amplifying 108P5H8 mRNAs are also described in the Examples. As will be understood by the skilled artisan, a great many different primers and probes can be prepared based on the sequences provided herein and used effectively to amplify and/or detect a 108P5H8 mRNA.

The 108P5H8 polynucleotides of the invention are useful for a variety of purposes, including but not limited to their use as probes and primers for the amplification and/or detection of the 108P5H8 gene(s), mRNA(s), or fragments thereof; as reagents for the diagnosis and/or prognosis of prostate cancer and other cancers; as coding sequences capable of directing the expression of 108P5H8 polypeptides; as tools for modulating or inhibiting the expression of the 108P5H8 gene(s) and/or translation of the 108P5H8 transcript(s); and as therapeutic agents.

The present invention includes the use of any probe as described herein to identify and isolate a 108P5H8 or 108P5H8 related nucleic acid sequence from a naturally occurring source, such as humans or other mammals, as well as the isolated nucleic acid sequence *per se*, which would comprise all or most of the sequences found in the probe used.

II.A.4.) Isolation of 108P5H8-Encoding Nucleic Acid Molecules

The 108P5H8 cDNA sequences described herein enable the isolation of other polynucleotides encoding 108P5H8 gene product(s), as well as the isolation of polynucleotides encoding 108P5H8 gene product homologs, alternatively spliced isoforms, allelic variants, and mutant forms of a 108P5H8 gene product as well as polynucleotides that encode analogs of 108P5H8-related proteins. Various molecular cloning methods that can be employed to isolate full length cDNAs encoding an 108P5H8 gene are well known (see, for example, Sambrook, J. *et al.*, Molecular Cloning: A Laboratory Manual, 2d edition, Cold Spring Harbor Press, New York, 1989; Current Protocols in Molecular Biology. Ausubel *et al.*, Eds., Wiley and Sons, 1995). For example, lambda phage cloning methodologies can be conveniently employed, using commercially available cloning systems (e.g., Lambda ZAP Express, Stratagene). Phage clones containing 108P5H8 gene cDNAs can be identified by probing with a labeled 108P5H8 cDNA or a fragment thereof. For example, in one embodiment, a 108P5H8 cDNA (e.g., Figure 2) or a portion thereof can be synthesized and used as a probe to retrieve overlapping and full-length cDNAs corresponding to a 108P5H8 gene. A 108P5H8 gene itself can be isolated by screening genomic DNA libraries, bacterial artificial chromosome libraries (BACs), yeast artificial chromosome libraries (YACs), and the like, with 108P5H8 DNA probes or primers.

II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems

The invention also provides recombinant DNA or RNA molecules containing an 108P5H8 polynucleotide, a fragment, analog or homologue thereof, including but not limited to phages, plasmids, phagemids, cosmids, YACs, BACs, as well as various viral and non-viral vectors well known in the art, and cells transformed or transfected with such recombinant DNA or RNA molecules. Methods for generating such molecules are well known (see, for example, Sambrook *et al.*, 1989, *supra*).

The invention further provides a host-vector system comprising a recombinant DNA molecule containing a 108P5H8 polynucleotide, fragment, analog or homologue thereof within a suitable prokaryotic or eukaryotic host cell. Examples of suitable eukaryotic host cells include a yeast cell, a plant cell, or an animal cell, such as a mammalian cell or an insect cell (e.g., a baculovirus-infectible cell such as an Sf9 or HighFive cell). Examples of suitable mammalian cells include various prostate cancer cell lines such as DU145 and TsuPr1, other transfectable or transducible prostate cancer cell lines, primary cells (PrEC), as well as a number of mammalian cells routinely used for the expression of recombinant proteins (e.g., COS, CHO, 293, 293T cells). More particularly, a polynucleotide comprising the coding sequence of 108P5H8 or a fragment, analog or homolog thereof can be used to generate 108P5H8 proteins or fragments thereof using any number of host-vector systems routinely used and widely known in the art.

A wide range of host-vector systems suitable for the expression of 108P5H8 proteins or fragments thereof are available, see for example, Sambrook *et al.*, 1989, *supra*; Current Protocols in Molecular Biology, 1995, *supra*). Preferred vectors for mammalian expression include but are not limited to pcDNA 3.1 myc-His-tag (Invitrogen) and the retroviral vector pSR α tkneo (Muller *et al.*, 1991, MCB 11:1785). Using these expression vectors, 108P5H8 can be expressed in several prostate cancer and non-prostate cell lines, including for example 293, 293T, rat-1, NIH 3T3 and TsuPr1. The host-vector systems of the invention are

useful for the production of a 108P5H8 protein or fragment thereof. Such host-vector systems can be employed to study the functional properties of 108P5H8 and 108P5H8 mutations or analogs.

Recombinant human 108P5H8 protein or an analog or homolog or fragment thereof can be produced by mammalian cells transfected with a construct encoding a 108P5H8-related nucleotide. For example, 293T cells can be transfected with an expression plasmid encoding 108P5H8 or fragment, analog or homolog thereof, a 108P5H8-related protein is expressed in the 293T cells, and the recombinant 108P5H8 protein is isolated using standard purification methods (e.g., affinity purification using anti-108P5H8 antibodies). In another embodiment, a 108P5H8 coding sequence is subcloned into the retroviral vector pSR α MSVtkneo and used to infect various mammalian cell lines, such as NIH 3T3, TsuPr1, 293 and rat-1 in order to establish 108P5H8 expressing cell lines. Various other expression systems well known in the art can also be employed. Expression constructs encoding a leader peptide joined in frame to a 108P5H8 coding sequence can be used for the generation of a secreted form of recombinant 108P5H8 protein.

As discussed herein, redundancy in the genetic code permits variation in 108P5H8 gene sequences. In particular, it is known in the art that specific host species often have specific codon preferences, and thus one can adapt the disclosed sequence as preferred for a desired host. For example, preferred analog codon sequences typically have rare codons (i.e., codons having a usage frequency of less than about 20% in known sequences of the desired host) replaced with higher frequency codons. Codon preferences for a specific species are calculated, for example, by utilizing codon usage tables available on the INTERNET such as at URL www.dna.affrc.go.jp/~nakamura/codon.html.

Additional sequence modifications are known to enhance protein expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon/intron splice site signals, transposon-like repeats, and/or other such well-characterized sequences that are deleterious to gene expression. The GC content of the sequence is adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. Where possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures. Other useful modifications include the addition of a translational initiation consensus sequence at the start of the open reading frame, as described in Kozak, *Mol. Cell Biol.*, 9:5073-5080 (1989). Skilled artisans understand that the general rule that eukaryotic ribosomes initiate translation exclusively at the 5' proximal AUG codon is abrogated only under rare conditions (see, e.g., Kozak PNAS 92(7): 2662-2666, (1995) and Kozak NAR 15(20): 8125-8148 (1987)).

III.) 108P5H8-related Proteins

Another aspect of the present invention provides 108P5H8-related proteins. Specific embodiments of 108P5H8 proteins comprise a polypeptide having all or part of the amino acid sequence of human 108P5H8 as shown in Figure 2 or Figure 3. Alternatively, embodiments of 108P5H8 proteins

comprise variant, homolog or analog polypeptides that have alterations in the amino acid sequence of 108P5H8 shown in Figure 2 or Figure 3.

In general, naturally occurring allelic variants of human 108P5H8 share a high degree of structural identity and homology (e.g., 90% or more homology). Typically, allelic variants of a 108P5H8 protein contain conservative amino acid substitutions within the 108P5H8 sequences described herein or contain a substitution of an amino acid from a corresponding position in a homologue of 108P5H8. One class of 108P5H8 allelic variants are proteins that share a high degree of homology with at least a small region of a particular 108P5H8 amino acid sequence, but further contain a radical departure from the sequence, such as a non-conservative substitution, truncation, insertion or frame shift. In comparisons of protein sequences, the terms, similarity, identity, and homology each have a distinct meaning as appreciated in the field of genetics. Moreover, orthology and paralogy can be important concepts describing the relationship of members of a given protein family in one organism to the members of the same family in other organisms.

Amino acid abbreviations are provided in Table II. Conservative amino acid substitutions can frequently be made in a protein without altering either the conformation or the function of the protein. Proteins of the invention can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 conservative substitutions. Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these hydrophobic amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa. Other substitutions can also be considered conservative, depending on the environment of the particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) can frequently be interchangeable, as can alanine (A) and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing pK's of these two amino acid residues are not significant. Still other changes can be considered "conservative" in particular environments (see, e.g. Table III herein; pages 13-15 "Biochemistry" 2nd ED. Lubert Stryer ed (Stanford University); Henikoff *et al.*, PNAS 1992 Vol 89 10915-10919; Lei *et al.*, J Biol Chem 1995 May 19; 270(20):11882-6).

Embodiments of the invention disclosed herein include a wide variety of art-accepted variants or analogs of 108P5H8 proteins such as polypeptides having amino acid insertions, deletions and substitutions. 108P5H8 variants can be made using methods known in the art such as site-directed mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis (Carter *et al.*, *Nucl. Acids Res.*, 13:4331 (1986); Zoller *et al.*, *Nucl. Acids Res.*, 10:6487 (1987)), cassette mutagenesis (Wells *et al.*, *Gene*, 34:315 (1985)), restriction selection mutagenesis (Wells *et al.*, *Philos. Trans. R. Soc. London SerA*, 317:415 (1986)) or other known techniques can be performed on the cloned DNA to produce the 108P5H8 variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence that is involved in a specific biological activity such as a protein-protein interaction.

Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions (Creighton, *The Proteins*, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)). If alanine substitution does not yield adequate amounts of variant, an isosteric amino acid can be used.

As defined herein, 108P5H8 variants, analogs or homologs, have the distinguishing attribute of having at least one epitope that is "cross reactive" with a 108P5H8 protein having an amino acid sequence of Figure 3. As used in this sentence, "cross reactive" means that an antibody or T cell that specifically binds to an 108P5H8 variant also specifically binds to a 108P5H8 protein having an amino acid sequence set forth in Figure 3. A polypeptide ceases to be a variant of a protein shown in Figure 3, when it no longer contains any epitope capable of being recognized by an antibody or T cell that specifically binds to the starting 108P5H8 protein. Those skilled in the art understand that antibodies that recognize proteins bind to epitopes of varying size, and a grouping of the order of about four or five amino acids, contiguous or not, is regarded as a typical number of amino acids in a minimal epitope. See, e.g., Nair *et al.*, J. Immunol 2000 165(12): 6949-6955; Hebbes *et al.*, Mol Immunol (1989) 26(9):865-73; Schwartz *et al.*, J Immunol (1985) 135(4):2598-608.

Other classes of 108P5H8-related protein variants share 70%, 75%, 80%, 85% or 90% or more similarity with an amino acid sequence of Figure 3, or a fragment thereof. Another specific class of 108P5H8 protein variants or analogs comprise one or more of the 108P5H8 biological motifs described herein or presently known in the art. Thus, encompassed by the present invention are analogs of 108P5H8 fragments (nucleic or amino acid) that have altered functional (e.g. immunogenic) properties relative to the starting fragment. It is to be appreciated that motifs now or which become part of the art are to be applied to the nucleic or amino acid sequences of Figure 2 or Figure 3.

As discussed herein, embodiments of the claimed invention include polypeptides containing less than the full amino acid sequence of a 108P5H8 protein shown in Figure 2 or Figure 3. For example, representative embodiments of the invention comprise peptides/proteins having any 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids of a 108P5H8 protein shown in Figure 2 or Figure 3.

Moreover, representative embodiments of the invention disclosed herein include polypeptides consisting of about amino acid 1 to about amino acid 10 of a 108P5H8 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 10 to about amino acid 20 of a 108P5H8 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 20 to about amino acid 30 of a 108P5H8 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 30 to about amino acid 40 of a 108P5H8 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 40 to about amino acid 50 of a 108P5H8 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 50 to about amino acid 60 of a 108P5H8 protein shown in Figure 2 or Figure 3, polypeptides

consisting of about amino acid 60 to about amino acid 70 of a 108P5H8 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 70 to about amino acid 80 of a 108P5H8 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 80 to about amino acid 90 of a 108P5H8 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 90 to about amino acid 100 of a 108P5H8 protein shown in Figure 2 or Figure 3, etc. throughout the entirety of a 108P5H8 amino acid sequence. Moreover, polypeptides consisting of about amino acid 1 (or 20 or 30 or 40 etc.) to about amino acid 20, (or 130, or 140 or 150 etc.) of a 108P5H8 protein shown in Figure 2 or Figure 3 are embodiments of the invention. It is to be appreciated that the starting and stopping positions in this paragraph refer to the specified position as well as that position plus or minus 5 residues.

108P5H8-related proteins are generated using standard peptide synthesis technology or using chemical cleavage methods well known in the art. Alternatively, recombinant methods can be used to generate nucleic acid molecules that encode a 108P5H8-related protein. In one embodiment, nucleic acid molecules provide a means to generate defined fragments of a 108P5H8 protein (or variants, homologs or analogs thereof).

III.A.) Motif-bearing Protein Embodiments

Additional illustrative embodiments of the invention disclosed herein include 108P5H8 polypeptides comprising the amino acid residues of one or more of the biological motifs contained within a 108P5H8 polypeptide sequence set forth in Figure 2 or Figure 3. Various motifs are known in the art, and a protein can be evaluated for the presence of such motifs by a number of publicly available Internet sites (see, e.g., URL addresses: pfam.wustl.edu/; http://searchlauncher.bcm.tmc.edu/seq-search/struct-predict.html; psort.ims.u-tokyo.ac.jp/; www.cbs.dtu.dk/; www.ebi.ac.uk/interpro/scan.html; www.expasy.ch/tools/scnpsit1.html; Epimatrix™ and Epimer™, Brown University, www.brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html; and BIMAS, bimas.dcrf.nih.gov/).

Motif bearing subsequences of all 108P5H8 variant proteins are set forth and identified in Table XIX.

Table XX sets forth several frequently occurring motifs based on pfam searches (see URL address pfam.wustl.edu/). The columns of Table XX list (1) motif name abbreviation, (2) percent identity found amongst the different member of the motif family, (3) motif name or description and (4) most common function; location information is included if the motif is relevant for location.

Polypeptides comprising one or more of the 108P5H8 motifs discussed above are useful in elucidating the specific characteristics of a malignant phenotype in view of the observation that the 108P5H8 motifs discussed above are associated with growth dysregulation and because 108P5H8 is overexpressed in certain cancers (See, e.g., Table I). Casein kinase II, cAMP and camp-dependent protein kinase, and Protein Kinase C, for example, are enzymes known to be associated with the development of the malignant phenotype (see e.g. Chen *et al.*, Lab Invest., 78(2): 165-174 (1998); Gaiddon *et al.*, Endocrinology 136(10): 4331-4338 (1995); Hall *et al.*, Nucleic Acids Research 24(6): 1119-1126 (1996); Peterziel *et al.*, Oncogene 18(46): 6322-6329 (1999) and O'Brian, Oncol. Rep. 5(2): 305-309 (1998)).

Moreover, both glycosylation and myristoylation are protein modifications also associated with cancer and cancer progression (see e.g. Dennis *et al.*, Biochem. Biophys. Acta 1473(1):21-34 (1999); Raju *et al.*, Exp. Cell Res. 235(1): 145-154 (1997)). Amidation is another protein modification also associated with cancer and cancer progression (see e.g. Treston *et al.*, J. Natl. Cancer Inst. Monogr. (13): 169-175 (1992)).

In another embodiment, proteins of the invention comprise one or more of the immunoreactive epitopes identified in accordance with art-accepted methods, such as the peptides set forth in Tables V-XVIII, XXII, and XXIII. CTL epitopes can be determined using specific algorithms to identify peptides within an I08P5H8 protein that are capable of optimally binding to specified HLA alleles (e.g., Table IV; Epimatrix™ and Epimer™, Brown University, URL www.brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html; and BIMAS, URL bimas.dcrt.nih.gov/.) Moreover, processes for identifying peptides that have sufficient binding affinity for HLA molecules and which are correlated with being immunogenic epitopes, are well known in the art, and are carried out without undue experimentation. In addition, processes for identifying peptides that are immunogenic epitopes, are well known in the art, and are carried out without undue experimentation either *in vitro* or *in vivo*.

Also known in the art are principles for creating analogs of such epitopes in order to modulate immunogenicity. For example, one begins with an epitope that bears a CTL or HTL motif (see, e.g., the HLA Class I and HLA Class II motifs/supermotifs of Table IV). The epitope is analogized by substituting out an amino acid at one of the specified positions, and replacing it with another amino acid specified for that position. For example, one can substitute out a deleterious residue in favor of any other residue, such as a preferred residue as defined in Table IV; substitute a less-preferred residue with a preferred residue as defined in Table IV; or substitute an originally-occurring preferred residue with another preferred residue as defined in Table IV. Substitutions can occur at primary anchor positions or at other positions in a peptide; see, e.g., Table IV.

A variety of references reflect the art regarding the identification and generation of epitopes in a protein of interest as well as analogs thereof. See, for example, WO 9733602 to Chesnut *et al.*; Sette, Immunogenetics 1999 50(3-4): 201-212; Sette *et al.*, J. Immunol. 2001 166(2): 1389-1397; Sidney *et al.*, Hum. Immunol. 1997 58(1): 12-20; Kondo *et al.*, Immunogenetics 1997 45(4): 249-258; Sidney *et al.*, J. Immunol. 1996 157(8): 3480-90; and Falk *et al.*, Nature 351: 290-6 (1991); Hunt *et al.*, Science 255:1261-3 (1992); Parker *et al.*, J. Immunol. 149:3580-7 (1992); Parker *et al.*, J. Immunol. 152:163-75 (1994); Kast *et al.*, 1994 152(8): 3904-12; Borrás-Cuesta *et al.*, Hum. Immunol. 2000 61(3): 266-278; Alexander *et al.*, J. Immunol. 2000 164(3): 1625-1633; Alexander *et al.*, PMID: 7895164, UI: 95202582; O'Sullivan *et al.*, J. Immunol. 1991 147(8): 2663-2669; Alexander *et al.*, Immunity 1994 1(9): 751-761 and Alexander *et al.*, Immunol. Res. 1998 18(2): 79-92.

Related embodiments of the inventions include polypeptides comprising combinations of the different motifs set forth in Table XIX, and/or, one or more of the predicted CTL epitopes of Tables V-XVIII, Table XXII, Table XXIII, , and/or, one or more of the T cell binding motifs known in the art. Preferred embodiments contain no insertions, deletions or substitutions either within the motifs or the

intervening sequences of the polypeptides. In addition, embodiments which include a number of either N-terminal and/or C-terminal amino acid residues on either side of these motifs may be desirable (to, for example, include a greater portion of the polypeptide architecture in which the motif is located). Typically the number of N-terminal and/or C-terminal amino acid residues on either side of a motif is between about 1 to about 100 amino acid residues, preferably 5 to about 50 amino acid residues.

108P5H8-related proteins are embodied in many forms, preferably in isolated form. A purified 108P5H8 protein molecule will be substantially free of other proteins or molecules that impair the binding of 108P5H8 to antibody, T cell or other ligand. The nature and degree of isolation and purification will depend on the intended use. Embodiments of a 108P5H8-related proteins include purified 108P5H8-related proteins and functional, soluble 108P5H8-related proteins. In one embodiment, a functional, soluble 108P5H8 protein or fragment thereof retains the ability to be bound by antibody, T cell or other ligand.

The invention also provides 108P5H8 proteins comprising biologically active fragments of a 108P5H8 amino acid sequence shown in Figure 2 or Figure 3. Such proteins exhibit properties of the starting 108P5H8 protein, such as the ability to elicit the generation of antibodies that specifically bind an epitope associated with the starting 108P5H8 protein; to be bound by such antibodies; to elicit the activation of HTL or CTL; and/or, to be recognized by HTL or CTL that also specifically bind to the starting protein.

108P5H8-related polypeptides that contain particularly interesting structures can be predicted and/or identified using various analytical techniques well known in the art, including, for example, the methods of Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis, or on the basis of immunogenicity. Fragments that contain such structures are particularly useful in generating subunit-specific anti-108P5H8 antibodies, or T cells or in identifying cellular factors that bind to 108P5H8.

CTL epitopes can be determined using specific algorithms to identify peptides within an 108P5H8 protein that are capable of optimally binding to specified HLA alleles (e.g., by using the SYFPEITHI site at World Wide Web URL syfpeithi.bmi-heidelberg.com/; the listings in Table IV(A)-(E); Epimatrix™ and Epimer™, Brown University, URL (www.brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html); and BIMAS, URL bimas.dcert.nih.gov/). Illustrating this, peptide epitopes from 108P5H8 that are presented in the context of human MHC class I molecules HLA-A1, A2, A3, A11, A24, B7 and B35 were predicted (Tables V-XVIII, XXII, and XXIII). Specifically, the complete amino acid sequence of the 108P5H8 protein and relevant portions of other variants, i.e., for HLA Class I predictions 9 flanking residues on either side of a point mutation, and for HLA Class II predictions 14 flanking residues on either side of a point mutation, were entered into the HLA Peptide Motif Search algorithm found in the Bioinformatics and Molecular Analysis Section (BIMAS) web site listed above; for HLA Class II the site SYFPEITHI at URL syfpeithi.bmi-heidelberg.com/ was used.

The HLA peptide motif search algorithm was developed by Dr. Ken Parker based on binding of specific peptide sequences in the groove of HLA Class I molecules, in particular HLA-A2 (see, e.g., Falk *et al.*, Nature 351: 290-6 (1991); Hunt *et al.*, Science 255:1261-3 (1992); Parker *et al.*, J. Immunol. 149:3580-

7 (1992); Parker *et al.*, J. Immunol. 152:163-75 (1994)). This algorithm allows location and ranking of 8-mer, 9-mer, and 10-mer peptides from a complete protein sequence for predicted binding to HLA-A2 as well as numerous other HLA Class I molecules. Many HLA class I binding peptides are 8-, 9-, 10 or 11-mers. For example, for class I HLA-A2, the epitopes preferably contain a leucine (L) or methionine (M) at position 2 and a valine (V) or leucine (L) at the C-terminus (see, e.g., Parker *et al.*, J. Immunol. 149:3580-7 (1992)). Selected results of 108P5H8 predicted binding peptides are shown in Tables V-XVIII, XXII, and XXIII herein. In Tables V-XVIII, the top 50 ranking candidates, 9-mers and 10-mers, for each family member are shown along with their location, the amino acid sequence of each specific peptide, and an estimated binding score. The binding score corresponds to the estimated half time of dissociation of complexes containing the peptide at 37°C at pH 6.5. Peptides with the highest binding score are predicted to be the most tightly bound to HLA Class I on the cell surface for the greatest period of time and thus represent the best immunogenic targets for T-cell recognition.

Actual binding of peptides to an HLA allele can be evaluated by stabilization of HLA expression on the antigen-processing defective cell line T2 (see, e.g., Xue *et al.*, Prostate 30:73-8 (1997) and Peshwa *et al.*, Prostate 36:129-38 (1998)). Immunogenicity of specific peptides can be evaluated *in vitro* by stimulation of CD8+ cytotoxic T lymphocytes (CTL) in the presence of antigen presenting cells such as dendritic cells.

It is to be appreciated that every epitope predicted by the BIMAS site, Epimer™ and Epimatrix™ sites, or specified by the HLA class I or class II motifs available in the art or which become part of the art such as set forth in Table IV (or determined using World Wide Web site URL syfpeithi.bmi-heidelberg.com/, or BIMAS, bimas.dcert.nih.gov/) are to be “applied” to a 108P5H8 protein in accordance with the invention. As used in this context “applied” means that a 108P5H8 protein is evaluated, e.g., visually or by computer-based patterns finding methods, as appreciated by those of skill in the relevant art. Every subsequence of a 108P5H8 protein of 8, 9, 10, or 11 amino acid residues that bears an HLA Class I motif, or a subsequence of 9 or more amino acid residues that bear an HLA Class II motif are within the scope of the invention.

III.B.) Expression of 108P5H8-related Proteins

In an embodiment described in the examples that follow, 108P5H8 can be conveniently expressed in cells (such as 293T cells) transfected with a commercially available expression vector such as a CMV-driven expression vector encoding 108P5H8 with a C-terminal 6XHis and MYC tag (pcDNA3.1/mycHis, Invitrogen or Tag5, GenHunter Corporation, Nashville TN). The Tag5 vector provides an IgGK secretion signal that can be used to facilitate the production of a secreted 108P5H8 protein in transfected cells. The secreted HIS-tagged 108P5H8 in the culture media can be purified, e.g., using a nickel column using standard techniques.

III.C.) Modifications of 108P5H8-related Proteins

Modifications of 108P5H8-related proteins such as covalent modifications are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues

of a 108P5H8 polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of a 108P5H8 protein. Another type of covalent modification of a 108P5H8 polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of a protein of the invention. Another type of covalent modification of 108P5H8 comprises linking a 108P5H8 polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The 108P5H8-related proteins of the present invention can also be modified to form a chimeric molecule comprising 108P5H8 fused to another, heterologous polypeptide or amino acid sequence. Such a chimeric molecule can be synthesized chemically or recombinantly. A chimeric molecule can have a protein of the invention fused to another tumor-associated antigen or fragment thereof. Alternatively, a protein in accordance with the invention can comprise a fusion of fragments of a 108P5H8 sequence (amino or nucleic acid) such that a molecule is created that is not, through its length, directly homologous to the amino or nucleic acid sequences shown in Figure 2 or Figure 3. Such a chimeric molecule can comprise multiples of the same subsequence of 108P5H8. A chimeric molecule can comprise a fusion of a 108P5H8-related protein with a polyhistidine epitope tag, which provides an epitope to which immobilized nickel can selectively bind, with cytokines or with growth factors. The epitope tag is generally placed at the amino- or carboxyl- terminus of a 108P5H8 protein. In an alternative embodiment, the chimeric molecule can comprise a fusion of a 108P5H8-related protein with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a 108P5H8 polypeptide in place of at least one variable region within an Ig molecule. In a preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see, e.g., U.S. Patent No. 5,428,130 issued June 27, 1995.

III.D.) Uses of 108P5H8-related Proteins

The proteins of the invention have a number of different specific uses. As 108P5H8 is highly expressed in prostate and other cancers, 108P5H8-related proteins are used in methods that assess the status of 108P5H8 gene products in normal versus cancerous tissues, thereby elucidating the malignant phenotype. Typically, polypeptides from specific regions of a 108P5H8 protein are used to assess the presence of perturbations (such as deletions, insertions, point mutations etc.) in those regions (such as regions containing one or more motifs). Exemplary assays utilize antibodies or T cells targeting 108P5H8-related proteins comprising the amino acid residues of one or more of the biological motifs contained within a 108P5H8 polypeptide sequence in order to evaluate the characteristics of this region in normal versus cancerous tissues or to elicit an immune response to the epitope. Alternatively, 108P5H8-related

5

0

15

20

25

30

39

32

Immunological non-antibody assays of the invention also comprise T cell immunogenicity assays (inhibitory or stimulatory) as well as major histocompatibility complex (MHC) binding assays.

5

10

15

20

30

in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, are effective. Administration of a 108P5H8 immunogen is often conducted by injection over a suitable time period and with use of a suitable adjuvant, as is understood in the art. During the immunization schedule, titers of antibodies can be taken to determine adequacy of antibody formation.

108P5H8 monoclonal antibodies can be produced by various means well known in the art. For example, immortalized cell lines that secrete a desired monoclonal antibody are prepared using the standard hybridoma technology of Kohler and Milstein or modifications that immortalize antibody-producing B cells, as is generally known. Immortalized cell lines that secrete the desired antibodies are screened by immunoassay in which the antigen is a 108P5H8-related protein. When the appropriate immortalized cell culture is identified, the cells can be expanded and antibodies produced either from *in vitro* cultures or from ascites fluid.

The antibodies or fragments of the invention can also be produced, by recombinant means. Regions that bind specifically to the desired regions of a 108P5H8 protein can also be produced in the context of chimeric or complementarity determining region (CDR) grafted antibodies of multiple species origin. Humanized or human 108P5H8 antibodies can also be produced, and are preferred for use in therapeutic contexts. Methods for humanizing murine and other non-human antibodies, by substituting one or more of the non-human antibody CDRs for corresponding human antibody sequences, are well known (see for example, Jones *et al.*, 1986, Nature 321: 522-525; Riechmann *et al.*, 1988, Nature 332: 323-327; Verhoeyen *et al.*, 1988, Science 239: 1534-1536). See also, Carter *et al.*, 1993, Proc. Natl. Acad. Sci. USA 89: 4285 and Sims *et al.*, 1993, J. Immunol. 151: 2296.

Methods for producing fully human monoclonal antibodies include phage display and transgenic methods (for review, see Vaughan *et al.*, 1998, Nature Biotechnology 16: 535-539). Fully human 108P5H8 monoclonal antibodies can be generated using cloning technologies employing large human Ig gene combinatorial libraries (i.e., phage display) (Griffiths and Hoogenboom, Building an *in vitro* immune system: human antibodies from phage display libraries. In: Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, Clark, M. (Ed.), Nottingham Academic, pp 45-64 (1993); Burton and Barbas, Human Antibodies from combinatorial libraries. *Id.*, pp 65-82). Fully human 108P5H8 monoclonal antibodies can also be produced using transgenic mice engineered to contain human immunoglobulin gene loci as described in PCT Patent Application WO98/24893, Kucherlapati and Jakobovits *et al.*, published December 3, 1997 (see also, Jakobovits, 1998, Exp. Opin. Invest. Drugs 7(4): 607-614; U.S. patents 6,162,963 issued 19 December 2000; 6,150,584 issued 12 November 2000; and, 6,114,598 issued 5 September 2000). This method avoids the *in vitro* manipulation required with phage display technology and efficiently produces high affinity authentic human antibodies.

Reactivity of 108P5H8 antibodies with an 108P5H8-related protein can be established by a number of well known means, including Western blot, immunoprecipitation, ELISA, and FACS analyses using, as appropriate, 108P5H8-related proteins, 108P5H8-expressing cells or extracts thereof. A 108P5H8 antibody or fragment thereof can be labeled with a detectable marker or conjugated to a second molecule. Suitable detectable markers include, but are not limited to, a radioisotope, a fluorescent compound, a

bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme. Further, bi-specific antibodies specific for two or more 108P5H8 epitopes are generated using methods generally known in the art. Homodimeric antibodies can also be generated by cross-linking techniques known in the art (e.g., Wolff *et al.*, Cancer Res. 53: 2560-2565).

V.) 108P5H8 Cellular Immune Responses

The mechanism by which T cells recognize antigens has been delineated. Efficacious peptide epitope vaccine compositions of the invention induce a therapeutic or prophylactic immune responses in very broad segments of the world-wide population. For an understanding of the value and efficacy of compositions of the invention that induce cellular immune responses, a brief review of immunology-related technology is provided.

A complex of an HLA molecule and a peptidic antigen acts as the ligand recognized by HLA-restricted T cells (Buus, S. *et al.*, *Cell* 47:1071, 1986; Babbitt, B. P. *et al.*, *Nature* 317:359, 1985; Townsend, A. and Bodmer, H., *Annu. Rev. Immunol.* 7:601, 1989; Germain, R. N., *Annu. Rev. Immunol.* 11:403, 1993). Through the study of single amino acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues that correspond to motifs required for specific binding to HLA antigen molecules have been identified and are set forth in Table IV (see also, e.g., Southwood, *et al.*, *J. Immunol.* 160:3363, 1998; Rammensee, *et al.*, *Immunogenetics* 41:178, 1995; Rammensee *et al.*, SYFPEITHI, access via World Wide Web at URL syfpeithi.bmi-heidelberg.com/; Sette, A. and Sidney, J. *Curr. Opin. Immunol.* 10:478, 1998; Engelhard, V. H., *Curr. Opin. Immunol.* 6:13, 1994; Sette, A. and Grey, H. M., *Curr. Opin. Immunol.* 4:79, 1992; Sinigaglia, F. and Hammer, J. *Curr. Biol.* 6:52, 1994; Ruppert *et al.*, *Cell* 74:929-937, 1993; Kondo *et al.*, *J. Immunol.* 155:4307-4312, 1995; Sidney *et al.*, *J. Immunol.* 157:3480-3490, 1996; Sidney *et al.*, *Human Immunol.* 45:79-93, 1996; Sette, A. and Sidney, J. *Immunogenetics* 1999 Nov; 50(3-4):201-12, Review).

Furthermore, x-ray crystallographic analyses of HLA-peptide complexes have revealed pockets within the peptide binding cleft/groove of HLA molecules which accommodate, in an allele-specific mode, residues borne by peptide ligands; these residues in turn determine the HLA binding capacity of the peptides in which they are present. (See, e.g., Madden, D.R. *Annu. Rev. Immunol.* 13:587, 1995; Smith, *et al.*, *Immunity* 4:203, 1996; Fremont *et al.*, *Immunity* 8:305, 1998; Stern *et al.*, *Structure* 2:245, 1994; Jones, E.Y. *Curr. Opin. Immunol.* 9:75, 1997; Brown, J. H. *et al.*, *Nature* 364:33, 1993; Guo, H. C. *et al.*, *Proc. Natl. Acad. Sci. USA* 90:8053, 1993; Guo, H. C. *et al.*, *Nature* 360:364, 1992; Silver, M. L. *et al.*, *Nature* 360:367, 1992; Matsumura, M. *et al.*, *Science* 257:927, 1992; Madden *et al.*, *Cell* 70:1035, 1992; Fremont, D. H. *et al.*, *Science* 257:919, 1992; Saper, M. A., Bjorkman, P. J. and Wiley, D. C., *J. Mol. Biol.* 219:277, 1991.)

Accordingly, the definition of class I and class II allele-specific HLA binding motifs, or class I or class II supermotifs allows identification of regions within a protein that are correlated with binding to particular HLA antigen(s).

Thus, by a process of HLA motif identification, candidates for epitope-based vaccines have been identified; such candidates can be further evaluated by HLA-peptide binding assays to determine binding affinity and/or the time period of association of the epitope and its corresponding HLA molecule. Additional confirmatory work can be performed to select, amongst these vaccine candidates, epitopes with preferred characteristics in terms of population coverage, and/or immunogenicity.

Various strategies can be utilized to evaluate cellular immunogenicity, including:

1) Evaluation of primary T cell cultures from normal individuals (*see, e.g., Wentworth, P. A. et al., Mol. Immunol.* 32:603, 1995; Celis, E. *et al., Proc. Natl. Acad. Sci. USA* 91:2105, 1994; Tsai, V. *et al., J. Immunol.* 158:1796, 1997; Kawashima, I. *et al., Human Immunol.* 59:1, 1998). This procedure involves the stimulation of peripheral blood lymphocytes (PBL) from normal subjects with a test peptide in the presence of antigen presenting cells *in vitro* over a period of several weeks. T cells specific for the peptide become activated during this time and are detected using, *e.g.,* a lymphokine- or ^{51}Cr -release assay involving peptide sensitized target cells.

2) Immunization of HLA transgenic mice (*see, e.g., Wentworth, P. A. et al., J. Immunol.* 26:97, 1996; Wentworth, P. A. *et al., Int. Immunol.* 8:651, 1996; Alexander, J. *et al., J. Immunol.* 159:4753, 1997). For example, in such methods peptides in incomplete Freund's adjuvant are administered subcutaneously to HLA transgenic mice. Several weeks following immunization, splenocytes are removed and cultured *in vitro* in the presence of test peptide for approximately one week. Peptide-specific T cells are detected using, *e.g.,* a ^{51}Cr -release assay involving peptide sensitized target cells and target cells expressing endogenously generated antigen.

3) Demonstration of recall T cell responses from immune individuals who have been either effectively vaccinated and/or from chronically ill patients (*see, e.g., Rehmann, B. et al., J. Exp. Med.* 181:1047, 1995; Doolan, D. L. *et al., Immunity* 7:97, 1997; Bertoni, R. *et al., J. Clin. Invest.* 100:503, 1997; Threlkeld, S. C. *et al., J. Immunol.* 159:1648, 1997; Diepolder, H. M. *et al., J. Virol.* 71:6011, 1997). Accordingly, recall responses are detected by culturing PBL from subjects that have been exposed to the antigen due to disease and thus have generated an immune response "naturally", or from patients who were vaccinated against the antigen. PBL from subjects are cultured *in vitro* for 1-2 weeks in the presence of test peptide plus antigen presenting cells (APC) to allow activation of "memory" T cells, as compared to "naive" T cells. At the end of the culture period, T cell activity is detected using assays including ^{51}Cr release involving peptide-sensitized targets, T cell proliferation, or lymphokine release.

VI.) 108P5H8 Transgenic Animals

Nucleic acids that encode a 108P5H8-related protein can also be used to generate either transgenic animals or "knock out" animals that, in turn, are useful in the development and screening of therapeutically useful reagents. In accordance with established techniques, cDNA encoding 108P5H8 can be used to clone genomic DNA that encodes 108P5H8. The cloned genomic sequences can then be used to generate transgenic animals containing cells that express DNA that encode 108P5H8. Methods for generating

transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 issued 12 April 1988, and 4,870,009 issued 26 September 1989. Typically, particular cells would be targeted for 108P5H8 transgene incorporation with tissue-specific enhancers.

Transgenic animals that include a copy of a transgene encoding 108P5H8 can be used to examine the effect of increased expression of DNA that encodes 108P5H8. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this aspect of the invention, an animal is treated with a reagent and a reduced incidence of a pathological condition, compared to untreated animals that bear the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of 108P5H8 can be used to construct a 108P5H8 "knock out" animal that has a defective or altered gene encoding 108P5H8 as a result of homologous recombination between the endogenous gene encoding 108P5H8 and altered genomic DNA encoding 108P5H8 introduced into an embryonic cell of the animal. For example, cDNA that encodes 108P5H8 can be used to clone genomic DNA encoding 108P5H8 in accordance with established techniques. A portion of the genomic DNA encoding 108P5H8 can be deleted or replaced with another gene, such as a gene encoding a selectable marker that can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector (see, e.g., Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected (see, e.g., Li *et al.*, *Cell*, 69:915 (1992)). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras (see, e.g., Bradley, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal, and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knock out animals can be characterized, for example, for their ability to defend against certain pathological conditions or for their development of pathological conditions due to absence of a 108P5H8 polypeptide.

VII.) Methods for the Detection of 108P5H8

Another aspect of the present invention relates to methods for detecting 108P5H8 polynucleotides and 108P5H8-related proteins, as well as methods for identifying a cell that expresses 108P5H8. The expression profile of 108P5H8 makes it a diagnostic marker for metastasized disease. Accordingly, the status of 108P5H8 gene products provides information useful for predicting a variety of factors including susceptibility to advanced stage disease, rate of progression, and/or tumor aggressiveness. As discussed in detail herein, the

status of 108P5H8 gene products in patient samples can be analyzed by a variety protocols that are well known in the art including immunohistochemical analysis, the variety of Northern blotting techniques including *in situ* hybridization, RT-PCR analysis (for example on laser capture micro-dissected samples), Western blot analysis and tissue array analysis.

More particularly, the invention provides assays for the detection of 108P5H8 polynucleotides in a biological sample, such as serum, bone, prostate, and other tissues, urine, semen, cell preparations, and the like. Detectable 108P5H8 polynucleotides include, for example, a 108P5H8 gene or fragment thereof, 108P5H8 mRNA, alternative splice variant 108P5H8 mRNAs, and recombinant DNA or RNA molecules that contain a 108P5H8 polynucleotide. A number of methods for amplifying and/or detecting the presence of 108P5H8 polynucleotides are well known in the art and can be employed in the practice of this aspect of the invention.

In one embodiment, a method for detecting an 108P5H8 mRNA in a biological sample comprises producing cDNA from the sample by reverse transcription using at least one primer; amplifying the cDNA so produced using an 108P5H8 polynucleotides as sense and antisense primers to amplify 108P5H8 cDNAs therein; and detecting the presence of the amplified 108P5H8 cDNA. Optionally, the sequence of the amplified 108P5H8 cDNA can be determined.

In another embodiment, a method of detecting a 108P5H8 gene in a biological sample comprises first isolating genomic DNA from the sample; amplifying the isolated genomic DNA using 108P5H8 polynucleotides as sense and antisense primers; and detecting the presence of the amplified 108P5H8 gene. Any number of appropriate sense and antisense probe combinations can be designed from a 192P1E1B nucleotide sequence (see, e.g., Figure 2) and used for this purpose.

The invention also provides assays for detecting the presence of an 108P5H8 protein in a tissue or other biological sample such as serum, semen, bone, prostate, urine, cell preparations, and the like. Methods for detecting a 108P5H8-related protein are also well known and include, for example, immunoprecipitation, immunohistochemical analysis, Western blot analysis, molecular binding assays, ELISA, ELIFA and the like. For example, a method of detecting the presence of a 108P5H8-related protein in a biological sample comprises first contacting the sample with a 108P5H8 antibody, a 108P5H8-reactive fragment thereof, or a recombinant protein containing an antigen binding region of a 108P5H8 antibody; and then detecting the binding of 108P5H8-related protein in the sample.

Methods for identifying a cell that expresses 108P5H8 are also within the scope of the invention. In one embodiment, an assay for identifying a cell that expresses a 108P5H8 gene comprises detecting the presence of 108P5H8 mRNA in the cell. Methods for the detection of particular mRNAs in cells are well known and include, for example, hybridization assays using complementary DNA probes (such as *in situ* hybridization using labeled 108P5H8 riboprobes, Northern blot and related techniques) and various nucleic acid amplification assays (such as RT-PCR using complementary primers specific for 108P5H8, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like). Alternatively, an assay for identifying a cell that expresses a 108P5H8 gene comprises detecting the presence of 108P5H8-related protein in the cell or secreted by the cell. Various methods for the detection of proteins are

well known in the art and are employed for the detection of 108P5H8-related proteins and cells that express 108P5H8-related proteins.

108P5H8 expression analysis is also useful as a tool for identifying and evaluating agents that modulate 108P5H8 gene expression. For example, 108P5H8 expression is significantly upregulated in prostate cancer, and is expressed in cancers of the tissues listed in Table 1. Identification of a molecule or biological agent that inhibits 108P5H8 expression or over-expression in cancer cells is of therapeutic value. For example, such an agent can be identified by using a screen that quantifies 108P5H8 expression by RT-PCR, nucleic acid hybridization or antibody binding.

VIII.) Methods for Monitoring the Status of 108P5H8-related Genes and Their Products

Oncogenesis is known to be a multistep process where cellular growth becomes progressively dysregulated and cells progress from a normal physiological state to precancerous and then cancerous states (see, e.g., Alers *et al.*, Lab Invest. 77(5): 437-438 (1997) and Isaacs *et al.*, Cancer Surv. 23: 19-32 (1995)). In this context, examining a biological sample for evidence of dysregulated cell growth (such as aberrant 108P5H8 expression in cancers) allows for early detection of such aberrant physiology, before a pathologic state such as cancer has progressed to a stage that therapeutic options are more limited and or the prognosis is worse. In such examinations, the status of 108P5H8 in a biological sample of interest can be compared, for example, to the status of 108P5H8 in a corresponding normal sample (e.g. a sample from that individual or alternatively another individual that is not affected by a pathology). An alteration in the status of 108P5H8 in the biological sample (as compared to the normal sample) provides evidence of dysregulated cellular growth. In addition to using a biological sample that is not affected by a pathology as a normal sample, one can also use a predetermined normative value such as a predetermined normal level of mRNA expression (see, e.g., Grever *et al.*, J. Comp. Neurol. 1996 Dec 9; 376(2): 306-14 and U.S. Patent No. 5,837,501) to compare 108P5H8 status in a sample.

The term "status" in this context is used according to its art accepted meaning and refers to the condition or state of a gene and its products. Typically, skilled artisans use a number of parameters to evaluate the condition or state of a gene and its products. These include, but are not limited to the location of expressed gene products (including the location of 108P5H8 expressing cells) as well as the level, and biological activity of expressed gene products (such as 108P5H8 mRNA, polynucleotides and polypeptides). Typically, an alteration in the status of 108P5H8 comprises a change in the location of 108P5H8 and/or 108P5H8 expressing cells and/or an increase in 108P5H8 mRNA and/or protein expression.

108P5H8 status in a sample can be analyzed by a number of means well known in the art, including without limitation, immunohistochemical analysis, *in situ* hybridization, RT-PCR analysis on laser capture micro-dissected samples, Western blot analysis, and tissue array analysis. Typical protocols for evaluating the status of a 108P5H8 gene and gene products are found, for example in Ausubel *et al.* eds., 1995, Current Protocols In Molecular Biology, Units 2 (Northern Blotting), 4 (Southern Blotting), 15 (Immunoblotting) and 18 (PCR Analysis). Thus, the status of 108P5H8 in a biological sample is evaluated by various

methods utilized by skilled artisans including, but not limited to genomic Southern analysis (to examine, for example perturbations in a 108P5H8 gene), Northern analysis and/or PCR analysis of 108P5H8 mRNA (to examine, for example alterations in the polynucleotide sequences or expression levels of 108P5H8 mRNAs), and, Western and/or immunohistochemical analysis (to examine, for example alterations in polypeptide sequences, alterations in polypeptide localization within a sample, alterations in expression levels of 108P5H8 proteins and/or associations of 108P5H8 proteins with polypeptide binding partners). Detectable 108P5H8 polynucleotides include, for example, a 108P5H8 gene or fragment thereof, 108P5H8 mRNA, alternative splice variants, 108P5H8 mRNAs, and recombinant DNA or RNA molecules containing a 108P5H8 polynucleotide.

The expression profile of 108P5H8 makes it a diagnostic marker for local and/or metastasized disease, and provides information on the growth or oncogenic potential of a biological sample. In particular, the status of 108P5H8 provides information useful for predicting susceptibility to particular disease stages, progression, and/or tumor aggressiveness. The invention provides methods and assays for determining 108P5H8 status and diagnosing cancers that express 108P5H8, such as cancers of the tissues listed in Table I. For example, because 108P5H8 mRNA is so highly expressed in prostate and other cancers relative to normal prostate tissue, assays that evaluate the levels of 108P5H8 mRNA transcripts or proteins in a biological sample can be used to diagnose a disease associated with 108P5H8 dysregulation, and can provide prognostic information useful in defining appropriate therapeutic options.

The expression status of 108P5H8 provides information including the presence, stage and location of dysplastic, precancerous and cancerous cells, predicting susceptibility to various stages of disease, and/or for gauging tumor aggressiveness. Moreover, the expression profile makes it useful as an imaging reagent for metastasized disease. Consequently, an aspect of the invention is directed to the various molecular prognostic and diagnostic methods for examining the status of 108P5H8 in biological samples such as those from individuals suffering from, or suspected of suffering from a pathology characterized by dysregulated cellular growth, such as cancer.

As described above, the status of 108P5H8 in a biological sample can be examined by a number of well-known procedures in the art. For example, the status of 108P5H8 in a biological sample taken from a specific location in the body can be examined by evaluating the sample for the presence or absence of 108P5H8 expressing cells (e.g. those that express 108P5H8 mRNAs or proteins). This examination can provide evidence of dysregulated cellular growth, for example, when 108P5H8-expressing cells are found in a biological sample that does not normally contain such cells (such as a lymph node), because such alterations in the status of 108P5H8 in a biological sample are often associated with dysregulated cellular growth. Specifically, one indicator of dysregulated cellular growth is the metastases of cancer cells from an organ of origin (such as the prostate) to a different area of the body (such as a lymph node). In this context, evidence of dysregulated cellular growth is important for example because occult lymph node metastases can be detected in a substantial proportion of patients with prostate cancer, and such metastases are associated with known predictors of disease progression (see, e.g., Murphy *et al.*, Prostate 42(4): 315-

317 (2000); Su *et al.*, *Semin. Surg. Oncol.* 18(1): 17-28 (2000) and Freeman *et al.*, *J Urol* 1995 Aug 154(2 Pt 1):474-8).

5 In one aspect, the invention provides methods for monitoring 108P5H8 gene products by determining the status of 108P5H8 gene products expressed by cells from an individual suspected of having a disease associated with dysregulated cell growth (such as hyperplasia or cancer) and then comparing the status so determined to the status of 108P5H8 gene products in a corresponding normal sample. The presence of aberrant 108P5H8 gene products in the test sample relative to the normal sample provides an indication of the presence of dysregulated cell growth within the cells of the individual.

10 In another aspect, the invention provides assays useful in determining the presence of cancer in an individual, comprising detecting a significant increase in 108P5H8 mRNA or protein expression in a test cell or tissue sample relative to expression levels in the corresponding normal cell or tissue. The presence of 108P5H8 mRNA can, for example, be evaluated in tissue samples including but not limited to those listed in Table I. The presence of significant 108P5H8 expression in any of these tissues is useful to indicate the emergence, presence and/or severity of a cancer, since the corresponding normal tissues do not express 108P5H8 mRNA or express it at lower levels.

15 In a related embodiment, 108P5H8 status is determined at the protein level rather than at the nucleic acid level. For example, such a method comprises determining the level of 108P5H8 protein expressed by cells in a test tissue sample and comparing the level so determined to the level of 108P5H8 expressed in a corresponding normal sample. In one embodiment, the presence of 108P5H8 protein is evaluated, for example, using immunohistochemical methods. 108P5H8 antibodies or binding partners capable of detecting 108P5H8 protein expression are used in a variety of assay formats well known in the art for this purpose.

20 In a further embodiment, one can evaluate the status of 108P5H8 nucleotide and amino acid sequences in a biological sample in order to identify perturbations in the structure of these molecules. These perturbations can include insertions, deletions, substitutions and the like. Such evaluations are useful because perturbations in the nucleotide and amino acid sequences are observed in a large number of proteins associated with a growth dysregulated phenotype (see, e.g., Marrogi *et al.*, 1999, *J. Cutan. Pathol.* 26(8):369-378). For example, a mutation in the sequence of 108P5H8 may be indicative of the presence or promotion of a tumor. Such assays therefore have diagnostic and predictive value where a mutation in 108P5H8 indicates a potential loss of function or increase in tumor growth.

25 A wide variety of assays for observing perturbations in nucleotide and amino acid sequences are well known in the art. For example, the size and structure of nucleic acid or amino acid sequences of 108P5H8 gene products are observed by the Northern, Southern, Western, PCR and DNA sequencing protocols discussed herein. In addition, other methods for observing perturbations in nucleotide and amino acid sequences such as single strand conformation polymorphism analysis are well known in the art (see, e.g., U.S. Patent Nos. 30 5,382,510 issued 7 September 1999, and 5,952,170 issued 17 January 1995).

35 Additionally, one can examine the methylation status of a 108P5H8 gene in a biological sample. Aberrant demethylation and/or hypermethylation of CpG islands in gene 5' regulatory regions frequently

occurs in immortalized and transformed cells, and can result in altered expression of various genes. For example, promoter hypermethylation of the pi-class glutathione S-transferase (a protein expressed in normal prostate but not expressed in >90% of prostate carcinomas) appears to permanently silence transcription of this gene and is the most frequently detected genomic alteration in prostate carcinomas (De Marzo *et al.*, Am. J. Pathol. 155(6): 1985-1992 (1999)). In addition, this alteration is present in at least 70% of cases of high-grade prostatic intraepithelial neoplasia (PIN) (Brooks *et al.*, Cancer Epidemiol. Biomarkers Prev., 1998, 7:531-536). In another example, expression of the LAGE-I tumor specific gene (which is not expressed in normal prostate but is expressed in 25-50% of prostate cancers) is induced by deoxy-azacytidine in lymphoblastoid cells, suggesting that tumoral expression is due to demethylation (Lethe *et al.*, Int. J. Cancer 76(6): 903-908 (1998)). A variety of assays for examining methylation status of a gene are well known in the art. For example, one can utilize, in Southern hybridization approaches, methylation-sensitive restriction enzymes that cannot cleave sequences that contain methylated CpG sites to assess the methylation status of CpG islands. In addition, MSP (methylation specific PCR) can rapidly profile the methylation status of all the CpG sites present in a CpG island of a given gene. This procedure involves initial modification of DNA by sodium bisulfite (which will convert all unmethylated cytosines to uracil) followed by amplification using primers specific for methylated versus unmethylated DNA. Protocols involving methylation interference can also be found for example in Current Protocols In Molecular Biology, Unit 12, Frederick M. Ausubel *et al.* eds., 1995.

Gene amplification is an additional method for assessing the status of 108P5H8. Gene amplification is measured in a sample directly, for example, by conventional Southern blotting or Northern blotting to quantitate the transcription of mRNA (Thomas, 1980, Proc. Natl. Acad. Sci. USA, 77:5201-5205), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies are employed that recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn are labeled and the assay carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Biopsied tissue or peripheral blood can be conveniently assayed for the presence of cancer cells using for example, Northern, dot blot or RT-PCR analysis to detect 108P5H8 expression. The presence of RT-PCR amplifiable 108P5H8 mRNA provides an indication of the presence of cancer. RT-PCR assays are well known in the art. RT-PCR detection assays for tumor cells in peripheral blood are currently being evaluated for use in the diagnosis and management of a number of human solid tumors. In the prostate cancer field, these include RT-PCR assays for the detection of cells expressing PSA and PSM (Verkaik *et al.*, 1997, Urol. Res. 25:373-384; Ghossein *et al.*, 1995, J. Clin. Oncol. 13:1195-2000; Heston *et al.*, 1995, Clin. Chem. 41:1687-1688).

A further aspect of the invention is an assessment of the susceptibility that an individual has for developing cancer. In one embodiment, a method for predicting susceptibility to cancer comprises detecting 108P5H8 mRNA or 108P5H8 protein in a tissue sample, its presence indicating susceptibility to cancer,

wherein the degree of 108P5H8 mRNA expression correlates to the degree of susceptibility. In a specific embodiment, the presence of 108P5H8 in prostate or other tissue is examined, with the presence of 108P5H8 in the sample providing an indication of prostate cancer susceptibility (or the emergence or existence of a prostate tumor). Similarly, one can evaluate the integrity 108P5H8 nucleotide and amino acid sequences in a biological sample, in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like. The presence of one or more perturbations in 108P5H8 gene products in the sample is an indication of cancer susceptibility (or the emergence or existence of a tumor).

The invention also comprises methods for gauging tumor aggressiveness. In one embodiment, a method for gauging aggressiveness of a tumor comprises determining the level of 108P5H8 mRNA or 108P5H8 protein expressed by tumor cells, comparing the level so determined to the level of 108P5H8 mRNA or 108P5H8 protein expressed in a corresponding normal tissue taken from the same individual or a normal tissue reference sample, wherein the degree of 108P5H8 mRNA or 108P5H8 protein expression in the tumor sample relative to the normal sample indicates the degree of aggressiveness. In a specific embodiment, aggressiveness of a tumor is evaluated by determining the extent to which 108P5H8 is expressed in the tumor cells, with higher expression levels indicating more aggressive tumors. Another embodiment is the evaluation of the integrity of 108P5H8 nucleotide and amino acid sequences in a biological sample, in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like. The presence of one or more perturbations indicates more aggressive tumors.

Another embodiment of the invention is directed to methods for observing the progression of a malignancy in an individual over time. In one embodiment, methods for observing the progression of a malignancy in an individual over time comprise determining the level of 108P5H8 mRNA or 108P5H8 protein expressed by cells in a sample of the tumor, comparing the level so determined to the level of 108P5H8 mRNA or 108P5H8 protein expressed in an equivalent tissue sample taken from the same individual at a different time, wherein the degree of 108P5H8 mRNA or 108P5H8 protein expression in the tumor sample over time provides information on the progression of the cancer. In a specific embodiment, the progression of a cancer is evaluated by determining 108P5H8 expression in the tumor cells over time, where increased expression over time indicates a progression of the cancer. Also, one can evaluate the integrity 108P5H8 nucleotide and amino acid sequences in a biological sample in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like, where the presence of one or more perturbations indicates a progression of the cancer.

The above diagnostic approaches can be combined with any one of a wide variety of prognostic and diagnostic protocols known in the art. For example, another embodiment of the invention is directed to methods for observing a coincidence between the expression of 108P5H8 gene and 108P5H8 gene products (or perturbations in 108P5H8 gene and 108P5H8 gene products) and a factor that is associated with malignancy, as a means for diagnosing and prognosticating the status of a tissue sample. A wide variety of factors associated with malignancy can be utilized, such as the expression of genes associated with malignancy (e.g. PSA, PSCA and PSM expression for prostate cancer etc.) as well as gross cytological observations (see, e.g., Bocking *et al.*,

1984, Anal. Quant. Cytol. 6(2):74-88; Epstein, 1995, Hum. Pathol. 26(2):223-9; Thorson *et al.*, 1998, Mod. Pathol. 11(6):543-51; Baisden *et al.*, 1999, Am. J. Surg. Pathol. 23(8):918-24). Methods for observing a coincidence between the expression of 108P5H8 gene and 108P5H8 gene products (or perturbations in 108P5H8 gene and 108P5H8 gene products) and another factor that is associated with malignancy are useful, for example, because the presence of a set of specific factors that coincide with disease provides information crucial for diagnosing and prognosticating the status of a tissue sample.

In one embodiment, methods for observing a coincidence between the expression of 108P5H8 gene and 108P5H8 gene products (or perturbations in 108P5H8 gene and 108P5H8 gene products) and another factor associated with malignancy entails detecting the overexpression of 108P5H8 mRNA or protein in a tissue sample, detecting the overexpression of PSA mRNA or protein in a tissue sample (or PSCA or PSM expression), and observing a coincidence of 108P5H8 mRNA or protein and PSA mRNA or protein overexpression (or PSCA or PSM expression). In a specific embodiment, the expression of 108P5H8 and PSA mRNA in prostate tissue is examined, where the coincidence of 108P5H8 and PSA mRNA overexpression in the sample indicates the existence of prostate cancer, prostate cancer susceptibility or the emergence or status of a prostate tumor.

Methods for detecting and quantifying the expression of 108P5H8 mRNA or protein are described herein, and standard nucleic acid and protein detection and quantification technologies are well known in the art. Standard methods for the detection and quantification of 108P5H8 mRNA include *in situ* hybridization using labeled 108P5H8 riboprobes, Northern blot and related techniques using 108P5H8 polynucleotide probes, RT-PCR analysis using primers specific for 108P5H8, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like. In a specific embodiment, semi-quantitative RT-PCR is used to detect and quantify 108P5H8 mRNA expression. Any number of primers capable of amplifying 108P5H8 can be used for this purpose, including but not limited to the various primer sets specifically described herein. In a specific embodiment, polyclonal or monoclonal antibodies specifically reactive with the wild-type 108P5H8 protein can be used in an immunohistochemical assay of biopsied tissue.

IX.) Identification of Molecules That Interact With 108P5H8

The 108P5H8 protein and nucleic acid sequences disclosed herein allow a skilled artisan to identify proteins, small molecules and other agents that interact with 108P5H8, as well as pathways activated by 108P5H8 via any one of a variety of art accepted protocols. For example, one can utilize one of the so-called interaction trap systems (also referred to as the "two-hybrid assay"). In such systems, molecules interact and reconstitute a transcription factor which directs expression of a reporter gene, whereupon the expression of the reporter gene is assayed. Other systems identify protein-protein interactions *in vivo* through reconstitution of a eukaryotic transcriptional activator, see, e.g., U.S. Patent Nos. 5,955,280 issued 21 September 1999, 5,925,523 issued 20 July 1999, 5,846,722 issued 8 December 1998 and 6,004,746 issued 21 December 1999. Algorithms are also available in the art for genome-based predictions of protein function (see, e.g., Marcotte, *et al.*, Nature 402: 4 November 1999, 83-86).

Alternatively one can screen peptide libraries to identify molecules that interact with 108P5H8 protein sequences. In such methods, peptides that bind to 108P5H8 are identified by screening libraries that encode a random or controlled collection of amino acids. Peptides encoded by the libraries are expressed as fusion proteins of bacteriophage coat proteins, the bacteriophage particles are then screened against the 108P5H8 protein(s).

Accordingly, peptides having a wide variety of uses, such as therapeutic, prognostic or diagnostic reagents, are thus identified without any prior information on the structure of the expected ligand or receptor molecule. Typical peptide libraries and screening methods that can be used to identify molecules that interact with 108P5H8 protein sequences are disclosed for example in U.S. Patent Nos. 5,723,286 issued 3 March 1998 and 5,733,731 issued 31 March 1998.

Alternatively, cell lines that express 108P5H8 are used to identify protein-protein interactions mediated by 108P5H8. Such interactions can be examined using immunoprecipitation techniques (see, e.g., Hamilton B.J., *et al.* Biochem. Biophys. Res. Commun. 1999, 261:646-51). 108P5H8 protein can be immunoprecipitated from 108P5H8-expressing cell lines using anti-108P5H8 antibodies. Alternatively, antibodies against His-tag can be used in a cell line engineered to express fusions of 108P5H8 and a His-tag (vectors mentioned above). The immunoprecipitated complex can be examined for protein association by procedures such as Western blotting, ³⁵S-methionine labeling of proteins, protein microsequencing, silver staining and two-dimensional gel electrophoresis.

Small molecules and ligands that interact with 108P5H8 can be identified through related embodiments of such screening assays. For example, small molecules can be identified that interfere with protein function, including molecules that interfere with 108P5H8's ability to mediate phosphorylation and de-phosphorylation, interaction with DNA or RNA molecules as an indication of regulation of cell cycles, second messenger signaling or tumorigenesis. Similarly, small molecules that modulate 108P5H8-related ion channel, protein pump, or cell communication functions are identified and used to treat patients that have a cancer that expresses 108P5H8 (see, e.g., Hille, B., *Ionic Channels of Excitable Membranes* 2nd Ed., Sinauer Assoc., Sunderland, MA, 1992). Moreover, ligands that regulate 108P5H8 function can be identified based on their ability to bind 108P5H8 and activate a reporter construct. Typical methods are discussed for example in U.S. Patent No. 5,928,868 issued 27 July 1999, and include methods for forming hybrid ligands in which at least one ligand is a small molecule. In an illustrative embodiment, cells engineered to express a fusion protein of 108P5H8 and a DNA-binding protein are used to co-express a fusion protein of a hybrid ligand/small molecule and a cDNA library transcriptional activator protein. The cells further contain a reporter gene, the expression of which is conditioned on the proximity of the first and second fusion proteins to each other, an event that occurs only if the hybrid ligand binds to target sites on both hybrid proteins. Those cells that express the reporter gene are selected and the unknown small molecule or the unknown ligand is identified. This method provides a means of identifying modulators which activate or inhibit 108P5H8.

An embodiment of this invention comprises a method of screening for a molecule that interacts with an 108P5H8 amino acid sequence shown in Figure 2 or Figure 3, comprising the steps of contacting a population of molecules with a 108P5H8 amino acid sequence, allowing the population of molecules and the 108P5H8 amino acid sequence to interact under conditions that facilitate an interaction, determining the presence of a molecule that interacts with the 108P5H8 amino acid sequence, and then separating molecules that do not interact with the 108P5H8 amino acid sequence from molecules that do. In a specific embodiment, the method further comprises purifying, characterizing and identifying a molecule that interacts with the 108P5H8 amino acid sequence. The identified molecule can be used to modulate a function performed by 108P5H8. In a preferred embodiment, the 108P5H8 amino acid sequence is contacted with a library of peptides.

X.) Therapeutic Methods and Compositions

The identification of 108P5H8 as a protein that is normally expressed in a restricted set of tissues, but which is also expressed in prostate and other cancers, opens a number of therapeutic approaches to the treatment of such cancers. As contemplated herein, 108P5H8 functions as a transcription factor involved in activating tumor-promoting genes or repressing genes that block tumorigenesis.

Accordingly, therapeutic approaches that inhibit the activity of a 108P5H8 protein are useful for patients suffering from a cancer that expresses 108P5H8. These therapeutic approaches generally fall into two classes. One class comprises various methods for inhibiting the binding or association of a 108P5H8 protein with its binding partner or with other proteins. Another class comprises a variety of methods for inhibiting the transcription of a 108P5H8 gene or translation of 108P5H8 mRNA.

X.A.) Anti-Cancer Vaccines

The invention provides cancer vaccines comprising a 108P5H8-related protein or 108P5H8-related nucleic acid. In view of the expression of 108P5H8, cancer vaccines prevent and/or treat 108P5H8-expressing cancers with minimal or no effects on non-target tissues. The use of a tumor antigen in a vaccine that generates humoral and/or cell-mediated immune responses as anti-cancer therapy is well known in the art and has been employed in prostate cancer using human PSMA and rodent PAP immunogens (Hodge *et al.*, 1995, *Int. J. Cancer* 63:231-237; Fong *et al.*, 1997, *J. Immunol.* 159:3113-3117).

Such methods can be readily practiced by employing a 108P5H8-related protein, or an 108P5H8-encoding nucleic acid molecule and recombinant vectors capable of expressing and presenting the 108P5H8 immunogen (which typically comprises a number of antibody or T cell epitopes). Skilled artisans understand that a wide variety of vaccine systems for delivery of immunoreactive epitopes are known in the art (see, e.g., Heryln *et al.*, *Ann Med* 1999 Feb 31(1):66-78; Maruyama *et al.*, *Cancer Immunol Immunother* 2000 Jun 49(3):123-32). Briefly, such methods of generating an immune response (e.g. humoral and/or cell-mediated) in a mammal, comprise the steps of: exposing the mammal's immune system to an immunoreactive epitope (e.g. an epitope present in a 108P5H8 protein shown in Figure 3 or analog or homolog thereof) so that the mammal generates an immune response that is specific for that

epitope (e.g. generates antibodies that specifically recognize that epitope). In a preferred method, a 108P5H8 immunogen contains a biological motif, see e.g., Tables V-XVIII, XXII, and XXIII, or a peptide of a size range from 108P5H8 indicated in Figure 5, Figure 6, Figure 7, Figure 8, and Figure 9.

The entire 108P5H8 protein, immunogenic regions or epitopes thereof can be combined and delivered by various means. Such vaccine compositions can include, for example, lipopeptides (e.g., Vitiello, A. *et al.*, *J. Clin. Invest.* 95:341, 1995), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, *et al.*, *Molec. Immunol.* 28:287-294, 1991; Alonso *et al.*, *Vaccine* 12:299-306, 1994; Jones *et al.*, *Vaccine* 13:675-681, 1995), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi *et al.*, *Nature* 344:873-875, 1990; Hu *et al.*, *Clin Exp Immunol.* 113:235-243, 1998), multiple antigen peptide systems (MAPs) (see e.g., Tam, J. P., *Proc. Natl. Acad. Sci. U.S.A.* 85:5409-5413, 1988; Tam, J.P., *J. Immunol. Methods* 196:17-32, 1996), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, M. E. *et al.*, In: *Concepts in vaccine development*, Kaufmann, S. H. E., ed., p. 379, 1996; Chakrabarti, S. *et al.*, *Nature* 320:535, 1986; Hu, S. L. *et al.*, *Nature* 320:537, 1986; Kieny, M.-P. *et al.*, *AIDS Bio/Technology* 4:790, 1986; Top, F. H. *et al.*, *J. Infect. Dis.* 124:148, 1971; Chanda, P. K. *et al.*, *Virology* 175:535, 1990), particles of viral or synthetic origin (e.g., Kofler, N. *et al.*, *J. Immunol. Methods.* 192:25, 1996; Eldridge, J. H. *et al.*, *Sem. Hematol.* 30:16, 1993; Falo, L. D., Jr. *et al.*, *Nature Med.* 7:649, 1995), adjuvants (Warren, H. S., Vogel, F. R., and Chedid, L. A. *Annu. Rev. Immunol.* 4:369, 1986; Gupta, R. K. *et al.*, *Vaccine* 11:293, 1993), liposomes (Reddy, R. *et al.*, *J. Immunol.* 148:1585, 1992; Rock, K. L., *Immunol. Today* 17:131, 1996), or, naked or particle absorbed cDNA (Ulmer, J. B. *et al.*, *Science* 259:1745, 1993; Robinson, H. L., Hunt, L. A., and Webster, R. G., *Vaccine* 11:957, 1993; Shiver, J. W. *et al.*, In: *Concepts in vaccine development*, Kaufmann, S. H. E., ed., p. 423, 1996; Cease, K. B., and Berzofsky, J. A., *Annu. Rev. Immunol.* 12:923, 1994 and Eldridge, J. H. *et al.*, *Sem. Hematol.* 30:16, 1993). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

In patients with 108P5H8-associated cancer, the vaccine compositions of the invention can also be used in conjunction with other treatments used for cancer, e.g., surgery, chemotherapy, drug therapies, radiation therapies, etc. including use in combination with immune adjuvants such as IL-2, IL-12, GM-CSF, and the like.

Cellular Vaccines:

CTL epitopes can be determined using specific algorithms to identify peptides within 108P5H8 protein that bind corresponding HLA alleles (see e.g., Table IV; Epimer™ and Epimatrix™, Brown University (URL www.brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html); and, BIMAS, (URL bimas.dcrt.nih.gov/; SYFPEITHI at URL syfpeithi.bmi-heidelberg.com/). In a preferred embodiment, a 108P5H8 immunogen contains one or more amino acid sequences identified using techniques well known in the art, such as the sequences shown in Tables V-XVIII, XXII, and XXIII or a peptide of 8, 9, 10 or 11 amino acids specified by an HLA Class I motif/supermotif (e.g., Table IV (A), Table IV (D), or Table IV

(E)) and/or a peptide of at least 9 amino acids that comprises an HLA Class II motif/supermotif (e.g., Table IV (B) or Table IV (C)). As is appreciated in the art, the HLA Class I binding groove is essentially closed ended so that peptides of only a particular size range can fit into the groove and be bound, generally HLA Class I epitopes are 8, 9, 10, or 11 amino acids long. In contrast, the HLA Class II binding groove is essentially open ended; therefore a peptide of about 9 or more amino acids can be bound by an HLA Class II molecule. Due to the binding groove differences between HLA Class I and II, HLA Class I motifs are length specific, i.e., position two of a Class I motif is the second amino acid in an amino to carboxyl direction of the peptide. The amino acid positions in a Class II motif are relative only to each other, not the overall peptide, i.e., additional amino acids can be attached to the amino and/or carboxyl termini of a motif-bearing sequence. HLA Class II epitopes are often 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids long, or longer than 25 amino acids.

Antibody-based Vaccines

A wide variety of methods for generating an immune response in a mammal are known in the art (for example as the first step in the generation of hybridomas). Methods of generating an immune response in a mammal comprise exposing the mammal's immune system to an immunogenic epitope on a protein (e.g. a 108P5H8 protein) so that an immune response is generated. A typical embodiment consists of a method for generating an immune response to 108P5H8 in a host, by contacting the host with a sufficient amount of at least one 108P5H8 B cell or cytotoxic T-cell epitope or analog thereof; and at least one periodic interval thereafter re-contacting the host with the 108P5H8 B cell or cytotoxic T-cell epitope or analog thereof. A specific embodiment consists of a method of generating an immune response against a 108P5H8-related protein or a man-made multiepitopic peptide comprising: administering 108P5H8 immunogen (e.g. a 108P5H8 protein or a peptide fragment thereof, an 108P5H8 fusion protein or analog etc.) in a vaccine preparation to a human or another mammal. Typically, such vaccine preparations further contain a suitable adjuvant (see, e.g., U.S. Patent No. 6,146,635) or a universal helper epitope such as a PADRE™ peptide (Epimmune Inc., San Diego, CA; see, e.g., Alexander *et al.*, J. Immunol. 2000 164(3); 164(3): 1625-1633; Alexander *et al.*, Immunity 1994 1(9): 751-761 and Alexander *et al.*, Immunol. Res. 1998 18(2): 79-92). An alternative method comprises generating an immune response in an individual against a 108P5H8 immunogen by: administering *in vivo* to muscle or skin of the individual's body a DNA molecule that comprises a DNA sequence that encodes an 108P5H8 immunogen, the DNA sequence operatively linked to regulatory sequences which control the expression of the DNA sequence; wherein the DNA molecule is taken up by cells, the DNA sequence is expressed in the cells and an immune response is generated against the immunogen (see, e.g., U.S. Patent No. 5,962,428). Optionally a genetic vaccine facilitator such as anionic lipids; saponins; lectins; estrogenic compounds; hydroxylated lower alkyls; dimethyl sulfoxide; and urea is also administered. In addition, an antiidiotypic antibody can be administered that mimics 108P5H8, in order to generate a response to the target antigen.

Nucleic Acid Vaccines:

Vaccine compositions of the invention include nucleic acid-mediated modalities. DNA or RNA that encode protein(s) of the invention can be administered to a patient. Genetic immunization methods can be employed to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing 108P5H8. Constructs comprising DNA encoding a 108P5H8-related protein/immunogen and appropriate regulatory sequences can be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded 108P5H8 protein/immunogen. Alternatively, a vaccine comprises a 108P5H8-related protein. Expression of the 108P5H8-related protein immunogen results in the generation of prophylactic or therapeutic humoral and cellular immunity against cells that bear a 108P5H8 protein. Various prophylactic and therapeutic genetic immunization techniques known in the art can be used (for review, see information and references published at Internet address www.genweb.com). Nucleic acid-based delivery is described, for instance, in Wolff *et al.*, *Science* 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivacaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (*see, e.g.*, U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, proteins of the invention can be expressed via viral or bacterial vectors. Various viral gene delivery systems that can be used in the practice of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbis virus (*see, e.g.*, Restifo, 1996, *Curr. Opin. Immunol.* 8:658-663; Tsang *et al.* *J. Natl. Cancer Inst.* 87:982-990 (1995)). Non-viral delivery systems can also be employed by introducing naked DNA encoding a 108P5H8-related protein into the patient (*e.g.*, intramuscularly or intradermally) to induce an anti-tumor response.

Vaccinia virus is used, for example, as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into a host, the recombinant vaccinia virus expresses the protein immunogenic peptide, and thereby elicits a host immune response. Vaccinia vectors and methods useful in immunization protocols are described in, *e.g.*, U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover *et al.*, *Nature* 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, *e.g.* adeno and adeno-associated virus vectors, retroviral vectors, *Salmonella typhi* vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein.

Thus, gene delivery systems are used to deliver a 108P5H8-related nucleic acid molecule. In one embodiment, the full-length human 108P5H8 cDNA is employed. In another embodiment, 108P5H8 nucleic acid molecules encoding specific cytotoxic T lymphocyte (CTL) and/or antibody epitopes, are employed.

Ex Vivo Vaccines

Various *ex vivo* strategies can also be employed to generate an immune response. One approach involves the use of antigen presenting cells (APCs) such as dendritic cells (DC) to present 108P5H8 antigen to

a patient's immune system. Dendritic cells express MHC class I and II molecules, B7 co-stimulator, and IL-12, and are thus highly specialized antigen presenting cells. In prostate cancer, autologous dendritic cells pulsed with peptides of the prostate-specific membrane antigen (PSMA) are being used in a Phase I clinical trial to stimulate prostate cancer patients' immune systems (Tjoa *et al.*, 1996, Prostate 28:65-69; Murphy *et al.*, 1996, Prostate 29:371-380). Thus, dendritic cells can be used to present 108P5H8 peptides to T cells in the context of MHC class I or II molecules. In one embodiment, autologous dendritic cells are pulsed with 108P5H8 peptides capable of binding to MHC class I and/or class II molecules. In another embodiment, dendritic cells are pulsed with the complete 108P5H8 protein. Yet another embodiment involves engineering the overexpression of a 108P5H8 gene in dendritic cells using various implementing vectors known in the art, such as adenovirus (Arthur *et al.*, 1997, Cancer Gene Ther. 4:17-25), retrovirus (Henderson *et al.*, 1996, Cancer Res. 56:3763-3770), lentivirus, adeno-associated virus, DNA transfection (Ribas *et al.*, 1997, Cancer Res. 57:2865-2869), or tumor-derived RNA transfection (Ashley *et al.*, 1997, J. Exp. Med. 186:1177-1182). Cells that express 108P5H8 can also be engineered to express immune modulators, such as GM-CSF, and used as immunizing agents.

X.B.) 108P5H8 as a Target for Antibody-based Therapy

108P5H8 is an attractive target for antibody-based therapeutic strategies. A number of antibody strategies are known in the art for targeting both extracellular and intracellular molecules (see, e.g., complement and ADCC mediated killing as well as the use of intrabodies). Because 108P5H8 is expressed by cancer cells of various lineages relative to corresponding normal cells, systemic administration of 108P5H8-immunoreactive compositions are prepared that exhibit excellent sensitivity without toxic, non-specific and/or non-target effects caused by binding of the immunoreactive composition to non-target organs and tissues. Antibodies specifically reactive with domains of 108P5H8 are useful to treat 108P5H8-expressing cancers systemically, either as conjugates with a toxin or therapeutic agent, or as naked antibodies capable of inhibiting cell proliferation or function.

108P5H8 antibodies can be introduced into a patient such that the antibody binds to 108P5H8 and modulates a function, such as an interaction with a binding partner, and consequently mediates destruction of the tumor cells and/or inhibits the growth of the tumor cells. Mechanisms by which such antibodies exert a therapeutic effect can include complement-mediated cytotoxicity, antibody-dependent cellular cytotoxicity, modulation of the physiological function of 108P5H8, inhibition of ligand binding or signal transduction pathways, modulation of tumor cell differentiation, alteration of tumor angiogenesis factor profiles, and/or apoptosis.

Those skilled in the art understand that antibodies can be used to specifically target and bind immunogenic molecules such as an immunogenic region of a 108P5H8 sequence shown in Figure 2 or Figure 3. In addition, skilled artisans understand that it is routine to conjugate antibodies to cytotoxic agents (see, e.g., Slevers *et al. Blood* 93:11 3678-3684 (June 1, 1999)). When cytotoxic and/or therapeutic agents are delivered directly to cells, such as by conjugating them to antibodies specific for a molecule

expressed by that cell (e.g. 108P5H8), the cytotoxic agent will exert its known biological effect (i.e. cytotoxicity) on those cells.

A wide variety of compositions and methods for using antibody-cytotoxic agent conjugates to kill cells are known in the art. In the context of cancers, typical methods entail administering to an animal having a tumor a biologically effective amount of a conjugate comprising a selected cytotoxic and/or therapeutic agent linked to a targeting agent (e.g. an anti-108P5H8 antibody) that binds to a marker (e.g. 108P5H8) expressed, accessible to binding or localized on the cell surfaces. A typical embodiment is a method of delivering a cytotoxic and/or therapeutic agent to a cell expressing 108P5H8, comprising conjugating the cytotoxic agent to an antibody that immunospecifically binds to a 108P5H8 epitope, and, exposing the cell to the antibody-agent conjugate. Another illustrative embodiment is a method of treating an individual suspected of suffering from metastasized cancer, comprising a step of administering parenterally to said individual a pharmaceutical composition comprising a therapeutically effective amount of an antibody conjugated to a cytotoxic and/or therapeutic agent.

Cancer immunotherapy using anti-108P5H8 antibodies can be done in accordance with various approaches that have been successfully employed in the treatment of other types of cancer, including but not limited to colon cancer (Arlen *et al.*, 1998, Crit. Rev. Immunol. 18:133-138), multiple myeloma (Ozaki *et al.*, 1997, Blood 90:3179-3186, Tsunenari *et al.*, 1997, Blood 90:2437-2444), gastric cancer (Kasprzyk *et al.*, 1992, Cancer Res. 52:2771-2776), B-cell lymphoma (Funakoshi *et al.*, 1996, J. Immunother. Emphasis Tumor Immunol. 19:93-101), leukemia (Zhong *et al.*, 1996, Leuk. Res. 20:581-589), colorectal cancer (Moun *et al.*, 1994, Cancer Res. 54:6160-6166; Velders *et al.*, 1995, Cancer Res. 55:4398-4403), and breast cancer (Shepard *et al.*, 1991, J. Clin. Immunol. 11:117-127). Some therapeutic approaches involve conjugation of naked antibody to a toxin or radioisotope, such as the conjugation of Y^{91} or I^{131} to anti-CD20 antibodies (e.g., ZevalinTM, IDEC Pharmaceuticals Corp. or BexxarTM, Coulter Pharmaceuticals), while others involve co-administration of antibodies and other therapeutic agents, such as HerceptinTM (trastuzumab) with paclitaxel (Genentech, Inc.). The antibodies can be conjugated to a therapeutic agent. To treat prostate cancer, for example, 108P5H8 antibodies can be administered in conjunction with radiation, chemotherapy or hormone ablation. Also, antibodies can be conjugated to a toxin such as calicheamicin (e.g., MylotargTM, Wyeth-Ayerst, Madison, NJ, a recombinant humanized IgG₄ kappa antibody conjugated to antitumor antibiotic calicheamicin) or a maytansinoid (e.g., taxane-based Tumor-Activated Prodrug, TAP, platform, ImmunoGen, Cambridge, MA, also see e.g., US Patent 5,416,064).

Although 108P5H8 antibody therapy is useful for all stages of cancer, antibody therapy can be particularly appropriate in advanced or metastatic cancers. Treatment with the antibody therapy of the invention is indicated for patients who have received one or more rounds of chemotherapy. Alternatively, antibody therapy of the invention is combined with a chemotherapeutic or radiation regimen for patients who have not received chemotherapeutic treatment. Additionally, antibody therapy can enable the use of reduced dosages of concomitant chemotherapy, particularly for patients who do not tolerate the toxicity of the chemotherapeutic agent very well. Fan *et al.* (Cancer Res. 53:4637-4642, 1993), Prewett *et al.*

(International J. of Onco. 9:217-224, 1996), and Hancock et al. (Cancer Res. 51:4575-4580, 1991) describe the use of various antibodies together with chemotherapeutic agents.

Although 108P5H8 antibody therapy is useful for all stages of cancer, antibody therapy can be particularly appropriate in advanced or metastatic cancers. Treatment with the antibody therapy of the invention is indicated for patients who have received one or more rounds of chemotherapy. Alternatively, antibody therapy of the invention is combined with a chemotherapeutic or radiation regimen for patients who have not received chemotherapeutic treatment. Additionally, antibody therapy can enable the use of reduced dosages of concomitant chemotherapy, particularly for patients who do not tolerate the toxicity of the chemotherapeutic agent very well.

Cancer patients can be evaluated for the presence and level of 108P5H8 expression, preferably using immunohistochemical assessments of tumor tissue, quantitative 108P5H8 imaging, or other techniques that reliably indicate the presence and degree of 108P5H8 expression. Immunohistochemical analysis of tumor biopsies or surgical specimens is preferred for this purpose. Methods for immunohistochemical analysis of tumor tissues are well known in the art.

Anti-108P5H8 monoclonal antibodies that treat prostate and other cancers include those that initiate a potent immune response against the tumor or those that are directly cytotoxic. In this regard, anti-108P5H8 monoclonal antibodies (mAbs) can elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites on complement proteins. In addition, anti-108P5H8 mAbs that exert a direct biological effect on tumor growth are useful to treat cancers that express 108P5H8. Mechanisms by which directly cytotoxic mAbs act include: inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism(s) by which a particular anti-108P5H8 mAb exerts an anti-tumor effect is evaluated using any number of *in vitro* assays that evaluate cell death such as ADCC, ADMMC, complement-mediated cell lysis, and so forth, as is generally known in the art.

In some patients, the use of murine or other non-human monoclonal antibodies, or human/mouse chimeric mAbs can induce moderate to strong immune responses against the non-human antibody. This can result in clearance of the antibody from circulation and reduced efficacy. In the most severe cases, such an immune response can lead to the extensive formation of immune complexes which, potentially, can cause renal failure. Accordingly, preferred monoclonal antibodies used in the therapeutic methods of the invention are those that are either fully human or humanized and that bind specifically to the target 108P5H8 antigen with high affinity but exhibit low or no antigenicity in the patient.

Therapeutic methods of the invention contemplate the administration of single anti-108P5H8 mAbs as well as combinations, or cocktails, of different mAbs. Such mAb cocktails can have certain advantages inasmuch as they contain mAbs that target different epitopes, exploit different effector mechanisms or combine directly cytotoxic mAbs with mAbs that rely on immune effector functionality. Such mAbs in combination can exhibit synergistic therapeutic effects. In addition, anti-108P5H8 mAbs

can be administered concomitantly with other therapeutic modalities, including but not limited to various chemotherapeutic agents, androgen-blockers, immune modulators (e.g., IL-2, GM-CSF), surgery or radiation. The anti-108P5H8 mAbs are administered in their "naked" or unconjugated form, or can have a therapeutic agent(s) conjugated to them.

Anti-108P5H8 antibody formulations are administered via any route capable of delivering the antibodies to a tumor cell. Routes of administration include, but are not limited to, intravenous, intraperitoneal, intramuscular, intratumor, intradermal, and the like. Treatment generally involves repeated administration of the anti-108P5H8 antibody preparation, via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1, .2, .3, .4, .5, .6, .7, .8, .9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 mg/kg body weight. In general, doses in the range of 10-1000 mg mAb per week are effective and well tolerated.

Based on clinical experience with the Herceptin™ mAb in the treatment of metastatic breast cancer, an initial loading dose of approximately 4 mg/kg patient body weight IV, followed by weekly doses of about 2 mg/kg IV of the anti-108P5H8 mAb preparation represents an acceptable dosing regimen. Preferably, the initial loading dose is administered as a 90 minute or longer infusion. The periodic maintenance dose is administered as a 30 minute or longer infusion, provided the initial dose was well tolerated. As appreciated by those of skill in the art, various factors can influence the ideal dose regimen in a particular case. Such factors include, for example, the binding affinity and half life of the Ab or mAbs used, the degree of 108P5H8 expression in the patient, the extent of circulating shed 108P5H8 antigen, the desired steady-state antibody concentration level, frequency of treatment, and the influence of chemotherapeutic or other agents used in combination with the treatment method of the invention, as well as the health status of a particular patient.

Optionally, patients should be evaluated for the levels of 108P5H8 in a given sample (e.g. the levels of circulating 108P5H8 antigen and/or 108P5H8 expressing cells) in order to assist in the determination of the most effective dosing regimen, etc. Such evaluations are also used for monitoring purposes throughout therapy, and are useful to gauge therapeutic success in combination with the evaluation of other parameters (for example, urine cytology and/or ImmunoCyt levels in bladder cancer therapy, or by analogy, serum PSA levels in prostate cancer therapy).

Anti-idiotypic anti-108P5H8 antibodies can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing a 108P5H8-related protein. In particular, the generation of anti-idiotypic antibodies is well known in the art; this methodology can readily be adapted to generate anti-idiotypic anti-108P5H8 antibodies that mimic an epitope on a 108P5H8-related protein (see, for example, Wagner *et al.*, 1997, Hybridoma 16: 33-40; Foon *et al.*, 1995, J. Clin. Invest. 96:334-342; Herlyn *et al.*, 1996, Cancer Immunol. Immunother. 43:65-76). Such an anti-idiotypic antibody can be used in cancer vaccine strategies.

X.C.) 108P5H8 as a Target for Cellular Immune Responses

Vaccines and methods of preparing vaccines that contain an immunogenically effective amount of one or more HLA-binding peptides as described herein are further embodiments of the invention. Furthermore, vaccines in accordance with the invention encompass compositions of one or more of the claimed peptides. A peptide can be present in a vaccine individually. Alternatively, the peptide can exist as a homopolymer comprising multiple copies of the same peptide, or as a heteropolymer of various peptides. Polymers have the advantage of increased immunological reaction and, where different peptide epitopes are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the pathogenic organism or tumor-related peptide targeted for an immune response. The composition can be a naturally occurring region of an antigen or can be prepared, *e.g.*, recombinantly or by chemical synthesis.

Carriers that can be used with vaccines of the invention are well known in the art, and include, *e.g.*, thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly L-lysine, poly L-glutamic acid, influenza, hepatitis B virus core protein, and the like. The vaccines can contain a physiologically tolerable (*i.e.*, acceptable) diluent such as water, or saline, preferably phosphate buffered saline. The vaccines also typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are examples of materials well known in the art. Additionally, as disclosed herein, CTL responses can be primed by conjugating peptides of the invention to lipids, such as tripalmitoyl-S-glycerylcysteinylserine (P₃CSS). Moreover, an adjuvant such as a synthetic cytosine-phosphorothiolated-guanine-containing (CpG) oligonucleotides has been found to increase CTL responses 10- to 100-fold. (see, *e.g.* Davila and Celis *J. Immunol.* 165:539-547 (2000))

Upon immunization with a peptide composition in accordance with the invention, via injection, aerosol, oral, transdermal, transmucosal, intrapleural, intrathecal, or other suitable routes, the immune system of the host responds to the vaccine by producing large amounts of CTLs and/or HTLs specific for the desired antigen. Consequently, the host becomes at least partially immune to later development of cells that express or overexpress 108P5H8 antigen, or derives at least some therapeutic benefit when the antigen was tumor-associated.

In some embodiments, it may be desirable to combine the class I peptide components with components that induce or facilitate neutralizing antibody and or helper T cell responses directed to the target antigen. A preferred embodiment of such a composition comprises class I and class II epitopes in accordance with the invention. An alternative embodiment of such a composition comprises a class I and/or class II epitope in accordance with the invention, along with a cross reactive HTL epitope such as PADRE™ (Epimmune, San Diego, CA) molecule (described *e.g.*, in U.S. Patent Number 5,736,142).

A vaccine of the invention can also include antigen-presenting cells (APC), such as dendritic cells (DC), as a vehicle to present peptides of the invention. Vaccine compositions can be created *in vitro*, following dendritic cell mobilization and harvesting, whereby loading of dendritic cells occurs *in vitro*. For example, dendritic cells are transfected, *e.g.*, with a minigene in accordance with the invention, or are pulsed with peptides. The dendritic cell can then be administered to a patient to elicit immune responses *in*

vivo. Vaccine compositions, either DNA- or peptide-based, can also be administered *in vivo* in combination with dendritic cell mobilization whereby loading of dendritic cells occurs *in vivo*.

Preferably, the following principles are utilized when selecting an array of epitopes for inclusion in a polypeptidic composition for use in a vaccine, or for selecting discrete epitopes to be included in a vaccine and/or to be encoded by nucleic acids such as a minigene. It is preferred that each of the following principles be balanced in order to make the selection. The multiple epitopes to be incorporated in a given vaccine composition may be, but need not be, contiguous in sequence in the native antigen from which the epitopes are derived.

1.) Epitopes are selected which, upon administration, mimic immune responses that have been observed to be correlated with tumor clearance. For HLA Class I this includes 3-4 epitopes that come from at least one tumor associated antigen (TAA). For HLA Class II a similar rationale is employed; again 3-4 epitopes are selected from at least one TAA (*see, e.g., Rosenberg et al., Science* 278:1447-1450). Epitopes from one TAA may be used in combination with epitopes from one or more additional TAAs to produce a vaccine that targets tumors with varying expression patterns of frequently-expressed TAAs.

2.) Epitopes are selected that have the requisite binding affinity established to be correlated with immunogenicity: for HLA Class I an IC_{50} of 500 nM or less, often 200 nM or less; and for Class II an IC_{50} of 1000 nM or less.

3.) Sufficient supermotif bearing-peptides, or a sufficient array of allele-specific motif-bearing peptides, are selected to give broad population coverage. For example, it is preferable to have at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess the breadth, or redundancy of, population coverage.

4.) When selecting epitopes from cancer-related antigens it is often useful to select analogs because the patient may have developed tolerance to the native epitope.

5.) Of particular relevance are epitopes referred to as "nested epitopes." Nested epitopes occur where at least two epitopes overlap in a given peptide sequence. A nested peptide sequence can comprise B cell, HLA class I and/or HLA class II epitopes. When providing nested epitopes, a general objective is to provide the greatest number of epitopes per sequence. Thus, an aspect is to avoid providing a peptide that is any longer than the amino terminus of the amino terminal epitope and the carboxyl terminus of the carboxyl terminal epitope in the peptide. When providing a multi-epitopic sequence, such as a sequence comprising nested epitopes, it is generally important to screen the sequence in order to insure that it does not have pathological or other deleterious biological properties.

6.) If a polypeptidic protein is created, or when creating a minigene, an objective is to generate the smallest peptide that encompasses the epitopes of interest. This principle is similar, if not the same as that employed when selecting a peptide comprising nested epitopes. However, with an artificial polypeptidic peptide, the size minimization objective is balanced against the need to integrate any spacer sequences between epitopes in the polypeptidic protein. Spacer amino acid residues can, for example, be introduced to avoid junctional epitopes (an epitope recognized by the immune system, not present in the

target antigen, and only created by the man-made juxtaposition of epitopes), or to facilitate cleavage between epitopes and thereby enhance epitope presentation. Junctional epitopes are generally to be avoided because the recipient may generate an immune response to that non-native epitope. Of particular concern is a junctional epitope that is a "dominant epitope." A dominant epitope may lead to such a zealous response that immune responses to other epitopes are diminished or suppressed.

7.) Where the sequences of multiple variants of the same target protein are present, potential peptide epitopes can also be selected on the basis of their conservancy. For example, a criterion for conservancy may define that the entire sequence of an HLA class I binding peptide or the entire 9-mer core of a class II binding peptide be conserved in a designated percentage of the sequences evaluated for a specific protein antigen.

X.C.1. Minigene Vaccines

A number of different approaches are available which allow simultaneous delivery of multiple epitopes. Nucleic acids encoding the peptides of the invention are a particularly useful embodiment of the invention. Epitopes for inclusion in a minigene are preferably selected according to the guidelines set forth in the previous section. A preferred means of administering nucleic acids encoding the peptides of the invention uses minigene constructs encoding a peptide comprising one or multiple epitopes of the invention.

The use of multi-epitope minigenes is described below and in, Ishioka *et al.*, *J. Immunol.* 162:3915-3925, 1999; An, L. and Whitton, J. L., *J. Virol.* 71:2292, 1997; Thomson, S. A. *et al.*, *J. Immunol.* 157:822, 1996; Whitton, J. L. *et al.*, *J. Virol.* 67:348, 1993; Hanke, R. *et al.*, *Vaccine* 16:426, 1998. For example, a multi-epitope DNA plasmid encoding supermotif- and/or motif-bearing epitopes derived 108P5H8, the PADRE® universal helper T cell epitope (or multiple HTL epitopes from 108P5H8), and an endoplasmic reticulum-translocating signal sequence can be engineered. A vaccine may also comprise epitopes that are derived from other TAAs.

The immunogenicity of a multi-epitopic minigene can be confirmed in transgenic mice to evaluate the magnitude of CTL induction responses against the epitopes tested. Further, the immunogenicity of DNA-encoded epitopes *in vivo* can be correlated with the *in vitro* responses of specific CTL lines against target cells transfected with the DNA plasmid. Thus, these experiments can show that the minigene serves to both: 1.) generate a CTL response and 2.) that the induced CTLs recognized cells expressing the encoded epitopes.

For example, to create a DNA sequence encoding the selected epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes may be reverse translated. A human codon usage table can be used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences may be directly adjoined, so that when translated, a continuous polypeptide sequence is created. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequences that can be reverse translated and included in the minigene sequence include: HLA class I epitopes, HLA class II epitopes, antibody epitopes, a ubiquitination signal

sequence, and/or an endoplasmic reticulum targeting signal. In addition, HLA presentation of CTL and HTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL or HTL epitopes; these larger peptides comprising the epitope(s) are within the scope of the invention.

5 The minigene sequence may be converted to DNA by assembling oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) may be synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides can be joined, for example, using T4 DNA ligase. This synthetic minigene, encoding the epitope polypeptide, can then be cloned into a desired expression vector.

10 Standard regulatory sequences well known to those of skill in the art are preferably included in the vector to ensure expression in the target cells. Several vector elements are desirable: a promoter with a down-stream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an *E. coli* origin of replication; and an *E. coli* selectable marker (e.g. ampicillin or kanamycin resistance). Numerous promoters can be used for this purpose, e.g., the human cytomegalovirus (hCMV) promoter. See, e.g., U.S. Patent Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.

15 Additional vector modifications may be desired to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene expression, and one or more synthetic or naturally-occurring introns could be incorporated into the transcribed region of the minigene. The inclusion of mRNA stabilization sequences and sequences for replication in mammalian cells may also be considered for increasing minigene expression.

20 Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate *E. coli* strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis. Bacterial cells harboring the correct plasmid can be stored as a master cell bank and a working cell bank.

25 In addition, immunostimulatory sequences (ISSs or CpGs) appear to play a role in the immunogenicity of DNA vaccines. These sequences may be included in the vector, outside the minigene coding sequence, if desired to enhance immunogenicity.

30 In some embodiments, a bi-cistronic expression vector which allows production of both the minigene-encoded epitopes and a second protein (included to enhance or decrease immunogenicity) can be used. Examples of proteins or polypeptides that could beneficially enhance the immune response if co-expressed include cytokines (e.g., IL-2, IL-12, GM-CSF), cytokine-inducing molecules (e.g., LclF), costimulatory molecules, or for HTL responses, pan-DR binding proteins (PADRE™, Epimmune, San Diego, CA). Helper (HTL) epitopes can be joined to intracellular targeting signals and expressed separately from expressed CTL epitopes; this allows direction of the HTL epitopes to a cell compartment different than that of the CTL epitopes. If required, this could facilitate more efficient entry of HTL epitopes into the HLA class II pathway, thereby improving HTL induction. In contrast to HTL or CTL

induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e.g. TGF- β) may be beneficial in certain diseases.

Therapeutic quantities of plasmid DNA can be produced for example, by fermentation in *E. coli*, followed by purification. Aliquots from the working cell bank are used to inoculate growth medium, and grown to saturation in shaker flasks or a bioreactor according to well-known techniques. Plasmid DNA can be purified using standard bioseparation technologies such as solid phase anion-exchange resins supplied by QIAGEN, Inc. (Valencia, California). If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods.

Purified plasmid DNA can be prepared for injection using a variety of formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). This approach, known as "naked DNA," is currently being used for intramuscular (IM) administration in clinical trials. To maximize the immunotherapeutic effects of minigene DNA vaccines, an alternative method for formulating purified plasmid DNA may be desirable. A variety of methods have been described, and new techniques may become available. Cationic lipids, glycolipids, and fusogenic liposomes can also be used in the formulation (see, e.g., as described by WO 93/24640; Mannino & Gould-Fogerite, *BioTechniques* 6(7): 682 (1988); U.S. Pat No. 5,279,833; WO 91/06309; and Felgner, *et al.*, *Proc. Nat'l Acad. Sci. USA* 84:7413 (1987). In addition, peptides and compounds referred to collectively as protective, interactive, non-condensing compounds (PINC) could also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.

Target cell sensitization can be used as a functional assay for expression and HLA class I presentation of minigene-encoded CTL epitopes. For example, the plasmid DNA is introduced into a mammalian cell line that is suitable as a target for standard CTL chromium release assays. The transfection method used will be dependent on the final formulation. Electroporation can be used for "naked" DNA, whereas cationic lipids allow direct *in vitro* transfection. A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). These cells are then chromium-51 (^{51}Cr) labeled and used as target cells for epitope-specific CTL lines; cytolysis, detected by ^{51}Cr release, indicates both production of, and HLA presentation of, minigene-encoded CTL epitopes. Expression of HTL epitopes may be evaluated in an analogous manner using assays to assess HTL activity.

In vivo immunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human HLA proteins are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g., IM for DNA in PBS, intraperitoneal (i.p.) for lipid-complexed DNA). Twenty-one days after immunization, splenocytes are harvested and restimulated for one week in the presence of peptides encoding each epitope being tested. Thereafter, for CTL effector cells, assays are conducted for cytolysis of peptide-loaded, ^{51}Cr -labeled target cells using standard techniques. Lysis of target cells that were sensitized by HLA loaded with peptide epitopes, corresponding to minigene-encoded epitopes, demonstrates DNA vaccine function for *in vivo*

Alternatively, the nucleic acids can be administered using ballistic delivery as described, for instance, in U.S. Patent No. 5,204,253. Using this technique, particles comprised solely of DNA are administered. In a further alternative embodiment, DNA can be adhered to particles, such as gold particles.

X.C.2. Combinations of CTL Peptides with Helper Peptides

For instance, the ability of a peptide to induce CTL activity can be enhanced by linking the peptide to a sequence which contains at least one epitope that is capable of inducing a T helper cell response. Although a CTL peptide can be directly linked to a T helper peptide, often CTL epitope/HTL epitope conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues and sometimes 10 or more residues. The CTL peptide epitope can be linked to the T helper peptide epitope either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated.

Alternatively, it is possible to prepare synthetic peptides capable of stimulating T helper lymphocytes, in a loosely HLA-restricted fashion, using amino acid sequences not found in nature (*see, e.g.,* PCT publication WO 95/07707). These synthetic compounds called Pan-DR-binding epitopes (*e.g.,* PADRE™, Epimmune, Inc., San Diego, CA) are designed to most preferably bind most HLA-DR (human HLA class II) molecules. For instance, a pan-DR-binding epitope peptide having the formula:

aKXVAAWTLKAAa (SEQ ID NO: 25854), where "X" is either cyclohexylalanine, phenylalanine, or tyrosine, and a is either D-alanine or L-alanine, has been found to bind to most HLA-DR alleles, and to stimulate the response of T helper lymphocytes from most individuals, regardless of their HLA type. An alternative of a pan-DR binding epitope comprises all "L" natural amino acids and can be provided in the form of nucleic acids that encode the epitope.

HTL peptide epitopes can also be modified to alter their biological properties. For example, they can be modified to include D-amino acids to increase their resistance to proteases and thus extend their serum half life, or they can be conjugated to other molecules such as lipids, proteins, carbohydrates, and the like to increase their biological activity. For example, a T helper peptide can be conjugated to one or more palmitic acid chains at either the amino or carboxyl termini.

X.C.3. Combinations of CTL Peptides with T Cell Priming Agents

In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which primes B lymphocytes or T lymphocytes. Lipids have been identified as agents capable of priming CTL *in vivo*. For example, palmitic acid residues can be attached to the ϵ - and α - amino groups of a lysine residue and then linked, *e.g.*, via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidated peptide can then be administered either directly in a micelle or particle, incorporated into a liposome, or emulsified in an adjuvant, *e.g.*, incomplete Freund's adjuvant. In a preferred embodiment, a particularly effective immunogenic composition comprises palmitic acid attached to ϵ - and α - amino groups of Lys, which is attached via linkage, *e.g.*, Ser-Ser, to the amino terminus of the immunogenic peptide.

As another example of lipid priming of CTL responses, *E. coli* lipoproteins, such as tripalmitoyl-S-glycerylcysteinylserine (P₃CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide (*see, e.g., Deres, et al., Nature* 342:561, 1989). Peptides of the invention can be coupled to P₃CSS, for example, and the lipopeptide administered to an individual to specifically prime an immune response to the target antigen. Moreover, because the induction of neutralizing antibodies can also be primed with P₃CSS-conjugated epitopes, two such compositions can be combined to more effectively elicit both humoral and cell-mediated responses.

X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL Peptides

An embodiment of a vaccine composition in accordance with the invention comprises *ex vivo* administration of a cocktail of epitope-bearing peptides to PBMC, or isolated DC therefrom, from the patient's blood. A pharmaceutical to facilitate harvesting of DC can be used, such as Progenipoiectin™ (Pharmacia-Monsanto, St. Louis, MO) or GM-CSF/IL-4. After pulsing the DC with peptides and prior to reinfusion into patients, the DC are washed to remove unbound peptides. In this embodiment, a vaccine comprises peptide-pulsed DCs which present the pulsed peptide epitopes complexed with HLA molecules on their surfaces.

The DC can be pulsed *ex vivo* with a cocktail of peptides, some of which stimulate CTL responses to 108P5H8. Optionally, a helper T cell (HTL) peptide, such as a natural or artificial loosely restricted HLA Class II peptide, can be included to facilitate the CTL response. Thus, a vaccine in accordance with the invention is used to treat a cancer which expresses or overexpresses 108P5H8.

X.D. Adoptive Immunotherapy

Antigenic 108P5H8-related peptides are used to elicit a CTL and/or HTL response *ex vivo*, as well. The resulting CTL or HTL cells, can be used to treat tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a therapeutic vaccine peptide or nucleic acid in accordance with the invention. *Ex vivo* CTL or HTL responses to a particular antigen are induced by incubating in tissue culture the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of antigen-presenting cells (APC), such as dendritic cells, and the appropriate immunogenic peptide. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cell (e.g., a tumor cell). Transfected dendritic cells may also be used as antigen presenting cells.

X.E. Administration of Vaccines for Therapeutic or Prophylactic Purposes

Pharmaceutical and vaccine compositions of the invention are typically used to treat and/or prevent a cancer that expresses or overexpresses 108P5H8. In therapeutic applications, peptide and/or nucleic acid compositions are administered to a patient in an amount sufficient to elicit an effective B cell, CTL and/or HTL response to the antigen and to cure or at least partially arrest or slow symptoms and/or complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on, e.g., the particular composition administered, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician.

For pharmaceutical compositions, the immunogenic peptides of the invention, or DNA encoding them, are generally administered to an individual already bearing a tumor that expresses 108P5H8. The peptides or DNA encoding them can be administered individually or as fusions of one or more peptide sequences. Patients can be treated with the immunogenic peptides separately or in conjunction with other treatments, such as surgery, as appropriate.

For therapeutic use, administration should generally begin at the first diagnosis of 108P5H8-associated cancer. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. The embodiment of the vaccine composition (*i.e.*, including, but not limited to embodiments such as peptide cocktails, polyepitopic polypeptides, minigenes, or TAA-specific CTLs or pulsed dendritic cells) delivered to the patient may vary according to the stage of the disease or the patient's health status. For example, in a patient with a tumor that expresses 108P5H8, a vaccine comprising 108P5H8-specific CTL may be more efficacious in killing tumor cells in patient with advanced disease than alternative embodiments.

It is generally important to provide an amount of the peptide epitope delivered by a mode of administration sufficient to effectively stimulate a cytotoxic T cell response; compositions which stimulate helper T cell responses can also be given in accordance with this embodiment of the invention.

The dosage for an initial therapeutic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1,000 μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg . Dosage values for a human typically range from about 500 μg to about 50,000 μg per 70 kilogram patient. Boosting dosages of between about 1.0 μg to about 50,000 μg of peptide pursuant to a boosting regimen over weeks to months may be administered depending upon the patient's response and condition as determined by measuring the specific activity of CTL and HTL obtained from the patient's blood. Administration should continue until at least clinical symptoms or laboratory tests indicate that the neoplasia, has been eliminated or reduced and for a period thereafter. The dosages, routes of administration, and dose schedules are adjusted in accordance with methodologies known in the art.

In certain embodiments, the peptides and compositions of the present invention are employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, as a result of the minimal amounts of extraneous substances and the relative nontoxic nature of the peptides in preferred compositions of the invention, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions relative to these stated dosage amounts.

The vaccine compositions of the invention can also be used purely as prophylactic agents. Generally the dosage for an initial prophylactic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1000 μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg . Dosage values for a human typically range from about 500 μg to about 50,000 μg per 70 kilogram patient. This is followed by boosting dosages of between about 1.0 μg to about 50,000 μg of peptide administered at defined intervals from about four weeks to six months after the initial administration of vaccine. The immunogenicity of the vaccine can be assessed by measuring the specific activity of CTL and HTL obtained from a sample of the patient's blood.

The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral, nasal, intrathecal, or local (e.g. as a cream or topical ointment) administration. Preferably, the pharmaceutical compositions are administered parentally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier.

A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well-known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration.

5 The concentration of peptides of the invention in the pharmaceutical formulations can vary widely, *i.e.*, from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, *etc.*, in accordance with the particular mode of administration selected.

that comprises a human unit dose of an acceptable carrier, in one embodiment an aqueous carrier, and is administered in a volume/quantity that is known by those of skill in the art to be used for administration of such compositions to humans (*see, e.g., Remington's Pharmaceutical Sciences*, 17th Edition, A. Gennaro, Editor, Mack Publishing Co., Easton, Pennsylvania, 1985). For example a peptide dose for initial immunization can be from about 1 to about 50,000 μg , generally 100-5,000 μg , for a 70 kg patient. For example, for nucleic acids an initial immunization may be performed using an expression vector in the form of naked nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to 1000 μg) can also be administered using a gene gun. Following an incubation period of 3-4 weeks, a booster dose is then administered. The booster can be recombinant fowlpox virus administered at a dose of $5 \cdot 10^7$ to $5 \cdot 10^9$ pfu.

20 For antibodies, a treatment generally involves repeated administration of the anti-108P5H8 antibody preparation, via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1 to about 10 mg/kg body weight. In general, doses in the range of 10-500 mg mAb per week are effective and well tolerated. Moreover, an initial loading dose of approximately 4 mg/kg patient body weight IV, followed by weekly doses of about 2 mg/kg IV of the anti- 108P5H8 mAb

25 preparation represents an acceptable dosing regimen. As appreciated by those of skill in the art, various factors can influence the ideal dose in a particular case. Such factors include, for example, half life of a composition, the binding affinity of an Ab, the immunogenicity of a substance, the degree of 108P5H8 expression in the patient, the extent of circulating shed 108P5H8 antigen, the desired steady-state concentration level, frequency of treatment, and the influence of chemotherapeutic or other agents used in

30 combination with the treatment method of the invention, as well as the health status of a particular patient. Non-limiting preferred human unit doses are, for example, 500 μ g - 1mg, 1mg - 50mg, 50mg - 100mg, 100mg - 200mg, 200mg - 300mg, 400mg - 500mg, 500mg - 600mg, 600mg - 700mg, 700mg - 800mg, 800mg - 900mg, 900mg - 1g, or 1mg - 700mg. In certain embodiments, the dose is in a range of 2-5 mg/kg body weight, e.g., with follow on weekly doses of 1-3 mg/kg; 0.5mg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10mg/kg body

35 weight followed, e.g., in two, three or four weeks by weekly doses; 0.5 - 10mg/kg body weight, e.g., followed in two, three or four weeks by weekly doses; 225, 250, 275, 300, 325, 350, 375, 400mg m² of

body area weekly; 1-600mg m² of body area weekly; 225-400mg m² of body area weekly; these does can be followed by weekly doses for 2, 3, 4, 5, 6, 7, 8, 9, 19, 11, 12 or more weeks.

In one embodiment, human unit dose forms of polynucleotides comprise a suitable dosage range or effective amount that provides any therapeutic effect. As appreciated by one of ordinary skill in the art a therapeutic effect depends on a number of factors, including the sequence of the polynucleotide, molecular weight of the polynucleotide and route of administration. Dosages are generally selected by the physician or other health care professional in accordance with a variety of parameters known in the art, such as severity of symptoms, history of the patient and the like. Generally, for a polynucleotide of about 20 bases, a dosage range may be selected from, for example, an independently selected lower limit such as about 0.1, 0.25, 0.5, 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400 or 500 mg/kg up to an independently selected upper limit, greater than the lower limit, of about 60, 80, 100, 200, 300, 400, 500, 750, 1000, 1500, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000 or 10,000 mg/kg. For example, a dose may be about any of the following: 0.1 to 100 mg/kg, 0.1 to 50 mg/kg, 0.1 to 25 mg/kg, 0.1 to 10 mg/kg, 1 to 500 mg/kg, 100 to 400 mg/kg, 200 to 300 mg/kg, 1 to 100 mg/kg, 100 to 200 mg/kg, 300 to 400 mg/kg, 400 to 500 mg/kg, 500 to 1000 mg/kg, 500 to 5000 mg/kg, or 500 to 10,000 mg/kg. Generally, parenteral routes of administration may require higher doses of polynucleotide compared to more direct application to the nucleotide to diseased tissue, as do polynucleotides of increasing length.

In one embodiment, human unit dose forms of T-cells comprise a suitable dosage range or effective amount that provides any therapeutic effect. As appreciated by one of ordinary skill in the art, a therapeutic effect depends on a number of factors. Dosages are generally selected by the physician or other health care professional in accordance with a variety of parameters known in the art, such as severity of symptoms, history of the patient and the like. A dose may be about 10⁴ cells to about 10⁶ cells, about 10⁶ cells to about 10⁸ cells, about 10⁸ to about 10¹¹ cells, or about 10⁸ to about 5 x 10¹⁰ cells. A dose may also about 10⁶ cells/m² to about 10¹⁰ cells/m², or about 10⁶ cells/m² to about 10⁸ cells/m².

Proteins(s) of the invention, and/or nucleic acids encoding the protein(s), can also be administered via liposomes, which may also serve to: 1) target the proteins(s) to a particular tissue, such as lymphoid tissue; 2) to target selectively to diseases cells; or, 3) to increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations, the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the peptide compositions. Liposomes for use in accordance with the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing

liposomes, as described in, e.g., Szoka, *et al.*, *Ann. Rev. Biophys. Bioeng.* 9:467 (1980), and U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.

For targeting cells of the immune system, a ligand to be incorporated into the liposome can include, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, *etc.* in a dose which varies according to, *inter alia*, the manner of administration, the peptide being delivered, and the stage of the disease being treated.

For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.

For aerosol administration, immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are about 0.01%-20% by weight, preferably about 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from about 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute about 0.1%-20% by weight of the composition, preferably about 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery.

XI.) Diagnostic and Prognostic Embodiments of 108P5H8.

As disclosed herein, 108P5H8 polynucleotides, polypeptides, reactive cytotoxic T cells (CTL), reactive helper T cells (HTL) and anti-polypeptide antibodies are used in well known diagnostic, prognostic and therapeutic assays that examine conditions associated with dysregulated cell growth such as cancer, in particular the cancers listed in Table I (see, e.g., both its specific pattern of tissue expression as well as its overexpression in certain cancers as described for example in Example 4).

108P5H8 can be analogized to a prostate associated antigen PSA, the archetypal marker that has been used by medical practitioners for years to identify and monitor the presence of prostate cancer (see, e.g., Merrill *et al.*, *J. Urol.* 163(2): 503-5120 (2000); Polascik *et al.*, *J. Urol.* Aug; 162(2):293-306 (1999) and Fortier *et al.*, *J. Nat. Cancer Inst.* 91(19): 1635-1640(1999)). A variety of other diagnostic markers are also used in similar contexts including p53 and K-ras (see, e.g., Tulchinsky *et al.*, *Int J Mol Med* 1999 Jul 4(1):99-102 and Minimoto *et al.*, *Cancer Detect Prev* 2000;24(1):1-12). Therefore, this disclosure of 108P5H8 polynucleotides and polypeptides (as well as 108P5H8 polynucleotide probes and anti-108P5H8 antibodies used to identify the presence of these molecules) and their properties allows skilled artisans to

utilize these molecules in methods that are analogous to those used, for example, in a variety of diagnostic assays directed to examining conditions associated with cancer.

Typical embodiments of diagnostic methods which utilize the 108P5H8 polynucleotides, polypeptides, reactive T cells and antibodies are analogous to those methods from well-established diagnostic assays which employ, e.g., PSA polynucleotides, polypeptides, reactive T cells and antibodies. For example, just as PSA polynucleotides are used as probes (for example in Northern analysis, see, e.g., Sharief *et al.*, Biochem. Mol. Biol. Int. 33(3):567-74(1994)) and primers (for example in PCR analysis, see, e.g., Okegawa *et al.*, J. Urol. 163(4): 1189-1190 (2000)) to observe the presence and/or the level of PSA mRNAs in methods of monitoring PSA overexpression or the metastasis of prostate cancers, the 108P5H8 polynucleotides described herein can be utilized in the same way to detect 108P5H8 overexpression or the metastasis of prostate and other cancers expressing this gene. Alternatively, just as PSA polypeptides are used to generate antibodies specific for PSA which can then be used to observe the presence and/or the level of PSA proteins in methods to monitor PSA protein overexpression (see, e.g., Stephan *et al.*, Urology 55(4):560-3 (2000)) or the metastasis of prostate cells (see, e.g., Alanen *et al.*, Pathol. Res. Pract. 192(3):233-7 (1996)), the 108P5H8 polypeptides described herein can be utilized to generate antibodies for use in detecting 108P5H8 overexpression or the metastasis of prostate cells and cells of other cancers expressing this gene.

Specifically, because metastases involves the movement of cancer cells from an organ of origin (such as the lung or prostate gland etc.) to a different area of the body (such as a lymph node), assays which examine a biological sample for the presence of cells expressing 108P5H8 polynucleotides and/or polypeptides can be used to provide evidence of metastasis. For example, when a biological sample from tissue that does not normally contain 108P5H8-expressing cells (lymph node) is found to contain 108P5H8-expressing cells such as the 108P5H8 expression seen in LAPC4 and LAPC9, xenografts isolated from lymph node and bone metastasis, respectively, this finding is indicative of metastasis.

Alternatively 108P5H8 polynucleotides and/or polypeptides can be used to provide evidence of cancer, for example, when cells in a biological sample that do not normally express 108P5H8 or express 108P5H8 at a different level are found to express 108P5H8 or have an increased expression of 108P5H8 (see, e.g., the 108P5H8 expression in the cancers listed in Table I and in patient samples etc. shown in the accompanying Figures). In such assays, artisans may further wish to generate supplementary evidence of metastasis by testing the biological sample for the presence of a second tissue restricted marker (in addition to 108P5H8) such as PSA, PSCA etc. (see, e.g., Alanen *et al.*, Pathol. Res. Pract. 192(3): 233-237 (1996)).

Just as PSA polynucleotide fragments and polynucleotide variants are employed by skilled artisans for use in methods of monitoring PSA, 108P5H8 polynucleotide fragments and polynucleotide variants are used in an analogous manner. In particular, typical PSA polynucleotides used in methods of monitoring PSA are probes or primers which consist of fragments of the PSA cDNA sequence. Illustrating this, primers used to PCR amplify a PSA polynucleotide must include less than the whole PSA sequence to function in the polymerase chain reaction. In the context of such PCR reactions, skilled artisans generally

create a variety of different polynucleotide fragments that can be used as primers in order to amplify different portions of a polynucleotide of interest or to optimize amplification reactions (see, e.g., Caetano-Anolles, G. *Biotechniques* 25(3): 472-476, 478-480 (1998); Robertson *et al.*, *Methods Mol. Biol.* 98:121-154 (1998)). An additional illustration of the use of such fragments is provided in Example 4, where a 108P5H8 polynucleotide fragment is used as a probe to show the expression of 108P5H8 RNAs in cancer cells. In addition, variant polynucleotide sequences are typically used as primers and probes for the corresponding mRNAs in PCR and Northern analyses (see, e.g., Sawai *et al.*, *Fetal Diagn. Ther.* 1996 Nov-Dec 11(6):407-13 and *Current Protocols In Molecular Biology*, Volume 2, Unit 2, Frederick M. Ausubel *et al.* eds., 1995)). Polynucleotide fragments and variants are useful in this context where they are capable of binding to a target polynucleotide sequence (e.g., a 108P5H8 polynucleotide shown in Figure 2 or variant thereof) under conditions of high stringency.

Furthermore, PSA polypeptides which contain an epitope that can be recognized by an antibody or T cell that specifically binds to that epitope are used in methods of monitoring PSA. 108P5H8 polypeptide fragments and polypeptide analogs or variants can also be used in an analogous manner. This practice of using polypeptide fragments or polypeptide variants to generate antibodies (such as anti-PSA antibodies or T cells) is typical in the art with a wide variety of systems such as fusion proteins being used by practitioners (see, e.g., *Current Protocols In Molecular Biology*, Volume 2, Unit 16, Frederick M. Ausubel *et al.* eds., 1995). In this context, each epitope(s) functions to provide the architecture with which an antibody or T cell is reactive. Typically, skilled artisans create a variety of different polypeptide fragments that can be used in order to generate immune responses specific for different portions of a polypeptide of interest (see, e.g., U.S. Patent No. 5,840,501 and U.S. Patent No. 5,939,533). For example it may be preferable to utilize a polypeptide comprising one of the 108P5H8 biological motifs discussed herein or a motif-bearing subsequence which is readily identified by one of skill in the art based on motifs available in the art. Polypeptide fragments, variants or analogs are typically useful in this context as long as they comprise an epitope capable of generating an antibody or T cell specific for a target polypeptide sequence (e.g. a 108P5H8 polypeptide shown in Figure 3).

As shown herein, the 108P5H8 polynucleotides and polypeptides (as well as the 108P5H8 polynucleotide probes and anti-108P5H8 antibodies or T cells used to identify the presence of these molecules) exhibit specific properties that make them useful in diagnosing cancers such as those listed in Table I. Diagnostic assays that measure the presence of 108P5H8 gene products, in order to evaluate the presence or onset of a disease condition described herein, such as prostate cancer, are used to identify patients for preventive measures or further monitoring, as has been done so successfully with PSA. Moreover, these materials satisfy a need in the art for molecules having similar or complementary characteristics to PSA in situations where, for example, a definite diagnosis of metastasis of prostatic origin cannot be made on the basis of a test for PSA alone (see, e.g., Alanen *et al.*, *Pathol. Res. Pract.* 192(3): 233-237 (1996)), and consequently, materials such as 108P5H8 polynucleotides and polypeptides (as well as the

108P5H8 polynucleotide probes and anti-108P5H8 antibodies used to identify the presence of these molecules) need to be employed to confirm a metastases of prostatic origin.

Finally, in addition to their use in diagnostic assays, the 108P5H8 polynucleotides disclosed herein have a number of other utilities such as their use in the identification of oncogenetic associated chromosomal abnormalities in the chromosomal region to which the 108P5H8 gene maps (see Example 3 below). Moreover, in addition to their use in diagnostic assays, the 108P5H8-related proteins and polynucleotides disclosed herein have other utilities such as their use in the forensic analysis of tissues of unknown origin (see, e.g., Takahama K Forensic Sci Int 1996 Jun 28;80(1-2): 63-9).

Additionally, 108P5H8-related proteins or polynucleotides of the invention can be used to treat a pathologic condition characterized by the over-expression of 108P5H8. For example, the amino acid or nucleic acid sequence of Figure 2 or Figure 3, or fragments of either, can be used to generate an immune response to a 108P5H8 antigen. Antibodies or other molecules that react with 108P5H8 can be used to modulate the function of this molecule, and thereby provide a therapeutic benefit.

XII.) Inhibition of 108P5H8 Protein Function

The invention includes various methods and compositions for inhibiting the binding of 108P5H8 to its binding partner or its association with other protein(s) as well as methods for inhibiting 108P5H8 function.

XII.A.) Inhibition of 108P5H8 With Intracellular Antibodies

In one approach, a recombinant vector that encodes single chain antibodies that specifically bind to 108P5H8 are introduced into 108P5H8 expressing cells via gene transfer technologies. Accordingly, the encoded single chain anti-108P5H8 antibody is expressed intracellularly, binds to 108P5H8 protein, and thereby inhibits its function. Methods for engineering such intracellular single chain antibodies are well known. Such intracellular antibodies, also known as "intrabodies", are specifically targeted to a particular compartment within the cell, providing control over where the inhibitory activity of the treatment is focused. This technology has been successfully applied in the art (for review, see Richardson and Marasco, 1995, TIBTECH vol. 13). Intrabodies have been shown to virtually eliminate the expression of otherwise abundant cell surface receptors (see, e.g., Richardson *et al.*, 1995, Proc. Natl. Acad. Sci. USA 92: 3137-3141; Beerli *et al.*, 1994, J. Biol. Chem. 269: 23931-23936; Deshane *et al.*, 1994, Gene Ther. 1: 332-337).

Single chain antibodies comprise the variable domains of the heavy and light chain joined by a flexible linker polypeptide, and are expressed as a single polypeptide. Optionally, single chain antibodies are expressed as a single chain variable region fragment joined to the light chain constant region. Well-known intracellular trafficking signals are engineered into recombinant polynucleotide vectors encoding such single chain antibodies in order to precisely target the intrabody to the desired intracellular compartment. For example, intrabodies targeted to the endoplasmic reticulum (ER) are engineered to incorporate a leader peptide and, optionally, a C-terminal ER retention signal, such as the KDEL amino acid motif. Intrabodies intended to exert activity in the nucleus are engineered to include a nuclear

localization signal. Lipid moieties are joined to intrabodies in order to tether the intrabody to the cytosolic side of the plasma membrane. Intrabodies can also be targeted to exert function in the cytosol. For example, cytosolic intrabodies are used to sequester factors within the cytosol, thereby preventing them from being transported to their natural cellular destination.

In one embodiment, intrabodies are used to capture 108P5H8 in the nucleus, thereby preventing its activity within the nucleus. Nuclear targeting signals are engineered into such 108P5H8 intrabodies in order to achieve the desired targeting. Such 108P5H8 intrabodies are designed to bind specifically to a particular 108P5H8 domain. In another embodiment, cytosolic intrabodies that specifically bind to a 108P5H8 protein are used to prevent 108P5H8 from gaining access to the nucleus, thereby preventing it from exerting any biological activity within the nucleus (e.g., preventing 108P5H8 from forming transcription complexes with other factors).

In order to specifically direct the expression of such intrabodies to particular cells, the transcription of the intrabody is placed under the regulatory control of an appropriate tumor-specific promoter and/or enhancer. In order to target intrabody expression specifically to prostate, for example, the PSA promoter and/or promoter/enhancer can be utilized (See, for example, U.S. Patent No. 5,919,652 issued 6 July 1999).

XII.B.) Inhibition of 108P5H8 with Recombinant Proteins

In another approach, recombinant molecules bind to 108P5H8 and thereby inhibit 108P5H8 function. For example, these recombinant molecules prevent or inhibit 108P5H8 from accessing/binding to its binding partner(s) or associating with other protein(s). Such recombinant molecules can, for example, contain the reactive part(s) of a 108P5H8 specific antibody molecule. In a particular embodiment, the 108P5H8 binding domain of a 108P5H8 binding partner is engineered into a dimeric fusion protein, whereby the fusion protein comprises two 108P5H8 ligand binding domains linked to the Fc portion of a human IgG, such as human IgG1. Such IgG portion can contain, for example, the C_H2 and C_H3 domains and the hinge region, but not the C_H1 domain. Such dimeric fusion proteins are administered in soluble form to patients suffering from a cancer associated with the expression of 108P5H8, whereby the dimeric fusion protein specifically binds to 108P5H8 and blocks 108P5H8 interaction with a binding partner. Such dimeric fusion proteins are further combined into multimeric proteins using known antibody linking technologies.

XII.C.) Inhibition of 108P5H8 Transcription or Translation

The present invention also comprises various methods and compositions for inhibiting the transcription of the 108P5H8 gene. Similarly, the invention also provides methods and compositions for inhibiting the translation of 108P5H8 mRNA into protein.

In one approach, a method of inhibiting the transcription of the 108P5H8 gene comprises contacting the 108P5H8 gene with a 108P5H8 antisense polynucleotide. In another approach, a method of inhibiting 108P5H8 mRNA translation comprises contacting a 108P5H8 mRNA with an antisense polynucleotide. In another approach, a 108P5H8 specific ribozyme is used to cleave a 108P5H8 message, thereby inhibiting translation. Such antisense and ribozyme based methods can also be directed to the

regulatory regions of the 108P5H8 gene, such as 108P5H8 promoter and/or enhancer elements. Similarly, proteins capable of inhibiting a 108P5H8 gene transcription factor are used to inhibit 108P5H8 mRNA transcription. The various polynucleotides and compositions useful in the aforementioned methods have been described above. The use of antisense and ribozyme molecules to inhibit transcription and translation is well known in the art.

Other factors that inhibit the transcription of 108P5H8 by interfering with 108P5H8 transcriptional activation are also useful to treat cancers expressing 108P5H8. Similarly, factors that interfere with 108P5H8 processing are useful to treat cancers that express 108P5H8. Cancer treatment methods utilizing such factors are also within the scope of the invention.

XII.D.) General Considerations for Therapeutic Strategies

Gene transfer and gene therapy technologies can be used to deliver therapeutic polynucleotide molecules to tumor cells synthesizing 108P5H8 (i.e., antisense, ribozyme, polynucleotides encoding intrabodies and other 108P5H8 inhibitory molecules). A number of gene therapy approaches are known in the art. Recombinant vectors encoding 108P5H8 antisense polynucleotides, ribozymes, factors capable of interfering with 108P5H8 transcription, and so forth, can be delivered to target tumor cells using such gene therapy approaches.

The above therapeutic approaches can be combined with any one of a wide variety of surgical, chemotherapy or radiation therapy regimens. The therapeutic approaches of the invention can enable the use of reduced dosages of chemotherapy (or other therapies) and/or less frequent administration, an advantage for all patients and particularly for those that do not tolerate the toxicity of the chemotherapeutic agent well.

The anti-tumor activity of a particular composition (e.g., antisense, ribozyme, intrabody), or a combination of such compositions, can be evaluated using various *in vitro* and *in vivo* assay systems. *In vitro* assays that evaluate therapeutic activity include cell growth assays, soft agar assays and other assays indicative of tumor promoting activity, binding assays capable of determining the extent to which a therapeutic composition will inhibit the binding of 108P5H8 to a binding partner, etc.

In vivo, the effect of a 108P5H8 therapeutic composition can be evaluated in a suitable animal model. For example, xenogenic prostate cancer models can be used, wherein human prostate cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice (Klein *et al.*, 1997, Nature Medicine 3: 402-408). For example, PCT Patent Application WO98/16628 and U.S. Patent 6,107,540 describe various xenograft models of human prostate cancer capable of recapitulating the development of primary tumors, micrometastasis, and the formation of osteoblastic metastases characteristic of late stage disease. Efficacy can be predicted using assays that measure inhibition of tumor formation, tumor regression or metastasis, and the like.

In vivo assays that evaluate the promotion of apoptosis are useful in evaluating therapeutic compositions. In one embodiment, xenografts from tumor bearing mice treated with the therapeutic composition can be examined for the presence of apoptotic foci and compared to untreated control

xenograft-bearing mice. The extent to which apoptotic foci are found in the tumors of the treated mice provides an indication of the therapeutic efficacy of the composition.

The therapeutic compositions used in the practice of the foregoing methods can be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material that when combined with the therapeutic composition retains the anti-tumor function of the therapeutic composition and is generally non-reactive with the patient's immune system. Examples include, but are not limited to, any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington's Pharmaceutical Sciences 16th Edition, A. Osal., Ed., 1980).

Therapeutic formulations can be solubilized and administered via any route capable of delivering the therapeutic composition to the tumor site. Potentially effective routes of administration include, but are not limited to, intravenous, parenteral, intraperitoneal, intramuscular, intratumor, intradermal, intraorgan, orthotopic, and the like. A preferred formulation for intravenous injection comprises the therapeutic composition in a solution of preserved bacteriostatic water, sterile unpreserved water, and/or diluted in polyvinylchloride or polyethylene bags containing 0.9% sterile Sodium Chloride for Injection, USP. Therapeutic protein preparations can be lyophilized and stored as sterile powders, preferably under vacuum, and then reconstituted in bacteriostatic water (containing for example, benzyl alcohol preservative) or in sterile water prior to injection.

Dosages and administration protocols for the treatment of cancers using the foregoing methods will vary with the method and the target cancer, and will generally depend on a number of other factors appreciated in the art.

XIII.) Kits

For use in the diagnostic and therapeutic applications described herein, kits are also within the scope of the invention. Such kits can comprise a carrier, package or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in the method. For example, the container(s) can comprise a probe that is or can be detectably labeled. Such probe can be an antibody or polynucleotide specific for a 108P5H8-related protein or a 108P5H8 gene or message, respectively. Where the method utilizes nucleic acid hybridization to detect the target nucleic acid, the kit can also have containers containing nucleotide(s) for amplification of the target nucleic acid sequence and/or a container comprising a reporter-means, such as a biotin-binding protein, such as avidin or streptavidin, bound to a reporter molecule, such as an enzymatic, florescent, or radioisotope label. The kit can include all or part of the amino acid sequence of Figure 2 or Figure 3 or analogs thereof, or a nucleic acid molecules that encodes such amino acid sequences.

The kit of the invention will typically comprise the container described above and one or more other containers comprising materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

A label can be present on the container to indicate that the composition is used for a specific therapy or non-therapeutic application, and can also indicate directions for either *in vivo* or *in vitro* use, such as those described above. Directions and or other information can also be included on an insert which is included with the kit.

EXAMPLES

Various aspects of the invention are further described and illustrated by way of the several examples that follow, none of which are intended to limit the scope of the invention.

Example 1: SSH-Generated Isolation of a cDNA Fragment of the 108P5H8 Gene

To isolate genes that are androgen regulated, the androgen-dependent prostate cancer cell line LNCaP was grown in media containing charcoal-stripped serum (steroid hormone depleted) for one week. The cells were subsequently stimulated with 10 nM mibolerone (synthetic androgen) for 9 h and were harvested as a source of mRNA. The 108P5H8 SSH cDNA sequence was derived from a subtraction consisting of LNCaP cells grown in presence of mibolerone minus LNCaP cells grown in absence of mibolerone.

The 108P5H8 SSH cDNA sequence of 448 bp (Figure 1), showed homology only to ESTs in the dbEST database. The full length 108P5H8 cDNAs and ORFs are described in Figure 2 with the protein sequences listed in Figure 3.

Materials and Methods

RNA Isolation:

Tumor tissues were homogenized in Trizol reagent (Life Technologies, Gibco BRL) using 10 ml/ g tissue or 10 ml/ 10⁸ cells to isolate total RNA. Poly A RNA was purified from total RNA using Qiagen's Oligotex mRNA Mini and Midi kits. Total and mRNA were quantified by spectrophotometric analysis (O.D. 260/280 nm) and analyzed by gel electrophoresis.

Oligonucleotides:

The following HPLC purified oligonucleotides were used.

DPNCDN (cDNA synthesis primer):

5'TTTTGATCAAGCTT₃₀3' (SEQ ID NO: 25865 714)

Adaptor 1:

5'CTAATACGACTCACTATAGGGCTCGAGCGGCCCGCCCGGCAG3' (SEQ ID NO: 25876 715)

3'GGCCCGTCCTAG5' (SEQ ID NO: 25887 716)

Adaptor 2:

5'GTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAG3' (SEQ ID NO: 25898717)

3'CGGCTCCTAG5' (SEQ ID NO: 259089718)

PCR primer 1:

5'CTAATACGACTCACTATAGGGC3' (SEQ ID NO: 25910749)

Nested primer (NP)1:

5'TCGAGCGGCCGCCCGGGCAGGA3' (SEQ ID NO: 25924720)

Nested primer (NP)2:

5'AGCGTGGTCGCGGCCGAGGA3' (SEQ ID NO: 25932721)

Suppression Subtractive Hybridization:

Suppression Subtractive Hybridization (SSH) was used to identify cDNAs corresponding to genes that are androgen regulated. The SSH reaction utilized cDNA from LNCaP prostate cancer cells grown in presence of mibolerone minus LNCaP cells grown in absence of mibolerone.

The cDNA derived from LNCaP prostate cancer cells grown in absence of mibolerone was used as the source of the "driver" cDNA, while the LNCaP prostate cancer cells grown in presence of mibolerone was used as the source of the "tester" cDNA. Double stranded cDNAs corresponding to tester and driver cDNAs were synthesized from 2 µg of poly(A)⁺ RNA isolated from the relevant tissue, as described above, using CLONTECH's PCR-Select cDNA Subtraction Kit and 1 ng of oligonucleotide DPNC DN as primer. First- and second-strand synthesis were carried out as described in the Kit's user manual protocol (CLONTECH Protocol No. PT1117-1, Catalog No. K1804-1). The resulting cDNA was digested with Dpn II for 3 hrs at 37°C. Digested cDNA was extracted with phenol/chloroform (1:1) and ethanol precipitated.

Tester cDNA was generated by diluting 1 µl of Dpn II digested cDNA from the relevant tissue source (see above) (400 ng) in 5 µl of water. The diluted cDNA (2 µl, 160 ng) was then ligated to 2 µl of Adaptor 1 and Adaptor 2 (10 µM), in separate ligation reactions, in a total volume of 10 µl at 16°C overnight, using 400 u of T4 DNA ligase (CLONTECH). Ligation was terminated with 1 µl of 0.2 M EDTA and heating at 72°C for 5 min.

The first hybridization was performed by adding 1.5 µl (600 ng) of driver cDNA to each of two tubes containing 1.5 µl (20 ng) Adaptor 1- and Adaptor 2- ligated tester cDNA. In a final volume of 4 µl, the samples were overlaid with mineral oil, denatured in an MJ Research thermal cycler at 98°C for 1.5 minutes, and then were allowed to hybridize for 8 hrs at 68°C. The two hybridizations were then mixed together with an additional 1 µl of fresh denatured driver cDNA and were allowed to hybridize overnight at

68°C. The second hybridization was then diluted in 200 µl of 20 mM Hepes, pH 8.3, 50 mM NaCl, 0.2 mM EDTA, heated at 70°C for 7 min. and stored at -20°C.

PCR Amplification, Cloning and Sequencing of Gene Fragments Generated from SSH:

To amplify gene fragments resulting from SSH reactions, two PCR amplifications were performed. In the primary PCR reaction 1 µl of the diluted final hybridization mix was added to 1 µl of PCR primer 1 (10 µM), 0.5 µl dNTP mix (10 µM), 2.5 µl 10 x reaction buffer (CLONTECH) and 0.5 µl 50 x Advantage cDNA polymerase Mix (CLONTECH) in a final volume of 25 µl. PCR 1 was conducted using the following conditions: 75°C for 5 min., 94°C for 25 sec., then 27 cycles of 94°C for 10 sec, 66°C for 30 sec, 72°C for 1.5 min. Five separate primary PCR reactions were performed for each experiment. The products were pooled and diluted 1:10 with water. For the secondary PCR reaction, 1 µl from the pooled and diluted primary PCR reaction was added to the same reaction mix as used for PCR 1, except that primers NP1 and NP2 (10 µM) were used instead of PCR primer 1. PCR 2 was performed using 10-12 cycles of 94°C for 10 sec, 68°C for 30 sec, and 72°C for 1.5 minutes. The PCR products were analyzed using 2% agarose gel electrophoresis.

The PCR products were inserted into pCR2.1 using the T/A vector cloning kit (Invitrogen). Transformed *E. coli* were subjected to blue/white and ampicillin selection. White colonies were picked and arrayed into 96 well plates and were grown in liquid culture overnight. To identify inserts, PCR amplification was performed on 1 ml of bacterial culture using the conditions of PCR1 and NP1 and NP2 as primers. PCR products were analyzed using 2% agarose gel electrophoresis.

Bacterial clones were stored in 20% glycerol in a 96 well format. Plasmid DNA was prepared, sequenced, and subjected to nucleic acid homology searches of the GenBank, dBest, and NCI-CGAP databases.

RT-PCR Expression Analysis:

First strand cDNAs can be generated from 1 µg of mRNA with oligo (dT)12-18 priming using the Gibco-BRL Superscript Preamplification system. The manufacturer's protocol was used which included an incubation for 50 min at 42°C with reverse transcriptase followed by RNase H treatment at 37°C for 20 min. After completing the reaction, the volume can be increased to 200 µl with water prior to normalization. First strand cDNAs from 16 different normal human tissues can be obtained from Clontech.

Normalization of the first strand cDNAs from multiple tissues was performed by using the primers 5'-atategccgcgtcgtcgtcgacaa-3' (SEQ ID NO: 25943-722) and 5'-agccacacgcagctcattgtagaagg-3' (SEQ ID NO: 25954-723) to amplify β-actin. First strand cDNA (5 µl) were amplified in a total volume of 50 µl containing 0.4 µM primers, 0.2 µM each dNTPs, 1XPCR buffer (Clontech, 10 mM Tris-HCL, 1.5 mM MgCl₂, 50 mM KCl, pH8.3) and 1X KlenTaq DNA polymerase (Clontech). Five µl of the PCR reaction can be removed at 18, 20, and 22 cycles and used for agarose gel electrophoresis. PCR was performed using an MJ Research thermal cycler under the following conditions: Initial denaturation can be at 94°C for 15 sec, followed by a 18, 20, and 22 cycles of 94°C for 15, 65°C for 2 min, 72°C for 5 sec. A final extension at 72°C was carried out for 2 min. After agarose gel electrophoresis, the band intensities of the 283 bp

β -actin bands from multiple tissues were compared by visual inspection. Dilution factors for the first strand cDNAs were calculated to result in equal β -actin band intensities in all tissues after 22 cycles of PCR. Three rounds of normalization can be required to achieve equal band intensities in all tissues after 22 cycles of PCR.

To determine expression levels of the 108P5H8 gene, 5 μ l of normalized first strand cDNA were analyzed by PCR using 26, and 30 cycles of amplification. Semi-quantitative expression analysis can be achieved by comparing the PCR products at cycle numbers that give light band intensities.

A typical RT-PCR expression analysis is shown in Figure 10. RT-PCR expression analysis was performed on first strand cDNAs generated using pools of tissues from multiple samples. The cDNAs were shown to be normalized using beta-actin PCR. Strong expression of 108P5H8 was observed in prostate cancer xenograft pool, prostate cancer pool and in the 2 different prostate cancer metastasis samples. Lower expression was detected in bladder cancer pool, kidney cancer pool, colon cancer pool, lung cancer pool, ovary cancer pool, breast cancer pool, metastasis pool, pancreas cancer pool, VP1 and VP2.

Example 2: Full Length Cloning of 108P5H8

To isolate genes that are androgen regulated, the androgen-dependent prostate cancer cell line LNCaP was grown in media containing 2% charcoal-stripped serum (steroid hormone depleted) for one week. The cells were then stimulated with 10 nM Mibolerone (synthetic androgen) for 9 hours and were harvested for RNA.

The gene 108P5H8 was derived from an experiment where cDNA derived from LNCaP cells that was androgen-deprived (by growing in the presence of charcoal-stripped serum) was subtracted from cDNA derived from LNCaP cells that were stimulated with mibolerone for 9 hours. The SSH DNA sequence of 448 bp (Figure 1) is novel and only exhibited homology to human EST sequences in the dbest database.

A full length 108P5H8 cDNA clone (108P5H8 v.1) of 2364 base pairs (bp) was cloned from a prostate library (Lambda ZAP Express, Stratagene) (Figure 2). The cDNA encodes a putative open reading frame (ORF) of 429 amino acids.

108P5H8 variant 2 and variant 3 were identified. The nucleic acid and protein sequences of all 3 variants are presented in figure 3 and figure 4. The alignments of all 3 108P5H8 variants are presented in figure 4. The nucleic acid sequences of variants 1 and 2 encode identical protein. 108P5H8 v.3 has a base pair variation with a C at position 342 of v.1 converted into G in v.3. This nucleotide change converted amino acid position 30 from aspartic acid in the 108P5H8 v.1 and v.2 protein sequence, to glutamic acid in 108P5H8 v.3.

Analysis of 108P5H8 protein sequence using the PSORT program (<http://psort.nibb.ac.jp:8800/form.html>) reveals 6 predicted transmembrane domains. Sequence analysis of 108P5H8 reveals homology to the human zinc transporter protein ZnT4 (Huang and Gitschier, 1997,

Nature Genetics 17:292). The 108P5H8 v.1 sequence includes novel 5' UTR and 3' UTR sequences, and the molecule contains 75% GC sequence, indicating possible translational regulatory sites.

To further confirm the parameters of a variant, a variety of techniques are available in the art, such as full-length cloning, proteomic validation, PCR-based validation, and 5' RACE validation, etc. (see e.g., Proteomic Validation: Brennan, S.O., *et al.*, Albumin banks peninsula: a new termination variant characterized by electrospray mass spectrometry, Biochem Biophys Acta. 1999 Aug 17;1433(1-2):321-6; Ferranti P, *et al.*, Differential splicing of pre-messenger RNA produces multiple forms of mature caprine alpha(s1)-casein, Eur J Biochem. 1997 Oct 1;249(1):1-7. For PCR-based Validation: Wellmann S, *et al.*, Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology, Clin Chem. 2001 Apr;47(4):654-60; Jia, H.P., *et al.*, Discovery of new human beta-defensins using a genomics-based approach, Gene. 2001 Jan 24; 263(1-2):211-8. For PCR-based and 5' RACE Validation: Brigle, K.E., *et al.*, Organization of the murine reduced folate carrier gene and identification of variant splice forms, Biochem Biophys Acta. 1997 Aug 7; 1353(2): 191-8).

It is known in the art that genomic regions are modulated in cancers. When the genomic region to which 108P5H8 maps is modulated in a particular cancer, the variants of 108P5H8 are modulated as well. Disclosed herein is that 108P5H8 has a particular expression profile. Variants of 108P5H8 that are structurally and/or functionally similar to 108P5H8 share this expression pattern, thus serving as tumor-associated markers/antigens.

Example 3: Chromosomal Localization

Chromosomal localization can implicate genes in disease pathogenesis. Several chromosome mapping approaches are available, including fluorescent *in situ* hybridization (FISH), human/hamster GeneBridge4 radiation hybrid (RH) panels (Walter *et al.*, 1994; Nature Genetics 7:22; Research Genetics, Huntsville Al), human-rodent somatic cell hybrid panels such as is available from the Coriell Institute (Camden, New Jersey), and genomic viewers utilizing BLAST homologies to sequenced and mapped genomic clones (NCBI, Bethesda, Maryland).

The chromosomal localization of 108P5H8 using the GeneBridge4 radiation hybrid panel was performed using the the following PCR primers:

108P5H8.1 5' TGCACACTGGACTTCGTAGAGTAA 3' (SEQ. ID. No.: 25965)

108P5H8.2 5' AAAGCTGTGAGAGTGGCTGAGAAA 3' (SEQ. ID. No.: 25976)

The resulting mapping vector for the 93 radiation hybrid panel DNAs was:

10010100110100010100000000000110100000001201100001011000100001011100010100010000020110110121

This mapping vector and the mapping program at <http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl> placed 108P5H8 to chromosome 15q15.2-q21.1.

Example 4: Expression Analysis of 108P5H8 in Normal Tissues and Patient Specimens

Expression of 108P5H8 was analyzed by RT-PCR (Figure 10). First strand cDNA was prepared from vital pool 1 (VP1: liver, lung and kidney), vital pool 2 (VP2, pancreas, colon and stomach), prostate xenograft pool (LAPC-4AD, LAPC-4AI, LAPC-9AD, LAPC-9AI), prostate cancer pool, bladder cancer pool, kidney cancer pool, colon cancer pool, lung cancer pool, ovary cancer pool, breast cancer pool, metastasis cancer pool, pancreas cancer pool, and from prostate cancer metastasis to lymph node from two different patients. Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to 108P5H8, was performed at 26 and 30 cycles of amplification. Strong expression of 108P5H8 was observed in prostate cancer xenograft pool, prostate cancer pool and in the 2 different prostate cancer metastasis samples. Lower expression was detected in bladder cancer pool, kidney cancer pool, colon cancer pool, lung cancer pool, ovary cancer pool, breast cancer pool, metastasis pool, pancreas cancer pool, VP1 and VP2.

Extensive Northern blot analysis of 108P5H8 in 16 human normal tissues confirmed the expression observed by RT-PCR (Figure 11). An approximately 7kb 108P5H8 transcript was strongly expressed in prostate. Significantly lower expression was detected in other tissues.

Figure 11C shows expression of 108P5H8 in prostate cancer xenografts. RNA was extracted from prostate cancer xenografts, LAPC-4AD, LAPC-4AI, LAPC-9AD, and LAPC-9AI. Northern blot with 10 µg of total RNA/lane was probed with 108P5H8 SSH sequence. Results showed expression of 108P5H8 in all four xenograft tissues. More detailed analysis of the xenografts shows that 108P5H8 is highly expressed in the xenografts even when grown within the tibia of mice (Fig. 12). The expression is increased when the LAPC-4 xenograft is grown within a human bone implant (LAPC-4 AD²). It is possible that the human bone environment increases and/or induces the expression of 108P5H8. Northern blot analysis also showed that 108P5H8 is expressed in all human cancer cell lines tested such as prostate, bladder, brain, lung, kidney, breast, testis and ovary cancer cell lines (Figure 13).

Expression of 108P5H8 was assayed in a panel of human cancers (T) and their respective matched normal tissues (N) on RNA dot blots (Figure 14). 108P5H8 expression was detected in prostate, kidney, uterus and stomach cancers. The expression detected in some normal adjacent tissues (isolated from diseased tissues), but not in normal tissues (isolated from healthy donors), may indicate that these tissues are not fully normal and that 108P5H8 may be expressed in early stage tumors. 108P5H8 was also expressed in all 9 human cancer cell lines tested.

To test expression of 108P5H8 in patient cancer specimens, RNA was extracted from prostate cancer tumors (T) and their matched normal adjacent tissue (N_{AT}). Northern blots with 10 µg of total RNA/lane were probed with 108P5H8 SSH sequence (Figure 15). Results showed expression of 108P5H8 in all prostate patient specimens tested.

108P5H8 was isolated from an experiment where cDNA derived from LNCaP cells that was androgen-deprived (by growing in the presence of charcoal-stripped serum) was subtracted from cDNA derived from LNCaP cells that were stimulated with mibolerone. To assess whether 108P5H8 is androgen-regulated, LNCaP cells were grown in charcoal-stripped medium and stimulated with the synthetic

androgen mibolerone, for either 14 or 24 hours (Figure 16). Northern blots with 10 µg of total RNA/lane were probed with either the 108P5H8 sequence (Figure 16A). Results show expression of 108P5H8 is not regulated by androgen. The experimental samples were confirmed by testing for the expression of the androgen-regulated prostate cancer gene PSA (Figure 16B). This experiment shows that, as expected, PSA levels go down in presence of charcoal-stripped serum, and expression is induced at 14 and 24 hours in presence of the synthetic androgen. A picture of the ethidium-bromide staining of the RNA gel is also presented (Figure 16C).

Figure 17 shows expression of 108P5H8 in cancer metastasis patient specimens. RNA was extracted from prostate cancer metastasis to lymph node isolated from 2 different patients, as well as from normal bladder (NB), normal kidney (NK), normal lung (NL), normal breast (NBr), normal ovary (NO), and normal pancreas (NPa). Northern blots with 10 µg of total RNA/lane was probed with 108P5H8 sequence. The results show expression of 108P5H8 in both cancer metastasis samples but not in normal tissues.

108P5H8 expression showed prostate restricted expression. Its strong expression detected in normal prostate and prostate cancer tissues and the low expression detected in other normal tissues indicate that 108P5H8 is therapeutic and prophylactic target and a diagnostic and prognostic marker for human cancers.

Example 5: Production of Recombinant 108P5H8 in Prokaryotic Systems

To express recombinant 108P5H8 in prokaryotic cells, the full or partial length 108P5H8 cDNA sequences can be cloned into any one of a variety of expression vectors known in the art. One or more of the following regions of 108P5H8 are expressed in these constructs, amino acids 1 to 429 of variant 1 or variant 2; or amino acids 1 to 388 of variant 4, or any 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 108P5H8, variants, or analogs thereof. In certain embodiments a region of 108P5H8 is expressed that encodes an amino acid not shared amongst at least one of the variants, such as a construct encoding the D to E mutation at amino acid 30.

A. *In vitro* transcription and translation constructs:

pCRII: To generate 108P5H8 sense and anti-sense RNA probes for RNA *in situ* investigations, pCRII constructs (Invitrogen, Carlsbad CA) are generated encoding either all or fragments of a 108P5H8 cDNA. The pCRII vector has Sp6 and T7 promoters flanking the insert to drive the transcription of 108P5H8 RNA for use as probes in RNA *in situ* hybridization experiments. These probes are used to analyze the cell and tissue expression of 108P5H8 at the RNA level. Transcribed 108P5H8 RNA representing the cDNA amino acid coding region of the 108P5H8 gene is used in *in vitro* translation systems such as the TnT™ Coupled Reticulolysate System (Promega, Corp., Madison, WI) to synthesize 108P5H8 protein.

B. Bacterial Constructs:

pGEX Constructs: To generate recombinant 108P5H8 proteins in bacteria that are fused to the Glutathione S-transferase (GST) protein, all or parts of a 108P5H8 cDNA protein coding sequence are fused to the GST gene by cloning into pGEX-6P-1 or any other GST- fusion vector of the pGEX family (Amersham Pharmacia Biotech, Piscataway, NJ). These constructs allow controlled expression of recombinant 108P5H8 protein sequences with GST fused at the amino-terminus and a six histidine epitope (6X His) at the carboxyl-terminus. The GST and 6X His tags permit purification of the recombinant fusion protein from induced bacteria with the appropriate affinity matrix and allow recognition of the fusion protein with anti-GST and anti-His antibodies. The 6X His tag is generated by adding 6 histidine codons to the cloning primer at the 3' end, e.g., of the open reading frame (ORF). A proteolytic cleavage site, such as the PreScission™ recognition site in pGEX-6P-1, may be employed such that it permits cleavage of the GST tag from 108P5H8-related protein. The ampicillin resistance gene and pBR322 origin permits selection and maintenance of the pGEX plasmids in *E. coli*.

In one embodiment, a GST-fusion protein was constructed and expressed that encoded amino acids 1-112. This protein was used as an immunogen for generation of a 108P5H8 specific polyclonal antibody as described in example 8.

pMAL Constructs: To generate, in bacteria, recombinant 108P5H8 proteins that are fused to maltose-binding protein (MBP), all or parts of a 108P5H8 cDNA protein coding sequence are fused to the MBP gene by cloning into the pMAL-c2X and pMAL-p2X vectors (New England Biolabs, Beverly, MA). These constructs allow controlled expression of recombinant 108P5H8 protein sequences with MBP fused at the amino-terminus and a 6X His epitope tag at the carboxyl-terminus. The MBP and 6X His tags permit purification of the recombinant protein from induced bacteria with the appropriate affinity matrix and allow recognition of the fusion protein with anti-MBP and anti-His antibodies. The 6X His epitope tag is generated by adding 6 histidine codons to the 3' cloning primer. A Factor Xa recognition site permits cleavage of the pMAL tag from 108P5H8. The pMAL-c2X and pMAL-p2X vectors are optimized to express the recombinant protein in the cytoplasm or periplasm respectively. Periplasm expression enhances folding of proteins with disulfide bonds.

pET Constructs: To express 108P5H8 in bacterial cells, all or parts of a 108P5H8 cDNA protein coding sequence are cloned into the pET family of vectors (Novagen, Madison, WI). These vectors allow tightly controlled expression of recombinant 108P5H8 protein in bacteria with and without fusion to proteins that enhance solubility, such as NusA and thioredoxin (Trx), and epitope tags, such as 6X His and S-Tag™ that aid purification and detection of the recombinant protein. For example, constructs are made utilizing pET NusA fusion system 43.1 such that regions of a 108P5H8 protein are expressed as amino-terminal fusions to NusA.

C. Yeast Constructs:

pESC Constructs: To express 108P5H8 in the yeast species *Saccharomyces cerevisiae* for generation of recombinant protein and functional studies, all or parts of a 108P5H8 cDNA protein coding

sequence are cloned into the pESC family of vectors each of which contain 1 of 4 selectable markers, HIS3, TRP1, LEU2, and URA3 (Stratagene, La Jolla, CA). These vectors allow controlled expression from the same plasmid of up to 2 different genes or cloned sequences containing either FlagTM or Myc epitope tags in the same yeast cell. This system is useful to confirm protein-protein interactions of 108P5H8. In addition, expression in yeast yields similar post-translational modifications, such as glycosylations and phosphorylations, that are found when expressed in eukaryotic cells.

pESP Constructs: To express 108P5H8 in the yeast species *Saccharomyces pombe*, all or parts of a 108P5H8 cDNA protein coding sequence are cloned into the pESP family of vectors. These vectors allow controlled high level of expression of a 108P5H8 protein sequence that is fused at either the amino terminus or at the carboxyl terminus to GST which aids purification of the recombinant protein. A FlagTM epitope tag allows detection of the recombinant protein with anti-FlagTM antibody.

Example 6: Production of Recombinant 108P5H8 in Eukaryotic Systems

A. Mammalian Constructs:

To express recombinant 108P5H8 in eukaryotic cells, the full or partial length 108P5H8 cDNA sequences can be cloned into any one of a variety of expression vectors known in the art. One or more of the following regions of 108P5H8 are expressed in these constructs, amino acids 1 to 429 of variant, variant 2 or variant 3; or any 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 108P5H8, variants, or analogs thereof. In certain embodiments a region of 108P5H8 is expressed that encodes an amino acid not shared amongst at least two variants.

The constructs can be transfected into any one of a wide variety of mammalian cells such as 293T cells. Transfected 293T cell lysates are probed with an anti-His epitope tag antibody or with anti-108P5H8 polyclonal antibodies to verify protein expression.

pcDNA4/HisMax Constructs: To express 108P5H8 in mammalian cells, a 108P5H8 ORF, or portions thereof, of 108P5H8 are cloned into pcDNA4/HisMax Version A (Invitrogen, Carlsbad, CA). Protein expression is driven from the cytomegalovirus (CMV) promoter and the SP16 translational enhancer. The recombinant protein has XpressTM and six histidine (6X His) epitopes fused to the amino-terminus. The pcDNA4/HisMax vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Zeocin resistance gene allows for selection of mammalian cells expressing the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in *E. coli*.

pcDNA3.1/MycHis Constructs: To express 108P5H8 in mammalian cells, a 108P5H8 ORF, or portions thereof, of 108P5H8 with a consensus Kozak translation initiation site were cloned into pcDNA3.1/MycHis Version A (Invitrogen, Carlsbad, CA). Protein expression is driven from the cytomegalovirus (CMV) promoter. The recombinant proteins have the myc epitope and 6X His epitope fused to the carboxyl-terminus. The pcDNA3.1/MycHis vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability, along

5

10

19

25

81

mammalian cells expressing the protein, and the ampicillin resistance gene permits selection of the plasmid in *E. coli*.

PsecFc: A 108P5H8 ORF, or portions thereof, is also cloned into psecFc. The psecFc vector was assembled by cloning the human immunoglobulin G1 (IgG) Fc (hinge, CH2, CH3 regions) into pSecTag2 (Invitrogen, California). This construct generates an IgG1 Fc fusion at the carboxyl-terminus of the 108P5H8 proteins, while fusing the IgGK signal sequence to N-terminus. 108P5H8 fusions utilizing the murine IgG1 Fc region are also used. The resulting recombinant 108P5H8 proteins are optimized for secretion into the media of transfected mammalian cells, and can be used as immunogens or to identify proteins such as ligands or receptors that interact with 108P5H8 protein. Protein expression is driven from the CMV promoter. The hygromycin resistance gene present in the vector allows for selection of mammalian cells that express the recombinant protein, and the ampicillin resistance gene permits selection of the plasmid in *E. coli*.

pSR α Constructs: To generate mammalian cell lines that express 108P5H8 constitutively, 108P5H8 ORF, or portions thereof, of 108P5H8 were cloned into pSR α constructs. Amphotropic and ecotropic retroviruses are generated by transfection of pSR α constructs into the 293T-10A1 packaging line or co-transfection of pSR α and a helper plasmid (containing deleted packaging sequences) into the 293 cells, respectively. The retrovirus is used to infect a variety of mammalian cell lines, resulting in the integration of the cloned gene, 108P5H8, into the host cell-lines. Protein expression is driven from a long terminal repeat (LTR). The Neomycin resistance gene present in the vector allows for selection of mammalian cells that express the protein, and the ampicillin resistance gene and ColE1 origin permit selection and maintenance of the plasmid in *E. coli*. The retroviral vectors can thereafter be used for infection and generation of various cell lines using, for example, PC3, NIH 3T3, TsuPr1, 293 or rat-1 cells. Results of expression of 108P5H8 protein driven from the pSR α in PC3 and NIH3T3 cells are shown in Figure 24.

Additional pSR α constructs are made that fuse an epitope tag such as the FLAGTM tag to the carboxyl-terminus of 108P5H8 sequences to allow detection using anti-Flag antibodies. For example, the FLAGTM sequence 5' gat tac aag gat gac gac gat aag 3' (SEQ. ID. No. 25987) is added to cloning primer at the 3' end of the ORF. Additional pSR α constructs are made to produce both amino-terminal and carboxyl-terminal GFP and myc/6X His fusion proteins of the full-length 108P5H8 proteins.

Additional Viral Vectors: Additional constructs are made for viral-mediated delivery and expression of 108P5H8. High virus titer leading to high level expression of 108P5H8 is achieved in viral delivery systems such as adenoviral vectors and herpes amplicon vectors. A 108P5H8 coding sequences or fragments thereof are amplified by PCR and subcloned into the AdEasy shuttle vector (Stratagene). Recombination and virus packaging are performed according to the manufacturer's instructions to generate adenoviral vectors. Alternatively, 108P5H8 coding sequences or fragments thereof are cloned into the HSV-1 vector (Imgenex) to generate herpes viral vectors. The viral vectors are thereafter used for infection of various cell lines such as PC3, NIH 3T3, 293 or rat-1 cells.

Regulated Expression Systems: To control expression of 108P5H8 in mammalian cells, coding sequences of 108P5H8, or portions thereof, are cloned into regulated mammalian expression systems such as the T-Rex System (Invitrogen), the GeneSwitch System (Invitrogen) and the tightly-regulated Ecdysone System (Sratagene). These systems allow the study of the temporal and concentration dependent effects of recombinant 108P5H8. These vectors are thereafter used to control expression of 108P5H8 in various cell lines such as PC3, NIH 3T3, 293 or rat-1 cells.

B. Baculovirus Expression Systems

To generate recombinant 108P5H8 proteins in a baculovirus expression system, 108P5H8 ORF, or portions thereof, are cloned into the baculovirus transfer vector pBlueBac 4.5 (Invitrogen), which provides a His-tag at the N-terminus. Specifically, pBlueBac-108P5H8 is co-transfected with helper plasmid pBac-N-Blue (Invitrogen) into SF9 (*Spodoptera frugiperda*) insect cells to generate recombinant baculovirus (see Invitrogen instruction manual for details). Baculovirus is then collected from cell supernatant and purified by plaque assay.

Recombinant 108P5H8 protein is then generated by infection of HighFive insect cells (Invitrogen) with purified baculovirus. Recombinant 108P5H8 protein can be detected using anti-108P5H8 or anti-His-tag antibody. 108P5H8 protein can be purified and used in various cell-based assays or as immunogen to generate polyclonal and monoclonal antibodies specific for 108P5H8.

Example 7. Antigenicity Profiles and Secondary Structure

Figure 5, Figure 6, Figure 7, Figure 8, and Figure 9 depict graphically five amino acid profiles of the 108P5H8 amino acid sequence (variant 1), each assessment is available by accessing the ProtScale website (URL www.expasy.ch/cgi-bin/protscale.pl) on the ExPasy molecular biology server.

These profiles: Figure 5, Hydrophilicity, (Hopp T.P., Woods K.R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828); Figure 6, Hydropathicity, (Kyte J., Doolittle R.F., 1982. J. Mol. Biol. 157:105-132); Figure 7, Percentage Accessible Residues (Janin J., 1979 Nature 277:491-492); Figure 8, Average Flexibility, (Bhaskaran R., and Ponnuswamy P.K., 1988. Int. J. Pept. Protein Res. 32:242-255); Figure 9, Beta-turn (Deleage, G., Roux B. 1987 Protein Engineering 1:289-294); and optionally others available in the art, such as on the ProtScale website, were used to identify antigenic regions of 108P5H8 protein. Each of the above amino acid profiles of 108P5H8 were generated using the following ProtScale parameters for analysis: 1) A window size of 9; 2) 100% weight of the window edges compared to the window center; and, 3) amino acid profile values normalized to lie between 0 and 1.

Hydrophilicity (Figure 5), Hydropathicity (Figure 6) and Percentage Accessible Residues (Figure 7) profiles were used to determine stretches of hydrophilic amino acids (i.e., values greater than 0.5 on the Hydrophilicity and Percentage Accessible Residues profiles, and values less than 0.5 on the Hydropathicity profile). Such regions are likely to be exposed to the aqueous environment, be present on the surface of the protein, and thus available for immune recognition, such as by antibodies.

Average Flexibility (Figure 8) and Beta-turn (Figure 9) profiles determine stretches of amino acids (i.e., values greater than 0.5 on the Beta-turn profile and the Average Flexibility profile) that are not

constrained in secondary structures such as beta sheets and alpha helices. Such regions are also more likely to be exposed on the protein and thus accessible to immune recognition, such as by antibodies.

Antigenic sequences of the full length 108P5H8 protein (variant 1) indicated, e.g., by the profiles set forth in Figure 5, Figure 6, Figure 7, Figure 8, and/or Figure 9 are used to prepare immunogens, either peptides or nucleic acids that encode them, to generate therapeutic and diagnostic anti-108P5H8 antibodies. The immunogen can be any 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more than 50 contiguous amino acids, or the corresponding nucleic acids that encode them, from 108P5H8 protein. In particular, peptide immunogens of the invention can comprise, a peptide region of at least 5 amino acids of Figure 2 in any whole number increment up to 429 that includes an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of Figure 5; a peptide region of at least 5 amino acids of Figure 2 in any whole number increment up to 429 that includes an amino acid position having a value less than 0.5 in the Hydrophobicity profile of Figure 6; a peptide region of at least 5 amino acids of Figure 2 in any whole number increment up to 429 that includes an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of Figure 7; a peptide region of at least 5 amino acids of Figure 2 in any whole number increment up to 429 that includes an amino acid position having a value greater than 0.5 in the Average Flexibility profile on Figure 8; and, a peptide region of at least 5 amino acids of Figure 2 in any whole number increment up to 429 that includes an amino acid position having a value greater than 0.5 in the Beta-turn profile of Figure 9. Peptide immunogens of the invention can also comprise nucleic acids that encode any of the foregoing.

All immunogens of the invention, peptide or nucleic acid, can be embodied in human unit dose form, or comprised by a composition that includes a pharmaceutical excipient compatible with human physiology.

The secondary structure of 108P5H8, namely the predicted presence and location of alpha helices, extended strands, and random coils, is predicted from the primary amino acid sequence of 108P5H8 variant 1 using the HNN - Hierarchical Neural Network method (Guermeur, 1997, http://pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_nn.html), accessed from the ExPasy molecular biology server (<http://www.expasy.ch/tools/>). The analysis indicates that 108P5H8 is composed of 49.88% alpha helix, 11.66% extended strand, and 38.46% random coil (Figure 18).

Analysis for the potential presence of transmembrane domains in 108P5H8 was carried out using a variety of transmembrane prediction algorithms accessed from the ExPasy molecular biology server (<http://www.expasy.ch/tools/>). The programs predict the presence of 6 transmembrane domains in 108P5H8. Shown graphically in Figure 19A and 19B are the results of analysis using the TMPred and TMHMM prediction programs, respectively, depicting the location of the 6 transmembrane domains. The results of each program, namely the amino acids encoding the transmembrane domains are summarized in Table XXI.

Example 8: Generation of 108P5H8 Polyclonal Antibodies

Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. In addition to immunizing with the full length 108P5H8 protein, computer algorithms are employed in design of immunogens that, based on amino acid sequence analysis contain characteristics of being antigenic and available for recognition by the immune system of the immunized host (see the Example entitled "Antigenicity Profiles and Secondary Structure"). Such regions would be predicted to be hydrophilic, flexible, in beta-turn conformations, and be exposed on the surface of the protein (see, e.g., Figure 5, Figure 6, Figure 7, Figure 8, or Figure 9 for amino acid profiles that indicate such regions of 108P5H8).

For example, 108P5H8 recombinant bacterial fusion proteins or peptides containing hydrophilic, flexible, beta-turn regions of 108P5H8 are used as antigens to generate polyclonal antibodies in New Zealand White rabbits. Such regions often reside in extracellular and intracellular loops between transmembrane domains. For example, such regions include, but are not limited to, amino acids 1-112 (intracellular amino terminus), amino acids 139-152 (1st extracellular loop), amino acids 201-214 (second extracellular loop), amino acids 294-307 (third extracellular loop), or amino acids 336-429 (carboxyl terminus). It is useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include, but are not limited to, keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. In one embodiment, a peptide encoding amino acids 294-307 of 108P5H8 is conjugated to KLH and used to immunize the rabbit. Alternatively the immunizing agent may include all or portions of a 108P5H8 protein, analogs or fusion proteins thereof. For example, a 108P5H8 amino acid sequence can be fused using recombinant DNA techniques to any one of a variety of fusion protein partners that are well known in the art, such as glutathione-S-transferase (GST) and HIS tagged fusion proteins. Such fusion proteins are purified from induced bacteria using the appropriate affinity matrix.

In one embodiment, a GST-fusion protein encoding amino acids 1-112 of 108P5H8 was produced and purified and used to immunize a rabbit. This polyclonal antibody specifically recognized both recombinant and endogenous 108P5H8 protein in cells and tissues. Figure 20 shows non-androgen-regulated expression of 108P5H8 in the prostate cancer cell lines LNCaP and LAPC4. The expression of 108P5H8 is cell surface as detected by the polyclonal antibody in LNCaP and LAPC4 cells (Figure 21) and when overexpressed in 293T cells (Figure 22). Figure 23 shows expression in prostate patient cancer samples, including metastatic disease, indicating the protein is a therapeutic target in both androgen-dependent and independent prostate cancer. 108P5H8 is also expressed in ovarian cancer, but not in normal ovary (Figure 23), indicating the protein is a therapeutic and diagnostic target in this disease as well.

In addition to GST-fusions, other recombinant bacterial fusion proteins that can be employed include maltose binding protein, LacZ, thioredoxin, NusA, or an immunoglobulin constant region (see the

section entitled "Production of 108P5H8 in Prokaryotic Systems" and Current Protocols In Molecular Biology, Volume 2, Unit 16, Frederick M. Ausubul *et al.* eds., 1995; Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L., Damle, N., and Ledbetter, L.(1991) J.Exp. Med. 174, 561-566).

In addition to bacterial-derived fusion proteins, mammalian-expressed protein antigens are also used. These antigens are expressed from mammalian expression vectors such as the Tag5 and Fc-fusion vectors (see the section entitled "Production of Recombinant 108P5H8 in Eukaryotic Systems"), and retain post-translational modifications such as glycosylations found in native protein. In one embodiment, the first extracellular loop of 108P5H8 (amino acids 139-152) is cloned into the Tag5 mammalian secretion vector. The recombinant protein is purified by metal chelate chromatography from tissue culture supernatants of 293T cells stably expressing the recombinant vector. The purified Tag5 108P5H8 protein is then used as immunogen.

During the immunization protocol, it is useful to mix or emulsify the antigen in adjuvants that enhance the immune response of the host animal. Examples of adjuvants include, but are not limited to, complete Freund's adjuvant (CFA) and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

In a typical protocol, rabbits are initially immunized subcutaneously with up to 200 µg, typically 100-200 µg, of fusion protein or peptide conjugated to KLH mixed in complete Freund's adjuvant (CFA). Rabbits are then injected subcutaneously every two weeks with up to 200 µg, typically 100-200 µg, of the immunogen in incomplete Freund's adjuvant (IFA). Test bleeds are taken approximately 7-10 days following each immunization and used to monitor the titer of the antiserum by ELISA.

To test reactivity and specificity of immune serum, such as the rabbit serum derived from immunization with Tag5 108P5H8 protein or KLH-coupled peptide encoding amino acids 294-307, the full-length 108P5H8 cDNA is cloned into pCDNA 3.1 myc-his expression vector (Invitrogen, see the Example entitled "Production of Recombinant 108P5H8 in Eukaryotic Systems"). After transfection of the constructs into 293T cells, cell lysates are probed with the anti-108P5H8 serum and with anti-His antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) to determine specific reactivity to denatured 108P5H8 protein using the Western blot technique (Figure 20). Immunoprecipitation and flow cytometric analyses of 293T and other recombinant 108P5H8-expressing cells determine recognition of native protein by the antiserum (Figure 22, Figure 24). In addition, Western blot, immunoprecipitation, fluorescent microscopy, and flow cytometric techniques using cells that endogenously express 108P5H8 are carried out to test specificity (Figure 20, Figure 21).

The anti-serum from the Tag5 108P5H8 immunized rabbit is affinity purified by passage over a column composed of the Tag5 antigen covalently coupled to Affigel matrix (BioRad, Hercules, Calif.). The serum is then further purified by protein G affinity chromatography to isolate the IgG fraction. Serum from rabbits immunized with the GST-fusion protein was purified by depletion of antibodies reactive to the fusion partner sequence (GST) by passage over an affinity column containing the GST alone and then by passage back over a GST-108P5H8 column to isolate gene specific antibodies. Sera from other His-tagged

antigens and peptide immunized rabbits as well as fusion partner depleted sera are affinity purified by passage over a column matrix composed of the original protein immunogen or free peptide.

Example 9: Generation of 108P5H8 Monoclonal Antibodies (mAbs)

In one embodiment, therapeutic mAbs to 108P5H8 comprise those that react with epitopes of the protein that would disrupt or modulate the biological function of 108P5H8, for example those that would disrupt its interaction with ligands, proteins, or substrates that mediate its biological activity. Immunogens for generation of such mAbs include those designed to encode or contain an entire 108P5H8 protein or its variants or regions of 108P5H8 protein predicted to be exposed on the cell surface and/or antigenic from computer analysis of the amino acid sequence (see, e.g., Figure 5, Figure 6, Figure 7, Figure 8, or Figure 9, and the Example entitled "Antigenicity Profiles and Secondary Structure"). Immunogens include peptides, recombinant bacterial proteins, and mammalian expressed Tag 5 proteins and human and murine IgG Fc fusion proteins. In addition, cells expressing high levels of 108P5H8, such as 293T-108P5H8 or 300.19-108P5H8 murine Pre-B cells, are used to immunize mice.

To generate mAbs to 108P5H8, mice are first immunized intraperitoneally (IP) with, typically, 10-50 µg of protein immunogen or 10^7 108P5H8-expressing cells mixed in complete Freund's adjuvant. Mice are then subsequently immunized IP every 2-4 weeks with, typically, 10-50 µg of protein immunogen or 10^7 cells mixed in incomplete Freund's adjuvant. Alternatively, MPL-TDM adjuvant is used in immunizations. In addition to the above protein and cell-based immunization strategies, a DNA-based immunization protocol is employed in which a mammalian expression vector encoding 108P5H8 sequence is used to immunize mice by direct injection of the plasmid DNA. For example, the predicted third extracellular loop, amino acids 294-307 of 108P5H8, is cloned into the Tag5 mammalian secretion vector and the recombinant vector is used as immunogen. In another example the amino acids are cloned into an Fc-fusion secretion vector in which a 108P5H8 sequence is fused at the amino-terminus to an IgK leader sequence and at the carboxyl-terminus to the coding sequence of the human or murine IgG Fc region. This recombinant vector is then used as immunogen. The plasmid immunization protocols are used in combination with purified proteins expressed from the same vector and with cells expressing 108P5H8.

During the immunization protocol, test bleeds are taken 7-10 days following an injection to monitor titer and specificity of the immune response. Once appropriate reactivity and specificity is obtained as determined by ELISA, Western blotting, immunoprecipitation, fluorescence microscopy, and flow cytometric analyses, fusion and hybridoma generation is then carried out with established procedures well known in the art (see, e.g., Harlow and Lane, 1988).

In one embodiment, monoclonal antibodies are derived from immunization of mice with 300.19 cells engineered to express high levels of 108P5H8 (>30,000 molecules per cell). Balb C mice are initially immunized intraperitoneally with 10^7 cells mixed in complete Freund's adjuvant. Mice are subsequently immunized every two weeks with 10^7 cells mixed in incomplete Freund's adjuvant for a total of three immunizations. Reactivity and specificity of serum to the full length 108P5H8 protein is monitored by Western blotting, immunoprecipitation and flow cytometry using various cells engineered to overexpress

108P5H8 protein (Figure 24). Mice showing the strongest reactivity are rested and given a final injection of cells in PBS and then sacrificed four days later. The spleens of the sacrificed mice are harvested and fused to SPO/2 myeloma cells using standard procedures (see, e.g., Harlow and Lane, 1988). Supernatants from HAT selected growth wells are screened by ELISA, Western blot, immunoprecipitation, fluorescent microscopy, and flow cytometry to identify 108P5H8 specific antibody-producing clones.

The binding affinity of a 108P5H8 monoclonal antibody is determined using standard technologies. Affinity measurements quantify the strength of antibody to epitope binding and are used to help define which 108P5H8 monoclonal antibodies preferred, e.g., for diagnostic or therapeutic use, as appreciated by one of skill in the art. The BIAcore system (Uppsala, Sweden) is a preferred method for determining binding affinity. The BIAcore system uses surface plasmon resonance (SPR, Welford K. 1991, Opt. Quant. Elect. 23:1; Morton and Myszk, 1998, Methods in Enzymology 295: 268) to monitor biomolecular interactions in real time. BIAcore analysis conveniently generates association rate constants, dissociation rate constants, equilibrium dissociation constants, and affinity constants.

Example 10: HLA Class I and Class II Binding Assays

HLA class I and class II binding assays using purified HLA molecules are performed in accordance with disclosed protocols (e.g., PCT publications WO 94/20127 and WO 94/03205; Sidney *et al.*, *Current Protocols in Immunology* 18.3.1 (1998); Sidney, *et al.*, *J. Immunol.* 154:247 (1995); Sette, *et al.*, *Mol. Immunol.* 31:813 (1994)). Briefly, purified MHC molecules (5 to 500 nM) are incubated with various unlabeled peptide inhibitors and 1-10 nM ¹²⁵I-radiolabeled probe peptides as described. Following incubation, MHC-peptide complexes are separated from free peptide by gel filtration and the fraction of peptide bound is determined. Typically, in preliminary experiments, each MHC preparation is titrated in the presence of fixed amounts of radiolabeled peptides to determine the concentration of HLA molecules necessary to bind 10-20% of the total radioactivity. All subsequent inhibition and direct binding assays are performed using these HLA concentrations.

Since under these conditions [label]<[HLA] and IC₅₀≥[HLA], the measured IC₅₀ values are reasonable approximations of the true K_D values. Peptide inhibitors are typically tested at concentrations ranging from 120 µg/ml to 1.2 ng/ml, and are tested in two to four completely independent experiments. To allow comparison of the data obtained in different experiments, a relative binding figure is calculated for each peptide by dividing the IC₅₀ of a positive control for inhibition by the IC₅₀ for each tested peptide (typically unlabeled versions of the radiolabeled probe peptide). For database purposes, and inter-experiment comparisons, relative binding values are compiled. These values can subsequently be converted back into IC₅₀ nM values by dividing the IC₅₀ nM of the positive controls for inhibition by the relative binding of the peptide of interest. This method of data compilation is accurate and consistent for comparing peptides that have been tested on different days, or with different lots of purified MHC.

Binding assays as outlined above may be used to analyze HLA supermotif and/or HLA motif-bearing peptides.

Example 11: Identification of HLA Supermotif- and Motif-Bearing CTL Candidate

Epitopes

HLA vaccine compositions of the invention can include multiple epitopes. The multiple epitopes can comprise multiple HLA supermotifs or motifs to achieve broad population coverage. This example illustrates the identification and confirmation of supermotif- and motif-bearing epitopes for the inclusion in such a vaccine composition. Calculation of population coverage is performed using the strategy described below.

Computer searches and algorithms for identification of supermotif and/or motif-bearing epitopes

The searches performed to identify the motif-bearing peptide sequences in the Example entitled "Antigenicity Profiles" and Tables V-XVIII, XXII, and XXIII employ the protein sequence data from the gene product of 108P5H8 set forth in Figures 2 and 3.

Computer searches for epitopes bearing HLA Class I or Class II supermotifs or motifs are performed as follows. All translated 108P5H8 protein sequences are analyzed using a text string search software program to identify potential peptide sequences containing appropriate HLA binding motifs; such programs are readily produced in accordance with information in the art in view of known motif/supermotif disclosures. Furthermore, such calculations can be made mentally.

Identified A2-, A3-, and DR-supermotif sequences are scored using polynomial algorithms to predict their capacity to bind to specific HLA-Class I or Class II molecules. These polynomial algorithms account for the impact of different amino acids at different positions, and are essentially based on the premise that the overall affinity (or ΔG) of peptide-HLA molecule interactions can be approximated as a linear polynomial function of the type:

$$"\Delta G" = a_{1i} \times a_{2i} \times a_{3i} \dots \times a_{ni}$$

where a_{ji} is a coefficient which represents the effect of the presence of a given amino acid (j) at a given position (i) along the sequence of a peptide of n amino acids. The crucial assumption of this method is that the effects at each position are essentially independent of each other (i.e., independent binding of individual side-chains). When residue j occurs at position i in the peptide, it is assumed to contribute a constant amount j_i to the free energy of binding of the peptide irrespective of the sequence of the rest of the peptide.

The method of derivation of specific algorithm coefficients has been described in Gulukota *et al.*, *J. Mol. Biol.* 267:1258-126, 1997; (see also Sidney *et al.*, *Human Immunol.* 45:79-93, 1996; and Southwood *et al.*, *J. Immunol.* 160:3363-3373, 1998). Briefly, for all i positions, anchor and non-anchor alike, the geometric mean of the average relative binding (ARB) of all peptides carrying j is calculated relative to the remainder of the group, and used as the estimate of j_i . For Class II peptides, if multiple alignments are possible, only the highest scoring alignment is utilized, following an iterative procedure. To calculate an algorithm score of a given peptide in a test set, the ARB values corresponding to the sequence of the peptide are multiplied. If this product exceeds a chosen threshold, the peptide is predicted to bind. Appropriate thresholds are chosen as a function of the degree of stringency of prediction desired.

Selection of HLA-A2 supertype cross-reactive peptides

Protein sequences from 108P5H8 are scanned utilizing motif identification software, to identify 8-, 9-, 10- and 11-mer sequences containing the HLA-A2-supermotif main anchor specificity. Typically, these sequences are then scored using the protocol described above and the peptides corresponding to the positive-scoring sequences are synthesized and tested for their capacity to bind purified HLA-A*0201 molecules *in vitro* (HLA-A*0201 is considered a prototype A2 supertype molecule).

These peptides are then tested for the capacity to bind to additional A2-supertype molecules (A*0202, A*0203, A*0206, and A*6802). Peptides that bind to at least three of the five A2-supertype alleles tested are typically deemed A2-supertype cross-reactive binders. Preferred peptides bind at an affinity equal to or less than 500 nM to three or more HLA-A2 supertype molecules.

Selection of HLA-A3 supermotif-bearing epitopes

The 108P5H8 protein sequence(s) scanned above is also examined for the presence of peptides with the HLA-A3-supermotif primary anchors. Peptides corresponding to the HLA A3 supermotif-bearing sequences are then synthesized and tested for binding to HLA-A*0301 and HLA-A*1101 molecules, the molecules encoded by the two most prevalent A3-supertype alleles. The peptides that bind at least one of the two alleles with binding affinities of ≤ 500 nM, often ≤ 200 nM, are then tested for binding cross-reactivity to the other common A3-supertype alleles (e.g., A*3101, A*3301, and A*6801) to identify those that can bind at least three of the five HLA-A3-supertype molecules tested.

Selection of HLA-B7 supermotif bearing epitopes

The 108P5H8 protein(s) scanned above is also analyzed for the presence of 8-, 9-, 10-, or 11-mer peptides with the HLA-B7-supermotif. Corresponding peptides are synthesized and tested for binding to HLA-B*0702, the molecule encoded by the most common B7-supertype allele (*i.e.*, the prototype B7 supertype allele). Peptides binding B*0702 with IC_{50} of ≤ 500 nM are identified using standard methods. These peptides are then tested for binding to other common B7-supertype molecules (e.g., B*3501, B*5101, B*5301, and B*5401). Peptides capable of binding to three or more of the five B7-supertype alleles tested are thereby identified.

Selection of A1 and A24 motif-bearing epitopes

To further increase population coverage, HLA-A1 and -A24 epitopes can also be incorporated into vaccine compositions. An analysis of the 108P5H8 protein can also be performed to identify HLA-A1- and A24-motif-containing sequences.

High affinity and/or cross-reactive binding epitopes that bear other motif and/or supermotifs are identified using analogous methodology.

Example 12: Confirmation of Immunogenicity

Cross-reactive candidate CTL A2-supermotif-bearing peptides that are identified as described herein are selected to confirm *in vitro* immunogenicity. Confirmation is performed using the following methodology:

Target Cell Lines for Cellular Screening:

The .221A2.1 cell line, produced by transferring the HLA-A2.1 gene into the HLA-A, -B, -C null mutant human B-lymphoblastoid cell line 721.221, is used as the peptide-loaded target to measure activity of HLA-A2.1-restricted CTL. This cell line is grown in RPMI-1640 medium supplemented with antibiotics, sodium pyruvate, nonessential amino acids and 10% (v/v) heat inactivated FCS. Cells that express an antigen of interest, or transfectants comprising the gene encoding the antigen of interest, can be used as target cells to confirm the ability of peptide-specific CTLs to recognize endogenous antigen.

Primary CTL Induction Cultures:

Generation of Dendritic Cells (DC): PBMCs are thawed in RPMI with 30 µg/ml DNase, washed twice and resuspended in complete medium (RPMI-1640 plus 5% AB human serum, non-essential amino acids, sodium pyruvate, L-glutamine and penicillin/streptomycin). The monocytes are purified by plating 10×10^6 PBMC/well in a 6-well plate. After 2 hours at 37°C, the non-adherent cells are removed by gently shaking the plates and aspirating the supernatants. The wells are washed a total of three times with 3 ml RPMI to remove most of the non-adherent and loosely adherent cells. Three ml of complete medium containing 50 ng/ml of GM-CSF and 1,000 U/ml of IL-4 are then added to each well. TNFα is added to the DCs on day 6 at 75 ng/ml and the cells are used for CTL induction cultures on day 7.

Induction of CTL with DC and Peptide: CD8+ T-cells are isolated by positive selection with Dynal immunomagnetic beads (Dynabeads® M-450) and the detach-bead® reagent. Typically about 200-250x10⁶ PBMC are processed to obtain 24x10⁶ CD8+ T-cells (enough for a 48-well plate culture). Briefly, the PBMCs are thawed in RPMI with 30µg/ml DNase, washed once with PBS containing 1% human AB serum and resuspended in PBS/1% AB serum at a concentration of 20x10⁶ cells/ml. The magnetic beads are washed 3 times with PBS/AB serum, added to the cells (140µl beads/20x10⁶ cells) and incubated for 1 hour at 4°C with continuous mixing. The beads and cells are washed 4x with PBS/AB serum to remove the nonadherent cells and resuspended at 100x10⁶ cells/ml (based on the original cell number) in PBS/AB serum containing 100µl/ml detach-bead® reagent and 30 µg/ml DNase. The mixture is incubated for 1 hour at room temperature with continuous mixing. The beads are washed again with PBS/AB/DNase to collect the CD8+ T-cells. The DC are collected and centrifuged at 1300 rpm for 5-7 minutes, washed once with PBS with 1% BSA, counted and pulsed with 40µg/ml of peptide at a cell concentration of 1-2x10⁶/ml in the presence of 3µg/ml β₂- microglobulin for 4 hours at 20°C. The DC are then irradiated (4,200 rads), washed 1 time with medium and counted again.

Setting up induction cultures: 0.25 ml cytokine-generated DC (at 1x10⁵ cells/ml) are co-cultured with 0.25ml of CD8+ T-cells (at 2x10⁶ cell/ml) in each well of a 48-well plate in the presence of 10 ng/ml of IL-7. Recombinant human IL-10 is added the next day at a final concentration of 10 ng/ml and rhuman IL-2 is added 48 hours later at 10 IU/ml.

Restimulation of the induction cultures with peptide-pulsed adherent cells: Seven and fourteen days after the primary induction, the cells are restimulated with peptide-pulsed adherent cells. The PBMCs are thawed and washed twice with RPMI and DNase. The cells are resuspended at 5x10⁶ cells/ml and irradiated at ~4200 rads. The PBMCs are plated at 2x10⁶ in 0.5 ml complete medium per well and

incubated for 2 hours at 37°C. The plates are washed twice with RPMI by tapping the plate gently to remove the nonadherent cells and the adherent cells pulsed with 10µg/ml of peptide in the presence of 3 µg/ml B₂ microglobulin in 0.25ml RPMI/5%AB per well for 2 hours at 37°C. Peptide solution from each well is aspirated and the wells are washed once with RPMI. Most of the media is aspirated from the induction cultures (CD8+ cells) and brought to 0.5 ml with fresh media. The cells are then transferred to the wells containing the peptide-pulsed adherent cells. Twenty four hours later recombinant human IL-10 is added at a final concentration of 10 ng/ml and recombinant human IL2 is added the next day and again 2-3 days later at 50IU/ml (Tsai *et al.*, *Critical Reviews in Immunology* 18(1-2):65-75, 1998). Seven days later, the cultures are assayed for CTL activity in a ⁵¹Cr release assay. In some experiments the cultures are assayed for peptide-specific recognition in the *in situ* IFNγ ELISA at the time of the second restimulation followed by assay of endogenous recognition 7 days later. After expansion, activity is measured in both assays for a side-by-side comparison.

Measurement of CTL lytic activity by ⁵¹Cr release.

Seven days after the second restimulation, cytotoxicity is determined in a standard (5 hr) ⁵¹Cr release assay by assaying individual wells at a single E:T. Peptide-pulsed targets are prepared by incubating the cells with 10µg/ml peptide overnight at 37°C.

Adherent target cells are removed from culture flasks with trypsin-EDTA. Target cells are labeled with 200µCi of ⁵¹Cr sodium chromate (Dupont, Wilmington, DE) for 1 hour at 37°C. Labeled target cells are resuspended at 10⁶ per ml and diluted 1:10 with K562 cells at a concentration of 3.3x10⁶/ml (an NK-sensitive erythroleukemia cell line used to reduce non-specific lysis). Target cells (100 µl) and effectors (100µl) are plated in 96 well round-bottom plates and incubated for 5 hours at 37°C. At that time, 100 µl of supernatant are collected from each well and percent lysis is determined according to the formula: [(cpm of the test sample- cpm of the spontaneous ⁵¹Cr release sample)/(cpm of the maximal ⁵¹Cr release sample- cpm of the spontaneous ⁵¹Cr release sample)] x 100.

Maximum and spontaneous release are determined by incubating the labeled targets with 1% Triton X-100 and media alone, respectively. A positive culture is defined as one in which the specific lysis (sample- background) is 10% or higher in the case of individual wells and is 15% or more at the two highest E:T ratios when expanded cultures are assayed.

In situ Measurement of Human IFNγ Production as an Indicator of Peptide-specific and Endogenous Recognition

Immulon 2 plates are coated with mouse anti-human IFNγ monoclonal antibody (4 µg/ml 0.1M NaHCO₃, pH8.2) overnight at 4°C. The plates are washed with Ca²⁺, Mg²⁺-free PBS/0.05% Tween 20 and blocked with PBS/10% FCS for two hours, after which the CTLs (100 µl/well) and targets (100 µl/well) are added to each well, leaving empty wells for the standards and blanks (which received media only). The target cells, either peptide-pulsed or endogenous targets, are used at a concentration of 1x10⁶ cells/ml. The plates are incubated for 48 hours at 37°C with 5% CO₂.

Recombinant human IFN-gamma is added to the standard wells starting at 400 pg or 1200pg/100 microliter/well and the plate incubated for two hours at 37°C. The plates are washed and 100 µl of biotinylated mouse anti-human IFN-gamma monoclonal antibody (2 microgram/ml in PBS/3%FCS/0.05% Tween 20) are added and incubated for 2 hours at room temperature. After washing again, 100 microliter HRP-streptavidin (1:4000) are added and the plates incubated for one hour at room temperature. The plates are then washed 6x with wash buffer, 100 microliter/well developing solution (TMB 1:1) are added, and the plates allowed to develop for 5-15 minutes. The reaction is stopped with 50 microliter/well 1M H₃PO₄ and read at OD450. A culture is considered positive if it measured at least 50 pg of IFN-gamma/well above background and is twice the background level of expression.

CTL Expansion.

Those cultures that demonstrate specific lytic activity against peptide-pulsed targets and/or tumor targets are expanded over a two week period with anti-CD3. Briefly, 5x10⁴ CD8+ cells are added to a T25 flask containing the following: 1x10⁶ irradiated (4,200 rad) PBMC (autologous or allogeneic) per ml, 2x10⁵ irradiated (8,000 rad) EBV- transformed cells per ml, and OKT3 (anti-CD3) at 30ng per ml in RPMI-1640 containing 10% (v/v) human AB serum, non-essential amino acids, sodium pyruvate, 25µM 2-mercaptoethanol, L-glutamine and penicillin/streptomycin. Recombinant human IL2 is added 24 hours later at a final concentration of 200IU/ml and every three days thereafter with fresh media at 50IU/ml. The cells are split if the cell concentration exceeds 1x10⁶/ml and the cultures are assayed between days 13 and 15 at E:T ratios of 30, 10, 3 and 1:1 in the ⁵¹Cr release assay or at 1x10⁶/ml in the *in situ* IFNγ assay using the same targets as before the expansion.

Cultures are expanded in the absence of anti-CD3⁺ as follows. Those cultures that demonstrate specific lytic activity against peptide and endogenous targets are selected and 5x10⁴ CD8⁺ cells are added to a T25 flask containing the following: 1x10⁶ autologous PBMC per ml which have been peptide-pulsed with 10 µg/ml peptide for two hours at 37°C and irradiated (4,200 rad); 2x10⁵ irradiated (8,000 rad) EBV-transformed cells per ml RPMI-1640 containing 10%(v/v) human AB serum, non-essential AA, sodium pyruvate, 25mM 2-ME, L-glutamine and gentamicin.

Immunogenicity of A2 supermotif-bearing peptides

A2-supermotif cross-reactive binding peptides are tested in the cellular assay for the ability to induce peptide-specific CTL in normal individuals. In this analysis, a peptide is typically considered to be an epitope if it induces peptide-specific CTLs in at least individuals, and preferably, also recognizes the endogenously expressed peptide.

Immunogenicity can also be confirmed using PBMCs isolated from patients bearing a tumor that expresses 108P5H8. Briefly, PBMCs are isolated from patients, re-stimulated with peptide-pulsed monocytes and assayed for the ability to recognize peptide-pulsed target cells as well as transfected cells endogenously expressing the antigen.

Evaluation of A*03/A11 immunogenicity

HLA-A3 supermotif-bearing cross-reactive binding peptides are also evaluated for immunogenicity using methodology analogous for that used to evaluate the immunogenicity of the HLA-A2 supermotif peptides.

Evaluation of B7 immunogenicity

Immunogenicity screening of the B7-supertype cross-reactive binding peptides identified as set forth herein are confirmed in a manner analogous to the confirmation of A2-and A3-supermotif-bearing peptides.

Peptides bearing other supermotifs/motifs, e.g., HLA-A1, HLA-A24 *etc.* are also confirmed using similar methodology

Example 13: Implementation of the Extended Supermotif to Improve the Binding Capacity of Native Epitopes by Creating Analogs

HLA motifs and supermotifs (comprising primary and/or secondary residues) are useful in the identification and preparation of highly cross-reactive native peptides, as demonstrated herein. Moreover, the definition of HLA motifs and supermotifs also allows one to engineer highly cross-reactive epitopes by identifying residues within a native peptide sequence which can be analoged to confer upon the peptide certain characteristics, e.g. greater cross-reactivity within the group of HLA molecules that comprise a supertype, and/or greater binding affinity for some or all of those HLA molecules. Examples of analoging peptides to exhibit modulated binding affinity are set forth in this example.

Analoging at Primary Anchor Residues

Peptide engineering strategies are implemented to further increase the cross-reactivity of the epitopes. For example, the main anchors of A2-supermotif-bearing peptides are altered, for example, to introduce a preferred L, I, V, or M at position 2, and I or V at the C-terminus.

To analyze the cross-reactivity of the analog peptides, each engineered analog is initially tested for binding to the prototype A2 supertype allele A*0201, then, if A*0201 binding capacity is maintained, for A2-supertype cross-reactivity.

Alternatively, a peptide is confirmed as binding one or all supertype members and then analoged to modulate binding affinity to any one (or more) of the supertype members to add population coverage.

The selection of analogs for immunogenicity in a cellular screening analysis is typically further restricted by the capacity of the parent wild type (WT) peptide to bind at least weakly, *i.e.*, bind at an IC₅₀ of 5000nM or less, to three or more A2 supertype alleles. The rationale for this requirement is that the WT peptides must be present endogenously in sufficient quantity to be biologically relevant. Analoged peptides have been shown to have increased immunogenicity and cross-reactivity by T cells specific for the parent epitope (*see, e.g.*, Parkhurst *et al.*, *J. Immunol.* 157:2539, 1996; and Pogue *et al.*, *Proc. Natl. Acad. Sci. USA* 92:8166, 1995).

In the cellular screening of these peptide analogs, it is important to confirm that analog-specific CTLs are also able to recognize the wild-type peptide and, when possible, target cells that endogenously express the epitope.

Analoging of HLA-A3 and B7-supermotif-bearing peptides

Analogs of HLA-A3 supermotif-bearing epitopes are generated using strategies similar to those employed in analoging HLA-A2 supermotif-bearing peptides. For example, peptides binding to 3/5 of the A3-supertype molecules are engineered at primary anchor residues to possess a preferred residue (V, S, M, or A) at position 2.

The analog peptides are then tested for the ability to bind A*03 and A*11 (prototype A3 supertype alleles). Those peptides that demonstrate ≤ 500 nM binding capacity are then confirmed as having A3-supertype cross-reactivity.

Similarly to the A2- and A3- motif bearing peptides, peptides binding 3 or more B7-supertype alleles can be improved, where possible, to achieve increased cross-reactive binding or greater binding affinity or binding half life. B7 supermotif-bearing peptides are, for example, engineered to possess a preferred residue (V, I, L, or F) at the C-terminal primary anchor position, as demonstrated by Sidney *et al.* (*J. Immunol.* 157:3480-3490, 1996).

Analoging at primary anchor residues of other motif and/or supermotif-bearing epitopes is performed in a like manner.

The analog peptides are then be confirmed for immunogenicity, typically in a cellular screening assay. Again, it is generally important to demonstrate that analog-specific CTLs are also able to recognize the wild-type peptide and, when possible, targets that endogenously express the epitope.

Analoging at Secondary Anchor Residues

Moreover, HLA supermotifs are of value in engineering highly cross-reactive peptides and/or peptides that bind HLA molecules with increased affinity by identifying particular residues at secondary anchor positions that are associated with such properties. For example, the binding capacity of a B7 supermotif-bearing peptide with an F residue at position 1 is analyzed. The peptide is then analoged to, for example, substitute L for F at position 1. The analoged peptide is evaluated for increased binding affinity, binding half life and/or increased cross-reactivity. Such a procedure identifies analoged peptides with enhanced properties.

Engineered analogs with sufficiently improved binding capacity or cross-reactivity can also be tested for immunogenicity in HLA-B7-transgenic mice, following for example, IFA immunization or lipopeptide immunization. Analoged peptides are additionally tested for the ability to stimulate a recall response using PBMC from patients with 108P5H8-expressing tumors.

Other analoging strategies

Another form of peptide analoging, unrelated to anchor positions, involves the substitution of a cysteine with α -amino butyric acid. Due to its chemical nature, cysteine has the propensity to form disulfide bridges and sufficiently alter the peptide structurally so as to reduce binding capacity.

Substitution of α -amino butyric acid for cysteine not only alleviates this problem, but has been shown to improve binding and crossbinding capabilities in some instances (*see, e.g.*, the review by Sette *et al.*, In: Persistent Viral Infections, Eds. R. Ahmed and I. Chen, John Wiley & Sons, England, 1999).

Thus, by the use of single amino acid substitutions, the binding properties and/or cross-reactivity of peptide ligands for HLA supertype molecules can be modulated.

Example 14. Identification and confirmation of 108P5H8-derived sequences with HLA-DR binding motifs

Peptide epitopes bearing an HLA class II supermotif or motif are identified and confirmed as outlined below using methodology similar to that described for HLA Class I peptides.

Selection of HLA-DR-supermotif-bearing epitopes

To identify 108P5H8-derived, HLA class II HTL epitopes, a 108P5H8 antigen is analyzed for the presence of sequences bearing an HLA-DR-motif or supermotif. Specifically, 15-mer sequences are selected comprising a DR-supermotif, comprising a 9-mer core, and three-residue N- and C-terminal flanking regions (15 amino acids total).

Protocols for predicting peptide binding to DR molecules have been developed (Southwood *et al.*, *J. Immunol.* 160:3363-3373, 1998). These protocols, specific for individual DR molecules, allow the scoring, and ranking, of 9-mer core regions. Each protocol not only scores peptide sequences for the presence of DR-supermotif primary anchors (*i.e.*, at position 1 and position 6) within a 9-mer core, but additionally evaluates sequences for the presence of secondary anchors. Using allele-specific selection tables (*see, e.g.*, Southwood *et al., ibid.*), it has been found that these protocols efficiently select peptide sequences with a high probability of binding a particular DR molecule. Additionally, it has been found that performing these protocols in tandem, specifically those for DR1, DR4w4, and DR7, can efficiently select DR cross-reactive peptides.

The 108P5H8-derived peptides identified above are tested for their binding capacity for various common HLA-DR molecules. All peptides are initially tested for binding to the DR molecules in the primary panel: DR1, DR4w4, and DR7. Peptides binding at least two of these three DR molecules are then tested for binding to DR2w2 β 1, DR2w2 β 2, DR6w19, and DR9 molecules in secondary assays. Finally, peptides binding at least two of the four secondary panel DR molecules, and thus cumulatively at least four of seven different DR molecules, are screened for binding to DR4w15, DR5w11, and DR8w2 molecules in tertiary assays. Peptides binding at least seven of the ten DR molecules comprising the primary, secondary, and tertiary screening assays are considered cross-reactive DR binders. 108P5H8-derived peptides found to bind common HLA-DR alleles are of particular interest.

Selection of DR3 motif peptides

Because HLA-DR3 is an allele that is prevalent in Caucasian, Black, and Hispanic populations, DR3 binding capacity is a relevant criterion in the selection of HTL epitopes. Thus, peptides shown to be candidates may also be assayed for their DR3 binding capacity. However, in view of the binding

specificity of the DR3 motif, peptides binding only to DR3 can also be considered as candidates for inclusion in a vaccine formulation.

To efficiently identify peptides that bind DR3, target 108P5H8 antigens are analyzed for sequences carrying one of the two DR3-specific binding motifs reported by Geluk *et al.* (*J. Immunol.* 152:5742-5748, 1994). The corresponding peptides are then synthesized and confirmed as having the ability to bind DR3 with an affinity of 1 μ M or better, i.e., less than 1 μ M. Peptides are found that meet this binding criterion and qualify as HLA class II high affinity binders.

DR3 binding epitopes identified in this manner are included in vaccine compositions with DR supermotif-bearing peptide epitopes.

Similarly to the case of HLA class I motif-bearing peptides, the class II motif-bearing peptides are analogized to improve affinity or cross-reactivity. For example, aspartic acid at position 4 of the 9-mer core sequence is an optimal residue for DR3 binding, and substitution for that residue often improves DR 3 binding.

Example 15: Immunogenicity of 108P5H8-derived HTL epitopes

This example determines immunogenic DR supermotif- and DR3 motif-bearing epitopes among those identified using the methodology set forth herein.

Immunogenicity of HTL epitopes are confirmed in a manner analogous to the determination of immunogenicity of CTL epitopes, by assessing the ability to stimulate HTL responses and/or by using appropriate transgenic mouse models. Immunogenicity is determined by screening for: 1.) *in vitro* primary induction using normal PBMC or 2.) recall responses from patients who have 108P5H8-expressing tumors.

Example 16: Calculation of phenotypic frequencies of HLA-supertypes in various ethnic backgrounds to determine breadth of population coverage

This example illustrates the assessment of the breadth of population coverage of a vaccine composition comprised of multiple epitopes comprising multiple supermotifs and/or motifs.

In order to analyze population coverage, gene frequencies of HLA alleles are determined. Gene frequencies for each HLA allele are calculated from antigen or allele frequencies utilizing the binomial distribution formulae $gf=1-(\text{SQRT}(1-af))$ (see, e.g., Sidney *et al.*, *Human Immunol.* 45:79-93, 1996). To obtain overall phenotypic frequencies, cumulative gene frequencies are calculated, and the cumulative antigen frequencies derived by the use of the inverse formula $[af=1-(1-Cgf)^2]$.

Where frequency data is not available at the level of DNA typing, correspondence to the serologically defined antigen frequencies is assumed. To obtain total potential supertype population coverage no linkage disequilibrium is assumed, and only alleles confirmed to belong to each of the supertypes are included (minimal estimates). Estimates of total potential coverage achieved by inter-loci combinations are made by adding to the A coverage the proportion of the non-A covered population that could be expected to be covered by the B alleles considered (e.g., $\text{total}=A+B*(1-A)$). Confirmed members

5

10

15

20

25

34

3

The results demonstrate that CTL lines obtained from animals primed with peptide epitope recognize endogenously synthesized 108P5H8 antigen. The choice of transgenic mouse model to be used for such an analysis depends upon the epitope(s) that are being evaluated. In addition to HLA-A*0201/K^b transgenic mice, several other transgenic mouse models including mice with human A11, which may also be used to evaluate A3 epitopes, and B7 alleles have been characterized and others (e.g., transgenic mice for HLA-A1 and A24) are being developed. HLA-DR1 and HLA-DR3 mouse models have also been developed, which may be used to evaluate HTL epitopes.

Example 18: Activity Of CTL-HTL Conjugated Epitopes In Transgenic Mice

This example illustrates the induction of CTLs and HTLs in transgenic mice, by use of a 108P5H8-derived CTL and HTL peptide vaccine compositions. The vaccine composition used herein comprise peptides to be administered to a patient with a 108P5H8-expressing tumor. The peptide composition can comprise multiple CTL and/or HTL epitopes. The epitopes are identified using methodology as described herein. This example also illustrates that enhanced immunogenicity can be achieved by inclusion of one or more HTL epitopes in a CTL vaccine composition; such a peptide composition can comprise an HTL epitope conjugated to a CTL epitope. The CTL epitope can be one that binds to multiple HLA family members at an affinity of 500 nM or less, or analogs of that epitope. The peptides may be lipidated, if desired.

Immunization procedures: Immunization of transgenic mice is performed as described (Alexander *et al.*, *J. Immunol.* 159:4753-4761, 1997). For example, A2/K^b mice, which are transgenic for the human HLA A2.1 allele and are used to confirm the immunogenicity of HLA-A*0201 motif- or HLA-A2 supermotif-bearing epitopes, and are primed subcutaneously (base of the tail) with a 0.1 ml of peptide in Incomplete Freund's Adjuvant, or if the peptide composition is a lipidated CTL/HTL conjugate, in DMSO/saline, or if the peptide composition is a polypeptide, in PBS or Incomplete Freund's Adjuvant. Seven days after priming, splenocytes obtained from these animals are restimulated with syngenic irradiated LPS-activated lymphoblasts coated with peptide.

Cell lines: Target cells for peptide-specific cytotoxicity assays are Jurkat cells transfected with the HLA-A2.1/K^b chimeric gene (e.g., Vitiello *et al.*, *J. Exp. Med.* 173:1007, 1991)

In vitro CTL activation: One week after priming, spleen cells (30x10⁶ cells/flask) are co-cultured at 37°C with syngeneic, irradiated (3000 rads), peptide coated lymphoblasts (10x10⁶ cells/flask) in 10 ml of culture medium/T25 flask. After six days, effector cells are harvested and assayed for cytotoxic activity.

Assay for cytotoxic activity: Target cells (1.0 to 1.5x10⁶) are incubated at 37°C in the presence of 200 µl of ⁵¹Cr. After 60 minutes, cells are washed three times and resuspended in R10 medium. Peptide is added where required at a concentration of 1 µg/ml. For the assay, 10⁴ ⁵¹Cr-labeled target cells are added to different concentrations of effector cells (final volume of 200 µl) in U-bottom 96-well plates. After a six hour incubation period at 37°C, a 0.1 ml aliquot of supernatant is removed from each well and radioactivity is determined in a Micromedic automatic gamma counter. The percent specific lysis is determined by the

formula: percent specific release = $100 \times (\text{experimental release} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release})$. To facilitate comparison between separate CTL assays run under the same conditions, % ^{51}Cr release data is expressed as lytic units/ 10^6 cells. One lytic unit is arbitrarily defined as the number of effector cells required to achieve 30% lysis of 10,000 target cells in a six hour ^{51}Cr release assay. To obtain specific lytic units/ 10^6 , the lytic units/ 10^6 obtained in the absence of peptide is subtracted from the lytic units/ 10^6 obtained in the presence of peptide. For example, if 30% ^{51}Cr release is obtained at the effector (E): target (T) ratio of 50:1 (i.e., 5×10^5 effector cells for 10,000 targets) in the absence of peptide and 5:1 (i.e., 5×10^4 effector cells for 10,000 targets) in the presence of peptide, the specific lytic units would be: $[(1/50,000) - (1/500,000)] \times 10^6 = 18 \text{ LU}$.

The results are analyzed to assess the magnitude of the CTL responses of animals injected with the immunogenic CTL/HTL conjugate vaccine preparation and are compared to the magnitude of the CTL response achieved using, for example, CTL epitopes as outlined above in the Example entitled "Confirmation of Immunogenicity". Analyses similar to this may be performed to confirm the immunogenicity of peptide conjugates containing multiple CTL epitopes and/or multiple HTL epitopes. In accordance with these procedures, it is found that a CTL response is induced, and concomitantly that an HTL response is induced upon administration of such compositions.

Example 19: Selection of CTL and HTL epitopes for inclusion in an 108P5H8-specific vaccine.

This example illustrates a procedure for selecting peptide epitopes for vaccine compositions of the invention. The peptides in the composition can be in the form of a nucleic acid sequence, either single or one or more sequences (i.e., minigene) that encodes peptide(s), or can be single and/or polyepitopic peptides.

The following principles are utilized when selecting a plurality of epitopes for inclusion in a vaccine composition. Each of the following principles is balanced in order to make the selection.

Epitopes are selected which, upon administration, mimic immune responses that are correlated with 108P5H8 clearance. The number of epitopes used depends on observations of patients who spontaneously clear 108P5H8. For example, if it has been observed that patients who spontaneously clear 108P5H8 generate an immune response to at least three (3) from 108P5H8 antigen, then three or four (3-4) epitopes should be included for HLA class I. A similar rationale is used to determine HLA class II epitopes.

Epitopes are often selected that have a binding affinity of an IC_{50} of 500 nM or less for an HLA class I molecule, or for class II, an IC_{50} of 1000 nM or less; or HLA Class I peptides with high binding scores from the BIMAS web site, at URL bimas.dcrt.nih.gov/.

In order to achieve broad coverage of the vaccine through out a diverse population, sufficient supermotif bearing peptides, or a sufficient array of allele-specific motif bearing peptides, are selected to give broad population coverage. In one embodiment, epitopes are selected to provide at least 80%

population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess breadth, or redundancy, of population coverage.

When creating polypeptidic compositions, or a minigene that encodes same, it is typically desirable to generate the smallest peptide possible that encompasses the epitopes of interest. The principles employed are similar, if not the same, as those employed when selecting a peptide comprising nested epitopes. For example, a protein sequence for the vaccine composition is selected because it has maximal number of epitopes contained within the sequence, *i.e.*, it has a high concentration of epitopes. Epitopes may be nested or overlapping (*i.e.*, frame shifted relative to one another). For example, with overlapping epitopes, two 9-mer epitopes and one 10-mer epitope can be present in a 10 amino acid peptide. Each epitope can be exposed and bound by an HLA molecule upon administration of such a peptide. A multi-epitopic, peptide can be generated synthetically, recombinantly, or via cleavage from the native source. Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polypeptidic peptide. Such a vaccine composition is administered for therapeutic or prophylactic purposes. This embodiment provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccine compositions. Additionally such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup that is presently unknown. Furthermore, this embodiment (absent the creating of any analogs) directs the immune response to multiple peptide sequences that are actually present in 108P5H8, thus avoiding the need to evaluate any junctional epitopes. Lastly, the embodiment provides an economy of scale when producing nucleic acid vaccine compositions. Related to this embodiment, computer programs can be derived in accordance with principles in the art, which identify in a target sequence, the greatest number of epitopes per sequence length.

A vaccine composition comprised of selected peptides, when administered, is safe, efficacious, and elicits an immune response similar in magnitude to an immune response that controls or clears cells that bear or overexpress 108P5H8.

Example 20: Construction of "Minigene" Multi-Epitope DNA Plasmids

This example discusses the construction of a minigene expression plasmid. Minigene plasmids may, of course, contain various configurations of B cell, CTL and/or HTL epitopes or epitope analogs as described herein.

A minigene expression plasmid typically includes multiple CTL and HTL peptide epitopes. In the present example, HLA-A2, -A3, -B7 supermotif-bearing peptide epitopes and HLA-A1 and -A24 motif-bearing peptide epitopes are used in conjunction with DR supermotif-bearing epitopes and/or DR3 epitopes. HLA class I supermotif or motif-bearing peptide epitopes derived 108P5H8, are selected such that multiple supermotifs/motifs are represented to ensure broad population coverage. Similarly, HLA class II epitopes are selected from 108P5H8 to provide broad population coverage, *i.e.* both HLA DR-1-4-7

supermotif-bearing epitopes and HLA DR-3 motif-bearing epitopes are selected for inclusion in the minigene construct. The selected CTL and HTL epitopes are then incorporated into a minigene for expression in an expression vector.

Such a construct may additionally include sequences that direct the HTL epitopes to the endoplasmic reticulum. For example, the Ii protein may be fused to one or more HTL epitopes as described in the art, wherein the CLIP sequence of the Ii protein is removed and replaced with an HLA class II epitope sequence so that HLA class II epitope is directed to the endoplasmic reticulum, where the epitope binds to an HLA class II molecules.

This example illustrates the methods to be used for construction of a minigene-bearing expression plasmid. Other expression vectors that may be used for minigene compositions are available and known to those of skill in the art.

The minigene DNA plasmid of this example contains a consensus Kozak sequence and a consensus murine kappa Ig-light chain signal sequence followed by CTL and/or HTL epitopes selected in accordance with principles disclosed herein. The sequence encodes an open reading frame fused to the Myc and His antibody epitope tag coded for by the pcDNA 3.1 Myc-His vector.

Overlapping oligonucleotides that can, for example, average about 70 nucleotides in length with 15 nucleotide overlaps, are synthesized and HPLC-purified. The oligonucleotides encode the selected peptide epitopes as well as appropriate linker nucleotides, Kozak sequence, and signal sequence. The final multiepitope minigene is assembled by extending the overlapping oligonucleotides in three sets of reactions using PCR. A Perkin/Elmer 9600 PCR machine is used and a total of 30 cycles are performed using the following conditions: 95°C for 15 sec, annealing temperature (5° below the lowest calculated T_m of each primer pair) for 30 sec, and 72°C for 1 min.

For example, a minigene is prepared as follows. For a first PCR reaction, 5 µg of each of two oligonucleotides are annealed and extended: In an example using eight oligonucleotides, i.e., four pairs of primers, oligonucleotides 1+2, 3+4, 5+6, and 7+8 are combined in 100 µl reactions containing *Pfu* polymerase buffer (1x= 10 mM KCL, 10 mM (NH₄)₂SO₄, 20 mM Tris-chloride, pH 8.75, 2 mM MgSO₄, 0.1% Triton X-100, 100 µg/ml BSA), 0.25 mM each dNTP, and 2.5 U of *Pfu* polymerase. The full-length dimer products are gel-purified, and two reactions containing the product of 1+2 and 3+4, and the product of 5+6 and 7+8 are mixed, annealed, and extended for 10 cycles. Half of the two reactions are then mixed, and 5 cycles of annealing and extension carried out before flanking primers are added to amplify the full length product. The full-length product is gel-purified and cloned into pCR-blunt (Invitrogen) and individual clones are screened by sequencing.

Example 21: The Plasmid Construct and the Degree to Which It Induces Immunogenicity.

The degree to which a plasmid construct, for example a plasmid constructed in accordance with the previous Example, is able to induce immunogenicity is confirmed *in vitro* by determining epitope presentation by APC following transduction or transfection of the APC with an epitope-expressing nucleic

acid construct. Such a study determines "antigenicity" and allows the use of human APC. The assay determines the ability of the epitope to be presented by the APC in a context that is recognized by a T cell by quantifying the density of epitope-HLA class I complexes on the cell surface. Quantitation can be performed by directly measuring the amount of peptide eluted from the APC (see, e.g., Sijts *et al.*, *J. Immunol.* 156:683-692, 1996; Demotz *et al.*, *Nature* 342:682-684, 1989); or the number of peptide-HLA class I complexes can be estimated by measuring the amount of lysis or lymphokine release induced by diseased or transfected target cells, and then determining the concentration of peptide necessary to obtain equivalent levels of lysis or lymphokine release (see, e.g., Kageyama *et al.*, *J. Immunol.* 154:567-576, 1995).

Alternatively, immunogenicity is confirmed through *in vivo* injections into mice and subsequent *in vitro* assessment of CTL and HTL activity, which are analyzed using cytotoxicity and proliferation assays, respectively, as detailed e.g., in Alexander *et al.*, *Immunity* 1:751-761, 1994.

For example, to confirm the capacity of a DNA minigene construct containing at least one HLA-A2 supermotif peptide to induce CTLs *in vivo*, HLA-A2.1/K^b transgenic mice, for example, are immunized intramuscularly with 100 µg of naked cDNA. As a means of comparing the level of CTLs induced by cDNA immunization, a control group of animals is also immunized with an actual peptide composition that comprises multiple epitopes synthesized as a single polypeptide as they would be encoded by the minigene.

Splenocytes from immunized animals are stimulated twice with each of the respective compositions (peptide epitopes encoded in the minigene or the polyepitopic peptide), then assayed for peptide-specific cytotoxic activity in a ⁵¹Cr release assay. The results indicate the magnitude of the CTL response directed against the A2-restricted epitope, thus indicating the *in vivo* immunogenicity of the minigene vaccine and polyepitopic vaccine.

It is, therefore, found that the minigene elicits immune responses directed toward the HLA-A2 supermotif peptide epitopes as does the polyepitopic peptide vaccine. A similar analysis is also performed using other HLA-A3 and HLA-B7 transgenic mouse models to assess CTL induction by HLA-A3 and HLA-B7 motif or supermotif epitopes, whereby it is also found that the minigene elicits appropriate immune responses directed toward the provided epitopes.

To confirm the capacity of a class II epitope-encoding minigene to induce HTLs *in vivo*, DR transgenic mice, or for those epitopes that cross react with the appropriate mouse MHC molecule, I-A^b-restricted mice, for example, are immunized intramuscularly with 100 µg of plasmid DNA. As a means of comparing the level of HTLs induced by DNA immunization, a group of control animals is also immunized with an actual peptide composition emulsified in complete Freund's adjuvant. CD4+ T cells, i.e. HTLs, are purified from splenocytes of immunized animals and stimulated with each of the respective compositions (peptides encoded in the minigene). The HTL response is measured using a ³H-thymidine incorporation proliferation assay, (see, e.g., Alexander *et al.* *Immunity* 1:751-761, 1994). The results indicate the magnitude of the HTL response, thus demonstrating the *in vivo* immunogenicity of the minigene.

DNA minigenes, constructed as described in the previous Example, can also be confirmed as a vaccine in combination with a boosting agent using a prime boost protocol. The boosting agent can consist of recombinant protein (e.g., Barnett *et al.*, *Aids Res. and Human Retroviruses* 14, Supplement 3:S299-S309, 1998) or recombinant vaccinia, for example, expressing a minigene or DNA encoding the complete protein of interest (see, e.g., Hanke *et al.*, *Vaccine* 16:439-445, 1998; Sedegah *et al.*, *Proc. Natl. Acad. Sci USA* 95:7648-53, 1998; Hanke and McMichael, *Immunol. Letters* 66:177-181, 1999; and Robinson *et al.*, *Nature Med.* 5:526-34, 1999).

For example, the efficacy of the DNA minigene used in a prime boost protocol is initially evaluated in transgenic mice. In this example, A2.1/K^b transgenic mice are immunized IM with 100 µg of a DNA minigene encoding the immunogenic peptides including at least one HLA-A2 supermotif-bearing peptide. After an incubation period (ranging from 3-9 weeks), the mice are boosted IP with 10⁷ pfu/mouse of a recombinant vaccinia virus expressing the same sequence encoded by the DNA minigene. Control mice are immunized with 100 µg of DNA or recombinant vaccinia without the minigene sequence, or with DNA encoding the minigene, but without the vaccinia boost. After an additional incubation period of two weeks, splenocytes from the mice are immediately assayed for peptide-specific activity in an ELISPOT assay. Additionally, splenocytes are stimulated *in vitro* with the A2-restricted peptide epitopes encoded in the minigene and recombinant vaccinia, then assayed for peptide-specific activity in an alpha, beta and/or gamma IFN ELISA.

It is found that the minigene utilized in a prime-boost protocol elicits greater immune responses toward the HLA-A2 supermotif peptides than with DNA alone. Such an analysis can also be performed using HLA-A11 or HLA-B7 transgenic mouse models to assess CTL induction by HLA-A3 or HLA-B7 motif or supermotif epitopes. The use of prime boost protocols in humans is described below in the Example entitled "Induction of CTL Responses Using a Prime Boost Protocol."

Example 22: Peptide Composition for Prophylactic Uses

Vaccine compositions of the present invention can be used to prevent 108P5H8 expression in persons who are at risk for tumors that bear this antigen. For example, a polypeptidic peptide epitope composition (or a nucleic acid comprising the same) containing multiple CTL and HTL epitopes such as those selected in the above Examples, which are also selected to target greater than 80% of the population, is administered to individuals at risk for a 108P5H8-associated tumor.

For example, a peptide-based composition is provided as a single polypeptide that encompasses multiple epitopes. The vaccine is typically administered in a physiological solution that comprises an adjuvant, such as Incomplete Freund's Adjuvant. The dose of peptide for the initial immunization is from about 1 to about 50,000 µg, generally 100-5,000 µg, for a 70 kg patient. The initial administration of vaccine is followed by booster dosages at 4 weeks followed by evaluation of the magnitude of the immune response in the patient, by techniques that determine the presence of epitope-specific CTL populations in a

PBMC sample. Additional booster doses are administered as required. The composition is found to be both safe and efficacious as a prophylaxis against 108P5H8-associated disease.

Alternatively, a composition typically comprising transfecting agents is used for the administration of a nucleic acid-based vaccine in accordance with methodologies known in the art and disclosed herein.

Example 23: Polyepitopic Vaccine Compositions Derived from Native 108P5H8 Sequences

A native 108P5H8 polypeptide sequence is analyzed, preferably using computer algorithms defined for each class I and/or class II supermotif or motif, to identify "relatively short" regions of the polypeptide that comprise multiple epitopes. The "relatively short" regions are preferably less in length than an entire native antigen. This relatively short sequence that contains multiple distinct or overlapping, "nested" epitopes is selected; it can be used to generate a minigene construct. The construct is engineered to express the peptide, which corresponds to the native protein sequence. The "relatively short" peptide is generally less than 250 amino acids in length, often less than 100 amino acids in length, preferably less than 75 amino acids in length, and more preferably less than 50 amino acids in length. The protein sequence of the vaccine composition is selected because it has maximal number of epitopes contained within the sequence, *i.e.*, it has a high concentration of epitopes. As noted herein, epitope motifs may be nested or overlapping (*i.e.*, frame shifted relative to one another). For example, with overlapping epitopes, two 9-mer epitopes and one 10-mer epitope can be present in a 10 amino acid peptide. Such a vaccine composition is administered for therapeutic or prophylactic purposes.

The vaccine composition will include, for example, multiple CTL epitopes from 108P5H8 antigen and at least one HTL epitope. This polyepitopic native sequence is administered either as a peptide or as a nucleic acid sequence which encodes the peptide. Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polyepitopic peptide.

The embodiment of this example provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccine compositions. Additionally such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup that is presently unknown. Furthermore, this embodiment (excluding an analoged embodiment) directs the immune response to multiple peptide sequences that are actually present in native 108P5H8, thus avoiding the need to evaluate any junctional epitopes. Lastly, the embodiment provides an economy of scale when producing peptide or nucleic acid vaccine compositions.

Related to this embodiment, computer programs are available in the art which can be used to identify in a target sequence, the greatest number of epitopes per sequence length.

Example 24: Polyepitopic Vaccine Compositions From Multiple Antigens

The 108P5H8 peptide epitopes of the present invention are used in conjunction with epitopes from other target tumor-associated antigens, to create a vaccine composition that is useful for the prevention or treatment of cancer that expresses 108P5H8 and such other antigens. For example, a vaccine composition can be provided as a single polypeptide that incorporates multiple epitopes from 108P5H8 as well as tumor-associated antigens that are often expressed with a target cancer associated with 108P5H8 expression, or can be administered as a composition comprising a cocktail of one or more discrete epitopes. Alternatively, the vaccine can be administered as a minigene construct or as dendritic cells which have been loaded with the peptide epitopes *in vitro*.

Example 25: Use of peptides to evaluate an immune response

Peptides of the invention may be used to analyze an immune response for the presence of specific antibodies, CTL or HTL directed to 108P5H8. Such an analysis can be performed in a manner described by Ogg *et al.*, *Science* 279:2103-2106, 1998. In this Example, peptides in accordance with the invention are used as a reagent for diagnostic or prognostic purposes, not as an immunogen.

In this example highly sensitive human leukocyte antigen tetrameric complexes ("tetramers") are used for a cross-sectional analysis of, for example, 108P5H8 HLA-A*0201-specific CTL frequencies from HLA A*0201-positive individuals at different stages of disease or following immunization comprising an 108P5H8 peptide containing an A*0201 motif. Tetrameric complexes are synthesized as described (Musey *et al.*, *N. Engl. J. Med.* 337:1267, 1997). Briefly, purified HLA heavy chain (A*0201 in this example) and β 2-microglobulin are synthesized by means of a prokaryotic expression system. The heavy chain is modified by deletion of the transmembrane-cytosolic tail and COOH-terminal addition of a sequence containing a BirA enzymatic biotinylation site. The heavy chain, β 2-microglobulin, and peptide are refolded by dilution. The 45-kD refolded product is isolated by fast protein liquid chromatography and then biotinylated by BirA in the presence of biotin (Sigma, St. Louis, Missouri), adenosine 5' triphosphate and magnesium. Streptavidin-phycoerythrin conjugate is added in a 1:4 molar ratio, and the tetrameric product is concentrated to 1 mg/ml. The resulting product is referred to as tetramer-phycoerythrin.

For the analysis of patient blood samples, approximately one million PBMCs are centrifuged at 300g for 5 minutes and resuspended in 50 μ l of cold phosphate-buffered saline. Tri-color analysis is performed with the tetramer-phycoerythrin, along with anti-CD8-Tricolor, and anti-CD38. The PBMCs are incubated with tetramer and antibodies on ice for 30 to 60 min and then washed twice before formaldehyde fixation. Gates are applied to contain >99.98% of control samples. Controls for the tetramers include both A*0201-negative individuals and A*0201-positive non-diseased donors. The percentage of cells stained with the tetramer is then determined by flow cytometry. The results indicate the number of cells in the PBMC sample that contain epitope-restricted CTLs, thereby readily indicating the extent of immune response to the 108P5H8 epitope, and thus the status of exposure to 108P5H8, or exposure to a vaccine that elicits a protective or therapeutic response.

Example 26: Use of Peptide Epitopes to Evaluate Recall Responses

The peptide epitopes of the invention are used as reagents to evaluate T cell responses, such as acute or recall responses, in patients. Such an analysis may be performed on patients who have recovered from 108P5H8-associated disease or who have been vaccinated with an 108P5H8 vaccine.

For example, the class I restricted CTL response of persons who have been vaccinated may be analyzed. The vaccine may be any 108P5H8 vaccine. PBMC are collected from vaccinated individuals and HLA typed. Appropriate peptide epitopes of the invention that, optimally, bear supermotifs to provide cross-reactivity with multiple HLA supertype family members, are then used for analysis of samples derived from individuals who bear that HLA type.

PBMC from vaccinated individuals are separated on Ficoll-Histopaque density gradients (Sigma Chemical Co., St. Louis, MO), washed three times in HBSS (GIBCO Laboratories), resuspended in RPMI-1640 (GIBCO Laboratories) supplemented with L-glutamine (2mM), penicillin (50U/ml), streptomycin (50 µg/ml), and HEPES (10mM) containing 10% heat-inactivated human AB serum (complete RPMI) and plated using microculture formats. A synthetic peptide comprising an epitope of the invention is added at 10 µg/ml to each well and HBV core 128-140 epitope is added at 1 µg/ml to each well as a source of T cell help during the first week of stimulation.

In the microculture format, 4×10^5 PBMC are stimulated with peptide in 8 replicate cultures in 96-well round bottom plate in 100 µl/well of complete RPMI. On days 3 and 10, 100 µl of complete RPMI and 20 U/ml final concentration of rIL-2 are added to each well. On day 7 the cultures are transferred into a 96-well flat-bottom plate and restimulated with peptide, rIL-2 and 10^5 irradiated (3,000 rad) autologous feeder cells. The cultures are tested for cytotoxic activity on day 14. A positive CTL response requires two or more of the eight replicate cultures to display greater than 10% specific ^{51}Cr release, based on comparison with non-diseased control subjects as previously described (Rehermann, *et al.*, *Nature Med.* 2:1104,1108, 1996; Rehermann *et al.*, *J. Clin. Invest.* 97:1655-1665, 1996; and Rehermann *et al.* *J. Clin. Invest.* 98:1432-1440, 1996).

Target cell lines are autologous and allogeneic EBV-transformed B-LCL that are either purchased from the American Society for Histocompatibility and Immunogenetics (ASHI, Boston, MA) or established from the pool of patients as described (Guilhot, *et al.* *J. Virol.* 66:2670-2678, 1992).

Cytotoxicity assays are performed in the following manner. Target cells consist of either allogeneic HLA-matched or autologous EBV-transformed B lymphoblastoid cell line that are incubated overnight with the synthetic peptide epitope of the invention at 10 µM, and labeled with 100 µCi of ^{51}Cr (Amersham Corp., Arlington Heights, IL) for 1 hour after which they are washed four times with HBSS.

Cytolytic activity is determined in a standard 4-h, split well ^{51}Cr release assay using U-bottomed 96 well plates containing 3,000 targets/well. Stimulated PBMC are tested at effector/target (E/T) ratios of 20-50:1 on day 14. Percent cytotoxicity is determined from the formula: $100 \times [(\text{experimental release} - \text{spontaneous release}) / \text{maximum release} - \text{spontaneous release}]$. Maximum release is determined by lysis of

targets by detergent (2% Triton X-100; Sigma Chemical Co., St. Louis, MO). Spontaneous release is <25% of maximum release for all experiments.

The results of such an analysis indicate the extent to which HLA-restricted CTL populations have been stimulated by previous exposure to 108P5H8 or an 108P5H8 vaccine.

Similarly, Class II restricted HTL responses may also be analyzed. Purified PBMC are cultured in a 96-well flat bottom plate at a density of 1.5×10^5 cells/well and are stimulated with 10 µg/ml synthetic peptide of the invention, whole 108P5H8 antigen, or PHA. Cells are routinely plated in replicates of 4-6 wells for each condition. After seven days of culture, the medium is removed and replaced with fresh medium containing 10U/ml IL-2. Two days later, 1 µCi ^3H -thymidine is added to each well and incubation is continued for an additional 18 hours. Cellular DNA is then harvested on glass fiber mats and analyzed for ^3H -thymidine incorporation. Antigen-specific T cell proliferation is calculated as the ratio of ^3H -thymidine incorporation in the presence of antigen divided by the ^3H -thymidine incorporation in the absence of antigen.

Example 27: Induction Of Specific CTL Response In Humans

A human clinical trial for an immunogenic composition comprising CTL and HTL epitopes of the invention is set up as an IND Phase I, dose escalation study and carried out as a randomized, double-blind, placebo-controlled trial. Such a trial is designed, for example, as follows:

A total of about 27 individuals are enrolled and divided into 3 groups:

Group I: 3 subjects are injected with placebo and 6 subjects are injected with 5 µg of peptide composition;

Group II: 3 subjects are injected with placebo and 6 subjects are injected with 50 µg peptide composition;

Group III: 3 subjects are injected with placebo and 6 subjects are injected with 500 µg of peptide composition.

After 4 weeks following the first injection, all subjects receive a booster inoculation at the same dosage.

The endpoints measured in this study relate to the safety and tolerability of the peptide composition as well as its immunogenicity. Cellular immune responses to the peptide composition are an index of the intrinsic activity of this the peptide composition, and can therefore be viewed as a measure of biological efficacy. The following summarize the clinical and laboratory data that relate to safety and efficacy endpoints.

Safety: The incidence of adverse events is monitored in the placebo and drug treatment group and assessed in terms of degree and reversibility.

Evaluation of Vaccine Efficacy: For evaluation of vaccine efficacy, subjects are bled before and after injection. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-

Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity.

The vaccine is found to be both safe and efficacious.

Example 28: Phase II Trials In Patients Expressing 108P5H8

Phase II trials are performed to study the effect of administering the CTL-HTL peptide compositions to patients having cancer that expresses 108P5H8. The main objectives of the trial are to determine an effective dose and regimen for inducing CTLs in cancer patients that express 108P5H8, to establish the safety of inducing a CTL and HTL response in these patients, and to see to what extent activation of CTLs improves the clinical picture of these patients, as manifested, e.g., by the reduction and/or shrinking of lesions. Such a study is designed, for example, as follows:

The studies are performed in multiple centers. The trial design is an open-label, uncontrolled, dose escalation protocol wherein the peptide composition is administered as a single dose followed six weeks later by a single booster shot of the same dose. The dosages are 50, 500 and 5,000 micrograms per injection. Drug-associated adverse effects (severity and reversibility) are recorded.

There are three patient groupings. The first group is injected with 50 micrograms of the peptide composition and the second and third groups with 500 and 5,000 micrograms of peptide composition, respectively. The patients within each group range in age from 21-65 and represent diverse ethnic backgrounds. All of them have a tumor that expresses 108P5H8.

Clinical manifestations or antigen-specific T-cell responses are monitored to assess the effects of administering the peptide compositions. The vaccine composition is found to be both safe and efficacious in the treatment of 108P5H8-associated disease.

Example 29: Induction of CTL Responses Using a Prime Boost Protocol

A prime boost protocol similar in its underlying principle to that used to confirm the efficacy of a DNA vaccine in transgenic mice, such as described above in the Example entitled "The Plasmid Construct and the Degree to Which It Induces Immunogenicity," can also be used for the administration of the vaccine to humans. Such a vaccine regimen can include an initial administration of, for example, naked DNA followed by a boost using recombinant virus encoding the vaccine, or recombinant protein/polypeptide or a peptide mixture administered in an adjuvant.

For example, the initial immunization may be performed using an expression vector, such as that constructed in the Example entitled "Construction of 'Minigene' Multi-Epitope DNA Plasmids" in the form of naked nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to 1000 µg) can also be administered using a gene gun. Following an incubation period of 3-4 weeks, a booster dose is then administered. The booster can be recombinant fowlpox virus administered at a dose of $5 \cdot 10^7$ to $5 \cdot 10^9$ pfu. An alternative recombinant virus, such as an MVA, canarypox, adenovirus, or adeno-associated virus, can also be used for the booster, or the polyepitopic

protein or a mixture of the peptides can be administered. For evaluation of vaccine efficacy, patient blood samples are obtained before immunization as well as at intervals following administration of the initial vaccine and booster doses of the vaccine. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity.

Analysis of the results indicates that a magnitude of response sufficient to achieve a therapeutic or protective immunity against 108P5H8 is generated.

Example 30: Administration of Vaccine Compositions Using Dendritic Cells (DC)

Vaccines comprising peptide epitopes of the invention can be administered using APCs, or "professional" APCs such as DC. In this example, peptide-pulsed DC are administered to a patient to stimulate a CTL response *in vivo*. In this method, dendritic cells are isolated, expanded, and pulsed with a vaccine comprising peptide CTL and HTL epitopes of the invention. The dendritic cells are infused back into the patient to elicit CTL and HTL responses *in vivo*. The induced CTL and HTL then destroy or facilitate destruction, respectively, of the target cells that bear the 108P5H8 protein from which the epitopes in the vaccine are derived.

For example, a cocktail of epitope-comprising peptides is administered *ex vivo* to PBMC, or isolated DC therefrom. A pharmaceutical to facilitate harvesting of DC can be used, such as Progenipoiectin™ (Monsanto, St. Louis, MO) or GM-CSF/IL-4. After pulsing the DC with peptides, and prior to reinfusion into patients, the DC are washed to remove unbound peptides.

As appreciated clinically, and readily determined by one of skill based on clinical outcomes, the number of DC reinfused into the patient can vary (see, e.g., *Nature Med.* 4:328, 1998; *Nature Med.* 2:52, 1996 and *Prostate* 32:272, 1997). Although 2.5×10^6 DC per patient are typically administered, larger number of DC, such as 10^7 or 10^8 can also be provided. Such cell populations typically contain between 50-90% DC.

In some embodiments, peptide-loaded PBMC are injected into patients without purification of the DC. For example, PBMC generated after treatment with an agent such as Progenipoiectin™ are injected into patients without purification of the DC. The total number of PBMC that are administered often ranges from 10^8 to 10^{10} . Generally, the cell doses injected into patients is based on the percentage of DC in the blood of each patient, as determined, for example, by immunofluorescence analysis with specific anti-DC antibodies. Thus, for example, if Progenipoiectin™ mobilizes 2% DC in the peripheral blood of a given patient, and that patient is to receive 5×10^6 DC, then the patient will be injected with a total of 2.5×10^8 peptide-loaded PBMC. The percent DC mobilized by an agent such as Progenipoiectin™ is typically estimated to be between 2-10%, but can vary as appreciated by one of skill in the art.

Ex vivo activation of CTL/HTL responses

Alternatively, *ex vivo* CTL or HTL responses to 108P5H8 antigens can be induced by incubating, in tissue culture, the patient's, or genetically compatible, CTL or HTL precursor cells together with a source

of APC, such as DC, and immunogenic peptides. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cells, *i.e.*, tumor cells.

Example 31: An Alternative Method of Identifying and Confirming Motif-Bearing Peptides

Another method of identifying and confirming motif-bearing peptides is to elute them from cells bearing defined MHC molecules. For example, EBV transformed B cell lines used for tissue typing have been extensively characterized to determine which HLA molecules they express. In certain cases these cells express only a single type of HLA molecule. These cells can be transfected with nucleic acids that express the antigen of interest, *e.g.* 108P5H8. Peptides produced by endogenous antigen processing of peptides produced as a result of transfection will then bind to HLA molecules within the cell and be transported and displayed on the cell's surface. Peptides are then eluted from the HLA molecules by exposure to mild acid conditions and their amino acid sequence determined, *e.g.*, by mass spectral analysis (*e.g.*, Kubo *et al.*, *J. Immunol.* 152:3913, 1994). Because the majority of peptides that bind a particular HLA molecule are motif-bearing, this is an alternative modality for obtaining the motif-bearing peptides correlated with the particular HLA molecule expressed on the cell.

Alternatively, cell lines that do not express endogenous HLA molecules can be transfected with an expression construct encoding a single HLA allele. These cells can then be used as described, *i.e.*, they can then be transfected with nucleic acids that encode 108P5H8 to isolate peptides corresponding to 108P5H8 that have been presented on the cell surface. Peptides obtained from such an analysis will bear motif(s) that correspond to binding to the single HLA allele that is expressed in the cell.

As appreciated by one in the art, one can perform a similar analysis on a cell bearing more than one HLA allele and subsequently determine peptides specific for each HLA allele expressed. Moreover, one of skill would also recognize that means other than transfection, such as loading with a protein antigen, can be used to provide a source of antigen to the cell.

Example 32: Complementary Polynucleotides

Sequences complementary to the 108P5H8-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring 108P5H8. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using, *e.g.*, OLIGO 4.06 software (National Biosciences) and the coding sequence of 108P5H8. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to a 108P5H8-encoding transcript.

Example 33: Purification of Naturally-occurring or Recombinant 108P5H8 Using 108P5H8**Specific Antibodies**

Naturally occurring or recombinant 108P5H8 is substantially purified by immunoaffinity chromatography using antibodies specific for 108P5H8. An immunoaffinity column is constructed by covalently coupling anti-108P5H8 antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing 108P5H8 are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of 108P5H8 (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/108P5H8 binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GCR.P is collected.

Example 34: Identification of Molecules Which Interact with 108P5H8

108P5H8, or biologically active fragments thereof, are labeled with 121 I Bolton-Hunter reagent. (See, e.g., Bolton *et al.* (1973) Biochem. J. 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled 108P5H8, washed, and any wells with labeled 108P5H8 complex are assayed. Data obtained using different concentrations of 108P5H8 are used to calculate values for the number, affinity, and association of 108P5H8 with the candidate molecules.

Example 35: *In vivo* Assay for 108P5H8 Tumor Growth Promotion

The effect of a 108P5H8 protein on tumor cell growth can be confirmed *in vivo* by gene overexpression in a variety of cancer cells such as those in Table I, including prostate, kidney, colon and bladder. For example, SCID mice can be injected SQ on each flank with 1×10^6 prostate, kidney, colon or bladder cancer cells (such as PC3, DU145, SCaBER, UM-UC-3, HT1376, SK-CO, Caco, RT4, T24, Caki, A-498 and SW839 cells) containing tkNeo empty vector or 108P5H8.

At least two strategies can be used:

(1) Constitutive 108P5H8 expression under regulation of a promoter such as a constitutive promoter obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), or from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, provided such promoters are compatible with the host cell systems.

(2) Regulated expression under control of an inducible vector system, such as ecdysone, tet, etc., can be used provided such promoters are compatible with the host cell systems. Tumor volume is then monitored at the appearance of palpable tumors or by following serum markers such as PSA. Tumor development is followed over time to validate that 108P5H8-expressing cells grow at a faster rate and/or

5

10

15

20

25

30

35

demonstrate the therapeutic use of anti-108P5H8 mAbs for the treatment of local and metastatic cancer. This example demonstrates that unconjugated 108P5H8 monoclonal antibodies are effective to inhibit the growth of human prostate tumor xenografts and human kidney xenografts grown in SCID mice.

Tumor inhibition using multiple unconjugated 108P5H8 mAbs

Materials and Methods

108P5H8 Monoclonal Antibodies:

Monoclonal antibodies are obtained against 108P5H8, such as described in the Example entitled "Generation of 108P5H8 Monoclonal Antibodies (mAbs)" or may be obtained commercially. The antibodies are characterized by ELISA, Western blot, FACS, and immunoprecipitation for their capacity to bind 108P5H8. Epitope mapping data for the anti-108P5H8 mAbs, as determined by ELISA and Western analysis, recognize epitopes on a 108P5H8 protein. Immunohistochemical analysis of cancer tissues and cells is performed with these antibodies.

The monoclonal antibodies are purified from ascites or hybridoma tissue culture supernatants by Protein-G Sepharose chromatography, dialyzed against PBS, filter sterilized, and stored at -20°C. Protein determinations are performed by a Bradford assay (Bio-Rad, Hercules, CA). A therapeutic monoclonal antibody or a cocktail comprising a mixture of individual monoclonal antibodies is prepared and used for the treatment of mice receiving subcutaneous or orthotopic injections of, e.g., LAPC-9 prostate tumor xenografts.

Cancer Xenografts and Cell Lines

The LAPC-9 xenograft, which expresses a wild-type androgen receptor and produces prostate-specific antigen (PSA), is passaged in 6- to 8-week-old male ICR-severe combined immunodeficient (SCID) mice (Taconic Farms) by s.c. trocar implant (Craft, N., *et al.*, 1999, Cancer Res. 59:5030-5036). Single-cell suspensions of tumor cells are prepared as described in Craft, *et al.* The prostate carcinoma cell lines PC3 and DU145 (American Type Culture Collection) are maintained in RPMI supplemented with L-glutamine and 10% FBS, and the kidney carcinoma line A498 (American Type Culture Collection) is maintained in DMEM supplemented with L-glutamine and 10% FBS.

PC3-108P5H8, DU145-108P5H8 and A498-108P5H8 cell populations are generated by retroviral gene transfer as described in Hubert, R.S., *et al.*, STEAP: A Prostate-specific Cell-surface Antigen Highly Expressed in Human Prostate Tumors, Proc Natl Acad Sci U S A, 1999. 96(25): p. 14523-14528. Anti-108P5H8 staining is detected by using, e.g., an FITC-conjugated goat anti-mouse antibody (Southern Biotechnology Associates) followed by analysis on a Coulter Epics-XL flow cytometer.

Xenograft Mouse Models.

Subcutaneous (s.c.) tumors are generated by injection of 1×10^6 LAPC-9, PC3, PC3-108P5H8, DU145 or DU145-108P5H8 cells mixed at a 1:1 dilution with Matrigel (Collaborative Research) in the right flank of male SCID mice. To test antibody efficacy on tumor formation, i.p. antibody injections are started on the same day as tumor-cell injections. As a control, mice are injected with either purified mouse IgG (ICN) or PBS; or a purified monoclonal antibody that recognizes an irrelevant antigen not expressed in

5

10

Anti-108P5H8 mAbs Inhibit Growth of 108P5H8-Expressing Xenograft-Cancer Tumors

15

20

25

30

35

retarding the growth of already established tumors and prolong the survival of treated mice. Moreover, anti-108P5H8 mAbs demonstrate a dramatic inhibitory effect on the spread of local prostate tumor to distal sites, even in the presence of a large tumor burden. Similar therapeutic effects are seen in the kidney cancer model. Thus, anti-108P5H8 mAbs are efficacious on major clinically relevant end points (tumor growth), prolongation of survival, and health.

Example 37: Therapeutic and Diagnostic use of Anti-108P5H8 Antibodies in Humans.

Anti-108P5H8 monoclonal antibodies are safely and effectively used for diagnostic, prophylactic, prognostic and/or therapeutic purposes in humans. Western blot and immunohistochemical analysis of cancer tissues and cancer xenografts with anti-108P5H8 mAb show strong extensive staining in carcinoma but significantly lower or undetectable levels in normal tissues. Detection of 108P5H8 in carcinoma and in metastatic disease demonstrates the usefulness of the mAb as a diagnostic and/or prognostic indicator. Anti-108P5H8 antibodies are therefore used in diagnostic applications such as immunohistochemistry of biopsy specimens to detect cancer from suspect patients.

As determined by immunofluorescence, anti-108P5H8 mAb specifically binds to carcinoma cells. Thus, anti-108P5H8 antibodies are used in diagnostic whole body imaging applications, such as radioimmunoscinigraphy and radioimmunotherapy, (see, e.g., Potamianos S., et. al. Anticancer Res 20(2A):925-948 (2000)) for the detection of localized and metastatic cancers that exhibit expression of 108P5H8. Shedding or release of an extracellular domain of 108P5H8 into the extracellular milieu, such as that seen for alkaline phosphodiesterase B10 (Meerson, N. R., Hepatology 27:563-568 (1998)), allows diagnostic detection of 108P5H8 by anti-108P5H8 antibodies in serum and/or urine samples from suspect patients.

Anti-108P5H8 antibodies that specifically bind 108P5H8 are used in therapeutic applications for the treatment of cancers that express 108P5H8. Anti-108P5H8 antibodies are used as an unconjugated modality and as conjugated form in which the antibodies are attached to one of various therapeutic or imaging modalities well known in the art, such as a prodrugs, enzymes or radioisotopes. In preclinical studies, unconjugated and conjugated anti-108P5H8 antibodies are tested for efficacy of tumor prevention and growth inhibition in the SCID mouse cancer xenograft models, e.g., LAPC9 (see, e.g., the Example entitled "Monoclonal Antibody-mediated Inhibition of Prostate and Kidney Tumors *In vivo*.") Conjugated and unconjugated anti-108P5H8 antibodies are used as a therapeutic modality in human clinical trials either alone or in combination with other treatments as described in following Examples.

Example 38: Human Clinical Trials for the Treatment and Diagnosis of Human Carcinomas through use of Human Anti-108P5H8 Antibodies *In vivo*

Antibodies are used in accordance with the present invention which recognize an epitope on 108P5H8, and are used in the treatment of certain tumors such as those listed in Table I. Based upon a number of factors, including 108P5H8 expression levels, tumors such as those listed in Table I are

presently preferred indications. In connection with each of these indications, three clinical approaches are successfully pursued.

I.) **Adjunctive therapy:** In adjunctive therapy, patients are treated with anti-108P5H8 antibodies in combination with a chemotherapeutic or antineoplastic agent and/or radiation therapy. Primary cancer targets, such as those listed in Table I, are treated under standard protocols by the addition of anti-108P5H8 antibodies to standard first and second line therapy. Protocol designs address effectiveness as assessed by reduction in tumor mass as well as the ability to reduce usual doses of standard chemotherapy. These dosage reductions allow additional and/or prolonged therapy by reducing dose-related toxicity of the chemotherapeutic agent. Anti-108P5H8 antibodies are utilized in several adjunctive clinical trials in combination with the chemotherapeutic or antineoplastic agents adriamycin (advanced prostrate carcinoma), cisplatin (advanced head and neck and lung carcinomas), taxol (breast cancer), and doxorubicin (preclinical).

II.) **Monotherapy:** In connection with the use of the anti-108P5H8 antibodies in monotherapy of tumors, the antibodies are administered to patients without a chemotherapeutic or antineoplastic agent. In one embodiment, monotherapy is conducted clinically in end stage cancer patients with extensive metastatic disease. Patients show some disease stabilization. Trials demonstrate an effect in refractory patients with cancerous tumors.

III.) **Imaging Agent:** Through binding a radionuclide (e.g., iodine or yttrium (^{131}I , ^{90}Y) to anti-108P5H8 antibodies, the radiolabeled antibodies are utilized as a diagnostic and/or imaging agent. In such a role, the labeled antibodies localize to both solid tumors, as well as, metastatic lesions of cells expressing 108P5H8. In connection with the use of the anti-108P5H8 antibodies as imaging agents, the antibodies are used as an adjunct to surgical treatment of solid tumors, as both a pre-surgical screen as well as a post-operative follow-up to determine what tumor remains and/or returns. In one embodiment, a ^{111}In -108P5H8 antibody is used as an imaging agent in a Phase I human clinical trial in patients having a carcinoma that expresses 108P5H8 (by analogy see, e.g., Divgi *et al. J. Natl. Cancer Inst.* 83:97-104 (1991)). Patients are followed with standard anterior and posterior gamma camera. The results indicate that primary lesions and metastatic lesions are identified

Dose and Route of Administration

As appreciated by those of ordinary skill in the art, dosing considerations can be determined through comparison with the analogous products that are in the clinic. Thus, anti-108P5H8 antibodies can be administered with doses in the range of 5 to 400 mg/m^2 , with the lower doses used, e.g., in connection with safety studies. The affinity of anti-108P5H8 antibodies relative to the affinity of a known antibody for its target is one parameter used by those of skill in the art for determining analogous dose regimens. Further, anti-108P5H8 antibodies that are fully human antibodies, as compared to the chimeric antibody, have slower clearance; accordingly, dosing in patients with such fully human anti-108P5H8 antibodies can be lower, perhaps in the range of 50 to 300 mg/m^2 , and still remain efficacious. Dosing in mg/m^2 , as

opposed to the conventional measurement of dose in mg/kg, is a measurement based on surface area and is a convenient dosing measurement that is designed to include patients of all sizes from infants to adults.

Three distinct delivery approaches are useful for delivery of anti-108P5H8 antibodies.

Conventional intravenous delivery is one standard delivery technique for many tumors. However, in connection with tumors in the peritoneal cavity, such as tumors of the ovaries, biliary duct, other ducts, and the like, intraperitoneal administration may prove favorable for obtaining high dose of antibody at the tumor and to also minimize antibody clearance. In a similar manner, certain solid tumors possess vasculature that is appropriate for regional perfusion. Regional perfusion allows for a high dose of antibody at the site of a tumor and minimizes short term clearance of the antibody.

Clinical Development Plan (CDP)

Overview: The CDP follows and develops treatments of anti-108P5H8 antibodies in connection with adjunctive therapy, monotherapy, and as an imaging agent. Trials initially demonstrate safety and thereafter confirm efficacy in repeat doses. Trials are open label comparing standard chemotherapy with standard therapy plus anti-108P5H8 antibodies. As will be appreciated, one criteria that can be utilized in connection with enrollment of patients is 108P5H8 expression levels in their tumors as determined by biopsy.

As with any protein or antibody infusion-based therapeutic, safety concerns are related primarily to (i) cytokine release syndrome, i.e., hypotension, fever, shaking, chills; (ii) the development of an immunogenic response to the material (i.e., development of human antibodies by the patient to the antibody therapeutic, or HAHA response); and, (iii) toxicity to normal cells that express 108P5H8. Standard tests and follow-up are utilized to monitor each of these safety concerns. Anti-108P5H8 antibodies are found to be safe upon human administration.

Example 39: Human Clinical Trial Adjunctive Therapy with Human Anti-108P5H8 Antibody and Chemotherapeutic Agent

A phase I human clinical trial is initiated to assess the safety of six intravenous doses of a human anti-108P5H8 antibody in connection with the treatment of a solid tumor, e.g., a cancer of a tissue listed in Table I. In the study, the safety of single doses of anti-108P5H8 antibodies when utilized as an adjunctive therapy to an antineoplastic or chemotherapeutic agent, such as cisplatin, topotecan, doxorubicin, adriamycin, taxol, or the like, is assessed. The trial design includes delivery of six single doses of an anti-108P5H8 antibody with dosage of antibody escalating from approximately about 25 mg/m² to about 275 mg/m² over the course of the treatment in accordance with the following schedule:

	Day 0	Day 7	Day 14	Day 21	Day 28	Day 35
mAb Dose	25	75	125	175	225	275
	mg/m ²	mg/m ²	mg/m ²	mg/m ²	mg/m ²	mg/m ²
Chemotherapy	+	+	+	+	+	+

(standard dose)

Patients are closely followed for one-week following each administration of antibody and chemotherapy. In particular, patients are assessed for the safety concerns mentioned above: (i) cytokine release syndrome, i.e., hypotension, fever, shaking, chills; (ii) the development of an immunogenic response to the material (i.e., development of human antibodies by the patient to the human antibody therapeutic, or HAHA response); and, (iii) toxicity to normal cells that express 108P5H8. Standard tests and follow-up are utilized to monitor each of these safety concerns. Patients are also assessed for clinical outcome, and particularly reduction in tumor mass as evidenced by MRI or other imaging.

The anti-108P5H8 antibodies are demonstrated to be safe and efficacious, Phase II trials confirm the efficacy and refine optimum dosing.

Example 40: Human Clinical Trial: Monotherapy with Human Anti-108P5H8 Antibody

Anti-108P5H8 antibodies are safe in connection with the above-discussed adjunctive trial, a Phase II human clinical trial confirms the efficacy and optimum dosing for monotherapy. Such trial is accomplished, and entails the same safety and outcome analyses, to the above-described adjunctive trial with the exception being that patients do not receive chemotherapy concurrently with the receipt of doses of anti-108P5H8 antibodies.

Example 41: Human Clinical Trial: Diagnostic Imaging with Anti-108P5H8 Antibody

Once again, as the adjunctive therapy discussed above is safe within the safety criteria discussed above, a human clinical trial is conducted concerning the use of anti-108P5H8 antibodies as a diagnostic imaging agent. The protocol is designed in a substantially similar manner to those described in the art, such as in Divgi *et al. J. Natl. Cancer Inst.* 83:97-104 (1991). The antibodies are found to be both safe and efficacious when used as a diagnostic modality.

Example 42: Homology Comparison of 108P5H8 to Known Sequences

The 108P5H8 protein is a six-transmembrane type 3 cell surface protein, consisting of 429 amino acids (table XXI). The 108P5H8 protein has 2 variant forms (Figure 3), with 108P5H8v.3 differing from 108P5H8 v.1 by one amino acid at position 30 (D to E). This alteration in amino acid at position 30 corresponds to a point mutation at nucleic acid position 90, making variant 3 a true SNP. Both 108P5H8 variants, 108P5H8 v.1 and 108P5H8 v.3 have a calculated molecular weight of 47.5 kDa, and pI of 6.11, and contain an ion efflux motif between amino acid 114-417. Proteins carrying the ion efflux motif are found to increase tolerance to divalent metal ions such as cadmium, zinc, and cobalt. These proteins are thought to be efflux pumps that remove these ions from cells (Kunito T et al, *Biosci Biotechnol Biochem* 1996, 60:699).

The 108P5H8 protein variants show homology to human zinc transporter 4 (gi 11432533); with 108P5H8v.1 sharing 100% identity and 100% homology with that protein over the entire length of the protein (Figure 25). 108P5H8v.2 share 100% identity and 100% homology with human zinc transporter ZNT4-gi 8134840 over the entire protein. As with the two 108P5H8 variants, ZNT4 (gi 8134840) and ZNT4-gi 11432533 differ by one amino acid at position 30, showing the same D to E change observed in 108P5H8v.3 and 108P5H8v.1. Based on sequence homology, 108P5H8 is conserved in various species, showing high homology to Rat ZNT4 (90% identity shown in Figure 25) and mouse ZNT4 (91% identity with gi 8134841).

Zinc has been shown to play an important role in the physiology and pathology of prostate epithelial cells. Zinc ions regulate the activity of chromatin and plasmalemma structures in seminal plasma, and participate in spermadhesin function (Holody D and Strzezek J. Acta Biochini Pol 1999, 46:935). In relation to prostate cancer, zinc was found to inhibit the activity of aminopeptidase N in prostate cancer cells (Ishii K et al, Int J Cancer 2001, 92:49). Efflux of Zn^{++} from the prostate by 108P5H8 or ZNT4 enhances the endogenous activity of aminopeptidase N, thereby increasing matrix degradation and tissue invasion by prostate cancer cells. In addition to its role in invasion, ZNT4 regulates apoptosis and proliferation of prostate cells. Accumulation of Zn^{++} within the prostate induces apoptosis of normal epithelial cells (Feng P et al, Mol Urol 2000, 4:31). Enhanced expression of ZNT4 in prostate cancer cells and the resulting efflux of Zn^{++} , allow reduced apoptosis, survival and proliferation of prostate cancer cells. Finally, intracellular Zn^{++} concentrations play a direct role in regulating gene transcription by zinc finger proteins.

This information indicates that 108P5H8 plays a role in the growth of cancer cells, supports cell survival, and regulates gene transcription by regulating events in the nucleus. Accordingly, when 108P5H8 functions as a regulator of cell transformation, tumor formation, or as a modulator of transcription involved in activating genes associated with inflammation, tumorigenesis or proliferation, 108P5H8 is used for therapeutic, diagnostic, prognostic and/or preventative purposes.

Example 43: Identification and Confirmation of Signal Transduction Pathways

Many mammalian proteins have been reported to interact with signaling molecules and to participate in regulating signaling pathways. (see, e.g., J. Neurochem. 2001; 76:217-223). Using immunoprecipitation and Western blotting techniques, proteins are identified that associate with 108P5H8 and mediate signaling events. Several pathways known to play a role in cancer biology can be regulated by 108P5H8, including phospholipid pathways such as PI3K, AKT, etc, adhesion and migration pathways, including FAK, Rho, Rac-1, etc, as well as mitogenic/survival cascades such as ERK, p38, etc. (Cell Growth Differ. 2000, 11:279; J. Biol. Chem. 1999, 274:801; Oncogene. 2000, 19:3003; J. Cell Biol. 1997, 138:913).

To confirm that 108P5H8 directly or indirectly activates known signal transduction pathways in cells, luciferase (luc) based transcriptional reporter assays are carried out in cells expressing individual

genes. These transcriptional reporters contain consensus-binding sites for known transcription factors that lie downstream of well-characterized signal transduction pathways. The reporters and examples of these associated transcription factors, signal transduction pathways, and activation stimuli are listed below.

1. NFkB-luc, NFkB/Rel; Ik-kinase/SAPK; growth/apoptosis/stress
2. SRE-luc, SRF/TCF/ELK1; MAPK/SAPK; growth/differentiation
3. AP-1-luc, FOS/JUN; MAPK/SAPK/PKC; growth/apoptosis/stress
4. ARE-luc, androgen receptor; steroids/MAPK; growth/differentiation/apoptosis
5. p53-luc, p53; SAPK; growth/differentiation/apoptosis
6. CRE-luc, CREB/ATF2; PKA/p38; growth/apoptosis/stress

Gene-mediated effects can be assayed in cells showing mRNA expression. Luciferase reporter plasmids can be introduced by lipid-mediated transfection (TFX-50, Promega). Luciferase activity, an indicator of relative transcriptional activity, is measured by incubation of cell extracts with luciferin substrate and luminescence of the reaction is monitored in a luminometer.

Signaling pathways activated by 108P5H8 are mapped and used for the identification and validation of therapeutic targets. When 108P5H8 is involved in cell signaling, it is used as target for diagnostic, prognostic, preventative and/or therapeutic purposes.

Example 44: Involvement in Tumor Progression

The 108P5H8 gene contributes to the growth of cancer cells. The role of 108P5H8 in tumor growth is confirmed in a variety of primary and transfected cell lines including prostate cell lines, as well as NIH 3T3 cells engineered to stably express 108P5H8. Parental cells lacking 108P5H8 and cells expressing 108P5H8 are evaluated for cell growth using a well-documented proliferation assay (Fraser, S.P., *et al.*, Prostate 2000; 44:61, Johnson, D.E., *et al.*, Anticancer Drugs 1996, 7:288).

To confirm the role of 108P5H8 in the transformation process, its effect in colony forming assays is investigated. Parental NIH-3T3 cells lacking 108P5H8 are compared to NIH-3T3 cells expressing 108P5H8, using a soft agar assay under stringent and more permissive conditions (Song, Z., *et al.*, Cancer Res. 2000; 60:6730).

To confirm the role of 108P5H8 in invasion and metastasis of cancer cells, a well-established assay is used, e.g., a Transwell Insert System assay (Becton Dickinson) (Cancer Res. 1999; 59:6010). Control cells, including prostate, colon, bladder and kidney cell lines lacking 108P5H8 are compared to corresponding cells expressing 108P5H8. Cells are loaded with the fluorescent dye, calcein, and plated in the top well of the Transwell insert coated with a basement membrane analog. Invasion is determined by fluorescence of cells in the lower chamber relative to the fluorescence of the entire cell population.

108P5H8 can also play a role in cell cycle and apoptosis. Parental cells and cells expressing 108P5H8 are compared for differences in cell cycle regulation using a well-established BrdU assay (Abdel-

Malek ZA., J Cell Physiol. 1988, 136:247). In short, cells are grown under both optimal (full serum) and limiting (low serum) conditions, labeled with BrdU and stained with anti-BrdU Ab and propidium iodide. Cells are analyzed for entry into the G1, S, and G2M phases of the cell cycle. Alternatively, the effect of stress on apoptosis is evaluated in control parental cells and cells expressing 108P5H8, including normal and tumor prostate, colon and lung cells. Engineered and parental cells are treated with various chemotherapeutic agents, such as etoposide, flutamide, etc., and protein synthesis inhibitors, such as cycloheximide. Cells are stained with annexin V-FITC and cell death is measured by FACS analysis. Modulation of cell death by 108P5H8 plays a critical role in regulating tumor progression and tumor load.

When 108P5H8 plays a role in cell growth, transformation, invasion or apoptosis, it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.

Example 45: Involvement in Angiogenesis

Angiogenesis or new capillary blood vessel formation is necessary for tumor growth (Hanahan, D., Folkman, J., Cell 1996, 86:353; Folkman, J., Endocrinology 1998, 139:441). Several assays have been developed to measure angiogenesis *in vitro* and *in vivo*, such as the tissue culture assays endothelial cell tube formation and endothelial cell proliferation. Using these assays as well as *in vitro* neo-vascularization, the role of 108P5H8 in angiogenesis, enhancement or inhibition, is confirmed.

For example, endothelial cells engineered to express 108P5H8 are evaluated using tube formation and proliferation assays. The effect of 108P5H8 is also confirmed in animal models *in vivo*. For example, cells either expressing or lacking 108P5H8 are implanted subcutaneously in immunocompromised mice. Endothelial cell migration and angiogenesis are evaluated 5-15 days later using immunohistochemistry techniques. 108P5H8 affects angiogenesis, and it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes

Example 46: Regulation of Transcription

The cellular localization of 108P5H8 (Table XXI) and its ability to regulate intracellular zinc ion concentrations, 108P5H8 is effectively used as a modulator of the transcriptional regulation of eukaryotic genes. Regulation of gene expression is confirmed, e.g., by studying gene expression in cells expressing or lacking 108P5H8. For this purpose, two types of experiments are performed.

In the first set of experiments, RNA from parental and 108P5H8-expressing cells are extracted and hybridized to commercially available gene arrays (Clontech) (Smid-Koopman, E., *et al.*, Br. J. Cancer, 2000, 83:246). Resting cells as well as cells treated with FBS or androgen are compared. Differentially expressed genes are identified in accordance with procedures known in the art. The differentially expressed genes are then mapped to biological pathways (Chen, K., *et al.* Thyroid 2001, 11:41).

In the second set of experiments, specific transcriptional pathway activation is evaluated using commercially available (Stratagene) luciferase reporter constructs including: NFkB-luc, SRE-luc, ELK1-luc, ARE-luc, p53-luc, and CRE-luc. These transcriptional reporters contain consensus binding sites for

known transcription factors that lie downstream of well-characterized signal transduction pathways, and represent a good tool to ascertain pathway activation and screen for positive and negative modulators of pathway activation.

Accordingly, it is found that 108P5H8 plays a role in gene regulation, and it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.

Example 47: Involvement in Cell Adhesion

Cell adhesion plays a critical role in tissue colonization and metastasis. 108P5H8 participates in cellular organization, and as a consequence cell adhesion and motility. To confirm the role of 108P5H8 in the regulation of cell adhesion, control cells lacking 108P5H8 are compared to cells expressing 108P5H8, using techniques previously described (see, e.g., Haier *et al.*, Br. J. Cancer, 1999, 80:1867; Lehr and Pienta, J. Natl. Cancer Inst. 1998, 90:118). Briefly, in one embodiment, cells labeled with a fluorescent indicator, such as calcein, are incubated in tissue culture wells coated with media alone or with matrix proteins. Adherent cells are detected by fluorimetric analysis and percent adhesion is calculated. In another embodiment, cells lacking or expressing 108P5H8 are analyzed for their ability to mediate cell-cell adhesion using similar experimental techniques as described above. Both of these experimental systems are used to identify proteins, antibodies and/or small molecules that modulate cell adhesion to extracellular matrix and cell-cell interaction. Cell adhesion plays a critical role in tumor growth, progression, and, colonization, and 108P5H8 is involved in these processes. Thus, 108P5H8 serves as a diagnostic, prognostic, preventative and/or therapeutic modality.

Example 48: Protein-Protein Association

Several ion transporters have been shown to interact with other proteins, thereby regulating gene transcription, gene sequence, as well as cell growth. Using immunoprecipitation techniques as well as two yeast hybrid systems, proteins are identified that associate with 108P5H8. Immunoprecipitates from cells expressing 108P5H8 and cells lacking 108P5H8 are compared for specific protein-protein associations.

Studies are performed to confirm the extent of association of 108P5H8 with effector molecules, such as nuclear proteins, transcription factors, kinases, phosphates, etc. Studies comparing 108P5H8 positive and 108P5H8 negative cells as well as studies comparing unstimulated/resting cells and cells treated with epithelial cell activators, such as cytokines, growth factors, androgen and anti-integrin Ab reveal unique interactions.

In addition, protein-protein interactions are confirmed using two yeast hybrid methodology (Curr. Opin. Chem. Biol. 1999, 3:64). A vector carrying a library of proteins fused to the activation domain of a transcription factor is introduced into yeast expressing a 108P5H8-DNA-binding domain fusion protein and a reporter construct. Protein-protein interaction is detected by colorimetric reporter activity. Specific association with effector molecules and transcription factors directs one of skill to the mode of action of

Thus it is found that 108P5H8 associates with proteins and small molecules. Accordingly, 108P5H8 and these proteins and small molecules are used for diagnostic, prognostic, preventative and/or therapeutic purposes.

To confirm that 108P5H8 functions as an ion channel, FACS analysis and electrophysiology

Using electrophysiology, uninjected oocytes and oocytes injected with gene-specific cRNA are compared for ion channel activity. Patch/voltage clamp assays are performed on oocytes in the presence or absence of selected ions, including calcium, zinc, etc. Ion channel activators (such as cAMP/GMP, forskolin, TPA, etc) and inhibitors (such as calciclude, conotoxin, TEA, tetrodotoxin, etc) are used to evaluate the function of 108P5H8 as ion channels (Schweitz H. et al. Proc. Natl. Acad. Sci. 1994. 91:878; Skryma R. et al. Prostate. 1997. 33:112).

When 108P5H8 functions as an ion channel, it is used as a target for diagnostic, preventative and therapeutic purposes.

124

To assess the expression of 108P5H8 protein in a prostate cancer cell line, preparations of cytocentrifuged LNCaP cells were stained using a rabbit polyclonal antibody to 108P5H8. Preparations of LNCaP cells were made from three differently treated cell populations to assess whether 108P5H8 is androgen regulated. The LNCaP cell preparations were made from cells grown in medium containing 10% fetal bovine serum; from cells grown for 72 hours in androgen free, serum depleted medium (by growing in charcoal dextran stripped medium); or from previously androgen starved cells which were subsequently stimulated with 10mmol mibolerone (a synthetic androgen) for 48 hours. The cells were spun down, washed twice (in buffer), resuspended (in buffer) and then centrifuged onto slides (1000 rpm for 2 minutes), allowed to dry and then fixed in acetone for 10 minutes. The cells were then incubated with rabbit polyclonal 108P5H8 for 3 hours (Figure 26 A-C), or rabbit IgG (Figure 26 D). The slides were washed three times in buffer then incubated in DAKO EnVisionTM peroxidase conjugated goat anti-rabbit secondary antibody (DAKO Corporation, Carpinteria, CA) for 1 hour. The cells were then washed in buffer, developed using the DAB kit (SIGMA Chemicals), counterstained using hematoxylin, and analyzed by bright field microscopy. The results showed strong expression of 108P5H8 in all three LNCaP cell preparations demonstrating that expression of 108P5H8 can be detected in this prostate cancer cell line and is not androgen related. This indicates that antibodies to 108P5H8 are useful in detecting non-androgen related cancer of the prostate; the protein is a useful marker.

Example 51: Detection of 108P5H8 protein in prostate cancer patient specimens by immunohistochemistry.

To assess the expression of 108P5H8 protein, prostate cancer specimens were obtained from prostate cancer patients and stained using a rabbit polyclonal antibody to 108P5H8. Frozen tissues were then cut into 4 micron sections and fixed in acetone for 10 minutes. The sections were then incubated with rabbit polyclonal 108P5H8 for 3 hours (Figure 27 A), or rabbit IgG (Figure 27 B). The slides were washed three times in buffer then incubated in DAKO EnVisionTM peroxidase conjugated goat anti-rabbit secondary antibody (DAKO Corporation, Carpinteria, CA) for 1 hour. The sections were then washed in buffer, developed using the DAB kit (SIGMA Chemicals), counterstained using hematoxylin, and analyzed by bright field microscopy. The results showed strong expression in the neoplastic glands of the prostate (Figure 27 A). These results further confirm the utility of 108P5H8 as a prostate tumor marker.

Throughout this application, various website data content, publications, patent applications and patents are referenced. (Websites are referenced by their Uniform Resource Locator, or URL, addresses on the World Wide Web.) The disclosures of each of these references are hereby incorporated by reference herein in their entireties.

The present invention is not to be limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and any that are functionally equivalent are within the scope of the invention. Various modifications to the models and methods of the

invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description and teachings, and are similarly intended to fall within the scope of the invention. Such modifications or other embodiments can be practiced without departing from the true scope and spirit of the invention.

TABLES

TABLE I: Tissues that Express 108P5H8 When Malignant

- Prostate
- Bladder
- Kidney
- Colon
- Lung
- Ovary
- Breast
- Pancreas
- Uterus
- Stomach

TABLE II: AMINO ACID ABBREVIATIONS

SINGLE LETTER	THREE LETTER	FULL NAME
F	Phe	phenylalanine
L	Leu	leucine
S	Ser	serine
Y	Tyr	tyrosine
C	Cys	cysteine
W	Trp	tryptophan
P	Pro	proline
H	His	histidine
Q	Gln	glutamine
R	Arg	arginine
I	Ile	isoleucine
M	Met	methionine
T	Thr	threonine
N	Asn	asparagine
K	Lys	lysine
V	Val	valine
A	Ala	alanine
D	Asp	aspartic acid
E	Glu	glutamic acid
G	Gly	glycine

TABLE III: AMINO ACID SUBSTITUTION MATRIX

Adapted from the GCG Software 9.0 BLOSUM62 amino acid substitution matrix (block substitution matrix). The higher the value, the more likely a substitution is found in related, natural proteins. (See URL www.ikp.unibe.ch/manual/blosum62.html)

5	A	C	D	E	F	G	H	I	K	L	M	N	P	Q	R	S	T	V	W	Y	.
	4	0	-2	-1	-2	0	-2	-1	-1	-1	-1	-2	-1	-1	-1	1	0	0	-3	-2	A
		9	-3	-4	-2	-3	-3	-1	-3	-1	-1	-3	-3	-3	-3	-1	-1	-1	-2	-2	C
			6	2	-3	-1	-1	-3	-1	-4	-3	1	-1	0	-2	0	-1	-3	-4	-3	D
				5	-3	-2	0	-3	1	-3	-2	0	-1	2	0	0	-1	-2	-3	-2	E
10					6	-3	-1	0	-3	0	0	-3	-4	-3	-3	-2	-2	-1	1	3	F
						6	-2	-4	-2	-4	-3	0	-2	-2	-2	0	-2	-3	-2	-3	G
							8	-3	-1	-3	-2	1	-2	0	0	-1	-2	-3	-2	2	H
								4	-3	2	1	-3	-3	-3	-3	-2	-1	3	-3	-1	I
15									5	-2	-1	0	-1	1	2	0	-1	-2	-3	-2	K
										4	2	-3	-3	-2	-2	-2	-1	1	-2	-1	L
											5	-2	-2	0	-1	-1	-1	1	-1	-1	M
												6	-2	0	0	1	0	-3	-4	-2	N
													7	-1	-2	-1	-1	-2	-4	-3	P
														5	1	0	-1	-2	-2	-1	Q
20															5	-1	-1	-3	-3	-2	R
																4	1	-2	-3	-2	S
																	5	0	-2	-2	T
																		4	-3	-1	V
																			11	2	W
25																				7	Y

TABLE IV (A)

SUPERMOTIFS	POSITION 2 (Primary Anchor)	POSITION 3 (Primary Anchor)	POSITION C Terminus (Primary Anchor)
A1	T <i>ILVMS</i>		FWY
A2	L <i>IVMATQ</i>		I <i>VMATL</i>
A3	V <i>SMATLI</i>		RK
A24	Y <i>FWIVLMT</i>		FIYWLM
B7	P		VILFMWYA
B27	RHK		FYLWMIVA
B44	ED		FWYLMIVA
B58	ATS		FWYLIVMA
B62	Q <i>LIVMP</i>		FWYMIVLA
MOTIFS			
A1	TSM		Y
A1		DEAS	Y
A2.1	L <i>MVQIAT</i>		V <i>LIMAT</i>
A3	L <i>MVISATFCGD</i>		KYRHFA
A11	V <i>TMLISAGNCDF</i>		KRYH
A24	Y <i>FWM</i>		FLIW
A*3101	M <i>VTALIS</i>		RK
A*3301	M <i>VALFIST</i>		RK
A*6801	A <i>VTMSLI</i>		RK
B*0702	P		LMFWYAIV
B*3501	P		LMFWYIVA
B51	P		LIVFWYAM
B*5301	P		IMFWYALV
B*5401	P		ATIVLMFWY

5 Bolded residues are preferred, italicized residues are less preferred: A peptide is considered motif-bearing if it has primary anchors at each primary anchor position for a motif or supermotif as specified in the above table.

TABLE IV (B): HLA CLASS II SUPERMOTIF

1	6	9
W, F, Y, V, .I, L	A, V, I, L, P, C, S, T	A, V, I, L, C, S, T, M, Y

TABLE IV (C)

MOTIFS		1° anchor 1	2	3	4	5	1° anchor 6	7	8	9
DR4	preferred	FMYLIVW	M	T		I	VSTCPALIM	MH		MH
	deleterious				W			R		WDE
DR1	preferred	MFLIVWY			PAMQ		VMATSPLIC	M		AVM
	deleterious		C	CH	FD	CWD		GDE	D	
DR7	preferred	MFLIVWY	M	W	A		IVMSACTPL	M		IV
	deleterious		C		G			GRD	N	G
<u>DR3</u>	<u>MOTIFS</u>	1° anchor 1	2	3	1° anchor 4	5	1° anchor 6			
motif a preferred		LIVMFY			D					
motif b preferred		LIVMFAY			DNQES T		KRH			
DR Super-motif		MFLIVWY					VMSTACPLI			

Italicized residues indicate less preferred or "tolerated" residues.

10024652 062302

Atty Docket: 511582002500

sd-70954

131

TABLE IV (D)

		POSITION								C-terminus
SUPER MOTIFS		1	2	3	4	5	6	7	8	
A1			^{1°} Anchor TILKMS							^{1°} Anchor FWY
A2			^{1°} Anchor LIVMAT Q							^{1°} Anchor LIVMAT
A3	preferred		^{1°} Anchor VSMAT LI	YFW (4/5)			YFW (3/5)	YFW (4/5)	P (4/5)	^{1°} Anchor RK
	deleterious	DE (3/5); P (5/5)		DE (4/5)						
A24			^{1°} Anchor YFW/HL MT							^{1°} Anchor FYWL M
B7	preferred	FWY (5/5) LIVM (3/5)	^{1°} Anchor P	FWY (4/5)					FWY (3/5)	^{1°} Anch or VILFM WYA
	deleterious	DE (3/5); P (5/5); G (4/5); A (3/5); QN (3/5)				DE (3/5)	G (4/5)	QN (4/5)	DE (4/5)	
B27			^{1°} Anchor RHK							^{1°} Anch or FYLL MVA
B44			^{1°} Anchor ED							^{1°} Anchor FWYLI MVA
B58			^{1°} Anchor ATS							^{1°} Anchor FWYLI VMA
B62			^{1°} Anchor QLIVMP							^{1°} Anchor FWYMIK LA

TABLE IV (E)

		1	2	3	4	5	6	7	8	9 or C-terminus	C-terminus
A1 9-mer	preferred deleterious	GFY W DE	<u>1°Anchor</u> STM	DEA RHKLIV MP	YFW A	G	P A	DEQ N	YFW	<u>1°Anchor</u> Y	
A1 9-mer	preferred deleterious	GRH K A	ASTCLIV M RHKDEP YFW	<u>1°Anchor</u> DEAS	GST G DE	PQN	AS TC RH K	LIV M PG	DE GP	<u>1°Anchor</u> Y	
A1 10-mer	preferred deleterious	YFW GP	<u>1°Anchor</u> STM	DEAQN RHKGLI VM	A DE	YFW QN RHK	PAS TC QN A YFW	GDE TC RHK	P A	<u>1°Anchor</u> or Y	
A1 10-mer	preferred deleterious	YFW RHK	STCLIV M RHKDEP Y FW	<u>1°Anchor</u> DEAS	A	YFW P	PG G	G PRH K	YFW QN	<u>1°Anchor</u> or Y	
A2.4 9-mer	preferred deleterious	YFW DEP	<u>1°Anchor</u> LMHQA T	YFW DERKH	STC	YFW	A RK H	P DER KH	<u>1°Anchor</u> VLMAT		
A2.4 10-mer	preferred deleterious	AYF W DEP	<u>1°Anchor</u> LMHQA T	LVIM DE	G RKH A	G P	G RKH	FYW L VIM DER KH	<u>1°Anchor</u> or VLMAT T		
A3	preferred deleterious	RHK DEP	<u>1°Anchor</u> LMVISA TECGD	YFW DE	PRH KYF W	A	YF W	P	<u>1°Anchor</u> KYRHF A		
A11	preferred deleterious	A DEP	<u>1°Anchor</u> VTLNIS AGNCDF	YFW	YFW	A	YF W	YFW A	P G	<u>1°Anchor</u> KRYH	
A24	preferred	YFW	<u>1°Anchor</u>		STC			YFW	YFW	<u>1°Anchor</u>	

Atty Docket: 511582002500

		1	2	3	4	5	6	7	8	9 or C terminus	C terminus
9-mer		RHK	YFWM							FLIW	
	deleterious	DEG		DE	G	QNP	DE RH K	G	AQN		
A24 10-mer	preferred		<u>1°Anchor</u> YFWM		P	YFW P		P			<u>1°Anchor</u> or FLIW
	deleterious			GDE	QN	RHK	DE	A	QN	DEA	
A310 +	preferred	RHK	<u>1°Anchor</u> MVTALLS	YFW	P		YF W	YFW	AP	<u>1°Anchor</u> RK	
	deleterious	DEP		DE		ADE	DE	DE	DE		
A330 +	preferred		<u>1°Anchor</u> MVALEI ST	YFW				AYF W		<u>1°Anchor</u> RK	
	deleterious	GP		DE							
A680 +	preferred	YFW STC	<u>1°Anchor</u> AVTMSL I			YFW LIV M		YFW	P	<u>1°Anchor</u> RK	
	deleterious	GP		DEG		RHK			A		
B070 2	preferred	RHK FWY	<u>1°Anchor</u> P	RHK		RHK	RH K	RHK	PA	<u>1°Anchor</u> LMFWY H/A	
	deleterious	DEQ NP		DEP	DE	DE	GD E	QN	DE		
B350 +	preferred	FWY LIV M	<u>1°Anchor</u> P	FWY				FWY		<u>1°Anchor</u> LMFWY H/A	
	deleterious	AGP				G	G				
B51	preferred	LIV MF WY	<u>1°Anchor</u> P	FWY	STC	FWY		G	FWY	<u>1°Anchor</u> LIVFWY AM	
	deleterious	AGP DER HKS TC				DE	G	DEQ N	GDE		
B530 +	preferred	LIV MF	<u>1°Anchor</u> P	FWY	STC	FWY		LIV MF	FWY	<u>1°Anchor</u> IMFWY	

		1	2	3	4	5	6	7	8	9 or C terminus	C terminus
		WY						WY		ALV	
	deleterious	AGP					G	RHK	DE		
		QN						QN			
B540	preferred	FWY	<i>1°Anchor</i>	FWYLI		LIV		ALI	FWY	<i>1°Anchor</i>	
+			P	VM		M		VM	AP	ATIVLM	
										FWY	
	deleterious	GPQ		GDEST		RHK	DE	QND	DE		
		NDE		G		DE		GE			

Italicized residues indicate less preferred or "tolerated" residues. The information in this Table is specific for 9-mers unless otherwise specified.

TABLE V(A)

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A1, 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	23	LNDTSAFDF	6.250	1.
2	148	LTDLSAILL	6.250	2.
3	141	MTDALHMLT	6.250	3.
4	303	IADPICTYV	5.000	4.
5	94	SCDNCSKQR	5.000	5.
6	356	SVEDLNIWS	4.500	6.
7	192	YILMGFLLY	2.500	7.
8	377	QLIPGSSSK	2.000	8.
9	178	RLEVL SAMI	1.800	9.
10	54	GSEAPERPV	1.350	10.
11	184	AMISVLLVY	1.250	11.
12	35	AGDEGLSRF	1.250	12.
13	285	SVGVLIAAY	1.000	13.
14	113	RLTIAAVLY	1.000	14.
15	76	LLDQDLPLT	1.000	15.
16	101	QREILKQRK	0.900	16.
17	331	ILEGVPSHL	0.900	17.
18	166	KSPTKRFTF	0.750	18.
19	31	FSDEAGDEG	0.750	19.
20	214	NGDIMLITA	0.625	20.
21	91	KVDSCDNCS	0.500	21.

TABLE V(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A1, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
22	34	EAGDEGLSR	0.500	22.
23	116	IAAVLYLLF	0.500	23.
24	288	VLIAAYIIR	0.500	24.
25	405	RCTIQLQSY	0.500	25.
26	340	NVDYIKEAL	0.500	26.
27	226	VAVNVIMGF	0.500	27.
28	289	LIAAYIIRF	0.500	28.
29	396	LLLNTFGMY	0.500	29.
30	125	MIGELVGGY	0.500	30.
31	397	LLNTFGMYR	0.500	31.
32	302	KIADPICTY	0.500	32.
33	83	LTNSQLSLK	0.500	33.
34	189	LLVYILMGF	0.500	34.
35	162	WLSSKSPTK	0.400	35.
36	267	DSLAVRAAF	0.300	36.
37	3	GSGAWKRLK	0.300	37.
38	70	QADDDSLD	0.250	38.
39	406	CTIQLQSYR	0.250	39.
40	335	VPSHLNVDY	0.250	40.
41	126	IGELVGGYI	0.225	41.
42	290	IAAYIIRFK	0.200	42.
43	310	YVFSLLVAF	0.200	43.
44	248	SLPSNSPTR	0.200	44.
45	197	FLLYEAVQR	0.200	45.
46	158	LLALWLSSK	0.200	46.
47	98	CSKQREILK	0.150	47.
48	265	GQDSLAVRA	0.150	48.
49	247	HSLPSNSPT	0.150	49.
50	414	RQEVDRICA	0.135	50.

TABLE VI (A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A1, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	303	IADPICTYVF	100.000	51.
2	91	KVDSCDNCSK	10.000	52.
3	148	LTDLSAIIIT	6.250	53.
4	36	GDEGLSRFNK	4.500	54.
5	178	RLEVL SAMIS	4.500	55.
6	247	HSLPSNSPTR	3.000	56.
7	54	GSEAPERPVN	2.700	57.
8	76	LLDQDLPLTN	2.500	58.
9	183	SAMISVLLVY	2.500	59.
10	70	QADDDSLLDQ	2.500	60.
11	284	QSVGVLIAAY	1.500	61.
12	340	NVDYIKEALM	1.000	62.
13	334	GVPSHLNVDY	1.000	63.
14	356	SVEDLNIWSL	0.900	64.
15	331	ILEGVPSHLN	0.900	65.
16	31	FSDEAGDEGL	0.750	66.
17	141	MTDALHMLTD	0.625	67.
18	396	LLLNTFGMYR	0.500	68.
19	225	GVAVNVIMGF	0.500	69.
20	22	FLNDTSAPDF	0.500	70.
21	287	GVLIAAYIIR	0.500	71.
22	346	EALMKIEDVY	0.500	72.
23	51	ADDGSEAPER	0.500	73.
24	188	VLLVYILMGF	0.500	74.
25	395	HLLNTFGMY	0.500	75.
26	288	VLIAAYIIRF	0.500	76.
27	115	TIAAVLYLLF	0.500	77.
28	126	IGELVGGYIA	0.450	78.
29	165	SKSPTKRFTF	0.250	79.
30	202	AVQRTIHMNY	0.250	80.
31	124	FMIGELVGGY	0.250	81.

TABLE VI (A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A1, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
32	279	LGDLVQSVGV	0.250	82.
33	298	KPEYKIADPI	0.225	83.
34	210	NYEINGDIML	0.225	84.
35	157	TLLALWLSSK	0.200	85.
36	289	LIAAYIIRFK	0.200	86.
37	350	KIEDVYSVED	0.180	87.
38	93	DSCDNC SKQR	0.150	88.
39	312	FSLLVAF TTF	0.150	89.
40	414	RQEVDR TCAN	0.135	90.
41	15	RKDDAPL FLN	0.125	91.
42	156	LTLLALWLSS	0.125	92.
43	83	LTNSQLSLKV	0.125	93.
44	172	FTFGFHRLEV	0.125	94.
45	214	NGDIMLITAA	0.125	95.
46	308	CTYVFSL LVA	0.125	96.
47	23	LNDSAFDFS	0.125	97.
48	35	AGDEGLSRFN	0.125	98.
49	191	VYILMGFLLY	0.125	99.
50	97	NCSKQREILK	0.100	100.

TABLE VII (A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A2, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	278	ALGDLVQSV	655.875	101.
2	268	SLAVRAAFV	382.536	102.
3	198	LLYEAVQRT	382.282	103.
4	75	SLLDQDLPL	324.068	104.
5	140	IMTDALHML	247.333	105.
6	122	LLFMIGELV	214.366	106.

TABLE VII(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A2, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
7	155	ILTLLALWL	199.738	107.
8	218	MLITAAVGV	118.238	108.
9	121	YLLFMIGEL	108.713	109.
10	323	IIWDTVVII	78.258	110.
11	409	QLQSYRQEV	69.552	111.
12	402	GMYRCTIQL	49.371	112.
13	118	AVLYLLFMI	45.057	113.
14	181	VLSAMISVL	34.246	114.
15	185	MISVLLVYI	30.849	115.
16	147	MLTDLSAII	29.814	116.
17	190	LVYILMGFL	16.722	117.
18	69	LQADDDSL	15.096	118.
19	194	LMGFLLYEA	14.029	119.
20	275	FVHALGDLV	13.717	120.
21	308	CTYVFSLLV	11.747	121.
22	76	LLDQDLPLT	11.655	122.
23	137	SLAIMTDAL	10.468	123.
24	68	TLQADDDSL	10.468	124.
25	315	LVAFTTFRI	9.001	125.
26	183	SAMISVLLV	8.221	126.
27	327	TVVIILEGV	6.859	127.
28	115	TIAAVLYLL	6.756	128.
29	153	AIILTLLAL	6.756	129.
30	319	TTFRIIWDT	6.606	130.
31	114	LTIAAVLYL	6.381	131.
32	87	QLSLKVDSC	5.599	132.
33	364	SLTSGKSTA	4.968	133.
34	357	VEDLNIWSL	4.872	134.
35	312	FSLLVAFIT	4.802	135.
36	193	ILMGFLLYE	4.506	136.
37	180	EVLSAMISV	3.884	137.

TABLE VIII(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A2, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
13	193	ILMGFLLYEA	71.872	163.
14	39	GLSRFNKLRV	69.552	164.
15	194	LMGFLLYEAV	62.765	165.
16	160	ALWLSSKSPT	61.852	166.
17	147	MLTDLSAII	61.047	167.
18	189	LLVYILMGFL	59.722	168.
19	190	LVYIILMGFLL	58.977	169.
20	12	SMLRKDDAPL	57.085	170.
21	198	LLYEAVQRTI	46.539	171.
22	408	IQLQSYRQEV	44.356	172.
23	140	IMTDALHMLT	37.513	173.
24	181	VLSAMISVLL	36.316	174.
25	139	AIMTDALHML	24.997	175.
26	68	TLQADDDSL	21.362	176.
27	397	LLNTFGMYRC	19.425	177.
28	172	FTFGFHRLEV	16.441	178.
29	219	LITAAVGAV	16.258	179.
30	227	AVNVIMGFLL	10.841	180.
31	364	SLTSGKSTAI	10.433	181.
32	356	SVEDLNIWSL	8.461	182.
33	318	FTTFRIIWD	8.213	183.
34	22	FLNDTSAFDF	8.152	184.
35	125	MIGELVGGYI	7.149	185.
36	348	LMKIEDVYSV	6.874	186.
37	345	KEALMKIEDV	5.335	187.
38	179	LEVLSAMISV	5.288	188.
39	285	SVGVLIAAYI	5.021	189.
40	144	ALHMLTDLA	4.968	190.
41	133	YIANSLAINT	4.713	191.
42	185	MISVLLVYIL	4.709	192.
43	150	DLSAIIITLL	3.685	193.

TABLE VIII(A)

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A2, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
44	389	VQSKANHLLL	3.682	194.
45	129	LVGGYIANSI	3.178	195.
46	319	TTFRIIWDTV	2.977	196.
47	307	ICTYVFSLLV	2.933	197.
48	5	GAWKRLKSMI	2.463	198.
49	401	FGMYRCTIQL	2.373	199.
50	332	LEGVPSHLNV	2.299	200.

TABLE IX(A)

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A3, 9-MERS

RANK	START POSITIO N	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	158	LLALWLSSK	90.000	201.
2	377	QLIPGSSSK	45.000	202.
3	184	AMISVLLVY	27.000	203.
4	397	LLNTFGMYR	24.000	204.
5	162	WLSSKSPTK	20.000	205.
6	39	GLSRFNKLR	18.000	206.
7	402	GMYRCTIQL	18.000	207.
8	314	LLVAFTTFR	18.000	208.
9	189	LLVYILMGF	13.500	209.
10	288	VLIAAYIIR	12.000	210.
11	361	NIWSLTSGK	10.000	211.
12	347	ALMKIEDVY	9.000	212.
13	313	SLLVAFTTF	9.000	213.
14	197	FLLYEAVQR	6.000	214.
15	396	LLLNTFGMY	5.400	215.
16	113	RLTIAAVLY	4.000	216.
17	248	SLPSNSPTR	4.000	217.
18	192	YILMGFLLY	3.600	218.

TABLE IX(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A3, 9-MERS				
RANK	START POSITIO N	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
19	302	KIADPICTY	2.700	219.
20	198	LLYEAVQRT	2.250	220.
21	294	IIRFKPEYK	2.000	221.
22	289	LIAAYIIRF	1.800	222.
23	293	YIIRFKPEY	1.800	223.
24	234	FLNQSGHR	1.800	224.
25	75	SLLDQDLPL	1.800	225.
26	122	LLFMIGELV	1.500	226.
27	310	YVFSLLVAF	1.500	227.
28	83	LTNSQLSLK	1.500	228.
29	146	HMLTDLIAI	1.350	229.
30	331	ILEGVPSHL	1.350	230.
31	155	ILTLLALWL	1.200	231.
32	181	VLSAMISVL	0.900	232.
33	395	HLLNTFGM	0.900	233.
34	194	LMGFLLYEA	0.900	234.
35	323	IIWDTVVII	0.900	235.
36	140	IMTDALHML	0.900	236.
37	150	DLSAIIITL	0.810	237.
38	287	GVLIAAYII	0.810	238.
39	100	KQREILKQR	0.608	239.
40	278	ALGDLVQSV	0.600	240.
41	409	QLQSYRQEV	0.600	241.
42	137	SLAIMTDAL	0.600	242.
43	68	TLQADDDSL	0.600	243.
44	285	SVGVLIAAY	0.600	244.
45	178	RLEVLSAMI	0.600	245.
46	119	VLYLLEFMIG	0.600	246.
47	147	MLTDLSAII	0.600	247.
48	13	MLRKDDAPL	0.600	248.
49	87	QLSLKVDSC	0.600	249.

TABLE IX(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A3, 9-MERS				
RANK	START POSITIO N	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
50	170	KRFTFGFHR	0.540	250.

TABLE X(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A3, 10-MERS				
RANK	START POSITIO N	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	157	TLLALWLSSK	135.000	251.
2	396	LLLNTFGMYR	36.000	252.
3	288	VLIAAYIIRF	27.000	253.
4	313	SLLVAFTTFR	18.000	254.
5	188	VLLVYILMGF	13.500	255.
6	124	FMIGELVGGY	8.100	256.
7	22	FLNDTSAPDF	6.000	257.
8	91	KVDSCDNCSK	6.000	258.
9	104	ILKQRKVKAR	6.000	259.
10	395	HLLLNTFGMY	5.400	260.
11	162	WLSSKSPTKR	4.000	261.
12	287	GVLIAAYIIR	3.600	262.
13	113	RLTIAAVLYL	3.600	263.
14	293	YIIRFKPEYK	3.000	264.
15	82	PLTNSQLSLK	3.000	265.
16	100	KQREILKQRK	2.700	266.
17	323	IIWDTVVIIL	2.700	267.
18	314	LLVAFTTFRI	2.700	268.
19	225	GVAVNVIMGF	2.700	269.
20	193	ILMGFLLYEA	2.025	270.
21	13	MLRKDDAPLF	2.000	271.
22	348	LMKIEDVYSV	1.800	272.
23	184	AMISVLLVYI	1.350	273.

TABLE X(A)

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A3, 10-MERS

RANK	START POSITIO N	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
24	334	GVPSHLNVDY	1.200	274.
25	147	MLTDLSAII	1.200	275.
26	39	GLSRFNKLRV	1.200	276.
27	202	AVQRTIHMNY	1.200	277.
28	20	PLFLNDTSAP	1.000	278.
29	376	IQLIPGSSSK	0.900	279.
30	190	LVYILMGFLL	0.900	280.
31	181	VLSAMISVLL	0.900	281.
32	12	SMLRKDDAPL	0.900	282.
33	119	VLVLLFMIGE	0.900	283.
34	397	LLNTFGMYRC	0.900	284.
35	146	HMLTDLSAII	0.900	285.
36	198	LLYEAVQRTI	0.675	286.
37	399	NTFGMYRCTI	0.675	287.
38	68	TLQADDDSL	0.600	288.
39	364	SLTSGKSTAI	0.600	289.
40	268	SLAVRAAFVH	0.600	290.
41	270	AVRAAFVHAL	0.540	291.
42	185	MISVLLVYIL	0.540	292.
43	160	ALWLSSKSPT	0.500	293.
44	402	GMYRCTIQLQ	0.450	294.
45	289	LIAAYIIRFK	0.450	295.
46	338	HLNVDYIKEA	0.450	296.
47	121	YLLFMIGELV	0.450	297.
48	197	FLLYEAVQRT	0.450	298.
49	377	QLIPGSSSKW	0.450	299.
50	150	DLSAIIITLL	0.405	300.

TABLE XI(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A11, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	83	LTNSQLSLK	1.000	301.
2	361	NIWSLTSGK	0.800	302.
3	377	QLIPGSSSK	0.600	303.
4	294	IIRFKPEYK	0.400	304.
5	162	WLSSKSPTK	0.400	305.
6	158	LLALWLSSK	0.400	306.
7	342	DYIKEALMK	0.360	307.
8	406	CTIQLQSYR	0.300	308.
9	288	VLIAAYIIR	0.240	309.
10	8	KRLKSMRLK	0.180	310.
11	287	GVLIAAYII	0.180	311.
12	100	KQREILKQR	0.180	312.
13	397	LLNTFGMYR	0.160	313.
14	39	GLSRFNKLR	0.120	314.
15	197	FLLYEAVQR	0.120	315.
16	234	FLLNQSGHR	0.120	316.
17	314	LLVAFTTFR	0.120	317.
18	205	RTIHMNYEI	0.090	318.
19	118	AVLYLLFMI	0.090	319.
20	103	EILKQRKVK	0.090	320.
21	248	SLPSNSPTR	0.080	321.
22	1	MAGSGAWKR	0.080	322.
23	170	KRFTFGFHR	0.072	323.
24	337	SHLNVDYIK	0.060	324.
25	315	LVAFITFRI	0.060	325.
26	109	KVKARLTIA	0.060	326.
27	187	SVLLVYILM	0.060	327.
28	37	DEGLSRFNK	0.054	328.
29	402	GMYRCTIQL	0.048	329.
30	190	LVYILMGFL	0.040	330.
31	310	YVFSLLVAF	0.040	331.

TABLE XI(A)

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A11, 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
32	308	CTYVFSLLV	0.040	332.
33	384	SKWEEVQSK	0.040	333.
34	98	CSKQREILK	0.040	334.
35	132	GYIANSLAI	0.036	335.
36	327	TVVIILEGV	0.030	336.
37	114	LTIAAVLYL	0.030	337.
38	34	EAGDEGLSR	0.024	338.
39	275	FVHALGDLV	0.020	339.
40	94	SCDNCSKQR	0.020	340.
41	49	VVADDGSEA	0.020	341.
42	282	LVQSVGLI	0.020	342.
43	290	IAAYIIRFK	0.020	343.
44	223	AVGVAVNVI	0.020	344.
45	92	VDSCDNCSK	0.020	345.
46	285	SVGVLIAAY	0.020	346.
47	340	NVDYIKEAL	0.020	347.
48	227	AVNVIMGFL	0.020	348.
49	270	AVRAAFVHA	0.020	349.
50	101	QREILKQRK	0.020	350.

TABLE XII(A)

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A11, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	91	KVDSCDNCSK	6.000	351.
2	287	GVLIAAYIIR	3.600	352.
3	100	KQREILKQRK	1.800	353.
4	376	IQLIPGSSSK	0.900	354.
5	157	TLLALWLSSK	0.600	355.
6	293	YIIRFKPEYK	0.600	356.

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A11, 10-MERS

148

TABLE XII(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A11, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
38	39	GLSRFNKLRV	0.024	388.
39	113	RLTIAAVLYL	0.024	389.
40	319	TTFRIIWDTV	0.020	390.
41	223	AVGVAVNVIM	0.020	391.
42	383	SSKWEEVQSK	0.020	392.
43	270	AVRAAFVHAL	0.020	393.
44	399	NTFGMYRCTI	0.020	394.
45	83	LTNSQLSLKV	0.020	395.
46	285	SVGVLIAAYI	0.020	396.
47	129	LVGGYIANSI	0.020	397.
48	340	NVDYIKEALM	0.020	398.
49	314	LLVAFTTFRI	0.018	399.
50	322	RIIWDTVVII	0.018	400.

TABLE XIII(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A24, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	191	VYILMGFLL	300.000	401.
2	199	LYEAVQRTI	105.000	402.
3	132	GYIANSLAI	75.000	403.
4	354	VYSVEDLNI	50.000	404.
5	171	RFTFGFHRL	48.000	405.
6	210	NYEINGDIM	37.500	406.
7	274	AFVHALGDL	30.000	407.
8	21	LFLNDTSAP	15.000	408.
9	106	KQRKVKARL	11.200	409.
10	38	EGLSRFNKL	9.504	410.
11	331	ILEGVPSHL	8.400	411.
12	227	AVNVIMGFL	8.400	412.

TABLE XIII(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A24, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
13	309	TYVFSLLVA	7.500	413.
14	75	SLLDQDLPL	7.200	414.
15	186	ISVLLVYIL	7.200	415.
16	388	EVQSKANHL	7.200	416.
17	130	VGGYIANSL	6.720	417.
18	307	ICTYVFSLL	6.720	418.
19	121	YLLFMIGEL	6.600	419.
20	153	AIILTLLAL	6.000	420.
21	166	KSPTKRFTF	6.000	421.
22	281	DLVQSVGV	6.000	422.
23	68	TLQADDDSL	6.000	423.
24	143	DALHMLTDL	6.000	424.
25	228	VNVIMGFLL	6.000	425.
26	80	DLPLTNSQL	6.000	426.
27	114	LTIAAVLYL	6.000	427.
28	150	DLSAIIITL	5.600	428.
29	340	NVDYIKEAL	5.600	429.
30	324	IWDTVVIIL	5.600	430.
31	115	TIAAVLYLL	5.600	431.
32	370	STAIVHIQL	5.600	432.
33	151	LSAIIITLL	5.600	433.
34	182	LSAMISVLL	5.600	434.
35	300	EYKIADPIC	5.000	435.
36	400	TFGMYRCTI	5.000	436.
37	412	SYRQEVDR	5.000	437.
38	6	AWKRLKSML	4.800	438.
39	190	LVYILMGFL	4.800	439.
40	69	LQADDDSL	4.800	440.
41	155	ILTLLALWL	4.800	441.
42	140	IMTDALHML	4.800	442.
43	189	LLVYILMGF	4.200	443.

TABLE XIII(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A24, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
44	226	VAVNVIMGF	4.200	444.
45	267	DSLAVRAAF	4.200	445.
46	13	MLRKDDAPL	4.000	446.
47	402	GMYRCTIQL	4.000	447.
48	2	AGSGAWKRL	4.000	448.
49	97	NCSKQREIL	4.000	449.
50	390	QSKANHLLL	4.000	450.

TABLE XIV(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A24, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	120	LYLLFMIGEL	330.000	451.
2	210	NYEINGDIML	300.000	452.
3	309	TYVFSLLVAF	180.000	453.
4	342	DYIKEALMKI	82.500	454.
5	132	GYIANSLAIM	37.500	455.
6	173	TFGFHRLEVL	20.000	456.
7	60	RPVNGAHPTL	12.000	457.
8	369	KSTAIVHIQL	11.200	458.
9	111	KARLTIAAVL	11.200	459.
10	339	LNVDYIKEAL	10.080	460.
11	330	IILEGVPSHL	10.080	461.
12	191	VYILMGFLLY	9.000	462.
13	392	KANHLLNNTF	8.640	463.
14	226	VAVNVIMGFL	8.400	464.
15	114	LTIAAVLYLL	8.400	465.
16	292	AYIIRFKPEY	8.250	466.
17	113	RLTIAAVLYL	8.000	467.
18	189	LLVYILMGFL	7.200	468.

TABLE XIV(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A24, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
19	356	SVEDLNIWSL	7.200	469.
20	154	IILTLLALWL	7.200	470.
21	403	MYRCTIQLQS	7.000	471.
22	412	SYRQEVDRTC	7.000	472.
23	129	LVGGYIANSI	6.720	473.
24	323	IIWDTVVIIL	6.720	474.
25	305	DPICTYVFSI	6.000	475.
26	152	SAIILTLLAL	6.000	476.
27	401	FGMYRCTIQL	6.000	477.
28	12	SMLRKDDAPL	6.000	478.
29	68	TLQADDDSLI	6.000	479.
30	354	VYSVEDLNIW	6.000	480.
31	81	LPLTNSQLSL	6.000	481.
32	227	AVNVIMGFLL	6.000	482.
33	139	AIMTDALHML	6.000	483.
34	136	NSLAIMTDAL	6.000	484.
35	388	EVQSKANHLL	6.000	485.
36	180	EVLSAMISVL	6.000	486.
37	74	DSLDDQDLPL	6.000	487.
38	150	DLSAIILTLL	5.600	488.
39	181	VLSAMISVLL	5.600	489.
40	300	EYKIADPICT	5.000	490.
41	185	MISVLLVYIL	4.800	491.
42	5	GAWKRLKSML	4.800	492.
43	147	MLTDLSAIIL	4.800	493.
44	31	FSDEAGDEGL	4.800	494.
45	298	KPEYKIADPI	4.200	495.
46	188	VLLVYILMGF	4.200	496.
47	273	AAFVHALGDL	4.000	497.
48	270	AVRAAFVHAL	4.000	498.
49	1	MAGSGAWKRL	4.000	499.

TABLE XIV(A)

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A24, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
50	96	DNCSKQREIL	4.000	500.

TABLE XV(A)

HLA PEPTIDE SCORING RESULTS - 108P5H8 - B7, 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	227	AVNVIMGFL	60.000	501.
2	106	KQRKVKARL	40.000	502.
3	13	MLRKDDAPL	40.000	503.
4	190	LVYILMGFL	20.000	504.
5	388	EVQSKANHL	20.000	505.
6	270	AVRAAFVHA	15.000	506.
7	2	AGSGAWKRL	12.000	507.
8	143	DALHMLTDL	12.000	508.
9	153	AIILTLLAL	12.000	509.
10	139	AIMTDALHM	9.000	510.
11	117	AAVLYLLFM	9.000	511.
12	340	NVDYIKEAL	6.000	512.
13	97	NCSKQREIL	6.000	513.
14	111	KARLTIAAV	6.000	514.
15	118	AVLYLLFMI	6.000	515.
16	223	AVGVAVNVI	6.000	516.
17	187	SVLLVYILM	5.000	517.
18	150	DLSAILTL	4.000	518.
19	307	ICTYVFSLL	4.000	519.
20	186	ISVLLVYIL	4.000	520.
21	130	VGGYIANSI	4.000	521.
22	151	LSAILTL	4.000	522.
23	182	LSAMISVLL	4.000	523.

TABLE XV(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - B7, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ. ID#
24	390	QSKANHLL	4.000	524.
25	155	ILTLLALWL	4.000	525.
26	402	GMRYCTIQL	4.000	526.
27	75	SLLDQDLPL	4.000	527.
28	69	LQADDDSL	4.000	528.
29	181	VLSAMISVL	4.000	529.
30	370	STAIVHIQL	4.000	530.
31	114	LTIAAVLYL	4.000	531.
32	281	DLVQSVGV	4.000	532.
33	80	DLPLTNSQL	4.000	533.
34	389	VQSKANHLL	4.000	534.
35	38	EGLSRFNKL	4.000	535.
36	115	TIAAVLYLL	4.000	536.
37	140	IMTDALHML	4.000	537.
38	68	TLQADDDSL	4.000	538.
39	174	FGFHRLEVL	4.000	539.
40	228	VNVIMGFLL	4.000	540.
41	121	YLLFMIGEL	4.000	541.
42	137	SLAIMTDAL	4.000	542.
43	5	GAWKRLKSM	3.000	543.
44	201	EAVQRTIHM	3.000	544.
45	57	APERPVNGA	2.700	545.
46	61	PVNGAHPTL	2.000	546.
47	282	LVQSVGVLI	2.000	547.
48	287	GVLIAAYII	2.000	548.
49	315	LVAFTTFRI	2.000	549.
50	40	LSRFNKL RV	2.000	550.

TABLE XVI(A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - B7, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	270	AVRAAFVHAL	600.000	551.
2	111	KARLTIAAVL	120.000	552.
3	60	RPVNGAHPTL	80.000	553.
4	81	LPLTNSQLSL	80.000	554.
5	305	DPICTYVFSL	80.000	555.
6	227	AVNVIMGFLL	60.000	556.
7	273	AAFVHALGDL	36.000	557.
8	139	AIMTDALHML	36.000	558.
9	388	EVQSKANHLL	20.000	559.
10	180	EVLSAMISVL	20.000	560.
11	190	LVYILMGFLL	20.000	561.
12	129	LVGGYIANSL	20.000	562.
13	223	AVGVAVNVIM	15.000	563.
14	5	GAWKRLKSML	12.000	564.
15	1	MAGSGAWKRL	12.000	565.
16	152	SAIILTLLAL	12.000	566.
17	401	FGMYRCTIQL	12.000	567.
18	226	VAVNVIMGFL	12.000	568.
19	335	VPSHLNVDYI	8.000	569.
20	356	SVEDLNIWSL	6.000	570.
21	19	APLFLNDTSA	6.000	571.
22	96	DNCSKQREIL	6.000	572.
23	294	IIRFKPEYKI	6.000	573.
24	113	RLTIAAVLYL	4.000	574.
25	150	DISAIILTLL	4.000	575.
26	339	LNVDYIKEAL	4.000	576.
27	240	GHRHSHSHSL	4.000	577.
28	147	MLTDLSAAIL	4.000	578.
29	330	IILEGVPSHL	4.000	579.
30	114	LTIAAVLYLL	4.000	580.
31	189	LLVYILMGFL	4.000	581.

TABLE XVII (A)				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - B35, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
7	201	EAVQRTIHM	6.000	607.
8	5	GAWKRLKSM	6.000	608.
9	203	VQRTIHMNY	6.000	609.
10	117	AAVLYLLFM	6.000	610.
11	106	KQKVKARL	6.000	611.
12	267	DSLAVRAAF	5.000	612.
13	151	LSAIILTLL	5.000	613.
14	182	LSAMISVLL	5.000	614.
15	186	ISVLLVYIL	5.000	615.
16	13	MLRKDDAPL	4.500	616.
17	60	RPVNGAHPT	4.000	617.
18	125	MIGELVGGY	4.000	618.
19	113	RLTIAAVLY	4.000	619.
20	405	RCTIQLQSY	4.000	620.
21	111	KARLTIAAV	3.600	621.
22	143	DALHMLTDL	3.000	622.
23	69	LQADDDSL	3.000	623.
24	116	IAAVLYLLF	3.000	624.
25	40	LSRFNKLRV	3.000	625.
26	226	VAVNVIMGF	3.000	626.
27	139	AIMTDALHM	3.000	627.
28	343	YIKEALMKI	2.400	628.
29	383	SSKWEEVQS	2.250	629.
30	19	APLFLNDTS	2.000	630.
31	192	YILMGFLLY	2.000	631.
32	293	YIIRFKPEY	2.000	632.
33	184	AMISVLLVY	2.000	633.
34	75	SLLDQDLPL	2.000	634.
35	187	SVLLVYILM	2.000	635.
36	224	VGAVNVIM	2.000	636.
37	81	LPLTNSQLS	2.000	637.

HLA PEPTIDE SCORING RESULTS - 108P5H8 - B35, 9-MERS

	RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
	38	133	YIANSLAIM	2.000	638.
	39	347	ALMKIEDVY	2.000	639.
	40	305	DPICTYVFS	2.000	640.
	41	285	SVGVLIAAY	2.000	641.
	42	140	IMTDALHML	2.000	642.
	43	395	HLLLNTFGM	2.000	643.
	44	396	LLLNTFGMY	2.000	644.
	45	68	TLQADDDSL	1.500	645.
	46	371	TAIVHIQLI	1.200	646.
	47	316	VAFITFRII	1.200	647.
	48	322	RIIWDTVVI	1.200	648.
	49	97	NCSKQREIL	1.000	649.
	50	181	VLSAMISVL	1.000	650.

HLA PEPTIDE SCORING RESULTS - 108P5H8 - B35, 10-MERS

	RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
	1	60	RPVNGAHPTL	40.000	651.
	2	305	DPICTYVFSL	20.000	652.
	3	81	LPLTNSQLSL	20.000	653.
	4	167	SPTKRFTFGF	20.000	654.
	5	111	KARLTIAAVL	18.000	655.
	6	369	KSTAIVHIQL	10.000	656.
	7	284	QSVGVLIAAY	10.000	657.
	8	186	ISVLLVYILM	10.000	658.
	9	138	LAIMTDALHM	9.000	659.
	10	335	VPSHLNVDYI	8.000	660.
	11	392	KANHLLLNTF	6.000	661.
	12	34	EAGDEGLSRF	6.000	662.

TABLE XVIII(A)				
H1A PEPTIDE SCORING RESULTS - 108P5H8 - B35, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
13	346	EALMKIEDVY	6.000	663.
14	116	IAAVLYLLFM	6.000	664.
15	183	SAMISVLLVY	6.000	665.
16	136	NSLAIMTDAL	5.000	666.
17	74	DSLDDQDLPL	5.000	667.
18	312	FSLLVAFITF	5.000	668.
19	163	LSSKSPTKRF	5.000	669.
20	298	KPEYKIADPI	4.800	670.
21	13	MLRKDDAPLF	4.500	671.
22	209	MNYEINGDIM	4.000	672.
23	40	LSRFNKL RVV	3.000	673.
24	270	AVRAAFVHAL	3.000	674.
25	273	AAFVHALGDL	3.000	675.
26	226	VAVNVIMGFL	3.000	676.
27	5	GAWKRLK SML	3.000	677.
28	1	MAGSGAWKRL	3.000	678.
29	152	SAIILTLLAL	3.000	679.
30	31	FSDEAGDEGL	3.000	680.
31	19	APLFLNDTSA	2.000	681.
32	4	SGAWKRLKSM	2.000	682.
33	113	RLTIAAVLYL	2.000	683.
34	395	HLLLNTFGMY	2.000	684.
35	147	MLTDLSAIL	2.000	685.
36	334	GVPSHLNVDY	2.000	686.
37	66	HPTLQADDDS	2.000	687.
38	339	LNVDYIKEAL	2.000	688.
39	249	LPSNSPTRGS	2.000	689.
40	323	IIWDTVVIIL	2.000	690.
41	330	IILEGVPSHL	2.000	691.
42	202	AVQRTIHMNY	2.000	692.
43	124	FMIGELVGGY	2.000	693.

TABLE XVIII(A)

HLA PEPTIDE SCORING RESULTS - 108P5H8 - B35, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
44	22	FLNDTSAFDF	2.000	694.
45	223	AVGVAVNVIM	2.000	695.
46	164	SSKSPTKRFT	1.500	696.
47	390	QSKANHLLN	1.500	697.
48	12	SMLRKDDAPL	1.500	698.
49	68	TLQADDDSL	1.500	699.
50	316	VAFTTFRIIW	1.500	700.

TABLE V (B) unique to variant 3 relative to variants 1 and 2

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A1, 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	23	LNDTSAFEF	6.250	701.
2	28	AFEFSDEAG	0.045	702.
3	25	DTSAFEFS	0.013	703.
4	28	SAFEFSDEA	0.010	704.
5	22	FLNDTSAFE	0.002	705.
6	26	TSAFEFSDE	0.002	706.
7	24	NDTSAFEFS	0.001	707.
8	29	FEFSDEAGD	0.000	708.
9	30	EFSDEAGDE	0.000	709.

TABLE VI (B) unique to variant 3 relative to variants 1 and 2

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A1, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	22	FLNDTSAFEF	0.500	710.
2	23	LNDTSAFEFS	0.125	711.
3	26	TSAFEFSDEA	0.015	712.

TABLE VI (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A1, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
4	27	SAFEFSDEAG	0.010	713.
5	28	AFEFSDEAGD	0.009	714.
6	25	DTSAFEFSDE	0.003	715.
7	30	EFSDDEAGDEG	0.001	716.
8	24	NDTSAFEFS	0.000	717.
9	21	LFLNDTSAFE	0.000	718.
10	29	FEFSDEAGDE	0.000	719.

TABLE VII (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A2, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	27	SAFEFSDEA	1.949	720.
2	22	FLNDTSAFE	1.546	721.
3	29	FEFSDEAGD	0.005	722.
4	23	LNDTSAFE	0.002	723.
5	24	NDTSAFEFS	0.001	724.
6	25	DTSAFEFS	0.000	725.
7	26	TSAFEFSDE	0.000	726.
8	28	AFEFSDEAG	0.000	727.
9	30	EFSDDEAGDE	0.000	728.

TABLE VIII (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A2, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	22	FLNDTSAFE	8.152	729.
2	26	TSAFEFSDEA	0.060	730.

TABLE VIII (B) unique to variant 3 relative to variants 1 and 2

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A2, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
3	27	SAFEFSDEAG	0.008	731.
4	23	LNDTSAFEF	0.002	732.
5	29	FEFSDEAGDE	0.001	733.
6	24	NDTSAFEFSD	0.000	734.
7	21	LFLNDTSAFE	0.000	735.
8	25	DTSAFEFSD	0.000	736.
9	30	EFSDDEAGDE	0.000	737.
10	28	AFEFSDEAGD	0.000	738.

TABLE IX (B) unique to variant 3 relative to variants 1 and 2

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A3, 9-MERS

RANK	START POSITIO N	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	27	SAFEFSDEA	0.045	739.
2	22	FLNDTSAFE	0.020	740.
3	23	LNDTSAFEF	0.012	741.
4	25	DTSAFEFSD	0.003	742.
5	29	FEFSDEAGD	0.000	743.
6	26	TSAFEFSDE	0.000	744.
7	24	NDTSAFEF	0.000	745.
8	28	AFEFSDEAG	0.000	746.
9	30	EFSDDEAGDE	0.000	747.

TABLE X (B) unique to variant 3 relative to variants 1 and 2

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A3, 10-MERS

RANK	START POSITIO N	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	22	FLNDTSAFEF	6.000	748.
2	26	TSAFEFSDEA	0.003	749.

TABLE X (B) unique to variant 3 relative to variants 1 and 2

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A3, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
3	27	SAFEFSDEAG	0.002	750.
4	25	DTSAFEFSDE	0.001	751.
5	23	LNDSAFEFS	0.000	752.
6	24	NDTSAFEFS	0.000	753.
7	29	FEFSDEAGDE	0.000	754.
8	21	LFLNDTSAFE	0.000	755.
9	28	AFEFSDEAGD	0.000	756.
10	30	EFSDDEAGDEG	0.000	757.

TABLE XI (B) unique to variant 3 relative to variants 1 and 2

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A11, 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	27	SAFEFSDEA	0.004	758.
2	23	LNDSAFEFS	0.001	759.
3	25	DTSAFEFS	0.001	760.
4	22	FLNDTSAFE	0.000	761.
5	28	AFEFSDEAG	0.000	762.
6	29	FEFSDEAGD	0.000	763.
7	30	EFSDDEAGDE	0.000	764.
8	24	NDTSAFEFS	0.000	765.
9	26	TSAFEFSDE	0.000	766.

TABLE XII (B) unique to variant 3 relative to variants 1 and 2

HLA PEPTIDE SCORING RESULTS - 108P5H8 - A11, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	22	FLNDTSAFEFS	0.012	767.
2	27	SAFEFSDEAG	0.000	768.

TABLE XII (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A11, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
3	21	LFLNDTSAFE	0.000	769.
4	25	DTSAFEFSD	0.000	770.
5	28	AFEFSDDEAGD	0.000	771.
6	26	TSAFEFSDEA	0.000	772.
7	29	FEFSDEAGDE	0.000	773.
8	24	NDTSAFEFSD	0.000	774.
9	30	EFSDDEAGDEG	0.000	775.
10	23	LNDTSAFEF	0.000	776.

TABLE XIII (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A24, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	23	LNDTSAFEF	2.200	777.
2	27	SAFEFSDEA	0.132	778.
3	28	AFEFSDDEAG	0.075	779.
4	30	EFSDDEAGDE	0.060	780.
5	22	FLNDTSAFE	0.018	781.
6	24	NDTSAFEF	0.012	782.
7	26	TSAFEFSDE	0.012	783.
8	25	DTSAFEFSD	0.010	784.
9	29	FEFSDEAGD	0.001	785.

TABLE XIV (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A24, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	22	FLNDTSAFEF	3.960	786.
2	23	LNDTSAFEF	0.120	787.

TABLE XIV (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - A24, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
3	26	TSAFEFSD	0.110	788.
4	28	AFEFSD	0.075	789.
5	21	LFLNDSAFE	0.075	790.
6	30	EFSD	0.066	791.
7	27	SAFEFSDEAG	0.012	792.
8	25	DTSAFEFSD	0.012	793.
9	24	NDTSAFEFSD	0.001	794.
10	29	FEFSDEAGDE	0.001	795.

TABLE XV (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - B7, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	27	SAFEFSDEA	0.300	796.
2	22	FLNDSAFE	0.010	797.
3	26	TSAFEFSD	0.010	798.
4	25	DTSAFEFSD	0.010	799.
5	23	LNDSAFEF	0.006	800.
6	24	NDTSAFEFSD	0.002	801.
7	30	EFSD	0.001	802.
8	29	FEFSDEAGD	0.001	803.
9	28	AFEFSD	0.001	804.

TABLE XVI (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - B7, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	26	TSAFEFSD	0.100	805.
2	27	SAFEFSDEAG	0.030	806.

TABLE XVI (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - B7, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
3	22	FLNDTSAFEF	0.020	807.
4	25	DTSAFEFSDE	0.010	808.
5	23	LNDSAFEFS	0.006	809.
6	30	EFSDDEAGDEG	0.001	810.
7	24	NDTSAFEFS	0.001	811.
8	29	FEFSDEAGDE	0.001	812.
9	21	LFLNDTSAFE	0.001	813.
10	28	AFEFSDEAGD	0.001	814.

TABLE XVII (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - B35, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	276	SAFEFSDEA	0.600	815.
2	23	LNDSAFEF	0.300	816.
3	26	TSAFEFSDE	0.075	817.
4	22	FLNDTSAFE	0.020	818.
5	24	NDTSAFEFS	0.010	819.
6	25	DTSAFEFS	0.010	820.
7	30	EFSDDEAGDE	0.003	821.
8	29	FEFSDEAGD	0.002	822.
9	28	AFEFSDEAG	0.000	823.

TABLE XVIII (B) unique to variant 3 relative to variants 1 and 2				
HLA PEPTIDE SCORING RESULTS - 108P5H8 - B35, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	22	FLNDTSAFEF	2.000	824.
2	26	TSAFEFSDEA	0.500	825.

TABLE XVIII (B) unique to variant 3 relative to variants 1 and 2				
H1A PEPTIDE SCORING RESULTS - 108P5H8 - B35, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
3	27	SAFEFSDEAG	0.060	826.
4	23	LNDTSAFEF	0.030	827.
5	25	DTSAFEFSD	0.015	828.
6	30	EFSDAGDEG	0.002	829.
7	29	FEFSDEAGD	0.002	830.
8	24	NDTSAFEFSD	0.001	831.
9	21	LFLNDTSAFE	0.001	832.
10	28	AFEFSDEAGD	0.000	833.

Table XIX: Motifs and Post-translational Modifications of 108P5H8

N-glycosylation site

Number of matches: 3

- 1 24-27 NDTS (SEQ. ID. No. 834)
- 2 97-100 NCSK (SEQ. ID. No. 835)
- 3 237-240 NQSG (SEQ. ID. No. 836)

cAMP- and cGMP-dependent protein kinase phosphorylation site

170-173 KRFT (SEQ. ID. No. 837)

Protein kinase C phosphorylation site

Number of matches: 7

- 1 89-91 SLK
- 2 164-166 SSK
- 3 383-385 SSK
- 4 169-171 TKR
- 5 320-322 TFR
- 6 367-369 SGK
- 7 164-166 SSK

Casein kinase II phosphorylation site

Number of matches: 5

- 1 27-30 SAFD (SEQ. ID. No. 838)
- 2 75-78 SLLD (SEQ. ID. No. 839)
- 3 258-261 SGCE (SEQ. ID. No. 840)
- 4 356-359 SVED (SEQ. ID. No. 841)
- 5 384-387 SKWE (SEQ. ID. No. 842)

N-myristoylation site

Number of matches: 6

- 1 64-69 GAHPTL (SEQ. ID. No. 843)
- 2 131-136 GGYIAN (SEQ. ID. No. 844)

5

- 3 225-230 GVAVNV (SEQ. ID. No. 845)
- 4 259-264 GCERNH (SEQ. ID. No. 846)
- 5 287-292 GVLIAA (SEQ. ID. No. 847)
- 6 402-407 GMYRCT (SEQ. ID. No. 848)

Leucine zipper pattern

69-90 LQADDDSLDQDLPLTNSQLSL (SEQ. ID. No. 849)

Name	avrg. % identity	Description	Potential Function
zF-C2H2	34%	Zinc finger, C2H2 type	Nucleic acid-binding protein functions as transcription factor, nuclear location probable
cytochrome b_N	68%	Cytochrome b(N-terminal)/b6/petB	membrane bound oxidase, generate superoxide
ig	19%	Immunoglobulin domain	domains are one hundred amino acids long and include a conserved intradomain disulfide bond.
WD40	18%	WD domain, G-beta repeat	tandem repeats of about 40 residues, each containing a Trp-Asp motif. Function in signal transduction and protein interaction
PDZ	23%	PDZ domain	may function in targeting signaling molecules to sub-membranous sites
LRR	28%	Leucine Rich Repeat	short sequence motifs involved in protein-protein interactions
pkinase	23%	Protein kinase domain	conserved catalytic core common to both serine/threonine and tyrosine protein kinases containing an ATP binding site and a catalytic site
PH	16%	PH domain	pleckstrin homology involved in intracellular signaling or as constituents of the cytoskeleton
EGF	34%	EGF-like domain	30-40 amino-acid long found in the extracellular domain of membrane-bound proteins or in secreted proteins
rvt	49%	Reverse transcriptase (RNA-dependent DNA polymerase)	
ank	25%	Ank repeat	Cytoplasmic protein, associates integral membrane proteins to the cytoskeleton
oxidored_q1	32%	NADH-Ubiquinone/plastoquinone (complex I), various chains	membrane associated. Involved in proton translocation across the membrane

Name	avrg. % identity	Description	Potential Function
<u>efhand</u>	24%	EF hand	calcium-binding domain, consists of a 12 residue loop flanked on both sides by a 12 residue alpha-helical domain
<u>rvp</u>	79%	Retroviral aspartyl protease	Aspartyl or acid proteases, centered on a catalytic aspartyl residue
<u>Collagen</u>	42%	Collagen triple helix repeat (20 copies)	extracellular structural proteins involved in formation of connective tissue. The sequence consists of the G-X-Y and the polypeptide chains forms a triple helix.
<u>fn3</u>	20%	Fibronectin type III domain	Located in the extracellular ligand-binding region of receptors and is about 200 amino acid residues long with two pairs of cysteines involved in disulfide bonds
<u>7tm_1</u>	19%	7 transmembrane receptor (rhodopsin family)	seven hydrophobic transmembrane regions, with the N-terminus located extracellularly while the C-terminus is cytoplasmic. Signal through G proteins

TABLE XXI: Properties of 108P5H8

Motifs and localization apply to 108P5H8 variants 1 and 2.

	Bioinformatic Program	URL	Outcome
ORF	ORF Finder	http://www.ncbi.nlm.gov/gorf	1290 (includes stop)
Protein Length	n/a	n/a	429 amino acids
Transmembrane region	TM Pred	http://www.ch.embnet.org/	6 TM, at amino acids 114-130, 147-163, 181-200, 217-236, 273-295, 306-324
	HMMTop	http://www.enzim.hu/hmmtop/	6 TM, at amino acid 113-130, 135-164, 179-202, 215-236, 271-296, 306-331
	Sosui	http://www.genome.ad.jp/SOSui/	6 TM, at amino acid 113-135, 141-163, 180-202, 215-237, 272-294, 308-330
	TMHMM	http://www.cbs.dtu.dk/services/TMHMM	6 TM, at amino acids 114-136, 146-165, 178-200, 215-237, 273-295, 310-332
Signal Peptide	Signal P	http://www.cbs.dtu.dk/services/SignalP/	indicates no signal
pl	pl/MW tool	http://www.expasy.ch/tools/	pl 6.11
Molecular weight	pl/MW tool	http://www.expasy.ch/tools/	47.5 kDa
Localization	PSORT	http://psort.nibb.ac.jp/	Plasma membrane 60%
	PSORT II	http://psort.nibb.ac.jp/	Plasma membrane 43%
	iPSORT	http://psort.nibb.ac.jp	No signal motif
Motifs	Pfam	http://www.sanger.ac.uk/Pfam/	Ribosomal protein L34; Cation efflux family
	Prints	http://www.biochem.ucl.ac.uk/	Rhodopsin
	Blocks	http://www.blocks.fhcrc.org/	No motif
	Prosite	http://www.genome.ad.jp/	No motif

5

Table XXII:

MHC Class 1 nonamer and decamer analysis of 108P5H8 for selected alleles. Listed are scores that fall within the top 50% (rounded up) of all scores for the selected allele.

HLA-A*0201-nomenclature										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
278	A	L	G	D	L	V	Q	S	V	30	==
121	V	L	L	F	M	I	C	E	L	29	==
153	A	I	I	L	T	L	L	A	L	28	==
137	S	L	A	I	M	T	D	A	L	27	==
75	S	L	L	D	Q	D	L	P	L	26	==
150	D	L	S	A	I	I	L	T	L	26	==
268	S	L	A	V	R	A	A	F	V	26	==
323	I	I	W	D	T	V	V	I	I	26	==
115	T	I	A	A	V	L	Y	L	L	25	==
140	I	M	T	D	A	L	H	M	L	25	==
181	V	L	S	A	M	I	S	V	L	25	==
218	M	L	I	T	A	A	V	G	V	25	==
343	Y	I	K	E	A	L	M	K	I	25	==
114	L	T	I	A	A	V	L	Y	L	23	==
122	L	L	F	M	I	C	E	L	V	23	==
146	H	M	L	T	D	L	S	A	I	23	==
155	I	L	T	L	L	A	L	W	L	23	==
185	M	I	S	V	L	L	V	Y	I	23	==
198	L	L	Y	E	A	V	Q	R	T	23	==
216	D	I	M	L	I	T	A	A	V	23	==
281	D	L	V	Q	S	V	G	V	L	23	==
330	I	I	L	E	C	V	P	S	H	23	==
331	I	L	E	C	V	P	S	H	L	23	==
409	Q	L	Q	S	Y	R	Q	E	V	23	==
13	M	L	R	K	D	D	A	P	L	22	==
68	T	L	Q	A	D	D	S	L		22	==
111	K	A	R	L	T	I	A	A	V	22	==
133	Y	I	A	N	S	L	A	I	M	22	==
183	S	A	M	I	S	V	L	L	V	22	==
306	P	I	C	T	Y	V	F	S	L	22	==
322	R	I	I	W	D	T	V	V	I	22	==
402	G	M	Y	R	C	T	I	Q	L	22	==
76	L	L	D	Q	D	L	P	L	T	21	==
147	M	L	T	D	L	S	A	I	I	21	==
193	I	L	M	G	F	L	L	Y	E	21	==
194	L	M	G	F	L	L	Y	E	A	21	==
220	I	T	A	A	V	C	V	A	V	21	==
349	M	K	I	E	D	V	Y	S	V	21	==
118	A	V	L	Y	L	L	F	M	I	20	==
124	F	M	I	C	E	L	V	G	G	20	==
158	L	L	A	L	W	L	S	S	K	20	==
178	R	L	E	V	L	S	A	M	I	20	==
212	E	I	N	C	D	I	M	L	I	20	==
222	A	A	V	C	V	A	V	N	V	20	==
270	V	R	A	A	F	V	H	A	L	20	172
80	D	L	P	L	T	N	S	Q	L	19	==
82	P	L	T	N	S	Q	L	S	L	19	==
104	T	T	K	Q	D	V	V	V	A	10	==

10024652 062302

Atty Docket: 511582002500

HLA-A*0201 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
278	A	L	G	D	L	V	Q	S	V	30	1968
121	Y	L	L	F	M	I	G	E	L	29	1969
153	A	I	I	L	T	L	L	A	L	28	1970
137	S	L	A	I	M	T	D	A	L	27	1971
75	S	L	L	D	Q	D	L	P	L	26	1972
150	D	L	S	A	I	I	L	T	L	26	1973
268	S	L	A	V	R	A	A	F	V	26	1974
323	I	I	W	D	T	V	V	I	I	26	1975
115	T	I	A	A	V	L	Y	L	L	25	1976
140	I	M	T	D	A	L	H	M	L	25	1977
181	V	L	S	A	M	I	S	V	L	25	1978
218	M	L	I	T	A	A	V	G	V	25	1979
343	Y	I	K	E	A	L	M	K	I	25	1980
114	L	T	I	A	A	V	L	Y	L	23	1981
122	L	L	F	M	I	G	E	L	V	23	1982
146	H	M	L	T	D	L	S	A	I	23	1983
155	I	L	T	L	L	A	L	W	L	23	1984
185	M	I	S	V	L	L	V	Y	I	23	1985
198	L	L	Y	E	A	V	Q	R	T	23	1986
216	D	I	M	L	I	T	A	A	V	23	1987
281	D	L	V	Q	S	V	G	V	L	23	1988
330	I	I	L	E	G	V	P	S	H	23	1989
331	I	L	E	G	V	P	S	H	L	23	1990
409	Q	L	Q	S	Y	R	Q	E	V	23	1991
13	M	L	R	K	D	D	A	P	L	22	1992
68	T	L	Q	A	D	D	D	S	L	22	1993
111	K	A	R	L	T	I	A	A	V	22	1994
133	Y	I	A	N	S	L	A	I	M	22	1995
183	S	A	M	I	S	V	L	L	V	22	1996
306	P	I	C	T	Y	V	F	S	L	22	1997
322	R	I	I	W	D	T	V	V	I	22	1998
402	G	M	Y	R	C	T	I	Q	L	22	1999
76	L	L	D	Q	D	L	P	L	T	21	2000
147	M	L	T	D	L	S	A	I	I	21	2001
193	I	L	M	G	F	L	L	Y	E	21	2002
194	L	M	G	F	L	L	Y	E	A	21	2003
220	I	T	A	A	V	G	V	A	V	21	2004
349	M	K	I	E	D	V	Y	S	V	21	2005

HLA-A*0201 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
118	A	V	L	Y	L	L	F	M	I	20	2006
124	F	M	I	G	E	L	V	G	G	20	2007
158	L	L	A	L	W	L	S	S	K	20	2008
178	R	L	E	V	L	S	A	M	I	20	2009
212	E	I	N	G	D	I	M	L	I	20	2010
222	A	A	V	G	V	A	V	N	V	20	2011
271	V	R	A	A	F	V	H	A	L	20	2012
80	D	L	P	L	T	N	S	Q	L	19	2013
82	P	L	T	N	S	Q	L	S	L	19	2014
104	I	L	K	Q	R	K	V	K	A	19	2015
143	D	A	L	H	M	L	T	D	L	19	2016
154	I	I	L	T	L	L	A	L	W	19	2017
188	V	L	L	V	Y	I	L	M	G	19	2018
223	A	V	G	V	A	V	N	V	I	19	2019
302	K	I	A	D	P	I	C	T	Y	19	2020
327	T	V	V	I	I	L	E	G	V	19	2021
364	S	L	T	S	G	K	S	T	A	19	2022
395	H	L	L	L	N	T	F	G	M	19	2023
41	S	R	F	N	K	L	R	V	V	18	2024
151	L	S	A	I	I	L	T	L	L	18	2025
186	I	S	V	L	L	V	Y	I	L	18	2026
190	L	V	Y	I	L	M	G	F	L	18	2027
230	V	I	M	G	F	L	L	N	Q	18	2028
303	I	A	D	P	I	C	T	Y	V	18	2029
346	E	A	L	M	K	I	E	D	V	18	2030
365	L	T	S	G	K	S	T	A	I	18	2031
370	S	T	A	I	V	H	I	Q	L	18	2032
371	T	A	I	V	H	I	Q	L	I	18	2033
377	Q	L	I	P	G	S	S	S	K	18	2034
45	K	L	R	V	V	V	A	D	D	17	2035
61	P	V	N	G	A	H	P	T	L	17	2036
87	Q	L	S	L	K	V	D	S	C	17	2037
184	A	M	I	S	V	L	L	V	Y	17	2038
205	R	T	I	H	M	N	Y	E	I	17	2039
219	L	I	T	A	A	V	G	V	A	17	2040
227	A	V	N	V	I	M	G	F	L	17	2041
289	L	I	A	A	Y	I	I	R	F	17	2042
308	C	T	Y	V	F	S	L	L	V	17	2043

HLA-A*0201 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
315	L	V	A	F	T	T	F	R	I	17	2044
357	V	E	D	L	N	I	W	S	L	17	2045
112	A	R	L	T	I	A	A	V	L	16	2046
117	A	A	V	L	Y	L	L	F	M	16	2047
125	M	I	G	E	L	V	G	G	Y	16	2048
139	A	I	M	T	D	A	L	H	M	16	2049
148	L	T	D	L	S	A	I	I	L	16	2050
152	S	A	I	I	L	T	L	L	A	16	2051
157	T	L	L	A	L	W	L	S	S	16	2052
174	F	G	F	H	R	L	E	V	L	16	2053
182	L	S	A	M	I	S	V	L	L	16	2054
189	L	L	V	Y	I	L	M	G	F	16	2055
211	Y	E	I	N	G	D	I	M	L	16	2056
274	A	F	V	H	A	L	G	D	L	16	2057
275	F	V	H	A	L	G	D	L	V	16	2058
280	G	D	L	V	Q	S	V	G	V	16	2059
282	L	V	Q	S	V	G	V	L	I	16	2060
287	G	V	L	I	A	A	Y	I	I	16	2061
293	Y	I	I	R	F	K	P	E	Y	16	2062
313	S	L	L	V	A	F	T	T	F	16	2063
324	I	W	D	T	V	V	I	I	L	16	2064
392	K	A	N	H	L	L	L	N	T	16	2065
5	G	A	W	K	R	L	K	S	M	15	2066
9	R	L	K	S	M	L	R	K	D	15	2067
22	F	L	N	D	T	S	A	F	D	15	2068
27	S	A	F	D	F	S	D	E	A	15	2069
69	L	Q	A	D	D	D	S	L	L	15	2070
102	R	E	I	L	K	Q	R	K	V	15	2071
129	L	V	G	G	Y	I	A	N	S	15	2072
144	A	L	H	M	L	T	D	L	S	15	2073
180	E	V	L	S	A	M	I	S	V	15	2074
192	Y	I	L	M	G	F	L	L	Y	15	2075
231	I	M	G	F	L	L	N	Q	S	15	2076
248	S	L	P	S	N	S	P	T	R	15	2077
295	I	R	F	K	P	E	Y	K	I	15	2078
310	Y	V	F	S	L	L	V	A	F	15	2079
314	L	L	V	A	F	T	T	F	R	15	2080
368	G	K	S	T	A	I	V	H	I	15	2081

HLA-A*0203 nonamers			
Pos	1 2 3 4 5 6 7 8 9	score	SEQ. ID. No.
49	V V A D D G S E A	12	850
63	N G A H P T L Q A	12	851
110	V K A R L T I A A	12	852
27	S A F D F S D E A	11	853
152	S A I I L T L L A	11	854
57	A P E R P V N G A	10	855
270	A V R A A F V H A	10	856
11	K S M L R K D D A	9	857
20	P L F L N D T S A	9	858
43	F N K L R V V V A	9	859
104	I L K Q R K V K A	9	860
109	K V K A R L T I A	9	861
127	G E L V G G Y I A	9	862
131	G G Y I A N S L A	9	863
136	N S L A I M T D A	9	864
145	L H M L T D L S A	9	865
176	F H R L E V L S A	9	866
194	L M G F L L Y E A	9	867
214	N G D I M L I T A	9	868
215	G D I M L I T A A	9	869
219	L I T A A V G V A	9	870
262	R N H G Q D S L A	9	871
265	G Q D S L A V R A	9	872
266	Q D S L A V R A A	9	873
283	V Q S V G V L I A	9	874
284	Q S V G V L I A A	9	875
296	R F K P E Y K I A	9	876
309	T Y V F S L L V A	9	877
339	L N V D Y I K E A	9	878
364	S L T S G K S T A	9	879
385	K W E E V Q S K A	9	880
414	R Q E V D R T C A	9	881

HLA-A1 nonamers			
Pos	1 2 3 4 5 6 7 8 9	score	SEQ. ID. No.

HLA-A26 nonamers									score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8		
192	Y	I	L	M	G	F	L	L	24	916
293	Y	I	I	R	F	K	P	E	24	917
115	T	I	A	A	V	L	Y	L	23	918
190	L	V	Y	I	L	M	G	F	23	919
212	E	I	N	G	D	I	M	L	23	920
306	P	I	C	T	Y	V	F	S	23	921
396	L	L	L	N	T	F	G	M	23	922
168	P	T	K	R	F	T	F	G	22	923
180	E	V	L	S	A	M	I	S	22	924
187	S	V	L	L	V	Y	I	L	22	925
227	A	V	N	V	I	M	G	F	22	926
313	S	L	L	V	A	F	T	T	22	927
61	P	V	N	G	A	H	P	T	21	928
121	Y	L	L	F	M	I	G	E	21	929
128	E	L	V	G	G	Y	I	A	21	930
181	V	L	S	A	M	I	S	V	21	931
326	D	T	V	V	I	I	L	E	21	932
38	E	G	L	S	R	F	N	K	20	933
148	L	T	D	L	S	A	I	I	20	934
331	I	L	E	G	V	P	S	H	20	935
340	N	V	D	Y	I	K	E	A	20	936
370	S	T	A	I	V	H	I	Q	20	937
35	A	G	D	E	G	L	S	R	19	938
113	R	L	T	I	A	A	V	L	19	939
139	A	I	M	T	D	A	L	H	19	940
171	R	F	T	F	G	F	H	R	19	941
343	Y	I	K	E	A	L	M	K	19	942
347	A	L	M	K	I	E	D	V	19	943
352	E	D	V	Y	S	V	E	D	19	944
416	E	V	D	R	T	C	A	N	19	945
13	M	L	R	K	D	D	A	P	18	946
21	L	F	L	N	D	T	S	A	18	947
75	S	L	L	D	Q	D	L	P	18	948
82	P	L	T	N	S	Q	L	S	18	949
103	E	I	L	K	Q	R	K	V	18	950
129	L	V	G	G	Y	I	A	N	18	951
137	S	L	A	I	M	T	D	A	18	952
143	D	A	L	H	M	L	T	D	18	953

Atty Docker: 511582002500

	HLA-A26 nonamers										
Pos	1	2	3	4	5	6	7	8	9	score	SEQ. ID. No.
216	D	I	M	L	I	T	A	A	V	18	954
267	D	S	L	A	V	R	A	A	F	18	955
274	A	F	V	H	A	L	G	D	L	18	956
330	I	I	L	E	G	V	P	S	H	18	957
399	N	T	F	G	M	Y	R	C	T	18	958
25	D	T	S	A	F	D	F	S	D	17	959
68	T	L	Q	A	D	D	D	S	L	17	960
83	L	T	N	S	Q	L	S	L	K	17	961
155	I	L	T	L	L	A	L	W	L	17	962
184	A	M	I	S	V	L	L	V	Y	17	963
230	V	I	M	G	F	L	L	N	Q	17	964
353	D	V	Y	S	V	E	D	L	N	17	965
395	H	L	L	L	N	T	F	G	M	17	966
405	R	C	T	I	Q	L	Q	S	Y	17	967
73	D	D	S	L	L	D	Q	D	L	16	968
116	I	A	A	V	L	Y	L	L	F	16	969
118	A	V	L	Y	L	L	F	M	I	16	970
154	I	I	L	T	L	L	A	L	W	16	971
177	H	R	L	E	V	L	S	A	M	16	972
185	M	I	S	V	L	L	V	Y	I	16	973
198	L	L	Y	E	A	V	Q	R	T	16	974
201	E	A	V	Q	R	T	I	H	M	16	975
225	G	V	A	V	N	V	I	M	G	16	976
226	V	A	V	N	V	I	M	G	F	16	977
229	N	V	I	M	G	F	L	L	N	16	978
270	A	V	R	A	A	F	V	H	A	16	979
278	A	L	G	D	L	V	Q	S	V	16	980
319	T	T	F	R	I	I	W	D	T	16	981
323	I	I	W	D	T	V	V	I	I	16	982
334	G	V	P	S	H	L	N	V	D	16	983
350	K	I	E	D	V	Y	S	V	E	16	984
378	L	I	P	G	S	S	S	K	W	16	985
9	R	L	K	S	M	L	R	K	D	15	986
17	D	D	A	P	L	F	L	N	D	15	987
76	L	L	D	Q	D	L	P	L	T	15	988
109	K	V	K	A	R	L	T	I	A	15	989
158	L	L	A	L	W	L	S	S	K	15	990
202	A	V	Q	R	T	I	H	M	N	15	991

HLA-A26 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
261	E	R	N	H	G	Q	D	S	L	15	992
327	T	V	V	I	I	L	E	G	V	15	993
373	I	V	H	I	Q	L	I	P	G	15	994
393	A	N	H	L	L	L	N	T	F	15	995
406	C	T	I	Q	L	Q	S	Y	R	15	996

HLA-A3 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
377	Q	L	I	P	G	S	S	S	K	35	997
113	R	L	T	I	A	A	V	L	Y	28	998
158	L	L	A	L	W	L	S	S	K	27	999
197	F	L	L	Y	E	A	V	Q	R	26	1000
103	E	I	L	K	Q	R	K	V	K	25	1001
162	W	L	S	S	K	S	P	T	K	25	1002
294	I	I	R	F	K	P	E	Y	K	25	1003
302	K	I	A	D	P	I	C	T	Y	23	1004
322	R	I	I	W	D	T	V	V	I	23	1005
347	A	L	M	K	I	E	D	V	Y	23	1006
270	A	V	R	A	A	F	V	H	A	22	1007
313	S	L	L	V	A	F	T	T	F	22	1008
192	Y	I	L	M	G	F	L	L	Y	21	1009
285	S	V	G	V	L	I	A	A	Y	21	1010
330	I	I	L	E	G	V	P	S	H	21	1011
361	N	I	W	S	L	T	S	G	K	21	1012
396	L	L	L	N	T	F	G	M	Y	21	1013
45	K	L	R	V	V	V	A	D	D	20	1014
155	I	L	T	L	L	A	L	W	L	20	1015
184	A	M	I	S	V	L	L	V	Y	20	1016
218	M	L	I	T	A	A	V	G	V	20	1017
268	S	L	A	V	R	A	A	F	V	20	1018
293	Y	I	I	R	F	K	P	E	Y	20	1019
342	D	Y	I	K	E	A	L	M	K	20	1020
350	K	I	E	D	V	Y	S	V	E	20	1021
364	S	L	T	S	G	K	S	T	A	20	1022
104	I	L	K	Q	R	K	V	K	A	19	1023
109	K	V	K	A	R	L	T	I	A	19	1024
150	D	L	S	A	I	I	L	T	L	19	1025

HLA-A3 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
153	A	I	I	L	T	L	L	A	L	19	1026
157	T	L	L	A	L	W	L	S	S	19	1027
181	V	L	S	A	M	I	S	V	L	19	1028
248	S	L	P	S	N	S	P	T	R	19	1029
288	V	L	I	A	A	Y	I	I	R	19	1030
310	Y	V	F	S	L	L	V	A	F	19	1031
328	V	V	I	I	L	E	G	V	P	19	1032
329	V	I	I	L	E	G	V	P	S	19	1033
331	I	L	E	G	V	P	S	H	L	19	1034
8	K	R	L	K	S	M	L	R	K	18	1035
49	V	V	A	D	D	G	S	E	A	18	1036
178	R	L	E	V	L	S	A	M	I	18	1037
229	N	V	I	M	G	F	L	L	N	18	1038
234	F	L	L	N	Q	S	G	H	R	18	1039
282	L	V	Q	S	V	G	V	L	I	18	1040
359	D	L	N	I	W	S	L	T	S	18	1041
397	L	L	N	T	F	G	M	Y	R	18	1042
39	G	L	S	R	F	N	K	L	R	17	1043
75	S	L	L	D	Q	D	L	P	L	17	1044
80	D	L	P	L	T	N	S	Q	L	17	1045
139	A	I	M	T	D	A	L	H	M	17	1046
193	I	L	M	G	F	L	L	Y	E	17	1047
202	A	V	Q	R	T	I	H	M	N	17	1048
223	A	V	G	V	A	V	N	V	I	17	1049
235	L	L	N	Q	S	G	H	R	H	17	1050
314	L	L	V	A	F	T	T	F	R	17	1051
411	Q	S	Y	R	Q	E	V	D	R	17	1052

HLA-B*0702 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
57	A	P	E	R	P	V	N	G	A	22	1053
60	R	P	V	N	G	A	H	P	T	18	1054
2	A	G	S	G	A	W	K	R	L	16	1055
13	M	L	R	K	D	D	A	P	L	15	1056
15	R	K	D	D	A	P	L	F	L	15	1057
106	K	Q	R	K	V	K	A	R	L	15	1058

~~Atty Docket: 511582002500~~

	HLA-B*0702 nonamers		
Pos	1 2 3 4 5 6 7 8 9	score	SEQ. ID. No.
150	D L S A I I L T L	15	1059
153	A I I L T L L A L	15	1060
97	N C S K Q R E I L	14	1061
112	A R L T I A A V L	14	1062
114	L T I A A V L Y L	14	1063
167	S P T K R F T F G	14	1064
181	V L S A M I S V L	14	1065
270	A V R A A F V H A	14	1066
271	V R A A F V H A L	14	1067
335	V P S H L N V D Y	14	1068
61	P V N G A H P T L	13	1069
63	N G A H P T L Q A	13	1070
75	S L L D Q D L P L	13	1071
137	S L A I M T D A L	13	1072
155	I L T L L A L W L	13	1073
182	L S A M I S V L L	13	1074
220	I T A A V G V A V	13	1075
227	A V N V I M G F L	13	1076
249	L P S N S P T R G	13	1077
305	D P I C T Y V F S	13	1078
324	I W D T V V I I L	13	1079
331	I L E G V P S H L	13	1080
389	V Q S K A N H L L	13	1081
390	Q S K A N H L L L	13	1082
6	A W K R L K S M L	12	1083
19	A P L F L N D T S	12	1084
38	E G L S R F N K L	12	1085
42	R F N K L R V V V	12	1086
73	D D S L L D Q D L	12	1087
82	P L T N S Q L S L	12	1088
115	T I A A V L Y L L	12	1089
151	L S A I I L T L L	12	1090
171	R F T F G F H R L	12	1091
186	I S V L L V Y I L	12	1092
222	A A V G V A V N V	12	1093
274	A F V H A L G D L	12	1094
281	D L V Q S V G V L	12	1095
298	K P E Y K I A D P	12	1096

HLA-B*0702 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
307	I	C	T	Y	V	F	S	L	L	12	1097
340	N	V	D	Y	I	K	E	A	L	12	1098
352	E	D	V	Y	S	V	E	D	L	12	1099
365	L	T	S	G	K	S	T	A	I	12	1100
379	I	P	G	S	S	S	K	W	E	12	1101
32	S	D	E	A	G	D	E	G	L	11	1102
54	G	S	E	A	P	E	R	P	V	11	1103
68	T	L	Q	A	D	D	D	S	L	11	1104
69	L	Q	A	D	D	D	S	L	L	11	1105
108	R	K	V	K	A	R	L	T	I	11	1106
111	K	A	R	L	T	I	A	A	V	11	1107
117	A	A	V	L	Y	L	L	F	M	11	1108
130	V	G	G	Y	I	A	N	S	L	11	1109
139	A	I	M	T	D	A	L	H	M	11	1110
140	I	M	T	D	A	L	H	M	L	11	1111
143	D	A	L	H	M	L	T	D	L	11	1112
148	L	T	D	L	S	A	I	I	L	11	1113
174	F	G	F	H	R	L	E	V	L	11	1114
176	F	H	R	L	E	V	L	S	A	11	1115
190	L	V	Y	I	L	M	G	F	L	11	1116
191	V	Y	I	L	M	G	F	L	L	11	1117
223	A	V	G	V	A	V	N	V	I	11	1118
228	V	N	V	I	M	G	F	L	L	11	1119
261	E	R	N	H	G	Q	D	S	L	11	1120
283	V	Q	S	V	G	V	L	I	A	11	1121
295	I	R	F	K	P	E	Y	K	I	11	1122
306	P	I	C	T	Y	V	F	S	L	11	1123
311	V	F	S	L	L	V	A	F	T	11	1124
322	R	I	I	W	D	T	V	V	I	11	1125
357	V	E	D	L	N	I	W	S	L	11	1126
370	S	T	A	I	V	H	I	Q	L	11	1127
388	E	V	Q	S	K	A	N	H	L	11	1128
402	G	M	Y	R	C	T	I	Q	L	11	1129

HLA-B*08 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
104	I	L	K	Q	R	K	V	K	A	26	1130

Att. Docket-514582002500-

HLA-B*08 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
13	M	L	R	K	D	D	A	P	L	22	1131
43	F	N	K	L	R	V	V	V	A	22	1132
343	Y	I	K	E	A	L	M	K	I	22	1133
388	E	V	Q	S	K	A	N	H	L	22	1134
107	Q	R	K	V	K	A	R	L	T	21	1135
294	I	I	R	F	K	P	E	Y	K	21	1136
6	A	W	K	R	L	K	S	M	L	20	1137
38	E	G	L	S	R	F	N	K	L	20	1138
390	Q	S	K	A	N	H	L	L	L	20	1139
89	S	L	K	V	D	S	C	D	N	19	1140
137	S	L	A	I	M	T	D	A	L	19	1141
164	S	S	K	S	P	T	K	R	F	19	1142
174	F	G	F	H	R	L	E	V	L	19	1143
75	S	L	L	D	Q	D	L	P	L	18	1144
80	D	L	P	L	T	N	S	Q	L	18	1145
87	Q	L	S	L	K	V	D	S	C	18	1146
98	C	S	K	Q	R	E	I	L	K	18	1147
109	K	V	K	A	R	L	T	I	A	18	1148
121	Y	L	L	F	M	I	G	E	L	18	1149
155	I	L	T	L	L	A	L	W	L	18	1150
181	V	L	S	A	M	I	S	V	L	18	1151
298	K	P	E	Y	K	I	A	D	P	18	1152
7	W	K	R	L	K	S	M	L	R	17	1153
56	E	A	P	E	R	P	V	N	G	17	1154
96	D	N	C	S	K	Q	R	E	I	17	1155
150	D	L	S	A	I	I	L	T	L	17	1156
268	S	L	A	V	R	A	A	F	V	17	1157
281	D	L	V	Q	S	V	G	V	L	17	1158
331	I	L	E	G	V	P	S	H	L	17	1159
346	E	A	L	M	K	I	E	D	V	17	1160
365	L	T	S	G	K	S	T	A	I	17	1161
9	R	L	K	S	M	L	R	K	D	16	1162
14	L	R	K	D	D	A	P	L	F	16	1163
68	T	L	Q	A	D	D	D	S	L	16	1164
82	P	L	T	N	S	Q	L	S	L	16	1165
106	K	Q	R	K	V	K	A	R	L	16	1166
153	A	I	I	L	T	L	L	A	L	16	1167
162	W	L	S	S	K	S	P	T	K	16	1168

HLA-B*08 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
166	K	S	P	T	K	R	F	T	F	16	1169
167	S	P	T	K	R	F	T	F	G	16	1170
168	P	T	K	R	F	T	F	G	F	16	1171
306	P	I	C	T	Y	V	F	S	L	15	1172
313	S	L	L	V	A	F	T	T	F	15	1173
5	G	A	W	K	R	L	K	S	M	14	1174
45	K	L	R	V	V	V	A	D	D	14	1175
115	T	I	A	A	V	L	Y	L	L	14	1176
143	D	A	L	H	M	L	T	D	L	14	1177
201	E	A	V	Q	R	T	I	H	M	14	1178
352	E	D	V	Y	S	V	E	D	L	14	1179
12	S	M	L	R	K	D	D	A	P	13	1180
105	L	K	Q	R	K	V	K	A	R	13	1181
111	K	A	R	L	T	I	A	A	V	13	1182
178	R	L	E	V	L	S	A	M	I	13	1183
186	I	S	V	L	L	V	Y	I	L	13	1184
189	L	L	V	Y	I	L	M	G	F	13	1185
212	E	I	N	G	D	I	M	L	I	13	1186
258	S	G	C	E	R	N	H	G	Q	13	1187
271	V	R	A	A	F	V	H	A	L	13	1188
323	I	I	W	D	T	V	V	I	I	13	1189
357	V	E	D	L	N	I	W	S	L	13	1190
383	S	S	K	W	E	E	V	Q	S	13	1191

5

HLA-B*1510 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
331	I	L	E	G	V	P	S	H	L	15	1192
2	A	G	S	G	A	W	K	R	L	14	1193
106	K	Q	R	K	V	K	A	R	L	14	1194
181	V	L	S	A	M	I	S	V	L	14	1195
276	V	H	A	L	G	D	L	V	Q	14	1196
281	D	L	V	Q	S	V	G	V	L	14	1197
61	P	V	N	G	A	H	P	T	L	13	1198
97	N	C	S	K	Q	R	E	I	L	13	1199
121	Y	L	L	F	M	I	G	E	L	13	1200

HLA-B*1510 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
140	I	M	T	D	A	L	H	M	L	13	1201
150	D	L	S	A	I	I	L	T	L	13	1202
171	R	F	T	F	G	F	H	R	L	13	1203
182	L	S	A	M	I	S	V	L	L	13	1204
186	I	S	V	L	L	V	Y	I	L	13	1205
271	V	R	A	A	F	V	H	A	L	13	1206
324	I	W	D	T	V	V	I	I	L	13	1207
374	V	H	I	Q	L	I	P	G	S	13	1208
15	R	K	D	D	A	P	L	F	L	12	1209
32	S	D	E	A	G	D	E	G	L	12	1210
69	L	Q	A	D	D	D	S	L	L	12	1211
112	A	R	L	T	I	A	A	V	L	12	1212
115	T	I	A	A	V	L	Y	L	L	12	1213
137	S	L	A	I	M	T	D	A	L	12	1214
155	I	L	T	L	L	A	L	W	L	12	1215
174	F	G	F	H	R	L	E	V	L	12	1216
207	I	H	M	N	Y	E	I	N	G	12	1217
211	Y	E	I	N	G	D	I	M	L	12	1218
227	A	V	N	V	I	M	G	F	L	12	1219
244	S	H	S	H	S	L	P	S	N	12	1220
246	S	H	S	L	P	S	N	S	P	12	1221
261	E	R	N	H	G	Q	D	S	L	12	1222
263	N	H	G	Q	D	S	L	A	V	12	1223
307	I	C	T	Y	V	F	S	L	L	12	1224
340	N	V	D	Y	I	K	E	A	L	12	1225
352	E	D	V	Y	S	V	E	D	L	12	1226
357	V	E	D	L	N	I	W	S	L	12	1227
389	V	Q	S	K	A	N	H	L	L	12	1228
6	A	W	K	R	L	K	S	M	L	11	1229
13	M	L	R	K	D	D	A	P	L	11	1230
38	E	G	L	S	R	F	N	K	L	11	1231
68	T	L	Q	A	D	D	D	S	L	11	1232
73	D	D	S	L	L	D	Q	D	L	11	1233
75	S	L	L	D	Q	D	L	P	L	11	1234
114	L	T	I	A	A	V	L	Y	L	11	1235
151	L	S	A	I	I	L	T	L	L	11	1236
153	A	I	I	L	T	L	L	A	L	11	1237
176	F	H	R	L	E	V	L	S	A	11	1238

HLA-B*1510 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
190	L	V	Y	I	L	M	G	F	L	11	1239
240	G	H	R	H	S	H	S	H	S	11	1240
242	R	H	S	H	S	H	S	L	P	11	1241
306	P	I	C	T	Y	V	F	S	L	11	1242
370	S	T	A	I	V	H	I	Q	L	11	1243
388	E	V	Q	S	K	A	N	H	L	11	1244
390	Q	S	K	A	N	H	L	L	L	11	1245
402	G	M	Y	R	C	T	I	Q	L	11	1246
35	A	G	D	E	G	L	S	R	F	10	1247
65	A	H	P	T	L	Q	A	D	D	10	1248
80	D	L	P	L	T	N	S	Q	L	10	1249
82	P	L	T	N	S	Q	L	S	L	10	1250
116	I	A	A	V	L	Y	L	L	F	10	1251
130	V	G	G	Y	I	A	N	S	L	10	1252
143	D	A	L	H	M	L	T	D	L	10	1253
145	L	H	M	L	T	D	L	S	A	10	1254
148	L	T	D	L	S	A	I	I	L	10	1255
191	V	Y	I	L	M	G	F	L	L	10	1256
228	V	N	V	I	M	G	F	L	L	10	1257
241	H	R	H	S	H	S	H	S	L	10	1258
274	A	F	V	H	A	L	G	D	L	10	1259
289	L	I	A	A	Y	I	I	R	F	10	1260
310	Y	V	F	S	L	L	V	A	F	10	1261
337	S	H	L	N	V	D	Y	I	K	10	1262
394	N	H	L	L	L	N	T	F	G	10	1263
164	S	S	K	S	P	T	K	R	F	9	1264
5	G	A	W	K	R	L	K	S	M	8	1265
14	L	R	K	D	D	A	P	L	F	8	1266
133	Y	I	A	N	S	L	A	I	M	8	1267
166	K	S	P	T	K	R	F	T	F	8	1268
177	H	R	L	E	V	L	S	A	M	8	1269
201	E	A	V	Q	R	T	I	H	M	8	1270
210	N	Y	E	I	N	G	D	I	M	8	1271
224	V	G	V	A	V	N	V	I	M	8	1272
267	D	S	L	A	V	R	A	A	F	8	1273
304	A	D	P	I	C	T	Y	V	F	8	1274
313	S	L	L	V	A	F	T	T	F	8	1275
21	L	F	L	N	D	T	S	A	F	7	1276

HLA-B*1510 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
55	S	E	A	P	E	R	P	V	N	7	1277
221	T	A	A	V	G	V	A	V	N	7	1278
226	V	A	V	N	V	I	M	G	F	7	1279
393	A	N	H	L	L	L	N	T	F	7	1280
395	H	L	L	L	N	T	F	G	M	7	1281

5

HLA-B*2705 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
8	K	R	L	K	S	M	L	R	K	30	1282
112	A	R	L	T	I	A	A	V	L	27	1283
295	I	R	F	K	P	E	Y	K	I	26	1284
170	K	R	F	T	F	G	F	H	R	25	1285
261	E	R	N	H	G	Q	D	S	L	25	1286
101	Q	R	E	I	L	K	Q	R	K	24	1287
177	H	R	L	E	V	L	S	A	M	24	1288
14	L	R	K	D	D	A	P	L	F	22	1289
241	H	R	H	S	H	S	H	S	L	22	1290
271	V	R	A	A	F	V	H	A	L	21	1291
106	K	Q	R	K	V	K	A	R	L	19	1292
35	A	G	D	E	G	L	S	R	F	18	1293
171	R	F	T	F	G	F	H	R	L	18	1294
377	Q	L	I	P	G	S	S	S	K	18	1295
406	C	T	I	Q	L	Q	S	Y	R	18	1296
163	L	S	S	K	S	P	T	K	R	17	1297
233	G	F	L	L	N	Q	S	G	H	17	1298
330	I	I	L	E	G	V	P	S	H	17	1299
342	D	Y	I	K	E	A	L	M	K	17	1300
402	G	M	Y	R	C	T	I	Q	L	17	1301
1	M	A	G	S	G	A	W	K	R	16	1302
41	S	R	F	N	K	L	R	V	V	16	1303
100	K	Q	R	E	I	L	K	Q	R	16	1304
121	Y	L	L	F	M	I	G	E	L	16	1305
150	D	L	S	A	I	I	L	T	L	16	1306
153	A	I	I	L	T	L	L	A	L	16	1307
186	I	S	V	L	L	V	Y	I	L	16	1308

Atty Docket: 511582002500

HLA-B*2705 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
197	F	L	L	Y	E	A	V	Q	R	16	1309
211	Y	E	I	N	G	D	I	M	L	16	1310
226	V	A	V	N	V	I	M	G	F	16	1311
256	R	G	S	G	C	E	R	N	H	16	1312
281	D	L	V	Q	S	V	G	V	L	16	1313
289	L	I	A	A	Y	I	I	R	F	16	1314
310	Y	V	F	S	L	L	V	A	F	16	1315
321	F	R	I	I	W	D	T	V	V	16	1316
357	V	E	D	L	N	I	W	S	L	16	1317
387	E	E	V	Q	S	K	A	N	H	16	1318
393	A	N	H	L	L	L	N	T	F	16	1319
2	A	G	S	G	A	W	K	R	L	15	1320
5	G	A	W	K	R	L	K	S	M	15	1321
15	R	K	D	D	A	P	L	F	L	15	1322
38	E	G	L	S	R	F	N	K	L	15	1323
82	P	L	T	N	S	Q	L	S	L	15	1324
103	E	I	L	K	Q	R	K	V	K	15	1325
108	R	K	V	K	A	R	L	T	I	15	1326
143	D	A	L	H	M	L	T	D	L	15	1327
155	I	L	T	L	L	A	L	W	L	15	1328
174	F	G	F	H	R	L	E	V	L	15	1329
181	V	L	S	A	M	I	S	V	L	15	1330
184	A	M	I	S	V	L	L	V	Y	15	1331
205	R	T	I	H	M	N	Y	E	I	15	1332
290	I	A	A	Y	I	I	R	F	K	15	1333
302	K	I	A	D	P	I	C	T	Y	15	1334
313	S	L	L	V	A	F	T	T	F	15	1335
331	I	L	E	G	V	P	S	H	L	15	1336
337	S	H	L	N	V	D	Y	I	K	15	1337
404	Y	R	C	T	I	Q	L	Q	S	15	1338

HLA-B*2709 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
112	A	R	L	T	I	A	A	V	L	25	1339
295	I	R	F	K	P	E	Y	K	I	22	1340
14	L	R	K	D	D	A	P	L	F	21	1341

Atty Docker: 311582002300

HLA-B*2709 nonamers									score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8		
241	H	R	H	S	H	S	H	S	21	1342
271	V	R	A	A	F	V	H	A	21	1343
41	S	R	F	N	K	L	R	V	20	1344
177	H	R	L	E	V	L	S	A	20	1345
261	E	R	N	H	G	Q	D	S	20	1346
321	F	R	I	I	W	D	T	V	19	1347
8	K	R	L	K	S	M	L	R	16	1348
171	R	F	T	F	G	F	H	R	16	1349
402	G	M	Y	R	C	T	I	Q	16	1350
15	R	K	D	D	A	P	L	F	15	1351
287	G	V	L	I	A	A	Y	I	15	1352
322	R	I	I	W	D	T	V	V	15	1353
108	R	K	V	K	A	R	L	T	14	1354
155	I	L	T	L	L	A	L	W	14	1355
170	K	R	F	T	F	G	F	H	14	1356
186	I	S	V	L	L	V	Y	I	14	1357
205	R	T	I	H	M	N	Y	E	14	1358
280	G	D	L	V	Q	S	V	G	14	1359
38	E	G	L	S	R	F	N	K	13	1360
42	R	F	N	K	L	R	V	V	13	1361
75	S	L	L	D	Q	D	L	P	13	1362
102	R	E	I	L	K	Q	R	K	13	1363
106	K	Q	R	K	V	K	A	R	13	1364
114	L	T	I	A	A	V	L	Y	13	1365
132	G	Y	I	A	N	S	L	A	13	1366
153	A	I	I	L	T	L	L	A	13	1367
222	A	A	V	G	V	A	V	N	13	1368
404	Y	R	C	T	I	Q	L	Q	13	1369
2	A	G	S	G	A	W	K	R	12	1370
46	L	R	V	V	V	A	D	D	12	1371
82	P	L	T	N	S	Q	L	S	12	1372
121	Y	L	L	F	M	I	G	E	12	1373
130	V	G	G	Y	I	A	N	S	12	1374
139	A	I	M	T	D	A	L	H	12	1375
140	I	M	T	D	A	L	H	M	12	1376
143	D	A	L	H	M	L	T	D	12	1377
150	D	L	S	A	I	I	L	T	12	1378

HLA-B*2709 nonamers										score	SEQ. ID.	
Pos	1	2	3	4	5	6	7	8	9		No.	
174	F	G	F	H	R	L	E	V	L	12	1379	
178	R	L	E	V	L	S	A	M	I	12	1380	
182	L	S	A	M	I	S	V	L	L	12	1381	
190	L	V	Y	I	L	M	G	F	L	12	1382	
227	A	V	N	V	I	M	G	F	L	12	1383	
255	T	R	G	S	G	C	E	R	N	12	1384	
274	A	F	V	H	A	L	G	D	L	12	1385	
281	D	L	V	Q	S	V	G	V	L	12	1386	
299	P	E	Y	K	I	A	D	P	I	12	1387	
307	I	C	T	Y	V	F	S	L	L	12	1388	
310	Y	V	F	S	L	L	V	A	F	12	1389	
324	I	W	D	T	V	V	I	I	L	12	1390	
333	E	G	V	P	S	H	L	N	V	12	1391	
349	M	K	I	E	D	V	Y	S	V	12	1392	
352	E	D	V	Y	S	V	E	D	L	12	1393	
368	G	K	S	T	A	I	V	H	I	12	1394	
381	G	S	S	S	K	W	E	E	V	12	1395	
388	E	V	Q	S	K	A	N	H	L	12	1396	
418	D	R	T	C	A	N	C	Q	S	12	1397	

HLA-B*5101 nonamers										score	SEQ. ID.	
Pos	1	2	3	4	5	6	7	8	9		No.	
316	V	A	F	T	T	F	R	I	I	26	1398	
143	D	A	L	H	M	L	T	D	L	25	1399	
222	A	A	V	G	V	A	V	N	V	23	1400	
183	S	A	M	I	S	V	L	L	V	22	1401	
346	E	A	L	M	K	I	E	D	V	22	1402	
371	T	A	I	V	H	I	Q	L	I	22	1403	
303	I	A	D	P	I	C	T	Y	V	21	1404	
111	K	A	R	L	T	I	A	A	V	20	1405	
126	I	G	E	L	V	G	G	Y	I	20	1406	
38	E	G	L	S	R	F	N	K	L	18	1407	
174	F	G	F	H	R	L	E	V	L	18	1408	
199	L	Y	E	A	V	Q	R	T	I	18	1409	
209	M	N	Y	E	I	N	G	D	I	18	1410	
286	V	G	V	L	I	A	A	Y	I	18	1411	

Pos	HLA-B*5101 nonamers									score	SEQ. ID. No.
	1	2	3	4	5	6	7	8	9		
323	I	I	W	D	T	V	V	I	I	18	1412
18	D	A	P	L	F	L	N	D	T	17	1413
343	Y	I	K	E	A	L	M	K	I	17	1414
96	D	N	C	S	K	Q	R	E	I	16	1415
159	L	A	L	W	L	S	S	K	S	16	1416
195	M	G	F	L	L	Y	E	A	V	16	1417
221	T	A	A	V	G	V	A	V	N	16	1418
223	A	V	G	V	A	V	N	V	I	16	1419
249	L	P	S	N	S	P	T	R	G	16	1420
269	L	A	V	R	A	A	F	V	H	16	1421
281	D	L	V	Q	S	V	G	V	L	16	1422
291	A	A	Y	I	I	R	F	K	P	16	1423
295	I	R	F	K	P	E	Y	K	I	16	1424
299	P	E	Y	K	I	A	D	P	I	16	1425
305	D	P	I	C	T	Y	V	F	S	16	1426
333	E	G	V	P	S	H	L	N	V	16	1427
2	A	G	S	G	A	W	K	R	L	15	1428
19	A	P	L	F	L	N	D	T	S	15	1429
41	S	R	F	N	K	L	R	V	V	15	1430
56	E	A	P	E	R	P	V	N	G	15	1431
81	L	P	L	T	N	S	Q	L	S	15	1432
130	V	G	G	Y	I	A	N	S	L	15	1433
150	D	L	S	A	I	I	L	T	L	15	1434
277	H	A	L	G	D	L	V	Q	S	15	1435
282	L	V	Q	S	V	G	V	L	I	15	1436
365	L	T	S	G	K	S	T	A	I	15	1437
1	M	A	G	S	G	A	W	K	R	14	1438
5	G	A	W	K	R	L	K	S	M	14	1439
53	D	G	S	E	A	P	E	R	P	14	1440
108	R	K	V	K	A	R	L	T	I	14	1441
134	I	A	N	S	L	A	I	M	T	14	1442
146	H	M	L	T	D	L	S	A	I	14	1443
220	I	T	A	A	V	G	V	A	V	14	1444
226	V	A	V	N	V	I	M	G	F	14	1445
290	I	A	A	Y	I	I	R	F	K	14	1446
315	L	V	A	F	T	T	F	R	I	14	1447
322	R	I	I	W	D	T	V	V	I	14	1448
324	I	W	D	T	V	V	I	I	L	14	1449

HLA-B*5101 nonamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
368	G	K	S	T	A	I	V	H	I	14	1450
379	I	P	G	S	S	S	K	W	E	14	1451
400	T	F	G	M	Y	R	C	T	I	14	1452
42	R	F	N	K	L	R	V	V	V	13	1453
57	A	P	E	R	P	V	N	G	A	13	1454
80	D	L	P	L	T	N	S	Q	L	13	1455
112	A	R	L	T	I	A	A	V	L	13	1456
116	I	A	A	V	L	Y	L	L	F	13	1457
117	A	A	V	L	Y	L	L	F	M	13	1458
118	A	V	L	Y	L	L	F	M	I	13	1459
138	L	A	I	M	T	D	A	L	H	13	1460
167	S	P	T	K	R	F	T	F	G	13	1461
181	V	L	S	A	M	I	S	V	L	13	1462
185	M	I	S	V	L	L	V	Y	I	13	1463
273	A	A	F	V	H	A	L	G	D	13	1464
279	L	G	D	L	V	Q	S	V	G	13	1465
287	G	V	L	I	A	A	Y	I	I	13	1466
308	C	T	Y	V	F	S	L	L	V	13	1467
321	F	R	I	I	W	D	T	V	V	13	1468
331	I	L	E	G	V	P	S	H	L	13	1469
335	V	P	S	H	L	N	V	D	Y	13	1470
349	M	K	I	E	D	V	Y	S	V	13	1471

HLA-A*0201 decamers											score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9	0		
139	A	I	M	T	D	A	L	H	M	L	26	1472
184	A	M	I	S	V	L	L	V	Y	I	26	1473
193	I	L	M	G	F	L	L	Y	E	A	26	1474
323	I	I	W	D	T	V	V	I	I	L	26	1475
348	L	M	K	I	E	D	V	Y	S	V	26	1476
198	L	L	Y	E	A	V	Q	R	T	I	25	1477
217	I	M	L	I	T	A	A	V	G	V	25	1478
12	S	M	L	R	K	D	D	A	P	L	24	1479
75	S	L	L	D	Q	D	L	P	L	T	24	1480
113	R	L	T	I	A	A	V	L	Y	L	24	1481
152	S	A	I	I	L	T	L	L	A	L	24	1482
277	H	A	L	G	D	L	V	Q	S	V	24	1483

Atty Docker: 511582002500

HLA-A*0201 decamers											score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9	0		
322	R	I	I	W	D	T	V	V	I	I	24	1484
330	I	I	L	E	G	V	P	S	H	L	24	1485
114	L	T	I	A	A	V	L	Y	L	L	23	1486
121	Y	L	L	F	M	I	G	E	L	V	23	1487
150	D	L	S	A	I	I	L	T	L	L	23	1488
154	I	I	L	T	L	L	A	L	W	L	23	1489
181	V	L	S	A	M	I	S	V	L	L	23	1490
185	M	I	S	V	L	L	V	Y	I	L	23	1491
39	G	L	S	R	F	N	K	L	R	V	22	1492
219	L	I	T	A	A	V	G	V	A	V	22	1493
270	A	V	R	A	A	F	V	H	A	L	22	1494
302	K	I	A	D	P	I	C	T	Y	V	22	1495
356	S	V	E	D	L	N	I	W	S	L	22	1496
129	L	V	G	G	Y	I	A	N	S	L	21	1497
172	F	T	F	G	F	H	R	L	E	V	21	1498
189	L	L	V	Y	I	L	M	G	F	L	21	1499
222	A	A	V	G	V	A	V	N	V	I	21	1500
273	A	A	F	V	H	A	L	G	D	L	21	1501
68	T	L	Q	A	D	D	D	S	L	L	20	1502
83	L	T	N	S	Q	L	S	L	K	V	20	1503
110	V	K	A	R	L	T	I	A	A	V	20	1504
120	L	Y	L	L	F	M	I	G	E	L	20	1505
146	H	M	L	T	D	L	S	A	I	I	20	1506
147	M	L	T	D	L	S	A	I	I	L	20	1507
194	L	M	G	F	L	L	Y	E	A	V	20	1508
197	F	L	L	Y	E	A	V	Q	R	T	20	1509
218	M	L	I	T	A	A	V	G	V	A	20	1510
294	I	I	R	F	K	P	E	Y	K	I	20	1511
314	L	L	V	A	F	T	T	F	R	I	20	1512
338	H	L	N	V	D	Y	I	K	E	A	20	1513
364	S	L	T	S	G	K	S	T	A	I	20	1514
365	L	T	S	G	K	S	T	A	I	V	20	1515
370	S	T	A	I	V	H	I	Q	L	I	20	1516
144	A	L	H	M	L	T	D	L	S	A	19	1517
149	T	D	L	S	A	I	I	L	T	L	19	1518
182	L	S	A	M	I	S	V	L	L	V	19	1519
281	D	L	V	Q	S	V	G	V	L	I	19	1520
117	A	A	V	L	Y	L	L	F	M	I	18	1521

Atty Docket: 511582002500

	HLA-A*0201 decamers		
Pos	1 2 3 4 5 6 7 8 9 0	score	SEQ. ID. No.
124	F M I G E L V G G Y	18	1522
125	M I G E L V G G Y I	18	1523
153	A I I L T L L A L W	18	1524
157	T L L A L W L S S K	18	1525
188	V L L V Y I L M G F	18	1526
221	T A A V G V A V N V	18	1527
326	D T V V I I L E G V	18	1528
329	V I I L E G V P S H	18	1529
81	L P L T N S Q L S L	17	1530
111	K A R L T I A A V L	17	1531
116	I A A V L Y L L F M	17	1532
160	A L W L S S K S P T	17	1533
180	E V L S A M I S V L	17	1534
190	L V Y I L M G F L L	17	1535
192	Y I L M G F L L Y E	17	1536
227	A V N V I M G F L L	17	1537
230	V I M G F L L N Q S	17	1538
280	G D L V Q S V G V L	17	1539
288	V L I A A Y I I R F	17	1540
305	D P I C T Y V F S L	17	1541
310	Y V F S L L V A F T	17	1542
319	T T F R I I W D T V	17	1543
345	K E A L M K I E D V	17	1544
399	N T F G M Y R C T I	17	1545
5	G A W K R L K S M L	16	1546
133	Y I A N S L A I M T	16	1547
137	S L A I M T D A L H	16	1548
142	T D A L H M L T D L	16	1549
145	L H M L T D L S A I	16	1550
158	L L A L W L S S K S	16	1551
208	H M N Y E I N G D I	16	1552
211	Y E I N G D I M L I	16	1553
215	G D I M L I T A A V	16	1554
285	S V G V L I A A Y I	16	1555
289	L I A A Y I I R F K	16	1556
351	I E D V Y S V E D L	16	1557
359	D L N I W S L T S G	16	1558
377	Q L I P G S S S K W	16	1559

Pos	HLA-A*0201 decamers										score	SEQ. ID. No.
	1	2	3	4	5	6	7	8	9	0		
408	I	Q	L	Q	S	Y	R	Q	E	V	16	1560
40	L	S	R	F	N	K	L	R	V	V	15	1561
41	S	R	F	N	K	L	R	V	V	V	15	1562
67	P	T	L	Q	A	D	D	D	S	L	15	1563
76	L	L	D	Q	D	L	P	L	T	N	15	1564
103	E	I	L	K	Q	R	K	V	K	A	15	1565
104	I	L	K	Q	R	K	V	K	A	R	15	1566
128	E	L	V	G	G	Y	I	A	N	S	15	1567
155	I	L	T	L	L	A	L	W	L	S	15	1568
226	V	A	V	N	V	I	M	G	F	L	15	1569
279	L	G	D	L	V	Q	S	V	G	V	15	1570
282	L	V	Q	S	V	G	V	L	I	A	15	1571
306	P	I	C	T	Y	V	F	S	L	L	15	1572
315	L	V	A	F	T	T	F	R	I	I	15	1573
342	D	Y	I	K	E	A	L	M	K	I	15	1574
347	A	L	M	K	I	E	D	V	Y	S	15	1575
367	S	G	K	S	T	A	I	V	H	I	15	1576
31	F	S	D	E	A	G	D	E	G	L	14	1577
79	Q	D	L	P	L	T	N	S	Q	L	14	1578
105	L	K	Q	R	K	V	K	A	R	L	14	1579
122	L	L	F	M	I	G	E	L	V	G	14	1580
140	I	M	T	D	A	L	H	M	L	T	14	1581
148	L	T	D	L	S	A	I	I	L	T	14	1582
177	H	R	L	E	V	L	S	A	M	I	14	1583
179	L	E	V	L	S	A	M	I	S	V	14	1584
220	I	T	A	A	V	G	V	A	V	N	14	1585
234	F	L	L	N	Q	S	G	H	R	H	14	1586
240	G	H	R	H	S	H	S	H	S	L	14	1587
262	R	N	H	G	Q	D	S	L	A	V	14	1588
268	S	L	A	V	R	A	A	F	V	H	14	1589
308	C	T	Y	V	F	S	L	L	V	A	14	1590
313	S	L	L	V	A	F	T	T	F	R	14	1591
331	I	L	E	G	V	P	S	H	L	N	14	1592
339	L	N	V	D	Y	I	K	E	A	L	14	1593
372	A	I	V	H	I	Q	L	I	P	G	14	1594
396	L	L	L	N	T	F	G	M	Y	R	14	1595
397	L	L	N	T	F	G	M	Y	R	C	14	1596
402	G	M	Y	R	C	T	I	Q	L	Q	14	1597

HLA-A*0201 decamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
1	M	A	G	S	G	A	W	K	R	L	1598
4	S	G	A	W	K	R	L	K	S	M	1599
14	L	R	K	D	D	A	P	L	F	L	1600
22	F	L	N	D	T	S	A	F	D	F	1601
56	E	A	P	E	R	P	V	N	G	A	1602
60	R	P	V	N	G	A	H	P	T	L	1603
119	V	L	Y	L	L	F	M	I	G	E	1604
132	G	Y	I	A	N	S	L	A	I	M	1605
134	I	A	N	S	L	A	I	M	T	D	1606
136	N	S	L	A	I	M	T	D	A	L	1607
138	L	A	I	M	T	D	A	L	H	M	1608
170	K	R	F	T	F	G	F	H	R	L	1609
173	T	F	G	F	H	R	L	E	V	L	1610
187	S	V	L	L	V	Y	I	L	M	G	1611
212	E	I	N	G	D	I	M	L	I	T	1612
213	I	N	G	D	I	M	L	I	T	A	1613
235	L	L	N	Q	S	G	H	R	H	S	1614
267	D	S	L	A	V	R	A	A	F	V	1615
278	A	L	G	D	L	V	Q	S	V	G	1616
321	F	R	I	I	W	D	T	V	V	I	1617
332	L	E	G	V	P	S	H	L	N	V	1618
335	V	P	S	H	L	N	V	D	Y	I	1619
350	K	I	E	D	V	Y	S	V	E	D	1620
353	D	V	Y	S	V	E	D	L	N	I	1621
391	S	K	A	N	H	L	L	L	N	T	1622
392	K	A	N	H	L	L	L	N	T	F	1623

HLA-A*0203 decamers										score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9		
109	K	V	K	A	R	L	T	I	A	A	1624
214	N	G	D	I	M	L	I	T	A	A	1625
265	G	Q	D	S	L	A	V	R	A	A	1626
283	V	Q	S	V	G	V	L	I	A	A	1627
110	V	K	A	R	L	T	I	A	A	V	1628
215	G	D	I	M	L	I	T	A	A	V	1629
266	Q	D	S	L	A	V	R	A	A	F	1630
284	Q	S	V	G	V	L	I	A	A	Y	1631

Atty Docket: S11582002500

Pos	HLA-A*0203 decamers										score	SEQ. ID. No.
	1	2	3	4	5	6	7	8	9	0		
10	L	K	S	M	L	R	K	D	D	A	10	1632
19	A	P	L	F	L	N	D	T	S	A	10	1633
26	T	S	A	F	D	F	S	D	E	A	10	1634
42	R	F	N	K	L	R	V	V	V	A	10	1635
48	V	V	V	A	D	D	G	S	E	A	10	1636
56	E	A	P	E	R	P	V	N	G	A	10	1637
62	V	N	G	A	H	P	T	L	Q	A	10	1638
103	E	I	L	K	Q	R	K	V	K	A	10	1639
108	R	K	V	K	A	R	L	T	I	A	10	1640
126	I	G	E	L	V	G	G	Y	I	A	10	1641
130	V	G	G	Y	I	A	N	S	L	A	10	1642
135	A	N	S	L	A	I	M	T	D	A	10	1643
144	A	L	H	M	L	T	D	L	S	A	10	1644
151	L	S	A	I	I	L	T	L	L	A	10	1645
175	G	F	H	R	L	E	V	L	S	A	10	1646
193	I	L	M	G	F	L	L	Y	E	A	10	1647
213	I	N	G	D	I	M	L	I	T	A	10	1648
218	M	L	I	T	A	A	V	G	V	A	10	1649
261	E	R	N	H	G	Q	D	S	L	A	10	1650
264	H	G	Q	D	S	L	A	V	R	A	10	1651
269	L	A	V	R	A	A	F	V	H	A	10	1652
282	L	V	Q	S	V	G	V	L	I	A	10	1653
295	I	R	F	K	P	E	Y	K	I	A	10	1654
308	C	T	Y	V	F	S	L	L	V	A	10	1655
338	H	L	N	V	D	Y	I	K	E	A	10	1656
363	W	S	L	T	S	G	K	S	T	A	10	1657
384	S	K	W	E	E	V	Q	S	K	A	10	1658
413	Y	R	Q	E	V	D	R	T	C	A	10	1659
11	K	S	M	L	R	K	D	D	A	P	9	1660
20	P	L	F	L	N	D	T	S	A	F	9	1661
27	S	A	F	D	F	S	D	E	A	G	9	1662
43	F	N	K	L	R	V	V	V	A	D	9	1663
49	V	V	A	D	D	G	S	E	A	P	9	1664
57	A	P	E	R	P	V	N	G	A	H	9	1665
63	N	G	A	H	P	T	L	Q	A	D	9	1666
104	I	L	K	Q	R	K	V	K	A	R	9	1667
127	G	E	L	V	G	G	Y	I	A	N	9	1668
131	G	G	Y	I	A	N	S	L	A	I	9	1669

Atty Docket: 511582002500

	HLA-A*0203 decamers											
Pos	1	2	3	4	5	6	7	8	9	0	score	SEQ. ID. No.
136	N	S	L	A	I	M	T	D	A	L	9	1670
145	L	H	M	L	T	D	L	S	A	I	9	1671
152	S	A	I	I	L	T	L	L	A	L	9	1672
176	F	H	R	L	E	V	L	S	A	M	9	1673
194	L	M	G	F	L	L	Y	E	A	V	9	1674
219	L	I	T	A	A	V	G	V	A	V	9	1675
262	R	N	H	G	Q	D	S	L	A	V	9	1676
270	A	V	R	A	A	F	V	H	A	L	9	1677
296	R	F	K	P	E	Y	K	I	A	D	9	1678
309	T	Y	V	F	S	L	L	V	A	F	9	1679
339	L	N	V	D	Y	I	K	E	A	L	9	1680
364	S	L	T	S	G	K	S	T	A	I	9	1681
385	K	W	E	E	V	Q	S	K	A	N	9	1682
414	R	Q	E	V	D	R	T	C	A	N	9	1683

	HLA-A1 decamers		
Pos	1 2 3 4 5 6 7 8 9 0	score	SEQ. ID. No.
191	V Y I L M G F L L Y	27	1684
183	S A M I S V L L V Y	24	1685
141	M T D A L H M L T D	22	1686
148	L T D L S A I I L T	22	1687
284	Q S V G V L I A A Y	20	1688
395	H L L L N T F G M Y	20	1689
16	K D D A P L F L N D	19	1690
112	A R L T I A A V L Y	18	1691
124	F M I G E L V G G Y	18	1692
76	L L D Q D L P L T N	17	1693
301	Y K I A D P I C T Y	17	1694
404	Y R C T I Q L Q S Y	17	1695
54	G S E A P E R P V N	16	1696
70	Q A D D D S L L D Q	16	1697
202	A V Q R T I H M N Y	16	1698
292	A Y I I R F K P E Y	16	1699
324	I W D T V V I I L E	16	1700
334	G V P S H L N V D Y	16	1701
346	E A L M K I E D V Y	16	1702
31	F S D E A G D E G L	15	1703

Any Docket: 511582002500

	HLA-A1 decamers		
Pos	1 2 3 4 5 6 7 8 9 0	score	SEQ. ID. No.
172	F T F G F H R L E V	15	1704
210	N Y E I N G D I M L	15	1705
303	I A D P I C T Y V F	15	1706
32	S D E A G D E G L S	14	1707
83	L T N S Q L S L K V	14	1708
331	I L E G V P S H L N	14	1709
344	I K E A L M K I E D	14	1710
3	G S G A W K R L K S	13	1711
23	L N D T S A F D F S	13	1712
182	L S A M I S V L L V	13	1713
308	C T Y V F S L L V A	13	1714
357	V E D L N I W S L T	13	1715

	HLA-A26 decamers											
Pos	1	2	3	4	5	6	7	8	9	0	score	SEQ. ID. No.
180	E	V	L	S	A	M	I	S	V	L	30	<u>1716</u>
225	G	V	A	V	N	V	I	M	G	F	27	<u>1717</u>
150	D	L	S	A	I	I	L	T	L	L	26	<u>1718</u>
115	T	I	A	A	V	L	Y	L	L	F	25	<u>1719</u>
288	V	L	I	A	A	Y	I	I	R	F	25	<u>1720</u>
388	E	V	Q	S	K	A	N	H	L	L	25	<u>1721</u>
114	L	T	I	A	A	V	L	Y	L	L	24	<u>1722</u>
188	V	L	L	V	Y	I	L	M	G	F	24	<u>1723</u>
356	S	V	E	D	L	N	I	W	S	L	24	<u>1724</u>
34	E	A	G	D	E	G	L	S	R	F	23	<u>1725</u>
139	A	I	M	T	D	A	L	H	M	L	23	<u>1726</u>
270	A	V	R	A	A	F	V	H	A	L	23	<u>1727</u>
306	P	I	C	T	Y	V	F	S	L	L	23	<u>1728</u>
323	I	I	W	D	T	V	V	I	I	L	23	<u>1729</u>
334	G	V	P	S	H	L	N	V	D	Y	23	<u>1730</u>
395	H	L	L	L	N	T	F	G	M	Y	23	<u>1731</u>
20	P	L	F	L	N	D	T	S	A	F	22	<u>1732</u>
128	E	L	V	G	G	Y	I	A	N	S	22	<u>1733</u>
185	M	I	S	V	L	L	V	Y	I	L	22	<u>1734</u>
202	A	V	Q	R	T	I	H	M	N	Y	22	<u>1735</u>
212	E	I	N	G	D	I	M	L	I	T	22	<u>1736</u>
330	I	I	L	E	G	V	P	S	H	L	22	<u>1737</u>

Atty Docket: 541582002500

Pos	HLA-A26 decamers										score	SEQ. ID. No.
	1	2	3	4	5	6	7	8	9	0		
25	D	T	S	A	F	D	F	S	D	E	21	1738
129	L	V	G	G	Y	I	A	N	S	L	21	1739
305	D	P	I	C	T	Y	V	F	S	L	21	1740
326	D	T	V	V	I	I	L	E	G	V	21	1741
13	M	L	R	K	D	D	A	P	L	F	20	1742
67	P	T	L	Q	A	D	D	D	S	L	20	1743
113	R	L	T	I	A	A	V	L	Y	L	20	1744
189	L	L	V	Y	I	L	M	G	F	L	20	1745
340	N	V	D	Y	I	K	E	A	L	M	20	1746
22	F	L	N	D	T	S	A	F	D	F	19	1747
37	D	E	G	L	S	R	F	N	K	L	19	1748
103	E	I	L	K	Q	R	K	V	K	A	19	1749
124	F	M	I	G	E	L	V	G	G	Y	19	1750
223	A	V	G	V	A	V	N	V	I	M	19	1751
359	D	L	N	I	W	S	L	T	S	G	19	1752
154	I	I	L	T	L	L	A	L	W	L	18	1753
173	T	F	G	F	H	R	L	E	V	L	18	1754
190	L	V	Y	I	L	M	G	F	L	L	18	1755
227	A	V	N	V	I	M	G	F	L	L	18	1756
284	Q	S	V	G	V	L	I	A	A	Y	18	1757
310	Y	V	F	S	L	L	V	A	F	T	18	1758
329	V	I	I	L	E	G	V	P	S	H	18	1759
353	D	V	Y	S	V	E	D	L	N	I	18	1760
68	T	L	Q	A	D	D	D	S	L	L	17	1761
72	D	D	D	S	L	L	D	Q	D	L	17	1762
147	M	L	T	D	L	S	A	I	I	L	17	1763
153	A	I	I	L	T	L	L	A	L	W	17	1764
181	V	L	S	A	M	I	S	V	L	L	17	1765
216	D	I	M	L	I	T	A	A	V	G	17	1766
229	N	V	I	M	G	F	L	L	N	Q	17	1767
230	V	I	M	G	F	L	L	N	Q	S	17	1768
322	R	I	I	W	D	T	V	V	I	I	17	1769
343	Y	I	K	E	A	L	M	K	I	E	17	1770
416	E	V	D	R	T	C	A	N	C	Q	17	1771
80	D	L	P	L	T	N	S	Q	L	S	16	1772
191	V	Y	I	L	M	G	F	L	L	Y	16	1773
205	R	T	I	H	M	N	Y	E	I	N	16	1774
220	I	T	A	A	V	G	V	A	V	N	16	1775

Atty Docker: 511582002500

	HLA-A26 decamers											
Pos	1	2	3	4	5	6	7	8	9	0	score	SEQ. ID. No.
281	D	L	V	Q	S	V	G	V	L	I	16	1776
301	Y	K	I	A	D	P	I	C	T	Y	16	1777
309	T	Y	V	F	S	L	L	V	A	F	16	1778
346	E	A	L	M	K	I	E	D	V	Y	16	1779
370	S	T	A	I	V	H	I	Q	L	I	16	1780
373	I	V	H	I	Q	L	I	P	G	S	16	1781
387	E	E	V	Q	S	K	A	N	H	L	16	1782
404	Y	R	C	T	I	Q	L	Q	S	Y	16	1783
96	D	N	C	S	K	Q	R	E	I	L	15	1784
104	I	L	K	Q	R	K	V	K	A	R	15	1785
118	A	V	L	Y	L	L	F	M	I	G	15	1786
132	G	Y	I	A	N	S	L	A	I	M	15	1787
141	M	T	D	A	L	H	M	L	T	D	15	1788
148	L	T	D	L	S	A	I	I	L	T	15	1789
152	S	A	I	I	L	T	L	L	A	L	15	1790
168	P	T	K	R	F	T	F	G	F	H	15	1791
170	K	R	F	T	F	G	F	H	R	L	15	1792
172	F	T	F	G	F	H	R	L	E	V	15	1793
187	S	V	L	L	V	Y	I	L	M	G	15	1794
193	I	L	M	G	F	L	L	Y	E	A	15	1795
282	L	V	Q	S	V	G	V	L	I	A	15	1796
289	L	I	A	A	Y	I	I	R	F	K	15	1797
315	L	V	A	F	T	T	F	R	I	I	15	1798
342	D	Y	I	K	E	A	L	M	K	I	15	1799
407	T	I	Q	L	Q	S	Y	R	Q	E	15	1800

	HLA-A3 decamers											
Pos	1	2	3	4	5	6	7	8	9	0	score	SEQ. ID. No.
157	T	L	L	A	L	W	L	S	S	K	29	1801
91	K	V	D	S	C	D	N	C	S	K	25	1802
293	Y	I	I	R	F	K	P	E	Y	K	25	1803
82	P	L	T	N	S	Q	L	S	L	K	24	1804
102	R	E	I	L	K	Q	R	K	V	K	23	1805
202	A	V	Q	R	T	I	H	M	N	Y	23	1806
268	S	L	A	V	R	A	A	F	V	H	23	1807
341	V	D	Y	I	K	E	A	L	M	K	22	1808
278	A	L	G	D	L	V	Q	S	V	G	21	1809

	HLA-A3 decamers		
Pos	1 2 3 4 5 6 7 8 9 0	score	SEQ. ID. No.
289	L I A A Y I I R F K	21	1810
328	V V I I L E G V P S	21	1811
377	Q L I P G S S S K W	21	1812
395	H L L L N T F G M Y	21	1813
396	L L L N T F G M Y R	21	1814
13	M L R K D D A P L F	20	1815
137	S L A I M T D A L H	20	1816
234	F L L N Q S G H R H	20	1817
334	G V P S H L N V D Y	20	1818
376	I Q L I P G S S S K	20	1819
20	P L F L N D T S A F	19	1820
45	K L R V V V A D D G	19	1821
154	I I L T L L A L W L	19	1822
180	E V L S A M I S V L	19	1823
198	L L Y E A V Q R T I	19	1824
216	D I M L I T A A V G	19	1825
270	A V R A A F V H A L	19	1826
275	F V H A L G D L V Q	19	1827
288	V L I A A Y I I R F	19	1828
322	R I I W D T V V I I	19	1829
22	F L N D T S A F D F	18	1830
48	V V V A D D G S E A	18	1831
76	L L D Q D L P L T N	18	1832
104	I L K Q R K V K A R	18	1833
112	A R L T I A A V L Y	18	1834
113	R L T I A A V L Y L	18	1835
115	T I A A V L Y L L F	18	1836
144	A L H M L T D L S A	18	1837
153	A I I L T L L A L W	18	1838
178	R L E V L S A M I S	18	1839
187	S V L L V Y I L M G	18	1840
190	L V Y I L M G F L L	18	1841
218	M L I T A A V G V A	18	1842
219	L I T A A V G V A V	18	1843
313	S L L V A F T T F R	18	1844
329	V I I L E G V P S H	18	1845
7	W K R L K S M L R K	17	1846
47	R V V V A D D G S E	17	1847

Pos	HLA-A3 decamers										score	SEQ. ID. No.
	1	2	3	4	5	6	7	8	9	0		
100	K	Q	R	E	I	L	K	Q	R	K	17	1848
109	K	V	K	A	R	L	T	I	A	A	17	1849
111	K	A	R	L	T	I	A	A	V	L	17	1850
122	L	L	F	M	I	G	E	L	V	G	17	1851
129	L	V	G	G	Y	I	A	N	S	L	17	1852
160	A	L	W	L	S	S	K	S	P	T	17	1853
188	V	L	L	V	Y	I	L	M	G	F	17	1854
196	G	F	L	L	Y	E	A	V	Q	R	17	1855
223	A	V	G	V	A	V	N	V	I	M	17	1856
281	D	L	V	Q	S	V	G	V	L	I	17	1857
285	S	V	G	V	L	I	A	A	Y	I	17	1858
287	G	V	L	I	A	A	Y	I	I	R	17	1859
330	I	I	L	E	G	V	P	S	H	L	17	1860
347	A	L	M	K	I	E	D	V	Y	S	17	1861
353	D	V	Y	S	V	E	D	L	N	I	17	1862
375	H	I	Q	L	I	P	G	S	S	S	17	1863
9	R	L	K	S	M	L	R	K	D	D	16	1864
39	G	L	S	R	F	N	K	L	R	V	16	1865
87	Q	L	S	L	K	V	D	S	C	D	16	1866
118	A	V	L	Y	L	L	F	M	I	G	16	1867
161	L	W	L	S	S	K	S	P	T	K	16	1868
162	W	L	S	S	K	S	P	T	K	R	16	1869
181	V	L	S	A	M	I	S	V	L	L	16	1870
225	G	V	A	V	N	V	I	M	G	F	16	1871
227	A	V	N	V	I	M	G	F	L	L	16	1872
229	N	V	I	M	G	F	L	L	N	Q	16	1873
327	T	V	V	I	I	L	E	G	V	P	16	1874
350	K	I	E	D	V	Y	S	V	E	D	16	1875
360	L	N	I	W	S	L	T	S	G	K	16	1876
409	Q	L	Q	S	Y	R	Q	E	V	D	16	1877
416	E	V	D	R	T	C	A	N	C	Q	16	1878
2	A	G	S	G	A	W	K	R	L	K	15	1879
33	D	E	A	G	D	E	G	L	S	R	15	1880
68	T	L	Q	A	D	D	D	S	L	L	15	1881
119	V	L	Y	L	L	F	M	I	G	E	15	1882
121	Y	L	L	F	M	I	G	E	L	V	15	1883
128	E	L	V	G	G	Y	I	A	N	S	15	1884
158	L	L	A	L	W	L	S	S	K	S	15	1885

Atty Docket: 511582002500

	HLA-A3 decamers		
Pos	1 2 3 4 5 6 7 8 9 0	score	SEQ. ID. No.
183	S A M I S V L L V Y	15	1886
301	Y K I A D P I C T Y	15	1887
61	P V N G A H P T L Q	14	1888
75	S L L D Q D L P L T	14	1889
103	E I L K Q R K V K A	14	1890
133	Y I A N S L A I M T	14	1891
147	M L T D L S A I I L	14	1892
193	I L M G F L L Y E A	14	1893
284	Q S V G V L I A A Y	14	1894
302	K I A D P I C T Y V	14	1895
331	I L E G V P S H L N	14	1896
356	S V E D L N I W S L	14	1897
359	D L N I W S L T S G	14	1898
383	S S K W E E V O S K	14	1899

	HLA-B*0702 decamers											
Pos	1	2	3	4	5	6	7	8	9	0	score	SEQ. ID. No.
60	R	P	V	N	G	A	H	P	T	L	22	<u>1900</u>
81	L	P	L	T	N	S	Q	L	S	L	22	<u>1901</u>
305	D	P	I	C	T	Y	V	F	S	L	21	<u>1902</u>
19	A	P	L	F	L	N	D	T	S	A	19	<u>1903</u>
335	V	P	S	H	L	N	V	D	Y	I	19	<u>1904</u>
167	S	P	T	K	R	F	T	F	G	F	18	<u>1905</u>
298	K	P	E	Y	K	I	A	D	P	I	18	<u>1906</u>
270	A	V	R	A	A	F	V	H	A	L	17	<u>1907</u>
111	K	A	R	L	T	I	A	A	V	L	15	<u>1908</u>
181	V	L	S	A	M	I	S	V	L	L	15	<u>1909</u>
389	V	Q	S	K	A	N	H	L	L	L	15	<u>1910</u>
113	R	L	T	I	A	A	V	L	Y	L	14	<u>1911</u>
150	D	L	S	A	I	I	L	T	L	L	14	<u>1912</u>
14	L	R	K	D	D	A	P	L	F	L	13	<u>1913</u>
57	A	P	E	R	P	V	N	G	A	H	13	<u>1914</u>
74	D	S	L	L	D	Q	D	L	P	L	13	<u>1915</u>
129	L	V	G	G	Y	I	A	N	S	L	13	<u>1916</u>
136	N	S	L	A	I	M	T	D	A	L	13	<u>1917</u>
139	A	I	M	T	D	A	L	H	M	L	13	<u>1918</u>
152	S	A	I	I	L	T	L	L	A	L	13	<u>1919</u>
154	I	I	L	T	L	L	A	L	W	L	13	<u>1920</u>

HLA-B*0702 decamers											score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9	0		
185	M	I	S	V	L	L	V	Y	I	L	13	1921
249	L	P	S	N	S	P	T	R	G	S	13	1922
351	I	E	D	V	Y	S	V	E	D	L	13	1923
12	S	M	L	R	K	D	D	A	P	L	12	1924
37	D	E	G	L	S	R	F	N	K	L	12	1925
42	R	F	N	K	L	R	V	V	V	A	12	1926
142	T	D	A	L	H	M	L	T	D	L	12	1927
149	T	D	L	S	A	I	I	L	T	L	12	1928
170	K	R	F	T	F	G	F	H	R	L	12	1929
173	T	F	G	F	H	R	L	E	V	L	12	1930
180	E	V	L	S	A	M	I	S	V	L	12	1931
222	A	A	V	G	V	A	V	N	V	I	12	1932
227	A	V	N	V	I	M	G	F	L	L	12	1933
240	G	H	R	H	S	H	S	H	S	L	12	1934
260	C	E	R	N	H	G	Q	D	S	L	12	1935
262	R	N	H	G	Q	D	S	L	A	V	12	1936
273	A	A	F	V	H	A	L	G	D	L	12	1937
280	G	D	L	V	Q	S	V	G	V	L	12	1938
323	I	I	W	D	T	V	V	I	I	L	12	1939
365	L	T	S	G	K	S	T	A	I	V	12	1940
369	K	S	T	A	I	V	H	I	Q	L	12	1941
379	I	P	G	S	S	S	K	W	E	E	12	1942
401	F	G	M	Y	R	C	T	I	Q	L	12	1943
1	M	A	G	S	G	A	W	K	R	L	11	1944
5	G	A	W	K	R	L	K	S	M	L	11	1945
31	F	S	D	E	A	G	D	E	G	L	11	1946
62	V	N	G	A	H	P	T	L	Q	A	11	1947
68	T	L	Q	A	D	D	D	S	L	L	11	1948
72	D	D	D	S	L	L	D	Q	D	L	11	1949
79	Q	D	L	P	L	T	N	S	Q	L	11	1950
96	D	N	C	S	K	Q	R	E	I	L	11	1951
105	L	K	Q	R	K	V	K	A	R	L	11	1952
114	L	T	I	A	A	V	L	Y	L	L	11	1953
116	I	A	A	V	L	Y	L	L	F	M	11	1954
135	A	N	S	L	A	I	M	T	D	A	11	1955
172	F	T	F	G	F	H	R	L	E	V	11	1956
189	L	L	V	Y	I	L	M	G	F	L	11	1957
212	E	I	N	G	D	I	M	L	I	T	11	1958

	HLA-B*0702 decamers											
Pos	1	2	3	4	5	6	7	8	9	0	score	SEQ. ID. No.
223	A	V	G	V	A	V	N	V	I	M	11	<u>1959</u>
226	V	A	V	N	V	I	M	G	F	L	11	<u>1960</u>
266	Q	D	S	L	A	V	R	A	A	F	11	<u>1961</u>
303	I	A	D	P	I	C	T	Y	V	F	11	<u>1962</u>
306	P	I	C	T	Y	V	F	S	L	L	11	<u>1963</u>
330	I	I	L	E	G	V	P	S	H	L	11	<u>1964</u>
339	L	N	V	D	Y	I	K	E	A	L	11	<u>1965</u>
387	E	E	V	Q	S	K	A	N	H	L	11	<u>1966</u>
388	E	V	Q	S	K	A	N	H	L	L	11	<u>1967</u>

MHC Class 1 nonamer and decamer analysis of 108P5H8 flanking the D to E mutation at amino acid 30. Listed are scores that fall within the top 50% (rounded up) of all scores for a selected allele of the 108P5H8 variant 1 sequence that does not contain the mutation.

HLA-A*0201 nonamers

Pos	1 2 3 4 5 6 7 8 9	score	SEQ. ID. No.
27	S A F E F S D E A	16	2082
22	F L N D T S A F E	15	2083

HLA-A*0203 nonamers

Pos	1 2 3 4 5 6 7 8 9	score	SEQ. ID. No.
27	S A F E F S D E A	11	2084

HLA-A26 nonamers

Pos	1 2 3 4 5 6 7 8 9	score	SEQ. ID. No.
25	D T S A F E F S D	17	2085

HLA-B*1510 nonamers

Pos	1 2 3 4 5 6 7 8 9	score	SEQ. ID. No.
-----	-------------------	-------	--------------------

HLA-B*5101 nonamers

Pos	1 2 3 4 5 6 7 8 9	score	SEQ. ID. No.
27	S A F E F S D E A	13	2087

HLA-A*0201 decamers

Pos	1 2 3 4 5 6 7 8 9 0	score	SEQ. ID. No.
22	F L N D T S A F E F	15	2088

HLA-A1 decamers

Pos	1 2 3 4 5 6 7 8 9 0	score	SEQ. ID. No.
23	L N D T S A F E F S	13	2089

HLA-A26 decamers

Pos	1 2 3 4 5 6 7 8 9 0	score	SEQ. ID. No.
25	D T S A F E F S D E	21	2090
22	F L N D T S A F E F	20	2091

HLA-A3 decamers

Pos	1 2 3 4 5 6 7 8 9 0	score	SEQ. ID. No.
22	F L N D T S A F E F	18	2092

Table XXIII:

MHC Class II 15-mer analysis of 108P5H8 for selected alleles. Listed are scores that fall within the top 50% (rounded up) of all scores for the selected allele.

Pos	HLA-DRB1*0101 15 - mers															score	SEQ. ID No.
	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5		
326	D	T	V	V	I	I	L	E	G	V	P	S	H	L	N	36	2093
188	V	L	L	V	Y	I	L	M	G	F	L	L	Y	E	A	35	2094
145	L	H	M	L	T	D	L	S	A	I	I	L	T	L	L	33	2095
123	L	F	M	I	G	E	L	V	G	G	Y	I	A	N	S	32	2096
152	S	A	I	I	L	T	L	L	A	L	W	L	S	S	K	32	2097
176	F	H	R	L	E	V	L	S	A	M	I	S	V	L	L	32	2098
283	V	Q	S	V	G	V	L	I	A	A	Y	I	I	R	F	32	2099
119	V	L	Y	L	L	F	M	I	G	E	L	V	G	G	Y	31	2100
225	G	V	A	V	N	V	I	M	G	F	L	L	N	Q	S	31	2101
359	D	L	N	I	W	S	L	T	S	G	K	S	T	A	I	31	2102
373	I	V	H	I	Q	L	I	P	G	S	S	S	K	W	E	31	2103
318	F	T	T	F	R	I	I	W	D	T	V	V	I	I	L	30	2104
40	L	S	R	F	N	K	L	R	V	V	V	A	D	D	G	29	2105
215	G	D	I	M	L	I	T	A	A	V	G	V	A	V	N	29	2106
11	K	S	M	L	R	K	D	D	A	P	L	F	L	N	D	28	2107
179	L	E	V	L	S	A	M	I	S	V	L	L	V	Y	I	28	2108
173	T	F	G	F	H	R	L	E	V	L	S	A	M	I	S	27	2109
272	R	A	A	F	V	H	A	L	G	D	L	V	Q	S	V	27	2110
309	T	Y	V	F	S	L	L	V	A	F	T	T	F	R	I	27	2111
371	T	A	I	V	H	I	Q	L	I	P	G	S	S	S	K	27	2112
153	A	I	I	L	T	L	L	A	L	W	L	S	S	K	S	26	2113
325	W	D	T	V	V	I	I	L	E	G	V	P	S	H	L	26	2114
4	S	G	A	W	K	R	L	K	S	M	L	R	K	D	D	25	2115
20	P	L	F	L	N	D	T	S	A	F	D	F	S	D	E	25	2116
46	L	R	V	V	V	A	D	D	G	S	E	A	P	E	R	25	2117
101	Q	R	E	I	L	K	Q	R	K	V	K	A	R	L	T	25	2118
142	T	D	A	L	H	M	L	T	D	L	S	A	I	I	L	25	2119
192	Y	I	L	M	G	F	L	L	Y	E	A	V	Q	R	T	25	2120
217	I	M	L	I	T	A	A	V	G	V	A	V	N	V	I	25	2121
279	L	G	D	L	V	Q	S	V	G	V	L	I	A	A	Y	25	2122
345	K	E	A	L	M	K	I	E	D	V	Y	S	V	E	D	25	2123
392	K	A	N	H	L	L	L	N	T	F	G	M	Y	R	C	25	2124
43	F	N	K	L	R	V	V	V	A	D	D	G	S	E	A	24	2125

	HLA-DRB1*0101 15 - mers																
Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	score	SEQ. ID No.
56	E	A	P	E	R	P	V	N	G	A	H	P	T	L	Q	24	2126
124	F	M	I	G	E	L	V	G	G	Y	I	A	N	S	L	24	2127
127	G	E	L	V	G	G	Y	I	A	N	S	L	A	I	M	24	2128
156	L	T	L	L	A	L	W	L	S	S	K	S	P	T	K	24	2129
183	S	A	M	I	S	V	L	L	V	Y	I	L	M	G	F	24	2130
284	Q	S	V	G	V	L	I	A	A	Y	I	I	R	F	K	24	2131
354	V	Y	S	V	E	D	L	N	I	W	S	L	T	S	G	24	2132
362	I	W	S	L	T	S	G	K	S	T	A	I	V	H	I	24	2133
18	D	A	P	L	F	L	N	D	T	S	A	F	D	F	S	23	2134
47	R	V	V	V	A	D	D	G	S	E	A	P	E	R	P	23	2135
78	D	Q	D	L	P	L	T	N	S	Q	L	S	L	K	V	23	2136
107	Q	R	K	V	K	A	R	L	T	I	A	A	V	L	Y	23	2137
148	L	T	D	L	S	A	I	I	L	T	L	L	A	L	W	23	2138
149	T	D	L	S	A	I	I	L	T	L	L	A	L	W	L	23	2139
157	T	L	L	A	L	W	L	S	S	K	S	P	T	K	R	23	2140
187	S	V	L	L	V	Y	I	L	M	G	F	L	L	Y	E	23	2141
213	I	N	G	D	I	M	L	I	T	A	A	V	G	V	A	23	2142
214	N	G	D	I	M	L	I	T	A	A	V	G	V	A	V	23	2143
277	H	A	L	G	D	L	V	Q	S	V	G	V	L	I	A	23	2144
280	G	D	L	V	Q	S	V	G	V	L	I	A	A	Y	I	23	2145
312	F	S	L	L	V	A	F	T	T	F	R	I	I	W	D	23	2146
351	I	E	D	V	Y	S	V	E	D	L	N	I	W	S	L	23	2147
383	S	S	K	W	E	E	V	Q	S	K	A	N	H	L	L	23	2148
81	L	P	L	T	N	S	Q	L	S	L	K	V	D	S	C	22	2149
113	R	L	T	I	A	A	V	L	Y	L	L	F	M	I	G	22	2150
144	A	L	H	M	L	T	D	L	S	A	I	I	L	T	L	22	2151
182	L	S	A	M	I	S	V	L	L	V	Y	I	L	M	G	22	2152
207	I	H	M	N	Y	E	I	N	G	D	I	M	L	I	T	22	2153
208	H	M	N	Y	E	I	N	G	D	I	M	L	I	T	A	22	2154
232	M	G	F	L	L	N	Q	S	G	H	R	H	S	H	S	22	2155
243	H	S	H	S	H	S	L	P	S	N	S	P	T	R	G	22	2156
265	G	Q	D	S	L	A	V	R	A	A	F	V	H	A	L	22	2157
328	V	V	I	I	L	E	G	V	P	S	H	L	N	V	D	22	2158
338	H	L	N	V	D	Y	I	K	E	A	L	M	K	I	E	22	2159
372	A	I	V	H	I	Q	L	I	P	G	S	S	S	K	W	22	2160
99	S	K	Q	R	E	I	L	K	Q	R	K	V	K	A	R	21	2161
305	D	P	I	C	T	Y	V	F	S	L	L	V	A	F	T	21	2162
340	N	V	D	Y	I	K	E	A	L	M	K	I	E	D	V	21	2163
111	K	A	R	L	T	I	A	A	V	L	Y	L	L	F	M	20	2164

HLA-DRB1*0101 15 - mers																	
Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	score	SEQ. ID No.
134	I	A	N	S	L	A	I	M	T	D	A	L	H	M	L	20	2165
141	M	T	D	A	L	H	M	L	T	D	L	S	A	I	I	20	2166
175	G	F	H	R	L	E	V	L	S	A	M	I	S	V	L	20	2167
194	L	M	G	F	L	L	Y	E	A	V	Q	R	T	I	H	20	2168
198	L	L	Y	E	A	V	Q	R	T	I	H	M	N	Y	E	20	2169
260	C	E	R	N	H	G	Q	D	S	L	A	V	R	A	A	20	2170
292	A	Y	I	I	R	F	K	P	E	Y	K	I	A	D	P	20	2171
298	K	P	E	Y	K	I	A	D	P	I	C	T	Y	V	F	20	2172
301	Y	K	I	A	D	P	I	C	T	Y	V	F	S	L	L	20	2173
307	I	C	T	Y	V	F	S	L	L	V	A	F	T	T	F	20	2174
329	V	I	I	L	E	G	V	P	S	H	L	N	V	D	Y	20	2175
346	E	A	L	M	K	I	E	D	V	Y	S	V	E	D	L	20	2176
348	L	M	K	I	E	D	V	Y	S	V	E	D	L	N	I	20	2177
356	S	V	E	D	L	N	I	W	S	L	T	S	G	K	S	20	2178
360	L	N	I	W	S	L	T	S	G	K	S	T	A	I	V	20	2179
401	F	G	M	Y	R	C	T	I	Q	L	Q	S	Y	R	Q	20	2180
104	I	L	K	Q	R	K	V	K	A	R	L	T	I	A	A	19	2181
109	K	V	K	A	R	L	T	I	A	A	V	L	Y	L	L	19	2182
117	A	A	V	L	Y	L	L	F	M	I	G	E	L	V	G	19	2183
118	A	V	L	Y	L	L	F	M	I	G	E	L	V	G	G	19	2184
150	D	L	S	A	I	I	L	T	L	L	A	L	W	L	S	19	2185
165	S	K	S	P	T	K	R	F	T	F	G	F	H	R	L	19	2186
171	R	F	T	F	G	F	H	R	L	E	V	L	S	A	M	19	2187
233	G	F	L	L	N	Q	S	G	H	R	H	S	H	S	H	19	2188
17	D	D	A	P	L	F	L	N	D	T	S	A	F	D	F	18	2189
28	A	F	D	F	S	D	E	A	G	D	E	G	L	S	R	18	2190
130	V	G	G	Y	I	A	N	S	L	A	I	M	T	D	A	18	2191
184	A	M	I	S	V	L	L	V	Y	I	L	M	G	F	L	18	2192
186	I	S	V	L	L	V	Y	I	L	M	G	F	L	L	Y	18	2193
189	L	L	V	Y	I	L	M	G	F	L	L	Y	E	A	V	18	2194
212	E	I	N	G	D	I	M	L	I	T	A	A	V	G	V	18	2195
223	A	V	G	V	A	V	N	V	I	M	G	F	L	L	N	18	2196
268	S	L	A	V	R	A	A	F	V	H	A	L	G	D	L	18	2197
313	S	L	L	V	A	F	T	T	F	R	I	I	W	D	T	18	2198
336	P	S	H	L	N	V	D	Y	I	K	E	A	L	M	K	18	2199

Pos	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	score	SEQ. ID. No.
11	K S M L R K D D A P L F L N D	30	2200
66	H P T L Q A D D D S L L D Q D	29	2201
137	S L A I M T D A L H M L T D L	28	2202
332	L E G V P S H L N V D Y I K E	27	2203
386	W E E V Q S K A N H L L L N T	26	2204
144	A L H M L T D L S A I I L T L	24	2205
87	Q L S L K V D S C D N C S K Q	23	2206
47	R V V V A D D G S E A P E R P	22	2207
72	D D D S L L D Q D L P L T N S	22	2208
74	D S L L D Q D L P L T N S Q L	22	2209
152	S A I I L T L L A L W L S S K	22	2210
320	T F R I I W D T V V I I L E G	22	2211
10	L K S M L R K D D A P L F L N	21	2212
19	A P L F L N D T S A F D F S D	21	2213
46	L R V V V A D D G S E A P E R	21	2214
113	R L T I A A V L Y L L F M I G	21	2215
178	R L E V L S A M I S V L L V Y	21	2216
210	N Y E I N G D I M L I T A A V	21	2217
328	V V I I L E G V P S H L N V D	21	2218
393	A N H L L L N T F G M Y R C T	21	2219
12	S M L R K D D A P L F L N D T	20	2220
18	D A P L F L N D T S A F D F S	20	2221
101	Q R E I L K Q R K V K A R L T	20	2222
111	K A R L T I A A V L Y L L F M	20	2223
122	L L F M I G E L V G G Y I A N	20	2224
145	L H M L T D L S A I I L T L L	20	2225
179	L E V L S A M I S V L L V Y I	20	2226
186	I S V L L V Y I L M G F L L Y	20	2227
187	S V L L V Y I L M G F L L Y E	20	2228
268	S L A V R A A F V H A L G D L	20	2229
299	P E Y K I A D P I C T Y V F S	20	2230
336	P S H L N V D Y I K E A L M K	20	2231
7	W K R L K S M L R K D D A P L	19	2232
20	P L F L N D T S A F D F S D E	19	2233
120	L Y L L F M I G E L V G G Y I	19	2234
127	G E L V G G Y I A N S L A I M	19	2235
148	L T D L S A I I L T L L A L W	19	2236
183	S A M I S V L L V Y I L M G F	19	2237
188	V L L V Y I L M G F L L Y E A	19	2238

HLA-DRB1*0301 (DR17) 15 - mers																	
Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	score	SEQ. ID. No.
200	Y	E	A	V	Q	R	T	I	H	M	N	Y	E	I	N	19	2239
225	G	V	A	V	N	V	I	M	G	F	L	L	N	Q	S	19	2240
286	V	G	V	L	I	A	A	Y	I	I	R	F	K	P	E	19	2241
292	A	Y	I	I	R	F	K	P	E	Y	K	I	A	D	P	19	2242
304	A	D	P	I	C	T	Y	V	F	S	L	L	V	A	F	19	2243
338	H	L	N	V	D	Y	I	K	E	A	L	M	K	I	E	19	2244
353	D	V	Y	S	V	E	D	L	N	I	W	S	L	T	S	19	2245
79	Q	D	L	P	L	T	N	S	Q	L	S	L	K	V	D	18	2246
158	L	L	A	L	W	L	S	S	K	S	P	T	K	R	F	18	2247
204	Q	R	T	I	H	M	N	Y	E	I	N	G	D	I	M	18	2248
223	A	V	G	V	A	V	N	V	I	M	G	F	L	L	N	18	2249
229	N	V	I	M	G	F	L	L	N	Q	S	G	H	R	H	18	2250
321	F	R	I	I	W	D	T	V	V	I	I	L	E	G	V	18	2251
325	W	D	T	V	V	I	I	L	E	G	V	P	S	H	L	18	2252
354	V	Y	S	V	E	D	L	N	I	W	S	L	T	S	G	18	2253
37	D	E	G	L	S	R	F	N	K	L	R	V	V	V	A	17	2254
77	L	D	Q	D	L	P	L	T	N	S	Q	L	S	L	K	17	2255
89	S	L	K	V	D	S	C	D	N	C	S	K	Q	R	E	17	2256
196	G	F	L	L	Y	E	A	V	Q	R	T	I	H	M	N	17	2257
221	T	A	A	V	G	V	A	V	N	V	I	M	G	F	L	17	2258
264	H	G	Q	D	S	L	A	V	R	A	A	F	V	H	A	17	2259
294	I	I	R	F	K	P	E	Y	K	I	A	D	P	I	C	17	2260
344	I	K	E	A	L	M	K	I	E	D	V	Y	S	V	E	17	2261
407	T	I	Q	L	Q	S	Y	R	Q	E	V	D	R	T	C	17	2262
163	L	S	S	K	S	P	T	K	R	F	T	F	G	F	H	16	2263
171	R	F	T	F	G	F	H	R	L	E	V	L	S	A	M	16	2264
206	T	I	H	M	N	Y	E	I	N	G	D	I	M	L	I	16	2265
258	S	G	C	E	R	N	H	G	Q	D	S	L	A	V	R	16	2266
276	V	H	A	L	G	D	L	V	Q	S	V	G	V	L	I	16	2267
337	S	H	L	N	V	D	Y	I	K	E	A	L	M	K	I	16	2268
3	G	S	G	A	W	K	R	L	K	S	M	L	R	K	D	15	2269
26	T	S	A	F	D	F	S	D	E	A	G	D	E	G	L	15	2270
94	S	C	D	N	C	S	K	Q	R	E	I	L	K	Q	R	15	2271
103	E	I	L	K	Q	R	K	V	K	A	R	L	T	I	A	15	2272
151	L	S	A	I	I	L	T	L	L	A	L	W	L	S	S	15	2273
290	I	A	A	Y	I	I	R	F	K	P	E	Y	K	I	A	15	2274

Atty Docket: 514582002500

	HLA-DRB1*0401 (DR4Dw4) 15 -mers																SEQ. ID.
Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	score	No.
383	S	S	K	W	E	E	V	Q	S	K	A	N	H	L	L	28	2275
138	L	A	I	M	T	D	A	L	H	M	L	T	D	L	S	26	2276
144	A	L	H	M	L	T	D	L	S	A	I	I	L	T	L	26	2277
196	G	F	L	L	Y	E	A	V	Q	R	T	I	H	M	N	26	2278
206	T	I	H	M	N	Y	E	I	N	G	D	I	M	L	I	26	2279
221	T	A	A	V	G	V	A	V	N	V	I	M	G	F	L	26	2280
312	F	S	L	L	V	A	F	T	T	F	R	I	I	W	D	26	2281
329	V	I	I	L	E	G	V	P	S	H	L	N	V	D	Y	26	2282
359	D	L	N	I	W	S	L	T	S	G	K	S	T	A	I	26	2283
4	S	G	A	W	K	R	L	K	S	M	L	R	K	D	D	22	2284
19	A	P	L	F	L	N	D	T	S	A	F	D	F	S	D	22	2285
40	L	S	R	F	N	K	L	R	V	V	V	A	D	D	G	22	2286
118	A	V	L	Y	L	L	F	M	I	G	E	L	V	G	G	22	2287
159	L	A	L	W	L	S	S	K	S	P	T	K	R	F	T	22	2288
173	T	F	G	F	H	R	L	E	V	L	S	A	M	I	S	22	2289
197	F	L	L	Y	E	A	V	Q	R	T	I	H	M	N	Y	22	2290
272	R	A	A	F	V	H	A	L	G	D	L	V	Q	S	V	22	2291
298	K	P	E	Y	K	I	A	D	P	I	C	T	Y	V	F	22	2292
309	T	Y	V	F	S	L	L	V	A	F	T	T	F	R	I	22	2293
318	F	T	T	F	R	I	I	W	D	T	V	V	I	I	L	22	2294
340	N	V	D	Y	I	K	E	A	L	M	K	I	E	D	V	22	2295
401	F	G	M	Y	R	C	T	I	Q	L	Q	S	Y	R	Q	22	2296
37	D	E	G	L	S	R	F	N	K	L	R	V	V	V	A	20	2297
46	L	R	V	V	V	A	D	D	G	S	E	A	P	E	R	20	2298
47	R	V	V	V	A	D	D	G	S	E	A	P	E	R	P	20	2299
59	E	R	P	V	N	G	A	H	P	T	L	Q	A	D	D	20	2300
66	H	P	T	L	Q	A	D	D	D	S	L	L	D	Q	D	20	2301
74	D	S	L	L	D	Q	D	L	P	L	T	N	S	Q	L	20	2302
78	D	Q	D	L	P	L	T	N	S	Q	L	S	L	K	V	20	2303
89	S	L	K	V	D	S	C	D	N	C	S	K	Q	R	E	20	2304
111	K	A	R	L	T	I	A	A	V	L	Y	L	L	F	M	20	2305
123	L	F	M	I	G	E	L	V	G	G	Y	I	A	N	S	20	2306
137	S	L	A	I	M	T	D	A	L	H	M	L	T	D	L	20	2307
142	T	D	A	L	H	M	L	T	D	L	S	A	I	I	L	20	2308
145	L	H	M	L	T	D	L	S	A	I	I	L	T	L	L	20	2309
148	L	T	D	L	S	A	I	I	L	T	L	L	A	L	W	20	2310
152	S	A	I	I	L	T	L	L	A	L	W	L	S	S	K	20	2311
153	A	I	I	L	T	L	L	A	L	W	L	S	S	K	S	20	2312

HLA-DRB1*0401 (DR4Dw4) 15 - mers																score	SEQ. ID. No.
Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5		
155	I	L	T	L	L	A	L	W	L	S	S	K	S	P	T	20	2313
156	L	T	L	L	A	L	W	L	S	S	K	S	P	T	K	20	2314
176	F	H	R	L	E	V	L	S	A	M	I	S	V	L	L	20	2315
178	R	L	E	V	L	S	A	M	I	S	V	L	L	V	Y	20	2316
179	L	E	V	L	S	A	M	I	S	V	L	L	V	Y	I	20	2317
182	L	S	A	M	I	S	V	L	L	V	Y	I	L	M	G	20	2318
183	S	A	M	I	S	V	L	L	V	Y	I	L	M	G	F	20	2319
187	S	V	L	L	V	Y	I	L	M	G	F	L	L	Y	E	20	2320
188	V	L	L	V	Y	I	L	M	G	F	L	L	Y	E	A	20	2321
191	V	Y	I	L	M	G	F	L	L	Y	E	A	V	Q	R	20	2322
192	Y	I	L	M	G	F	L	L	Y	E	A	V	Q	R	T	20	2323
195	M	G	F	L	L	Y	E	A	V	Q	R	T	I	H	M	20	2324
210	N	Y	E	I	N	G	D	I	M	L	I	T	A	A	V	20	2325
216	D	I	M	L	I	T	A	A	V	G	V	A	V	N	V	20	2326
217	I	M	L	I	T	A	A	V	G	V	A	V	N	V	I	20	2327
225	G	V	A	V	N	V	I	M	G	F	L	L	N	Q	S	20	2328
228	V	N	V	I	M	G	F	L	L	N	Q	S	G	H	R	20	2329
229	N	V	I	M	G	F	L	L	N	Q	S	G	H	R	H	20	2330
233	G	F	L	L	N	Q	S	G	H	R	H	S	H	S	H	20	2331
268	S	L	A	V	R	A	A	F	V	H	A	L	G	D	L	20	2332
273	A	A	F	V	H	A	L	G	D	L	V	Q	S	V	G	20	2333
276	V	H	A	L	G	D	L	V	Q	S	V	G	V	L	I	20	2334
280	G	D	L	V	Q	S	V	G	V	L	I	A	A	Y	I	20	2335
283	V	Q	S	V	G	V	L	I	A	A	Y	I	I	R	F	20	2336
291	A	A	Y	I	I	R	F	K	P	E	Y	K	I	A	D	20	2337
308	C	T	Y	V	F	S	L	L	V	A	F	T	T	F	R	20	2338
311	V	F	S	L	L	V	A	F	T	T	F	R	I	I	W	20	2339
320	T	F	R	I	I	W	D	T	V	V	I	I	L	E	G	20	2340
326	D	T	V	V	I	I	L	E	G	V	P	S	H	L	N	20	2341
336	P	S	H	L	N	V	D	Y	I	K	E	A	L	M	K	20	2342
338	H	L	N	V	D	Y	I	K	E	A	L	M	K	I	E	20	2343
345	K	E	A	L	M	K	I	E	D	V	Y	S	V	E	D	20	2344
346	E	A	L	M	K	I	E	D	V	Y	S	V	E	D	L	20	2345
348	L	M	K	I	E	D	V	Y	S	V	E	D	L	N	I	20	2346
351	I	E	D	V	Y	S	V	E	D	L	N	I	W	S	L	20	2347
354	V	Y	S	V	E	D	L	N	I	W	S	L	T	S	G	20	2348
362	I	W	S	L	T	S	G	K	S	T	A	I	V	H	I	20	2349
373	I	V	H	I	Q	L	I	P	G	S	S	S	K	W	E	20	2350

Any Docket: 511582002500

	HLA-DRB1*0401 (DR4Dw4) 15 -mers																
Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	score	SEQ. ID. No.
16	K	D	D	A	P	L	F	L	N	D	T	S	A	F	D	18	2351
24	N	D	T	S	A	F	D	F	S	D	E	A	G	D	E	18	2352
34	E	A	G	D	E	G	L	S	R	F	N	K	L	R	V	18	2353
77	L	D	Q	D	L	P	L	T	N	S	Q	L	S	L	K	18	2354
86	S	Q	L	S	L	K	V	D	S	C	D	N	C	S	K	18	2355
99	S	K	Q	R	E	I	L	K	Q	R	K	V	K	A	R	18	2356
128	E	L	V	G	G	Y	I	A	N	S	L	A	I	M	T	18	2357
129	L	V	G	G	Y	I	A	N	S	L	A	I	M	T	D	18	2358
134	I	A	N	S	L	A	I	M	T	D	A	L	H	M	L	18	2359
149	T	D	L	S	A	I	I	L	T	L	L	A	L	W	L	18	2360
170	K	R	F	T	F	G	F	H	R	L	E	V	L	S	A	18	2361
175	G	F	H	R	L	E	V	L	S	A	M	I	S	V	L	18	2362
213	I	N	G	D	I	M	L	I	T	A	A	V	G	V	A	18	2363
255	T	R	G	S	G	C	E	R	N	H	G	Q	D	S	L	18	2364
277	H	A	L	G	D	L	V	Q	S	V	G	V	L	I	A	18	2365
305	D	P	I	C	T	Y	V	F	S	L	L	V	A	F	T	18	2366
353	D	V	Y	S	V	E	D	L	N	I	W	S	L	T	S	18	2367
356	S	V	E	D	L	N	I	W	S	L	T	S	G	K	S	18	2368
367	S	G	K	S	T	A	I	V	H	I	Q	L	I	P	G	18	2369
382	S	S	S	K	W	E	E	V	Q	S	K	A	N	H	L	18	2370
387	E	E	V	Q	S	K	A	N	H	L	L	L	N	T	F	18	2371
392	K	A	N	H	L	L	L	N	T	F	G	M	Y	R	C	18	2372
404	Y	R	C	T	I	Q	L	Q	S	Y	R	Q	E	V	D	18	2373
411	Q	S	Y	R	Q	E	V	D	R	T	C	A	N	C	Q	18	2374
412	S	Y	R	Q	E	V	D	R	T	C	A	N	C	Q	S	18	2375
28	A	F	D	F	S	D	E	A	G	D	E	G	L	S	R	16	2376
130	V	G	G	Y	I	A	N	S	L	A	I	M	T	D	A	16	2377
169	T	K	R	F	T	F	G	F	H	R	L	E	V	L	S	16	2378
171	R	F	T	F	G	F	H	R	L	E	V	L	S	A	M	16	2379
208	H	M	N	Y	E	I	N	G	D	I	M	L	I	T	A	16	2380
231	I	M	G	F	L	L	N	Q	S	G	H	R	H	S	H	16	2381
294	I	I	R	F	K	P	E	Y	K	I	A	D	P	I	C	16	2382
315	L	V	A	F	T	T	F	R	I	I	W	D	T	V	V	16	2383
322	R	I	I	W	D	T	V	V	I	I	L	E	G	V	P	16	2384
352	E	D	V	Y	S	V	E	D	L	N	I	W	S	L	T	16	2385
360	L	N	I	W	S	L	T	S	G	K	S	T	A	I	V	16	2386
398	L	N	T	F	G	M	Y	R	C	T	I	Q	L	Q	S	16	2387
410	L	Q	S	Y	R	Q	E	V	D	R	T	C	A	N	C	16	2388

HLA-DRB1*0401 (DR4Dw4) 15 -mers																SEQ. ID.	
Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	score	No.
107	Q	R	K	V	K	A	R	L	T	I	A	A	V	L	Y	15	2389
386	W	E	E	V	Q	S	K	A	N	H	L	L	L	N	T	15	2390
7	W	K	R	L	K	S	M	L	R	K	D	D	A	P	L	14	2391
11	K	S	M	L	R	K	D	D	A	P	L	F	L	N	D	14	2392
18	D	A	P	L	F	L	N	D	T	S	A	F	D	F	S	14	2393
43	F	N	K	L	R	V	V	V	A	D	D	G	S	E	A	14	2394
45	K	L	R	V	V	V	A	D	D	G	S	E	A	P	E	14	2395
73	D	D	S	L	L	D	Q	D	L	P	L	T	N	S	Q	14	2396
80	D	L	P	L	T	N	S	Q	L	S	L	K	V	D	S	14	2397
87	Q	L	S	L	K	V	D	S	C	D	N	C	S	K	Q	14	2398
101	Q	R	E	I	L	K	Q	R	K	V	K	A	R	L	T	14	2399
113	R	L	T	I	A	A	V	L	Y	L	L	F	M	I	G	14	2400
116	I	A	A	V	L	Y	L	L	F	M	I	G	E	L	V	14	2401
117	A	A	V	L	Y	L	L	F	M	I	G	E	L	V	G	14	2402
119	V	L	Y	L	L	F	M	I	G	E	L	V	G	G	Y	14	2403
120	L	Y	L	L	F	M	I	G	E	L	V	G	G	Y	I	14	2404
122	L	L	F	M	I	G	E	L	V	G	G	Y	I	A	N	14	2405
126	I	G	E	L	V	G	G	Y	I	A	N	S	L	A	I	14	2406
127	G	E	L	V	G	G	Y	I	A	N	S	L	A	I	M	14	2407
131	G	G	Y	I	A	N	S	L	A	I	M	T	D	A	L	14	2408
158	L	L	A	L	W	L	S	S	K	S	P	T	K	R	F	14	2409
185	M	I	S	V	L	L	V	Y	I	L	M	G	F	L	L	14	2410
200	Y	E	A	V	Q	R	T	I	H	M	N	Y	E	I	N	14	2411
214	N	G	D	I	M	L	I	T	A	A	V	G	V	A	V	14	2412
215	G	D	I	M	L	I	T	A	A	V	G	V	A	V	N	14	2413
227	A	V	N	V	I	M	G	F	L	L	N	Q	S	G	H	14	2414
279	L	G	D	L	V	Q	S	V	G	V	L	I	A	A	Y	14	2415
285	S	V	G	V	L	I	A	A	Y	I	I	R	F	K	P	14	2416
286	V	G	V	L	I	A	A	Y	I	I	R	F	K	P	E	14	2417
287	G	V	L	I	A	A	Y	I	I	R	F	K	P	E	Y	14	2418
300	E	Y	K	I	A	D	P	I	C	T	Y	V	F	S	L	14	2419
304	A	D	P	I	C	T	Y	V	F	S	L	L	V	A	F	14	2420
313	S	L	L	V	A	F	T	T	F	R	I	I	W	D	T	14	2421
321	F	R	I	I	W	D	T	V	V	I	I	L	E	G	V	14	2422
325	W	D	T	V	V	I	I	L	E	G	V	P	S	H	L	14	2423
327	T	V	V	I	I	L	E	G	V	P	S	H	L	N	V	14	2424
328	V	V	I	I	L	E	G	V	P	S	H	L	N	V	D	14	2425
332	L	E	G	V	P	S	H	L	N	V	D	Y	I	K	E	14	2426

HLA-DRB1*0401 (DR4Dw4) 15 - mers																	
Pos																score	SEQ. ID.
	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5		No.
341	V	D	Y	I	K	E	A	L	M	K	I	E	D	V	Y	14	2427
370	S	T	A	I	V	H	I	Q	L	I	P	G	S	S	S	14	2428
371	T	A	I	V	H	I	Q	L	I	P	G	S	S	S	K	14	2429
375	H	I	Q	L	I	P	G	S	S	S	K	W	E	E	V	14	2430
376	I	Q	L	I	P	G	S	S	S	K	W	E	E	V	Q	14	2431
395	H	L	L	L	N	T	F	G	M	Y	R	C	T	I	Q	14	2432
400	T	F	G	M	Y	R	C	T	I	Q	L	Q	S	Y	R	14	2433
407	T	I	Q	L	Q	S	Y	R	Q	E	V	D	R	T	C	14	2434
414	R	Q	E	V	D	R	T	C	A	N	C	Q	S	S	S	14	2435

HLA-DRB1*1101 15 - mers															score	SEQ. ID.	
Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4		5	No.
197	F	L	L	Y	E	A	V	Q	R	T	I	H	M	N	Y	25	2436
40	L	S	R	F	N	K	L	R	V	V	V	A	D	D	G	23	2437
169	T	K	R	F	T	F	G	F	H	R	L	E	V	L	S	22	2438
173	T	F	G	F	H	R	L	E	V	L	S	A	M	I	S	22	2439
43	F	N	K	L	R	V	V	V	A	D	D	G	S	E	A	21	2440
101	Q	R	E	I	L	K	Q	R	K	V	K	A	R	L	T	21	2441
153	A	I	I	L	T	L	L	A	L	W	L	S	S	K	S	21	2442
233	G	F	L	L	N	Q	S	G	H	R	H	S	H	S	H	21	2443
276	V	H	A	L	G	D	L	V	Q	S	V	G	V	L	I	21	2444
288	V	L	I	A	A	Y	I	I	R	F	K	P	E	Y	K	21	2445
7	W	K	R	L	K	S	M	L	R	K	D	D	A	P	L	20	2446
8	K	R	L	K	S	M	L	R	K	D	D	A	P	L	F	20	2447
120	L	Y	L	L	F	M	I	G	E	L	V	G	G	Y	I	20	2448
176	F	H	R	L	E	V	L	S	A	M	I	S	V	L	L	20	2449
411	Q	S	Y	R	Q	E	V	D	R	T	C	A	N	C	Q	20	2450
116	I	A	A	V	L	Y	L	L	F	M	I	G	E	L	V	19	2451
214	N	G	D	I	M	L	I	T	A	A	V	G	V	A	V	19	2452
280	G	D	L	V	Q	S	V	G	V	L	I	A	A	Y	I	19	2453
322	R	I	I	W	D	T	V	V	I	I	L	E	G	V	P	19	2454
325	W	D	T	V	V	I	I	L	E	G	V	P	S	H	L	19	2455
359	D	L	N	I	W	S	L	T	S	G	K	S	T	A	I	19	2456
142	T	D	A	L	H	M	L	T	D	L	S	A	I	I	L	18	2457
185	M	I	S	V	L	L	V	Y	I	L	M	G	F	L	L	18	2458
229	N	V	I	M	G	F	L	L	N	Q	S	G	H	R	H	18	2459
290	I	A	A	Y	I	I	R	F	K	P	E	Y	K	I	A	18	2460
294	I	I	R	F	K	P	E	Y	K	I	A	D	P	I	C	18	2461

	HLA-DRB1*1101 15 - mers																
Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	score	SEQ. ID. No.
309	T	Y	V	F	S	L	L	V	A	F	T	T	F	R	I	18	2462
326	D	T	V	V	I	I	L	E	G	V	P	S	H	L	N	18	2463
345	K	E	A	L	M	K	I	E	D	V	Y	S	V	E	D	18	2464
367	S	G	K	S	T	A	I	V	H	I	Q	L	I	P	G	18	2465
370	S	T	A	I	V	H	I	Q	L	I	P	G	S	S	S	18	2466
373	I	V	H	I	Q	L	I	P	G	S	S	S	S	K	W	E	2467
4	S	G	A	W	K	R	L	K	S	M	L	R	K	D	D	17	2468
138	L	A	I	M	T	D	A	L	H	M	L	T	D	L	S	17	2469
189	L	L	V	Y	I	L	M	G	F	L	L	Y	E	A	V	17	2470
269	L	A	V	R	A	A	F	V	H	A	L	G	D	L	V	17	2471
318	F	T	T	F	R	I	I	W	D	T	V	V	I	I	L	17	2472
28	A	F	D	F	S	D	E	A	G	D	E	G	L	S	R	16	2473
37	D	E	G	L	S	R	F	N	K	L	R	V	V	V	A	16	2474
98	C	S	K	Q	R	E	I	L	K	Q	R	K	V	K	A	16	2475
121	Y	L	L	F	M	I	G	E	L	V	G	G	Y	I	A	16	2476
383	S	S	K	W	E	E	V	Q	S	K	A	N	H	L	L	16	2477
401	F	G	M	Y	R	C	T	I	Q	L	Q	S	Y	R	Q	16	2478
1	M	A	G	S	G	A	W	K	R	L	K	S	M	L	R	15	2479
145	L	H	M	L	T	D	L	S	A	I	I	L	T	L	L	15	2480
239	S	G	H	R	H	S	H	S	H	S	L	P	S	N	S	15	2481
323	I	I	W	D	T	V	V	I	I	L	E	G	V	P	S	15	2482
397	L	L	N	T	F	G	M	Y	R	C	T	I	Q	L	Q	15	2483
34	E	A	G	D	E	G	L	S	R	F	N	K	L	R	V	14	2484
83	L	T	N	S	Q	L	S	L	K	V	D	S	C	D	N	14	2485
123	L	F	M	I	G	E	L	V	G	G	Y	I	A	N	S	14	2486
158	L	L	A	L	W	L	S	S	K	S	P	T	K	R	F	14	2487
183	S	A	M	I	S	V	L	L	V	Y	I	L	M	G	F	14	2488
200	Y	E	A	V	Q	R	T	I	H	M	N	Y	E	I	N	14	2489
225	G	V	A	V	N	V	I	M	G	F	L	L	N	Q	S	14	2490
235	L	L	N	Q	S	G	H	R	H	S	H	S	H	S	L	14	2491
237	N	Q	S	G	H	R	H	S	H	S	H	S	L	P	S	14	2492
246	S	H	S	L	P	S	N	S	P	T	R	G	S	G	C	14	2493
248	S	L	P	S	N	S	P	T	R	G	S	G	C	E	R	14	2494
254	P	T	R	G	S	G	C	E	R	N	H	G	Q	D	S	14	2495
342	D	Y	I	K	E	A	L	M	K	I	E	D	V	Y	S	14	2496
361	N	I	W	S	L	T	S	G	K	S	T	A	I	V	H	14	2497
44	N	K	L	R	V	V	V	A	D	D	G	S	E	A	P	13	2498
71	A	D	D	D	S	L	L	D	Q	D	L	P	L	T	N	13	2499
78	D	Q	D	L	P	L	T	N	S	Q	L	S	L	K	V	13	2500

Att'y Docket 514582002500

	HLA-DRB1*1101 15 - mers																
Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	score	SEQ. ID. No.
113	R	L	T	I	A	A	V	L	Y	L	L	F	M	I	G	13	2501
119	V	L	Y	L	L	F	M	I	G	E	L	V	G	G	Y	13	2502
124	F	M	I	G	E	L	V	G	G	Y	I	A	N	S	L	13	2503
128	E	L	V	G	G	Y	I	A	N	S	L	A	I	M	T	13	2504
135	A	N	S	L	A	I	M	T	D	A	L	H	M	L	T	13	2505
141	M	T	D	A	L	H	M	L	T	D	L	S	A	I	I	13	2506
148	L	T	D	L	S	A	I	I	L	T	L	L	A	L	W	13	2507
149	T	D	L	S	A	I	I	L	T	L	L	A	L	P	W	13	2508
156	L	T	L	L	A	L	W	L	S	S	K	S	P	T	K	13	2509
179	L	E	V	L	S	A	M	I	S	V	L	L	V	Y	I	13	2510
188	V	L	L	V	Y	I	L	M	G	F	L	L	Y	E	A	13	2511
216	D	I	M	L	I	T	A	A	V	G	V	A	V	N	V	13	2512
263	N	H	G	Q	D	S	L	A	V	R	A	A	F	V	H	13	2513
273	A	A	F	V	H	A	L	G	D	L	V	Q	S	V	G	13	2514
283	V	Q	S	V	G	V	L	I	A	A	Y	I	I	R	F	13	2515
308	C	T	Y	V	F	S	L	L	V	A	F	T	T	F	R	13	2516
329	V	I	I	L	E	G	V	P	S	H	L	N	V	D	Y	13	2517
336	P	S	H	L	N	V	D	Y	I	K	E	A	L	M	K	13	2518
338	H	L	N	V	D	Y	I	K	E	A	L	M	K	I	E	13	2519
410	L	Q	S	Y	R	Q	E	V	D	R	T	C	A	N	C	13	2520
17	D	D	A	P	L	F	L	N	D	T	S	A	F	D	F	12	2521
46	L	R	V	V	V	A	D	D	G	S	E	A	P	E	R	12	2522
47	R	V	V	V	A	D	D	G	S	E	A	P	E	R	P	12	2523
56	E	A	P	E	R	P	V	N	G	A	H	P	T	L	Q	12	2524
75	S	L	L	D	Q	D	L	P	L	T	N	S	Q	L	S	12	2525
103	E	I	L	K	Q	R	K	V	K	A	R	L	T	I	A	12	2526
107	Q	R	K	V	K	A	R	L	T	I	A	A	V	L	Y	12	2527
117	A	A	V	L	Y	L	L	F	M	I	G	E	L	V	G	12	2528
126	I	G	E	L	V	G	G	Y	I	A	N	S	L	A	I	12	2529
152	S	A	I	I	L	T	L	L	A	L	W	L	S	S	K	12	2530
155	I	L	T	L	L	A	L	W	L	S	S	K	S	P	T	12	2531
157	T	L	L	A	L	W	L	S	S	K	S	P	T	K	R	12	2532
182	L	S	A	M	I	S	V	L	L	V	Y	I	L	M	G	12	2533
187	S	V	L	L	V	Y	I	L	M	G	F	L	L	Y	E	12	2534
191	V	Y	I	L	M	G	F	L	L	Y	E	A	V	Q	R	12	2535
192	Y	I	L	M	G	F	L	L	Y	E	A	V	Q	R	T	12	2536
204	Q	R	T	I	H	M	N	Y	E	I	N	G	D	I	M	12	2537
211	Y	E	I	N	G	D	I	M	L	I	T	A	A	V	G	12	2538
212	E	I	N	G	D	I	M	L	I	T	A	A	V	G	V	12	2539

HLA-DRB1*1101 15 - mers															score	SEQ. ID.	
Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4		No.	
222	A	A	V	G	V	A	V	N	V	I	M	G	F	L	12	2540	
228	V	N	V	I	M	G	F	L	L	N	Q	S	G	H	12	2541	
243	H	S	H	S	H	S	L	P	S	N	S	P	T	R	12	2542	
315	L	V	A	F	T	T	F	R	I	I	W	D	T	V	12	2543	
348	L	M	K	I	E	D	V	Y	S	V	E	D	L	N	12	2544	
351	I	E	D	V	Y	S	V	E	D	L	N	I	W	S	12	2545	
352	E	D	V	Y	S	V	E	D	L	N	I	W	S	L	12	2546	
354	V	Y	S	V	E	D	L	N	I	W	S	L	T	S	12	2547	
356	S	V	E	D	L	N	I	W	S	L	T	S	G	K	12	2548	
357	V	E	D	L	N	I	W	S	L	T	S	G	K	S	12	2549	
371	T	A	I	V	H	I	Q	L	I	P	G	S	S	S	12	2550	
372	A	I	V	H	I	Q	L	I	P	G	S	S	S	K	12	2551	
391	S	K	A	N	H	L	L	L	N	T	F	G	M	Y	12	2552	

MHC Class II analysis of 108P5H8 flanking the D to E mutation at amino acid 30. Listed are scores that fall within the top 50% (rounded up) of all scores for a selected allele of the 108P5H8 variant 1 sequence that does not contain the mutation.

HLA-DRB1*0101 15 - mers

Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	score	SEQ. ID.
																	No.
20	P	L	F	L	N	D	T	S	A	F	E	F	S	D	E	25	2553
18	D	A	P	L	F	L	N	D	T	S	A	F	E	F	S	23	2554
17	D	D	A	P	L	F	L	N	D	T	S	A	F	E	F	18	2555
28	A	F	E	F	S	D	E	A	G	D	E	G	L	S	R	18	2556

HLA-DRB1*0301 (DR17) 15 - mers

Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	score	SEQ. ID.
																	No.
19	A	P	L	F	L	N	D	T	S	A	F	E	F	S	D	21	2557
18	D	A	P	L	F	L	N	D	T	S	A	F	E	F	S	20	2558
20	P	L	F	L	N	D	T	S	A	F	E	F	S	D	E	19	2559
26	T	S	A	F	E	F	S	D	E	A	G	D	E	G	L	15	2560

HLA-DRB1*0401 (DR4Dw4) 15 - mers

Pos	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	score	SEQ. ID.
																	No.
19	A	P	L	F	L	N	D	T	S	A	F	E	F	S	D	22	2561
16	K	D	D	A	P	L	F	L	N	D	T	S	A	F	E	18	2562
24	N	D	T	S	A	F	E	F	S	D	E	A	G	D	E	18	2563
28	A	F	E	F	S	D	E	A	G	D	E	G	L	S	R	16	2564

Atty Docket: 511582002500

18	D A P L F L N D T S A F E F S	14	2565
----	-------------------------------	----	------

HLA-DRB1*1101 15 - mers

Pos	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	score	SEQ. ID.
			No.
28	A F E F S D E A G D E G L S R	16	2566
17	D D A P L F L N D T S A F E F	12	2567

5

10

CLAIMS:

1. A composition comprising:
a substance that modulates the status of 108P5H8, or a molecule that is modulated by 108P5H8
whereby the status of a cell that expresses 108P5H8 is modulated.
2. The composition of claim 1, further comprising a pharmaceutically acceptable carrier.
3. A pharmaceutical composition that comprises the composition of claim 1 in a human unit
dose form.
4. A composition of claim 1 wherein the substance comprises an antibody or fragment
thereof that specifically binds to a 108P5H8-related protein.
5. The antibody or fragment thereof of claim 4, which is monoclonal.
6. A recombinant protein comprising an antigen-binding region of a monoclonal antibody of
claim 5.
7. The antibody or fragment thereof of claim 4, which is labeled with a detectable marker.
8. The recombinant protein of claim 6, which is labeled with a detectable marker.
9. The antibody fragment of an antibody of claim 4, which is an Fab, F(ab')₂, Fv or sFv
fragment.
10. The antibody of claim 4, which is a human antibody, a humanized antibody or a chimeric
antibody.
11. A non-human transgenic animal that produces an antibody of claim 4.
12. A hybridoma that produces an antibody of claim 5.
13. A single chain monoclonal antibody that immunospecifically binds to a 108P5H8-related
protein, and that comprises the variable domains of the heavy and light chains of a monoclonal antibody of
claim 5.

14. A vector comprising a polynucleotide that encodes a single chain monoclonal antibody of claim 13.

15. A method of delivering a cytotoxic agent or a diagnostic agent to a cell that expresses 108P5H8, said method comprising:
providing the cytotoxic agent or the diagnostic agent conjugated to an antibody or fragment thereof of claim 4; and,
exposing the cell to the antibody-agent or fragment-agent conjugate.

16. A composition of claim 1 wherein the substance comprises a polynucleotide that encodes an antibody or fragment thereof either of which immunospecifically binds to an 108P5H8-related protein.

17. A composition of claim 3 wherein the substance comprises a 108P5H8-related protein.

18. The composition of claim 17, further comprising antigen presenting cells.

19. The composition of claim 1 wherein the substance comprises an analog of a peptide of eight, nine, ten, or eleven contiguous amino acids of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574).

20. A composition of claim 1 wherein the substance comprises a CTL polypeptide epitope of the amino acid sequence of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574), with a *proviso* that the epitope is not the entire amino acid sequence of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574).

21. The composition of claim 20 wherein the CTL epitope comprises a polypeptide selected from Tables V-XVIII, XXII, and XXIII, with a *proviso* that the epitope is not the entire amino acid sequence of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574).

22. A composition of claim 1 wherein the substance comprises an antibody polypeptide epitope of the amino acid sequence of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574), with a *proviso* that the epitope is not the entire amino acid sequence of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574).

23. A composition of claim 22 wherein the antibody epitope comprises a peptide region of at least 5 amino acids of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574) in any whole number increment up to 875 that includes an amino acid position selected from: an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of Figure 5, an amino acid position having a value less than 0.5 in the Hydrophobicity profile of Figure 6; an amino acid position having a value greater than 0.5 in the Percent

Accessible Residues profile of Figure 7; an amino acid position having a value greater than 0.5 in the Average Flexibility profile on Figure 8; or an amino acid position having a value greater than 0.5 in the Beta-turn profile of Figure 9, with a *proviso* that the epitope is not the entire amino acid sequence of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574).

24. The recombinant protein of claim 23, which comprises murine antigen binding region residues and human constant region residues.

25. A polynucleotide that encodes an analog peptide of claim 19.

26. A composition of claim 1 wherein the substance comprises a polynucleotide that comprises an 108P5H8-related protein coding sequence, with a *proviso* that the coding sequence does not encode the entire amino acid sequence of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574).

27. The composition of claim 26 in human unit dose form.

28. A composition of claim 26 comprising a polynucleotide from position number 44 through number 2671 of Figure 2 (SEQ ID Nos.: 2569, 2571, 2573).

29. The composition of claim 28 wherein T is substituted with U.

30. A composition of claim 32 that comprises the coding sequence for the polynucleotide of Figure 2 (SEQ ID Nos.: 2569, 2571, 2573).

31. The composition of claim 30 wherein T is substituted with U.

32. A composition of claim 26 comprising a polynucleotide that encodes an 108P5H8-related protein that is at least 90% homologous to the entire amino acid sequence shown in Figure 2 (SEQ ID Nos.: 2570, 2572, 2574).

33. The composition of claim 32 wherein the polynucleotide encodes an 108P5H8-related protein that is at least 90% identical to the entire amino acid sequence shown in Figure 2 (SEQ ID Nos.: 2570, 2572, 2574).

34. A composition of claim 26 wherein the substance comprises a polynucleotide that encodes at least one peptide set forth in Tables V-XVIII, XXII, and XXIII, with a *proviso* that the amino acid sequence of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574) is not encoded.

5 35. A composition of claim 26 comprising a polynucleotide that encodes a peptide region of at least 5 amino acids of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574Q:—) that includes an amino acid position selected from: an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of Figure 5, an amino acid position having a value less than 0.5 in the Hydrophobicity profile of Figure 6; an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of Figure 7; an amino acid position having a value greater than 0.5 in the Average Flexibility profile on Figure 8; or an amino acid position having a value greater than 0.5 in the Beta-turn profile of Figure 9, with a *proviso* that the entire amino acid sequence of Figure 2 (SEQ ID Nos.: 2570, 2572, 2574Q:—) is not encoded.

10 36. A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 26.

15 37. A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 28.

38. A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 29.

20 39. A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 30, in human unit dose form.

25 40. A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 31.

41. A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 32.

30 42. A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 33.

43. A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 34.

35 44. A pharmaceutical composition of claim 1 wherein the substance comprises a ribozyme that cleaves a polynucleotide having 108P5H8 coding sequence and a physiologically acceptable carrier.

5 46. A pharmaceutical composition of claim 1 wherein the substance comprises human T cells, wherein said T cells specifically recognize a 108P5H8 peptide sequence in the context of a particular HLA molecule.

10 comprising:
administering to the cells the composition of claim 1.

15 administering to said cells an antibody or fragment thereof either of which specifically bind to a 108P5H8-related protein.

20 administering to said cells a vector that encodes a single chain monoclonal antibody that immunospecifically binds to an 108P5H8-related protein.

25 administering to said cells an 108P5H8-related protein.

administering to said cells a vector that comprises a polynucleotide comprising a 108P5H8-related protein coding sequence.

administering to said cells an antisense polynucleotide complementary to a polynucleotide having
35 a 108P5H8 coding sequence.

53. A method of claim 47 of inhibiting growth of cancer cells that express 108P5H8, the method comprising steps of:
administering to said cells a ribozyme that cleaves a polynucleotide having 108P5H8 coding sequence.

54. A method of claim 47 of inhibiting growth of cancer cells that express 108P5H8 and a particular HLA molecule, the method comprising steps of:
administering to said cells human T cells, wherein said T cells specifically recognize an 108P5H8 peptide sequence in the context of the particular HLA molecule.

55. A method of treating a patient who bears cancer cells that express 108P5118, the method comprising:
administering to the patient the composition of claim 1.

56. A method of claim 55 for treating a patient who bears cancer cells that expresses 108P5H8, the method comprising steps of:
administering to said patient an antibody or fragment thereof either of which specifically binds to a 108P5H8-related protein.

57. A method of claim 55 for treating a patient who bears cancer cells that expresses 108P5H8, the method comprising steps of:
administering to said patient a vector that encodes an antibody or fragment thereof either of which immunospecifically bind to an 108P5H8-related protein.

58. A method of claim 57 for treating a patient with a cancer that expresses 108P5H8, the method comprising steps of:

administering to said patient a vector that delivers a single chain monoclonal antibody coding sequence, whereby the encoded single chain antibody is expressed intracellularly within cancer cells that express 108P5H8.

59. A method of claim 55 for treating a patient who bears cancer cells that express 108P5H8, the method comprising steps of:
administering to said patient an 108P5H8-related protein.

60. A method of claim 55 for treating a patient who bears cancer cells that express 108P5H8, the method comprising steps of:

administering to said patient a vector that comprises a polynucleotide comprising a 108P5H8-related protein coding sequence.

61. A method of claim 55 for treating a patient who bears cancer cells that express 108P5H8, the method comprising steps of:
administering to said patient an antisense polynucleotide complementary to a polynucleotide having a 108P5H8 coding sequence.

62. A method of claim 55 for treating a patient who bears cancer cells that express 108P5H8, the method comprising steps of:
administering to said patient a ribozyme that cleaves a polynucleotide having an 108P5H8 coding sequence.

63. A method of claim 55 for treating a patient who bears cancer cells that express 108P5H8, the method comprising steps of:
administering to said patient a nucleic acid molecule that encodes a ribozyme that cleaves a polynucleotide having an 108P5H8 coding sequence.

64. A method of claim 55 for treating a patient who bears cancer cells that express 108P5H8 and a particular HLA molecule, the method comprising steps of:
administering to said patient human T cells, wherein said T cells specifically recognize an 108P5H8 peptide sequence in the context of the particular HLA molecule.

65. A method of generating a mammalian immune response directed to 108P5H8, the method comprising:
exposing cells of the mammal's immune system to an immunogenic portion of
a) an 108P5H8-related protein and/or
b) a nucleotide sequence that encodes said protein,
whereby an immune response is generated to 108P5H8.

66. A method of inducing an immune response of claim 65, said method comprising:
providing a 108P5H8-related protein that comprises at least one T cell or at least one B cell epitope;
contacting the epitope with a mammalian immune system T cell or B cell respectively, whereby the T cell or B cell is induced.

68. The method of claim 66 wherein the immune system cell is a T cell that is a cytotoxic T cell (CTL), whereby the activated CTL kills an autologous cell that expresses the 108P5H8-related protein.

70. An assay for detecting the presence of a 108P5H8-related protein or polynucleotide in a biological sample from a patient who has or who is suspected of having cancer, comprising steps of:

determining that there is a complex of the substance and 108P5H8-related protein or the substance and 108P5H8-related polynucleotide, respectively.

contacting the sample with an antibody or fragment thereof either of which specifically bind to the 108P5H8-related protein; and,

72. The assay in accordance with claim 70 further comprising a step of:

taking a sample from a patient who has or who is suspected of having cancer.

contacting the sample with a polynucleotide probe that specifically hybridizes to the polynucleotide of Figure 2 (SEQ ID Nos.: 2569, 2571, & 2573); and,

detecting the presence of a hybridization complex formed by the hybridization of the probe with 108P5H8 polynucleotide in the sample, wherein the presence of the hybridization complex indicates the presence of 108P5H8 polynucleotide within the sample.

74. An assay in accordance with claim 70 for detecting the presence of 108P5H8 mRNA in a biological sample from a patient who has or who is suspected of having cancer, said method comprising:

producing cDNA from the sample by reverse transcription using at least one primer;
amplifying the cDNA so produced using 108P5H8 polynucleotides as sense and antisense primers,
wherein the 108P5H8 polynucleotides used as the sense and antisense primers are capable of amplifying
108P5H8 cDNA; and

detecting the presence of the amplified 108P5H8 cDNA.

75. A method for monitoring 108P5H8 gene products in a biological sample from a patient
who has or who is suspected of having cancer, the method comprising:

determining the status of 108P5H8 gene products expressed by cells in a tissue sample from an
individual;

comparing the status so determined to the status of 108P5H8 gene products in a corresponding
normal sample; and,

identifying the presence of aberrant 108P5H8 gene products in the sample relative to the normal
sample.

76. A method of monitoring the presence of cancer in an individual comprising: performing
the method of claim 75 whereby the presence of elevated gene products 108P5H8 mRNA or 108P5H8
protein in the test sample relative to the normal tissue sample indicates the presence or status of a cancer.

77. The method of claim 76 wherein the cancer occurs in a tissue set forth in Table I.

ABSTRACT

A novel gene (designated 108P5H8) and its encoded protein, and variants thereof, are described wherein 108P5H8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 108P5H8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 108P5H8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P1E1B can be used in active or passive immunization.

5



10024652 062802

PATENT #6
Docket No. 511582002500

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL 744471223 US

Date of Deposit: June 28, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Box Missing Parts, Washington, D.C. 20231.

Tami M. Procopio
Tami M. Procopio

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Pia M. CHALLITA-EID, *et al.*

Serial No.: 10/024,652

Filing Date: December 17, 2001

For: NUCLEIC ACID AND ENCODED ZINC
TRANSPORTER ENTITLED 108P5H8
USEFUL IN TREATMENT AND
DETECTION OF CANCER

Examiner: To be assigned

Group Art Unit: 1645

SUBMISSION OF SUBSTITUTE DRAWINGS

BOX MISSING PARTS
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Attached please find 44 sheets of substitute drawings in compliance with 37 C.F.R. 1.84,
in connection with the above-identified application.

Respectfully submitted,

Kate H. Murashige

Dated: June 28, 2002

By: Kate H. Murashige
Registration No. (29,959)

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

Acc/ Docket: 511582002500

Figure 1: 108P5H8 SSH sequence of 448 nucleotides (SEQ ID:)

```

1 GATCCAGATT TCTCTGCACA CTGGACTTCG TAGAGTAAGT GTGGTAGACA AAGAGACTAC
61 ACTGCACAAC CACCAGTGAA TATCATTGCT AAGAAGACTT TGGGTCGTGT TTCTCAGCCA
121 CTCTCACAGC TTTTGTAGAC TTATTTGATT TTGAAACAAG CAGTTAGCTA AATCTATTTT
181 CCTTTTATGC ATATATGTTA ATTGGCTCAA CTTAATATGG TGTTCTTACA GAATATGAGC
241 CCATTTGAAA TAAGGTTTGA GGCAATTTTG CTGTTGGCTC TGATTTGTAT ATAGCAAATT
301 TAAAGGTACA GAGTGTTCCT TAGATAGAAG ATTAGTTCAT TTGGTTCATT TGTCTTTGA
361 AGCAAGCCAA GCTCATGAGC CAGTTGGTTA TTTGTCATAA ATGAACACCC ATCACTATAT
421 GCTATGTTGA GGGGAGGCAA GGCTGATC

```

Figure 2A. The cDNA (SEQ ID. NO. :) and amino acid sequence (SEQ ID. NO. :) of 108P5H8 v.1. The start methionine is underlined. The open reading frame extends from nucleic acid 253-1542 including the stop codon.

```

1 gccggcctccagcagcgggcgcgggcgcgagcacgacccactctcctgcggccgcg
61 ggtggagcagcgcgagcccgctcgtgagccggcgggggcggggagatgagttgcggc
121 cccgcggcagcgccccaggatggggagggacgcgcggcactgcctcgcagaactggcgct
181 ccggtgaagtaggcgcgcggcgccgtccgcctcccccgaagccgttcgcgacgcggcgcg
1 M A G S G A W K R L K S M L R K
241 tcagcctctgccATGGCCGGCTCTGGCGCGTGAAGCGCCTCAAATCTATGCTAAGGAAG
17 D D A P L F L N D T S A F D F S D E A G
301 GATGATGCGCCGCTGTTTTTAAATGACACCAGCGCCTTTGACTTCTCGGATGAGGCGGG
37 D E G L S R F N K L R V V V A D D G S E
361 GACGAGGGGCTTTCTCGGTTCAACAACTTCGAGTTGTGGTGGCCGATGACGTTCCGAA
57 A P E R P V N G A H P T L Q A D D D S L
421 GCCCCGGAAGGCCTGTAAACGGGGCGCACCCGACCCTCCAGGCCGACGATGATTCCTTA
77 L D Q D L P L T N S Q L S L K V D S C D
481 CTGGACCAAGACTTACCTTTGACCAACAGTCAGCTGAGTTTGAAGGTGGACTCCTGTGAC
97 N C S K Q R E I L K Q R K V K A R L T I
541 AACTGCAGCAAACAGAGAGAGATACTGAAGCAGAGAAAGGTGAAAGCCAGGTTGACCATT
117 A A V L Y L L F M I G E L V G G Y I A N
601 GCTGCCGTTCTGTACTTGCTTTTCATGATTGGAGAACTTGTAGGTGGATACATTGCAAAT
137 S L A I M T D A L H M L T D L S A I I L
661 AGCCTAGCAATCATGACAGATGCACTTCATATGTTAACTGACCTAAGCGCCATCATCTACT
157 T L L A L W L S S K S P T K R F T F G F
721 ACCCTGCTTGCTTTGTGGCTATCATCAAATCACCAACCAAAGATTACCTTTGGATT
177 H R L E V L S A M I S V L L V Y I L M G

```

...ty Docket: 511582002500

781 CATCGCTTAGAGGTTTTGTCAGCTATGATTAGTGTGCTGTTGGTGTATATACTTATGGGA
197 F L L Y E A V Q R T I H M N Y E I N G D
841 TTCCTCTTATATGAAGCTCTGCAAAGAACTATCCATATGAACTATGAAATAAATGGAGAT
217 I M L I T A A V G V A V N V I M G F L L
901 ATAATGCTCATCACCGCAGCTGTTGGAGTTGCAGTTAATGTAATAATGGGGTTTCTGTTG
237 N Q S G H R H S H S H S L P S N S P T R
961 AACCAGTCTGGTCACCGTCACTCCCATTCCCCTCCCTGCCTTCAAATTCCTTACCAGA
257 G S G C E R N H G Q D S L A V R A A F V
1021 GGTTCCTGGGTGTGAACGTAACCATGGGCAGGATAGCCTGGCAGTGAGAGCTGCATTGTGA
277 H A L G D L V Q S V G V L I A A Y I I R
1081 CATGCTTGGGAGATTGGTACAGAGTGTGGTGTGCTAATAGCTGCATACATCATACGA
297 F K P E Y K I A D P I C T Y V F S L L V
1141 TTCAAGCCAGAATACAAGATTGCTGACCCCATCTGTACATACGTATTTTCATTACTTGTG
317 A F T T F R I I W D T V V I I L E G V P
1201 GCTTTTACAACATTTCGAATCATATGGGATACAGTAGTTATAATACTAGAAGGTGTGCCA
337 S H L N V D Y I K E A L M K I E D V Y S
1261 AGCCATTGAATGTAGACTATATCAAAGAAGCCTTGATGAAAATAGAAGATGTATATTCA
357 V E D L N I W S L T S G K S T A I V H I
1321 GTCGAAGATTTAAATATCTGGTCTCTCACTTCAGGAAAATCTACTGCCATAGTTACATA
377 Q L I P G S S S K W E E V Q S K A N H L
1381 CAGCTAATTCCTGGAAGTTCATCTAAATGGGAGGAAGTACAGTCCAAAGCAAACCATTTA
397 L L N T F G M Y R C T I Q L Q S Y R Q E
1441 TTATTGAACACATTGGGCATGTATAGATGTACTATTTCAGCTTCAGAGTTACAGGCAAGAA
417 V D R T C A N C Q S S S P *
1501 GTGGACAGAACTTGTGCAAATTGTCAGAGTTCTAGTCCCTAAttttatgtattttgggaa
1561 ctccctgccttattttatccctgcagtcacagacttgagagcaataaatgcaaactaaatga
1621 gaaaatggaatccctgacagctgtgtccgtatcaagcatcagtcctctcaaacagttgccc
1681 cagcctgacagtgctagtctctgttttaattggtaaaaggagactttgccataattttcaga
1741 tgaagatgtttcccaaactgtttacagaatgagatgtgactctacagatacctcatag
1801 aagacaatccaagatcatacttcattaacttgacagagtacgtgtcttaaaggaagcatc
1861 aagaattcaatattttgcatttaaaaaatactttttaaggccattttatattaagccagtgc
1921 tggaaaactgaattttttttattatgtataataatctcgacacccagcttctggaattgc
1981 tgctttctttttacagaaattactacccaacagatttcaggaagtactagtagttatccc
2041 aaaagtggaaataagcatgtattcctaagtgtttcagaaatgttttatttcacacataagt
2101 cttaatgttattgttatgattatactttataaacaaccttttccagatgctacagggttt
2161 tgaatctcaaagttaacatttttccatttttgtaactcttagaaccaaatctttatttatt
2221 gtggtcactgttattaaatgatttaggaataactttcaatattattctgaatggctgaag

Atty Docket: 511582002500

2281 ttagtcttaaaactcaaattactatatgatgatttaaaacaaaataaaagagcgaggatgg
2341 ggaaaaaaaaaaaaaaaaaaaaa

J. Docket: 511582002500

Figure 2B. The cDNA (SEQ ID. NO. :____) and amino acid sequence (SEQ ID. NO. :____) of 108P5H8 v.2. The start methionine is underlined. The open reading frame extends from nucleic acid 1-1290 including the stop codon.

```
1 M A G S G A W K R L K S M L R K D D A P
1 ATGGCCGCTCTGGCGCGTGAAGCGCCTCAAATCTATGCTAAGGAAGGATGATGCGCCG
21 L F L N D T S A F D F S D E A G D E G L
61 CTGTTTTTAAATGACACCAGCGCCTTTGACTTCTCGGATGAGGCGGGGGACGAGGGGCTT
41 S R F N K L R V V V A D D G S E A P E R
121 TCTCGGTTCAACAACTTCGAGTTGTGGTGGCCGATGACGGTCCGAAGCCCCGAAAGG
61 P V N G A H P T L Q A D D D S L L D Q D
181 CCTGTTAACGGGGCGACCCGACCCTCCAGGCCGACGATGATTCCTTACTGGACCAAGAC
81 L P L T N S Q L S L K V D S C D N C S K
241 TTACCTTTGACCAACAGTCAGCTGAGTTTGAAGGTGGACTCCTGTGACAACTGCAGCAAA
101 Q R E I L K Q R K V K A R L T I A A V L
301 CAGAGAGAGATACTGAAGCAGAGAAAGGTGAAAGCCAGGTTGACCATTGCTGCCGTTCTG
121 Y L L F M I G E L V G G Y I A N S L A I
361 TACTTGCTTTTCATGATTGGAGAAGCTGTAGGTGGATACATTGCAAATAGCCTAGCAATC
141 M T D A L H M L T D L S A I I L T L L A
421 ATGACAGATGCACTTCATATGTTAACTGACCTAAGCGCCATCATACTCACCCCTGCTTGCT
161 L W L S S K S P T K R F T F G F H R L E
481 TTGTGGCTATCATCAAATCACCAACCAAAAGATTACCTTTGGATTTCATCGCTTAGAG
181 V L S A M I S V L L V Y I L M G F L L Y
541 GTTTTGTGAGCTATGATTAGTGTGCTGTTGGTGTATATACTTATGGGATTCCTCTTATAT
201 E A V Q R T I H M N Y E I N G D I M L I
601 GAAGCTGTGCAAAGAACTATCCATATGAACTATGAAATAAATGGAGATATAATGCTCATC
221 T A A V G V A V N V I M G F L L N Q S G
661 ACCGCAGCTGTTGAGTTGAGTTAATGTAATAATGGGGTTTCTGTTGAACCACTGCTGGT
241 H R H S H S H S L P S N S P T R G S G C
721 CACCGTCACTCCCATTCCTCCCTGCCTTCAAATTCCTTACCAGAGGTTCTGGGTGT
261 E R N H G Q D S L A V R A A F V H A L G
781 GAACGTAACCATGGGCAGGATAGCCTGGCAGTGAGAGCTGCATTTGTACATGCTTTGGGA
281 D L V Q S V G V L I A A Y I I R F K P E
841 GATTTGGTACAGAGTGTGGTGTGCTAATAGCTGCATACATCATACGATTCAAGCCAGAA
301 Y K I A D P I C T Y V F S L L V A F T T
901 TACAAGATTGCTGATCCCATCTGTACATACGTATTTTCATTACTTGTGGCTTTTACAACA
321 F R I I W D T V V I I L E G V P S H L N
```


County Docket: 511582002500

284

Docket: 511582002500

Figure 2C. The cDNA (SEQ ID. NO. :____) and amino acid sequence (SEQ ID. NO. :____) of 108P5H8 v.3. The start methionine is underlined. The open reading frame extends from nucleic acid 1-1290 including the stop codon.

```
1 M A G S G A W K R L K S M L R K D D A P
1 ATGGCCGGCTCTGGCGCTGGAAGCGCCTCAAATCTATGCTAAGGAAGGATGATGCGCCG
21 L F L N D T S A F E F S D E A G D E G L
61 CTGTTTTTAAATGACACCAGCGCCTTTGAGTTCTCGGATGAGGCGGGGACGAGGGGCTT
41 S R F N K L R V V V A D D G S E A P E R
121 TCTCGGTTCAACAAACTTCGAGTTGTGGTGGCCGATGACGGTTCCGAAGCCCCGGAAGG
61 P V N G A H P T L Q A D D D S L L D Q D
181 CCTGTTAACGGGGCGCACCCGACCCTCCAGGCCGACGATGATTCCTTACTGGACCAAGAC
81 L P L T N S Q L S L K V D S C D N C S K
241 TTACCTTTGACCAACAGTCAGCTGAGTTTGAAGGTGGACTCCTGTGACAACTGCAGCAAA
101 Q R E I L K Q R K V K A R L T I A A V L
301 CAGAGAGAGATACTGAAGCAGAGAAAGGTGAAAGCCAGGTTGACCATTGCTGCCGTTCTG
121 Y L L F M I G E L V G G Y I A N S L A I
361 TACTTGCTTTTCATGATTGGAGAACTTGTAGGTGGATACATTGCAAATAGCCTAGCAATC
141 M T D A L H M L T D L S A I I L T L L A
421 ATGACAGATGCACTTCATATGTTAACTGACCTAAGCGCCATCATACTCACCCCTGCTTGCT
161 L W L S S K S P T K R F T F G F H R L E
481 TTGTGGCTATCATCAAAATCACCAACCAAAAGATTACCTTTGGATTTCATCGCTTAGAG
181 V L S A M I S V L L V Y I L M G F L L Y
541 CTTTTGTCAGCTATGATTAGTGTGCTGTGGTGTATATACTTATGGGATTCCTCTTATAT
201 E A V Q R T I H M N Y E I N G D I M L I
601 GAAGCTGTGCAAAGAACTATCCATATGAACTATGAAATAAATGGAGATATAATGCTCATC
221 T A A V G V A V N V I M G F L L N Q S G
661 ACCGCAGCTGTTGGAGTTGCAGTTAATGTAATAATGGGGTTTCTGTTGAACCACTCTGGT
241 H R H S H S H S L P S N S P T R G S G C
721 CACCGTCACTCCCATTCCTCCCTGCCTTCAAATTCCCCTACCAGAGGTTCTGGGTGT
261 E R N H G Q D S L A V R A A F V H A L G
781 GAACGTAACCATGGGCAGGATAGCCTGGCAGTGAGAGCTGCATTTGTACATGCTTTGGGA
281 D L V Q S V G V L I A A Y I I R F K P E
841 GATCTGGTACAGAGTGTGGTGTGCTAATAGTGCATACATCATACGATTCAAGCCAGAA
301 Y K I A D P I C T Y V F S L L V A F T T
901 TACAAGATTGCTGACCCCATCTGTACATACGTATTTTCATTACTTGTGGCTTTTACAACA
```

sd-70954

Atty Docket: 511582002500

Figure 3:

Figure 3A. Amino acid sequence corresponding to 108P5H8 v.1 and 108P5H8 v.2
(SEQ ID. NO. : ____). The 108P5H8 v.1 and 108P5H8 v.2 proteins have 429 amino acids.

```

1  MAGSGAWKRL  KSMRLRKDDAP  LFLNDTSAFD  FSDEAGDEGL  SRFNKL RVVV  ADDGSEAPER
61  PVNGAHPTLQ  ADDDSLDDQD  LPLTNSQLSL  KVDSCDNCSK  QREILKQRKV  KARLTIAAVL
121 YLLFMIGELV  GGYIANSLAI  MTDALHMLTD  LSAILLTLLA  LWLSSKSPTK  RFTFGFHRLE
181 VLSAMISVLL  VYILMGFLLY  EAVQRTIHMN  YEINGDIMLI  TAAVGAVNV  IMGFLLNQSG
241 HRHSHSHSLP  SNSPTRGSGC  ERNHGQDSL  A  VRAAFVHALG  DLVQSVGVLI  AAYIIRFKPE
301 YKIADPICTY  VFSLLVAFTT  FRIIWDTVVI  ILEGVPSHLN  VDYIKEALMK  IEDVYSVEDL
361 NIWSLTSGKS  TAIVHIQLIP  GSSSKWEEVQ  SKANHLLLNT  FGMYRCTIQL  QSYRQEVDR
421 CANCQSSSP*

```

Figure 3B. Amino acid sequence corresponding to 108P5H8 v.3 (SEQ ID. NO. : ____).
The 108P5H8 v.3 protein has 429 amino acids.

```

1  MAGSGAWKRL  KSMRLRKDDAP  LFLNDTSAFE  FSDEAGDEGL  SRFNKL RVVV  ADDGSEAPER
61  PVNGAHPTLQ  ADDDSLDDQD  LPLTNSQLSL  KVDSCDNCSK  QREILKQRKV  KARLTIAAVL
121 YLLFMIGELV  GGYIANSLAI  MTDALHMLTD  LSAILLTLLA  LWLSSKSPTK  RFTFGFHRLE
181 VLSAMISVLL  VYILMGFLLY  EAVQRTIHMN  YEINGDIMLI  TAAVGAVNV  IMGFLLNQSG
241 HRHSHSHSLP  SNSPTRGSGC  ERNHGQDSL  A  VRAAFVHALG  DLVQSVGVLI  AAYIIRFKPE
301 YKIADPICTY  VFSLLVAFTT  FRIIWDTVVI  ILEGVPSHLN  VDYIKEALMK  IEDVYSVEDL
361 NIWSLTSGKS  TAIVHIQLIP  GSSSKWEEVQ  SKANHLLLNT  FGMYRCTIQL  QSYRQEVDR
421 CANCQSSSP*

```

Figure 4:

Figure 4A Nucleic acid sequence alignment of the 3 variants of 108P5H8. Highlighted in yellow and underlined are the variations between the variants. The ORF extends from nucleotides 253-1542 of 108P5H8 v.1.

1	15	16	30	31	45	46	60	61	75	76	
90											
	v.1 GCGGGCCTCCAGCAG CCGCGCGCGCGGGCG CGAGCAGACCCAC TCTCCTGCGGCCGCG GGTGGAGCAGCGCGA										
	GCGCGCCTCGCTGAG										
	v.2 -----										

	v.3 -----										

180	91	105	106	120	121	135	136	150	151	165	166
	v.1 CCGCGCGGGGGGGG GAGATGAGTTGCGG CCGCGCGCAGCGCCC CAGGATGGGAGGGA CGCGCGGCACTGCC										
	TCGAGAACTGGCGCT										
	v.2 -----										

	v.3 -----										

270	181	195	196	210	211	225	226	240	241	255	256
	v.1 CCGGTGAAGTAGGCG CCGCGCGCGGTCGCG CTCGCCCAAGCCGTT CCGCACCGGCGCGC TCAGCCTCTGCCATG										
	GCGGGCTCTGGCGCG										
	v.2 -----										
	-----ATG										
	GCGGGCTCTGGCGCG										
	v.3 -----										
	-----ATG										
	GCGGGCTCTGGCGCG										

108P5H8 v.1

289

sd-70954

	901	915 916	930 931	945 946	960 961	975 976
990						
V.1 ATAATGCTCATCACC						
CGTCACTCCCATCC						
V.2 ATAATGCTCATCACC						
CGTCACTCCCATCC						
V.3 ATAATGCTCATCACC						
CGTCACTCCCATCC						
1066						
V.1 CACTCCCTGCCTTCA						
AGAGCTGCATTGTGA						
V.2 CACTCCCTGCCTTCA						
AGAGCTGCATTGTGA						
V.3 CACTCCCTGCCTTCA						
AGAGCTGCATTGTGA						
1156						
V.1 CATGCTTTGGGAGAT						
AAGATTGCTGA ^{CCCC}						
V.2 CATGCTTTGGGAGAT						
AAGATTGCTGA ^{CCCC}						
V.3 CATGCTTTGGGAGAT						
AAGATTGCTGA ^{CCCC}						
1246						
V.1 ATCTGFACATACGTA						
CTAGAAGGTTGTGCCA						

V.2 ATCTGTACATACGTA TTTTCATTACTTGTG GCTTTTACAACATTT CGAATCATATATGGGAT ACAGTAGTTATAATA
CTAGAAGGTGTGCCA
V.3 ATCTGTACATACGTA TTTTCATTACTTGTG GCTTTTACAACATTT CGAATCATATATGGGAT ACAGTAGTTATAATA
CTAGAAGGTGTGCCA

1261 1275 1276 1290 1291 1305 1306 1320 1321 1335
1336 1350
V.1 AGCCATTTGAATGTA GACTATATCAAAAGAA GCCTTGATGAAAATA GAAGATGTATATTCA GTCGAAGATTTTAAAT
ATCTGGTCTCTCACT
V.2 AGCCATTTGAATGTA GACTATATCAAAAGAA GCCTTGATGAAAATA GAAGATGTATATTCA GTCGAAGATTTTAAAT
ATCTGGTCTCTCACT
V.3 AGCCATTTGAATGTA GACTATATCAAAAGAA GCCTTGATGAAAATA GAAGATGTATATTCA GTCGAAGATTTTAAAT
ATCTGGTCTCTCACT

1351 1365 1366 1380 1381 1395 1396 1410 1411 1425
1426 1440
V.1 TCAGGAAAATCTACT GCCATAGTTACACATA CAGCTAAATTCCTGGA AGTTCAATCTAAATGG GAGGAAGTACAGTCC
AAAGCAAACCATTTA
V.2 TCAGGAAAATCTACT GCCATAGTTACACATA CAGCTAAATTCCTGGA AGTTCAATCTAAATGG GAGGAAGTACAGTCC
AAAGCAAACCATTTA
V.3 TCAGGAAAATCTACT GCCATAGTTACACATA CAGCTAAATTCCTGGA AGTTCAATCTAAATGG GAGGAAGTACAGTCC
AAAGCAAACCATTTA

1441 1455 1456 1470 1471 1485 1486 1500 1501 1515
1516 1530
V.1 TTATTGAACACATTT GGCAATGTATAGATGT ACTATTACAGCTTCAG AGTTACAGGCAAGAA GTGGACAGAACTTGT
GCAAAATTGTCAGAGT
V.2 TTATTGAACACATTT GGCAATGTATAGATGT ACTATTACAGCTTCAG AGTTACAGGCAAGAA GTGGACAGAACTTGT
GCAAAATTGTCAGAGT
V.3 TTATTGAACACATTT GGCAATGTATAGATGT ACTATTACAGCTTCAG AGTTACAGGCAAGAA GTGGACAGAACTTGT
GCAAAATTGTCAGAGT

1531	1545	1546	1560	1561	1575	1576	1590	1591	1605
1606									
v.1	TCTAGTCCCTAAATTT	TATGTATT--TTGGG	AACCTCCTG-----C	CTTATTATTACCTGCA	GTCA	CAGACTTGAGA			
GCAATAAATGCAAAAC									
v.2	TCTAGTCCCTAAATTT	TATGTATT--TTGGG	GACTCCTG-----C	CTTATTATTACCTGCA	GTCA	CAGACTTGAGA			
GCAATAAATGCAAAAC									
v.3	TCTAGTCCCTAAATTT	TATGTATTGTTT ^{TT} AG	CATTGCTGAATTCAC	TTTATTATTACCTGCA	GTCA	CAGACTTGAGA			
GCAATAAATGCAAAAC									

1696
1621 1635 1636 1650 1651 1665 1680 1681 1695
1710
v.1 CTAATGAGAAAATG GAATCCCTGACAGCT GTGTCCGTATCAAGC ATCAGTCTCTCAAAC AGTTGCCCCAGCCTG
ACAGTGCTAGTCTCT
v.2 CTAATGAGAAAATG GAATCCCTGACAGCT GTGTCCGTATCAAGC ATCAGTCTCTCAAAC AGTTGCCCCAGCCTG
ACAGTGCTAGTCTCT
v.3 CTAATGAGAAAATG GAATCCCTGACAGCT GTGTCCGTATCAAGC ATCAGTCTCTCAAAC AGTTGCCCCAGCCTG
ACAGTGCTAGTCTCT

[illegible]

1876
1801 1815 1816 1830 1831 1845 1846 1860 1861 1875
1890
v.1 ACCTCATAGAAGACA ATCCAAGATCATACT TCATTAACTTGACAG AGTACGTGCTTAA GGAAGCATCAAGAAT
TCAATATTTGCATT

-----v.2 ACCTCATAG-----

v.3 ACCTCATAG-----

1891	1905	1906	1920	1921	1935	1936	1950	1951	1965
------	------	------	------	------	------	------	------	------	------

1980

1966
1980
1986

TCGACACCCAGCTTC

v.2

v.3

	1981	1995	1996	2010	2011	2025	2026	2040	2041	2055
--	------	------	------	------	------	------	------	------	------	------

2070

2056
-- 1 TACCAATTGCGCCGCCCTTT CTTTTTATCAGAAAATT ACTACCCAACAGATT TCAGGAAGTACTAGT AGTTATTCCTCAAAGT

2070

GGAATAAGCATGTAT

v.2

v.3

2071 2085 2086 2100 2101 2115 2116 2130·2131 2145

2160

2146
2160
CACAATAAGCTCTTAAT GTTATTGTTATGATT ATACTTTATAAACAA

CCTTTCCAGATGCT

v.2

v.3-----

2161 2175 2176 2190 2191 2205 2206 2220 2221 2235 2236
 2250
 v.1 ACAGGGTTTGAATC TCAAAGTTAACATTT TTCAATTATTGTAAAT CTTAGAACCACAAATCT TTATTATTGTGGTC
 ACTGTTATTAAATGA
 v.2 -----

 v.3 -----

2251 2265 2266 2280 2281 2295 2296 2310 2311 2325
 2326 2340
 v.1 TTAGGAAATACCTT CAAATATTATTCTGAA TGGCTGAAGTTAGTC TTAAACTCAAATTAC TATATGATGATTTAA
 AACAAAATAAAAGAG
 v.2 -----


 v.3 -----

2341 2355 2356 2370
 v.1 CGAGGATGGGAAAA AAAAAAAAAAAAAAAA AAA 2364
 v.2 ----- 1548
 v.3 ----- 1557

MEMORANDUM FOR THE RECORD


296

Figure 5: 108P5H8 Hydrophilicity profile
(Hopp T.P., Woods K.R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828)




sd-70959

Figure 6: 108P5H8 Hydropathicity Profile
(Kyte J., Doolittle R.F., 1982. J. Mol. Biol. 157:105-132)




sd-70959

Figure 7: 108P5H8 % Accessible Residues Profile
(Janin J., 1979. Nature 277:491-492)




sd-70959

Figure 8: 108P5H8 Average Flexibility Profile
(Bhaskaran R., Ponnuswamy P.K., 1988.
Int. J. Pept. Protein Res. 32:242-255)



sd-70959

Figure 9: 108P5H8 Beta-turn Profile
(Deleage, G., Roux B. 1987. Protein Engineering 1:289-294)



sd-70959

Figure 10 Expression of 108P5H8 by RT-PCR




Figure 11 Expression of 108P5H8 in Prostate Cancer Xenografts and restricted normal tissues




Figure 12 Expression of 108P5H8 in prostate cancer xenografts




Figure 13 Expression of 108P5H8/ZnT4 in prostate and multiple cancer cell lines




Figure 14 Expression of 108P5H8 in Human Cancers




Figure 15 Expression of 108P5H8 in prostate cancer patients samples




Figure 16 108P5H8 is not Androgen-Regulated





Figure 17 Expression of 108P5H8 in Prostate Cancer Metastasis Specimens



*Met1 = Prostate cancer metastasis to lymph
node from patient 1*

*Met2 = Prostate cancer metastasis to lymph
node from patient 2*

NB = normal bladder

NK = normal kidney

NL = normal lung


NBr = normal breast

NO = normal ovary

NPa = normal pancreas


Figure 19: Transmembrane region prediction of 108P5H8

A



Transmembrane domains

THMM posterior probabilities for Sequence




B

sd-70949

100024652 100024652

Figure 20: Androgen-independent expression of 108P5H8 in prostate cancer cells



sd-70950

Figure 21: Surface expression of 108P5H8 in prostate cancer cells





Figure 22: Surface expression of 108P5H8 in 293T cells

Flow cytometry




Anti-His pAb

Anti-108P5H8 pAb

Fluorescence
microscopy




293T-108P5H8



293T-vector


Anti-108P5H8 pAb

Figure 23: Expression of 108P5H8 in prostate and ovarian cancer patient specimens



sd-70963

**Figure 24: Expression of 108P5H8
in engineered cell lines**



sd-70962

Figure 25: Alignment of 108P5H8 v.1 protein with members of the zinc transporter family.

A-Alignment of 108P5H8 with the human zinc transporter 4, i.e. gi 11432533

Identities = 429/429 (100%), Positives = 429/429 (100%)

```

108P5: 1  MAGSGAWKRLKSMRLKDDAPLFLNDTSAFDFSDEAGDEGLSRFNKLRVVVADDGSEAPER 60
          MAGSGAWKRLKSMRLKDDAPLFLNDTSAFDFSDEAGDEGLSRFNKLRVVVADDGSEAPER
Sbjct: 1  MAGSGAWKRLKSMRLKDDAPLFLNDTSAFDFSDEAGDEGLSRFNKLRVVVADDGSEAPER 60

108P5: 61  PVNGAHPTLQADDDSLDQDLPLTNSQLSLKVDSCDNCSKQREILKQKVKARLTIAAVL 120
          PVNGAHPTLQADDDSLDQDLPLTNSQLSLKVDSCDNCSKQREILKQKVKARLTIAAVL
Sbjct: 61  PVNGAHPTLQADDDSLDQDLPLTNSQLSLKVDSCDNCSKQREILKQKVKARLTIAAVL 120

108P5: 121 YLLFMIGELVGGYIANSIAIMTDALHMLTDLISAIILTLALWLSSKSPTKRFTFGFHRLE 180
          YLLFMIGELVGGYIANSIAIMTDALHMLTDLISAIILTLALWLSSKSPTKRFTFGFHRLE
Sbjct: 121 YLLFMIGELVGGYIANSIAIMTDALHMLTDLISAIILTLALWLSSKSPTKRFTFGFHRLE 180

108P5: 181 VLSAMISVLLVYILMGFLLYEAVQRTIHMNYEINGDIMLITAAVGVAENVIMGFLLNQSG 240
          VLSAMISVLLVYILMGFLLYEAVQRTIHMNYEINGDIMLITAAVGVAENVIMGFLLNQSG
Sbjct: 181 VLSAMISVLLVYILMGFLLYEAVQRTIHMNYEINGDIMLITAAVGVAENVIMGFLLNQSG 240

108P5: 241 HRHSHSHSLPSNSPTRGSGCERNHGQDSLAVRAAFVHALGDLVQSVGLIAAYIIRFKPE 300
          HRHSHSHSLPSNSPTRGSGCERNHGQDSLAVRAAFVHALGDLVQSVGLIAAYIIRFKPE
Sbjct: 241 HRHSHSHSLPSNSPTRGSGCERNHGQDSLAVRAAFVHALGDLVQSVGLIAAYIIRFKPE 300

108P5: 301 YKIADPICTYVFSLLVAFTTTFRIIWDTVVIILEGVPSHLNVDYIKEALMKIEDVYSVEDL 360
          YKIADPICTYVFSLLVAFTTTFRIIWDTVVIILEGVPSHLNVDYIKEALMKIEDVYSVEDL
Sbjct: 301 YKIADPICTYVFSLLVAFTTTFRIIWDTVVIILEGVPSHLNVDYIKEALMKIEDVYSVEDL 360

108P5: 361 NIWSLTSGKSTAIVHIQLIPGSSSKWEEVQSKANHLLNTFGMYRCTIQLQSYRQEVDR 420
          NIWSLTSGKSTAIVHIQLIPGSSSKWEEVQSKANHLLNTFGMYRCTIQLQSYRQEVDR
Sbjct: 361 NIWSLTSGKSTAIVHIQLIPGSSSKWEEVQSKANHLLNTFGMYRCTIQLQSYRQEVDR 420

108P5: 421 CANCQSSSP 429
          CANCQSSSP
Sbjct: 421 CANCQSSSP 429

```

B-Alignment of 108P5H8 with the human zinc transporter ZNT4, i.e. gi 8134840

Identities = 428/429 (99%), Positives = 429/429 (99%)

```

108P5: 1  MAGSGAWKRLKSMRLKDDAPLFLNDTSAFDFSDEAGDEGLSRFNKLRVVVADDGSEAPER 60
          MAGSGAWKRLKSMRLKDDAPLFLNDTSAF+FSDEAGDEGLSRFNKLRVVVADDGSEAPER
Sbjct: 1  MAGSGAWKRLKSMRLKDDAPLFLNDTSAFDFSDEAGDEGLSRFNKLRVVVADDGSEAPER 60

108P5: 61  PVNGAHPTLQADDDSLDQDLPLTNSQLSLKVDSCDNCSKQREILKQKVKARLTIAAVL 120
          PVNGAHPTLQADDDSLDQDLPLTNSQLSLKVDSCDNCSKQREILKQKVKARLTIAAVL
Sbjct: 61  PVNGAHPTLQADDDSLDQDLPLTNSQLSLKVDSCDNCSKQREILKQKVKARLTIAAVL 120

108P5: 121 YLLFMIGELVGGYIANSIAIMTDALHMLTDLISAIILTLALWLSSKSPTKRFTFGFHRLE 180
          YLLFMIGELVGGYIANSIAIMTDALHMLTDLISAIILTLALWLSSKSPTKRFTFGFHRLE
Sbjct: 121 YLLFMIGELVGGYIANSIAIMTDALHMLTDLISAIILTLALWLSSKSPTKRFTFGFHRLE 180

108P5: 181 VLSAMISVLLVYILMGFLLYEAVQRTIHMNYEINGDIMLITAAVGVAENVIMGFLLNQSG 240
          VLSAMISVLLVYILMGFLLYEAVQRTIHMNYEINGDIMLITAAVGVAENVIMGFLLNQSG
Sbjct: 181 VLSAMISVLLVYILMGFLLYEAVQRTIHMNYEINGDIMLITAAVGVAENVIMGFLLNQSG 240

108P5: 241 HRHSHSHSLPSNSPTRGSGCERNHGQDSLAVRAAFVHALGDLVQSVGLIAAYIIRFKPE 300
          HRHSHSHSLPSNSPTRGSGCERNHGQDSLAVRAAFVHALGDLVQSVGLIAAYIIRFKPE
Sbjct: 241 HRHSHSHSLPSNSPTRGSGCERNHGQDSLAVRAAFVHALGDLVQSVGLIAAYIIRFKPE 300

```

108P5: 301 YKIADPICTYVFSLLVAFTTFRIIWDTVVIIIEGVPSHLNVDYIKEALMKIEDVYSVEDL 360
 YKIADPICTYVFSLLVAFTTFRIIWDTVVIIIEGVPSHLNVDYIKEALMKIEDVYSVEDL
 Sbjct: 301 YKIADPICTYVFSLLVAFTTFRIIWDTVVIIIEGVPSHLNVDYIKEALMKIEDVYSVEDL 360

108P5: 361 NIWSLTSGKSTAIVHIQLIPGSSSKWEEVQSKANHLLNTFGMYRCTIQLQSYRQEVDR 420
 NIWSLTSGKSTAIVHIQLIPGSSSKWEEVQSKANHLLNTFGMYRCTIQLQSYRQEVDR
 Sbjct: 361 NIWSLTSGKSTAIVHIQLIPGSSSKWEEVQSKANHLLNTFGMYRCTIQLQSYRQEVDR 420

108P5: 421 CANCQSSSP 429
 CANCQSSSP
 Sbjct: 421 CANCQSSSP 429

C-Alignment of 108P5H8 with the rat zinc transporter ZNT-4, i.e. gi 8134837

Identities = 387/430 (90%), Positives = 407/430 (94%), Gaps = 3/430 (0%)

108P5: 1 MAGSGAWKRLKSMRLRKDDAPLFLNDTSAFDFSDEAGDEGLSRFNKL RVVVADDGSEAPER 60
 MAG GAWKRLKS+LRKDDAPLFLNDTSAFDF DE DEGLSRFNKL RVVVADD SEAPER
 Sbjct: 1 MAGPGAWKRLKSLLRKDDAPLFLNDTSAFDFLDEVSEGLSRFNKL RVVVADDSEAPER 60

108P5: 61 PVNGAHP LQADDDSLDQDLPLTNSQLSLKVDSCDNCSKQREILKQKVKARLTIAAVL 120
 PVNGAHP LQADDDSLDQ+LPLTNSQLSLK+D CDNCSK+RE+LKQKVK RLTIAAVL
 Sbjct: 61 PVNGAHPALQADDDSLDQELPLTNSQLSLKMDPCDNCSKRRELLKQKVKTRLTIAAVL 120

108P5: 121 YLLFMIGELVGGYIANS LAIMTDALHMLTDLSAI ILTLLALWLSKSPTRFTFGFHRLE 180
 YLLFMIGELVGGY+ANSLA IMTDALHMLTDLSAI ILTLLALWLSKSPTRFTFGFHRLE
 Sbjct: 121 YLLFMIGELVGGYMANSLA IMTDALHMLTDLSAI ILTLLALWLSKSPTRFTFGFHRLE 180

108P5: 181 VLSAMISVLLVYILMGFLLYEAVQRTIHMNYEINGDIMLITA AVGVAVNVIMGFLNQG-- 238
 VLSAMISV+LVY+LMGFLLYEAVQRTIHMNYEINGD+MLITA AVGVAVNVIMGFLNQG
 Sbjct: 181 VLSAMISVMLVYVLMGFLLYEAMQRTIHMNYEINGDVMLITA AVGVAVNVIMGFLNQGSG 240


108P5: 239 SGHRHSHSHSLPSNSPTRGSGCERNHGQDSLAVRAAFVHALGDLVQSVGVLIAAYIIRFK 298
 H H+HSHSLPSNSP+ S +HGQDSLAVRAAFVHALGDLVQSVGVLIAAYIIRFK
 Sbjct: 241 HHSHAHSHSLPSNSPSMVSS-GHSHGQDSLAVRAAFVHALGDLVQSVGVLIAAYIIRFK 299

108P5: 299 PEYKIADPICTYVFSLLVAFTTFRIIWDTVVIIIEGVPSHLNVDYIKEALMKIEDVYSVE 358
 PEYKIADPICTY+FSLLVAFTT RIIWDTVVIIIEGVPSHLNVDYIKE+LMKIEDVYSVE
 Sbjct: 300 PEYKIADPICTYIFSLVAFTTLRIIWDTVVIIIEGVPSHLNVDYIKESLMKIEDVYSVE 359

108P5: 359 DLNIWSLTSGKSTAIVHIQLIPGSSSKWEEVQSKANHLLNTFGMYRCTIQLQSYRQEVDR 418
 DLNIWSLTSGK+TAIVH+QLIPGSSSKWEEVQSKA HLLNTFGMY+CT+QLQSYRQEV
 Sbjct: 360 DLNIWSLTSGKATAIVHMLIPGSSSKWEEVQSKAKHLLNTFGMYKCTVQLQSYRQEV 419


108P5: 419 RTCANCQSSS 428
 RTCANCQSSS
 Sbjct: 420 RTCANCQSSS 429

Figure 26: Expression of 108P5H8 in LNCaP cells



10024652 .062802


Figure 27:
Expression of 108P5H8 in Prostate Carcinoma
(Gleason grade 6)



sd-70960

10024652 .062802

Figure 28A




*There are three insertions in variant 3: GT, AATTCA and C at 1553, 1566 and 1784, respectively; numbering is relevant to variant 1.

sd-70957

100246512 062002

Figure 28B



sd-71098

CHANG